Compounds for complexation of rare earth elements and/or s-, p-, d- block metals, their coordination compounds, peptide conjugates, method of their preparation and use thereof

State of Art

The present invention relates to new macrocyclic compounds suitable as cross-bridged chelators for complexation of rare earth elements and/or s-, p-, d- block metals, forming extremely stable coordination compounds. These coordination compounds are suitable for use as labels for quantitative detection of peptide conjugates, and/or as contrast agents for magnetic resonance imaging. The invention further relates to a method of preparation of the chelators and to a method of tracing peptide/protein containing medicaments.

Background Art

Metal elements find biomedical applications such as imaging contrast agents, radiotherapeutic agents or bioanalytical labels. For most of these applications, it is necessary to bind the metal in a stable chelate that can be covalently linked to other molecules, such as targeting vectors based on peptides or antibodies. The most universal example of a chelator applicable to majority of metal elements is DOTA ( 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid) and its derivatives. A broad range of other chelators have been developed specifically for particular metal elements. [Price E. W., Orvig C. (2014), Chem. Soc. Rev. 43(1), 260 - 290],

Rare earth elements (scandium - Sc, yttrium - Y, lanthanum - La, cerium - Ce, praseodymium - Pr, neodymium - Nd, promethium - Pm, samarium - Sm, europium - Eu, gadolinium - Gd, terbium - Tb, dysprosium - Dy, holmium - Ho, erbium - Er, thulium - Tm, ytterbium - Yb and lutetium - Lu) are a group of metals that offer a broad range of medical applications. Radiopharmaceuticals based on ⁹⁰ Y, ¹⁵³ Sm and ¹⁷⁷ Lu are approved by FDA, clinical trials are ongoing with ¹⁶⁶ Ho, and others show advantageous properties for Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT) or therapy ( ⁴⁴ Sc, ⁴⁷ Sc, ⁸⁶ Y, ¹⁴⁹ Pm, ¹⁵⁹ Gd, ¹⁴⁹ Tb, ¹⁶¹ Tb, ¹⁶⁵ Dy, ¹⁶¹ Ho, ¹⁶⁹ Er and ¹⁷⁵ Yb). Stable, non-radioactive Gd chelates are in clinical use as contrast agents for Magnetic Resonance Imaging (MRI). Stable isotopes of rare earth elements also serve as labels for analytical purposes. Compounds of interest labeled in this way can be visualized, traced and quantified based on unique luminescence or isotope mass of the elements that have zero background in biological systems. The unique isotope mass is especially useful, as it allows many compounds to be quantified simultaneously in a single analysis (multiplexing), typically with the use of inductively -coupled plasma mass spectrometry (ICP-MS) [Bodenmiller B. et al. (2012), Nat. Biotechnol. 30(9), 858-867], Other metal elements from s-, p- and d-block of the periodic system, such as ⁸⁹ Sr, ²²³ Ra, ^117m Sn, ²¹² Pb, ²¹³ Bi, ⁶⁴ Cu, ²²⁵ Ac, find use in radiopharmaceutical compounds for imaging or therapy.

For practical use, metal chelates must be very stable, so that the metal ion cannot easily escape from the chelator and detach from the carrier molecule. In this respect, thermodynamic stability constant provides insufficient information, because most applications proceed under conditions far from thermodynamic equilibrium (e.g. in- vivo). Instead, kinetic inertness that characterizes the rate at which the metal ion escapes from the chelate under given conditions must be considered. Kinetic inertness strongly correlates with rigidity of the chelator. Acyclic chelators of the type DTP A (diethylenetriaminepentaacetic acid) have more flexible structure and provide lower kinetic inertness than macrocyclic chelators of the type DOTA, which are more rigid. Chelates with high kinetic inertness are desirable particularly for in-vivo applications, where the metal chelate is challenged with excess of competing biogenic chelators and metal ions. For this reason, the rigid and kinetically inert macrocyclic chelators are preferred to the flexible acyclic ones. For example, practically all radiopharmaceuticals based on the radionuclide ¹⁷⁷ Lu (half-life 6.7 days) that are approved or in development make use of the macrocyclic chelator DOTA, as the metal must remain bound to the targeting molecule in-vivo for weeks in order to have the desired curative effect. Similarly, in MRI contrast agents, macrocyclic chelates of gadolinium(III) are preferred to the acyclic DTP A type. It has been recently found that significant amount of free gadolinium is released in-vivo from the acyclic agents and deposited in human brain for long time. [Fur M. L., Caravan P. (2019), Metallomics 11(2), 240-254] In response to this finding and to prevent potential harm to patients, the use of the acyclic MRI contrast agents has been severely restricted around the globe by drug-regulating agencies. It is therefore likely that the importance of kinetic inertness of metal chelates will grow in medical and other applications, and chelators providing higher inertness will be needed.

Methods to further increase kinetic inertness rely on reinforcement and rigidification of the macrocyclic chelators with additional rings. For example, a cross-bridged macrocyclic chelator cb-TE2A (4,11- bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane ) provides much more inert chelates with copper(II) ion than the non-cross-bridged analogues [Boswell C. A. et al. (2004), J. Med. Chem. 47(6), 1465- 1474], Another similar chelator cb-TEDPA (6,6'-((1,4,8,11-Tetraazabicyclo[6.6.2]hexadecane-4,11- diyl)bis(methylene))dipicolinic acid) was shown to provide exceptionally inert lanthanide(III) chelates [Rodriguez-Rodriguez A. et al. (2016), Inorg. Chem. 55(5), 2227-2239], Another cyclen-based cross-bridged chelator provided extremely inert copper(II) chelates [Esteves, C. V. et al. (2013), Inorg. Chem. 52(9), 5138- 5153], A common feature of these chelators is that the bridge is independent from the coordinating pendant arms and is oriented on the opposite side from the pendant arms in the chelate. Chelators where the bridge connected the pendant arms themselves have also been made, but the effect on stability of the chelates was strongly negative [Vipond, J. et al. (2007), Inorg. Chem. 46(7), 2584-2595], There are also practical limitations when too high kinetic inertness becomes counterproductive. This is because the energy barrier that the metal ion must overcome on the way out of the chelate is similar to the barrier that it has to overcome on the way in during chelate formation. Generally, the more inert a chelate is, the more difficult it is to make. The formation kinetics can be accelerated with high temperature and long reaction times. However, such reaction conditions are often incompatible with sensitive targeting vectors (e.g. antibodies) and/or half-life of metal radionuclides in preparation of radiopharmaceuticals.

There remains a strong need for new types of chelators, which would form highly kinetically inert metal complexes quickly and under mild synthetic conditions.

Disclosure of Invention

We have circumvented problems of the background art with a new type of chelators, which form a bridge after complexation of the metal ion that rigidifies the structure and increases kinetic inertness. The bridge is formed between two coordinating pendant arms based on cycloaddition reaction between alkyne and azide substituents on the opposite pendant arms. This reaction does not require catalyzation by Cu(I) ions as is usually the case, and occurs spontaneously after formation of a non-bridged chelate. The chelator therefore acts as a one-way trap for the metal ion. Initial formation of the non-bridged chelate is relatively fast. Then, a bridge is formed that traps the metal inside the chelator. For rare earth elements, the resulting bridged chelates show extremely high kinetic inertness that is up to 6 orders of magnitude higher than for the analogous chelates with DOTA. Such unusually high inertness allows new uses of the chelates as analytical labels that can withstand harsh hydrolytic conditions in concentrated acids and can be quantified in the lysate as intact chelates with liquid chromatography - mass spectrometry (LC-MS). The use of LC-MS is advantageous, as it is much more common instrument than ICP-MS. The extremely high inertness is also advantageous for potential in-vivo use of the chelates, such as MRI contrast agents or radiopharmaceuticals, as no free metal is released in-vivo from the coordination compounds, therefore no metal deposit occurs in human or animal body.

The compounds according to the present invention are capable of acting as extremely efficient molecular traps, which can coordinate metal ions in an extremely stable, rigid and well defined manner. The ligands can be prepared in relatively a few number of steps of organic synthesis. After coordination of the metal ion, the click reaction is performed between the azide group and a triple bond present in opposite pendant arms of the macrocycle, forming a triazole bridge, and enclosing the metal ion within the cage (forming the so-called click- zipped complex). The formation of triazole is irreversible and is depicted in Scheme 1 below.

Scheme 1. Schematic representation of the click-zip principle illustrated on the example of ligand TD647.

In first aspect, the subject of the present invention relates to compounds of general formula (I) wherein

Y is selected from a group consisting of nitrogen (N); N -oxide (N ⁺ -O-);

R ¹ is selected from the group consisting of H; halogen; -OH; -N ₃ ; -(CH ₂ ) _n N ₃ , wherein n is an integer in the range of from 1 to 3; -NR ₂ , wherein R is independently selected from H or C ₁ to C ₆ alkyl, which may be branched or linear; -(CH ₂ ) _n NR ₂ , wherein n and R are as defined above; C ₆ to C ₁₀ aryl, which can optionally be substituted with -NH ₂ , - NO ₂ , -N ₃ , -COOH, -CH ₂ CI and/or -CH ₂ COOH; C ₇ to C ₁₀ arylalkyl, which can optionally be substituted with -NH ₂ , -NO ₂ , -N ₃ , COOH, CH ₂ Cl and/or

CH ₂ COOH;

-CF ₃ ; -COOR, wherein R is as defined above; -(CH ₂ ) _n COOR, wherein n and R are as defined above; -SH; -SO ₃ H; -SO ₂ Ar. wherein Ar is phenyl; NO ₂ ;

R ² is wherein n is an integer in the range of from 1 to 3; preferably, R ² is or more preferably R ² is

A are independently selected from the group consisting of H; -(CH ₂ ) _n COOH, wherein n is an integer from 1 to 3; -CH(CH ₃ )COOH; -CH((CH ₂ ) _n CH ₃ )COOH, wherein n is as defined above; -CH ₂ P(=O)(OR) ₂ , wherein R is as defined above; -CH((CH ₂ ) _n COOH)COOH, wherein n is an integer from 1 to 3;

-CH((CH ₂ ) _n NH ₂ )COOH, wherein n is an integer from 1 to 3; -CH ₂ C(=O)(NH ₂ ); -CH ₂ C(=O)(NH)-CH ₂ COOH; -CH ₂ P(=O)(OH)(Ar), wherein Ar is phenyl, which can optionally be substituted with C ₁ to C ₆ alkyl;

Z is selected from a group consisting of wherein

R ³ is

R ⁴ is selected from the group consisting of H; halogen; piperidinyl; trimethylsilyl; triisopropylsilyl; phenyl; C ₁ to C ₆ alkyl, which may be branched or linear; CT to C ₆ cycloalkyl; -CF ₃ ; -(CH ₂ ) _n NHR ⁶ , wherein n is an integer in the range of from 1 to 3 and R ⁶ is selected from H, fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl and benzyloxycarbonyl; -C(CH ₃ ) ₂ (NHR ⁶ ), wherein R ⁶ is as defined above; adamantyl;

-(CH ₂ ) _n COOH, wherein n is as defined above; C ₆ to C ₁₀ aryl, which can optionally be substituted with -NH ₂ ,

-NO ₂ , -N ₃ , -COOH, CH ₂ Cl and/or -CH ₂ COOH;

R ⁵ is R ¹ or wherein R ⁴ is as defined above; preferably R ⁵ is H; -CF ₃ ; halogen; -OH; C ₇ to C ₁₀ arylalkyl, which can optionally be substituted with -NH ₂ , -NO ₂ , -COOH, -CH ₂ Cl and/or -CH ₂ COOH; or and/or R ² and R ³ together form a 1,2,3-triazole group of formula wherein

R ⁴ is defined above; with the proviso that at most one A is H.

When the compounds of this invention contain a chiral centre, then all enantiomers, mixtures of enantiomers and racemates fall within the framework of the present invention. The present invention further includes the compounds of general formula (I) in the form of salts with alkali metals, ammonium or amines, as well as in the form of addition salts with acids.

The term „halogen“ means any iozotop of F, Cl, Br, and I; in particular, this term includes non-radioactive izotopes, such as ¹⁹ F, ³⁵ Cl, ³⁷ Cl, ⁷⁹ Br, ⁸¹ Br, ¹²⁷ I; and radioizotopes, such as ¹⁸ F, ³⁶ Cl, ⁷⁷ Br, ⁸³ Br, ¹²³ I, ¹²⁴ I, ¹²⁵ I, 1 ³¹ I. In one embodiment, A are independently selected from the group consisting of H; -(CH ₂ ) _n COOH, wherein n is an integer from 1 to 3; -CH(CH ₃ )COOH; -CH((CH ₂ ) _n CH ₃ )COOH, wherein n is an integer from 1 to 3; -CH ₂ P(=O)(OR) ₂ , wherein R is as defined above; -CH ₂ C(=O)(NH ₂ ); -CH ₂ C(=O)(NH)-CH ₂ COOH; -CH ₂ P(=O)(OH)(Ar), wherein Ar is phenyl, which can optionally be substituted with C ₁ to C ₆ , alkyl.

In one embodiment, R ¹ is selected from the group consisting of H; halogen; -OH; -N ₃ ; -CH ₂ N ₃ ; -NR ₂ , wherein R is independently selected from H or C ₁ to C ₆ alkyl, which may be branched or linear; -CH ₂ NR ₂ , wherein R are as defined above; C ₆ to C ₁₀ aryl, which can optionally be substituted with -NH ₂ , -NO ₂ , -COOH and/or -CH ₂ COOH; C ₇ to C ₁₀ arylalkyl, which can optionally be substituted with -NH ₂ , -NO ₂ , -COOH, -CH ₂ CI and/or -CH ₂ COOH; -CF ₃ ; -COOR, wherein R is as defined above; -(CH ₂ ) _n COOR, wherein n and R are as defined above; ; -CH ₂ CH(OMe) ₂ ; -SH; -SO ₃ H; -SO ₂ Ar, wherein Ar is phenyl; NO ₂ ; preferably R ¹ is selected from H; halogen; -OH; -N ₃ ; -CH ₂ N ₃ ; -N(CH ₃ ) ₂ ; phenyl; carboxyphenyl; -CF ₃ ;

COOR, wherein R is as defined above; and

In one embodiment, R ⁴ is selected from the group consisting of H; halogen; piperidinyl; trimethylsilyl; triisopropylsilyl; phenyl; C ₁ to C ₆ , alkyl, which may be branched or linear; C ₃ to C ₆ , cycloalkyl; -CF ₃ ; - CH ₂ NHR ⁶ , wherein R ⁶ is selected from H, fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl and benzyloxycarbonyl; -C(CH ₃ ) ₂ (NHR ⁶ ), wherein R ⁶ is as defined above; adamantyl; preferably R ⁴ is selected from the group consisting of H; trifluoromethyl; 4-piperidinyl; -CH ₂ -NH ₂ ; phenyl; cyclopropyl; adamantyl; terc-butyl; trimethylsilyl (TMS); triisopropylsilyl (TIPS); halogen (F, Cl, Br, I);

-C(CH ₃ ) ₂ NH ₂ ; and -C(CH ₃ ) ₂ NHBoc. More preferably, R ⁴ is hydrogen.

In one embodiment of the present invention, the compounds of general formula (I) comprises the following substituents:

Y is nitrogen (N);

R ¹ is selected from the group consisting of H; halogen; -OH; -N ₃ ; -CH ₂ N ₃ ; -NR ₂ , wherein R is independently selected from H or C ₁ to C ₆ , alkyl, which may be branched or linear; C ₆ to C ₁₀ aryl, which can optionally be substituted with -NH ₂ , -NO ₂ , -COOH and/or -CH ₂ COOH; C ₇ to C ₁₀ arylalkyl, which can optionally be substituted with -NH ₂ , -NO ₂ , -COOH, -CH ₂ CI and/or -CH ₂ COOH; -CF ₂ ; -COOR, wherein R is as defined above; -CH ₂ CH(OMe) ₂ ;

R ² is

A are independently selected from the group consisting of H; -(CH ₂ ) _n COOH, wherein n is an integer from 1 to 3; -CH(CH ₃ )COOH; -CH((CH ₂ ) _n CH ₃ )COOH, wherein n is as defined above; -CH ₂ P(=O)(OR) ₂ , wherein R is as defined above; -CH ₂ C(=O)(NH ₂ ); -CH ₂ C(=O)(NH)-CH ₂ COOH; -CH ₂ P(=O)(OH)(Ar), wherein Ar is phenyl, which can optionally be substituted with C ₁ to C ₆ alkyl;

Z is selected from a group consisting of wherein

R ³ is

R ⁴ is selected from the group consisting of H; halogen; piperidinyl; trimethylsilyl; triisopropylsilyl; phenyl; C ₁ to C ₆ alkyl, which may be branched or linear; C ₃ to C ₆ cycloalkyl; -CF ₃ -;CH ₂ NHR ⁶ , wherein R ⁶ is selected from H, fluorenylmethyloxykarbonyl and benzyloxycarbonyl; -C(CH ₃ ) ₂ (NHR ⁶ ), wherein R ⁶ is as defined above; adamantyl;

R ⁵ is H; -CF ₂ ; halogen; -OH; C ₇ to C ₁₀ arylalkyl, which can optionally be substituted with -NH ₂ , -NO ₂ ,

-COOH, -CH ₂ Cl and/or -CH ₂ COOH; or wherein R ⁴ is as defined above; and/or R ² and R ³ together form a 1,2,3-triazole group of formula wherein R ⁴ is defined above; with the proviso that at most one A is H.

In one preferred embodiment, Y is nitrogen, thus forming a pendant arm comprising a pyridyl moiety, substituted with R ¹ and R ² .

In one embodiment, R ¹ is in meta-position from Y, and para-position from R ² -CH: In one embodiment, R ¹ is in meta-position from Y, and orto-position from R ² -CH _: In another embodiment, R ¹ is in para-position from Y.

In one preferred embodiment, R ² is

Preferably, R ² is and R ¹ is selected from the group comprising H, phenyl, carboxyphenyl, halogen (preferably Cl), trifluoromethyl, carboxyl, carboxylic ester or amine, more preferably R ¹ is H or carboxyphenyl.

In one embodiment, Z is 3

In one preferred embodiment, Z is and R ³ and R ⁵ are as defined above. Preferably, Z is even more preferably, Z is

In the compound of general formula (I), A can be the same or different. Preferably, A are the same.

In one embodiment, Z is

In one embodiment, Z is

In one embodiment, A is selected from the group comprising -(CH ₂ )COOH; -(CH ₂ ) ₂ COOH;

-CH ₂ P(=O)(OEt) ₂ ; -CH ₂ P(=O)(OH) ₂ ; -CH ₂ P(=O)(OH)(OEt); -CH ₂ P(=O)(Ph)(OH); -(CH ₂ )COONH ₂ ; -(CH ₂ )C(=O)NH-CH ₂ COOH; -(CH ₂ )COO ^t Bu; -CH(CH ₂ COOH)COOH.

Preferably, A is selected from the group comprising -(CH ₂ )COOH; -CH ₂ P(=O)(OEt) ₂ ; -CH ₂ P(=O)(OH) ₂ ;

-CH ₂ P(=O)(OH)(OEt); and -CH ₂ P(=O)(Ph)(OH). Most preferably, A is -(CH ₂ )COOH.

In one embodiment, Y is nitrogen; R ¹ is selected from the group consisting of H; Cl; -N(CH ₃ ) ₂ ; phenyl, which can optionally be substituted with -COOH or -CH ₂ COOH; benzyl, which can optionally be substituted with -COOH or -CH ₂ COOH; -CF ₃ ; -COOCH ₃ ; -COOCH(CH ₃ ) ₂ ;

-COO ^t Bu; -SH;

A are independently selected from the group consisting of H; -(CH ₂ ) _n COOH, wherein n is 1 or 2; -CH ₂ P(=O)(OH) ₂ ; -CH ₂ P(=O)(OH)(OEt); -CH ₂ P(=O)(OEt) ₂ ; -CH ₂ C(=O)(NH ₂ ); -CH ₂ C(=O)(NH)- CH ₂ COOH; -CH ₂ P(=O)(OH)(Ph);

Z is selected from a group consisting of wherein

R ³ is

R ⁴ is selected from the group consisting of H; halogen; piperidinyl; trimethylsilyl; triisopropylsilyl; phenyl; cyclopropyl, terc-butyl; -CF ₃ ; -CH ₂ NH ₂ ; -CH ₂ N(H)(Fmoc); -C(CH ₃ ) ₂ (NH ₂ ); -C(CH ₃ ) ₂ (NHBoc); adamantyl;

R ⁵ is H or , wherein R ⁴ is as defined above; with the proviso that at most one A is H.

In one preferred embodiment, Z is R ³ is ; R ⁴ and R ⁵ are as defined above, preferably R ⁴ and R ⁵ are H. In another embodiment, R ² and R ³ together form a 1,2,3 -triazole group of formula or wherein R ⁴ is as defined above, preferably R ⁴ is hydrogen. In such embodiment, a bridge is formed between two opposite nitrogen atoms of the cyclen moiety, and the compound of general formula (I) thus forms a cage-like structure. The bridge is an entity of general formula (Ila) or (Ilb) wherein

L is a linker selected from the group consisting of

10 and R ¹ , R ⁴ and R ⁵ are as defined above. The linker L is derived from the group Z defined above. Preferably, L is more preferably L is

In one preferred embodiment, the compound of general formula (I) is selected from the group comprising compounds with the following combinations of substituents:

Y is N ⁺ -O-; R ¹ , R ⁴ and R ⁵ is H:

Y is N; R ¹ , R ⁴ and R ⁵ is H: CH

Y is N; Z is and R ² is

Y is N; and R ² and R ³ together form a 1,2,3 -triazole group of formula

Y is N; and R ² and R ³ together form a 1,2,3 -triazole group of formula

Y is N; R ¹ is phenyl; and R ² is and R ³ is

Y is N; A is -(CH ₂ )COOH; R ¹ is H; and R ² is Y is N; A is -(CH ₂ )COOH; R ² is and Z is

Y is N; A is -CH(CH ₃ )COOH; R ² is and Z is

In the most preferred embodiment, the compound of general formula (I) is selected from the group comprising compounds, wherein Y is nitrogen, Z is and the remaining substituents are present in the following combinations:

In another aspect, the subject of the present invention is a method of synthesis of the compounds of general formula (I), comprising the following steps: i) providing an alkyne intermediate of general formula Z-Cl, wherein Z is as defined above; ii) providing an azide intermediate of general formula (III)

(III); wherein Y, R ¹ and R ² are as defined above; iii) providing a cyclen derivative of general formula (IV)

(IV), wherein pA is selected from the group comprising -(CH ₂ ) _n COO ^t Bu, wherein n is an integer from 1 to 3; benzyloxycarbonyl; -CH(CH ₃ )COO ^t Bu; -CH(CH ₃ )COOR, wherein R is tert-butyl, methyl or ethyl;

-CH((CH ₂ ) _n CH ₃ )COOR, wherein n and R are as defined above; -CH((CH ₂ ) _n COOR)COOR, wherein n is as defined above and R are independently selected from tert-butyl, methyl or ethyl;-CH ₂ P(=O)(OR) ₂ , wherein R is C ₁ to C ₆ alkyl, which may be branched or linear; -CH ₂ C(=O)(NH ₂ ); -CH ₂ C(=O)(NH)-CH ₂ COOH; - CH ₂ P(=O)(OH)(Ar), wherein Ar is phenyl, which can optionally be substituted with C ₁ to C ₆ alkyl; preferably pA is selected from the group comprising -CH ₂ COOtBu: -CH ₂ P(O)(OEt) ₂ ; -(CH ₂ ) ₂ COOtBu; iv-A) reacting the cyclen derivative of general formula (IV) with alkyne intermediate Z-Cl to obtain an intermediate of general formula (V)

(V), wherein Z and pA are as defined above; or iv-B) reacting the cyclen derivative of general formula (IV) with the azide intermediate of general formula (III) to obtain an intermediate of general formula (VI)

(VI), wherein Y, R ¹ , R ² and pA are as defined above; v-A) reacting the intermediate of general formula (V) with the azide intermediate of general formula (III) to obtain an intermediate of general formula (VII)

(VII) wherein Y, R ¹ , R ² , pA and Z are as defined above; or v-B) reacting the intermediate of general formula (VI) with the alkyne intermediate Z-Cl to obtain the intermediate of general formula (VII); vi) optionally, hydrolysis of protecting groups, resulting in the compound of general formula (I).

In general, compounds of general formula Z-Cl can be obtained commercially or can be synthesised using Pd(0) catalyzed Sonogashira cross-coupling reaction from corresponding 2-halopyridines (preferably Br, I) and terminal alkynes or silyl-protected acetylenes.

Compounds of general formula (III) can be obtained from 2,6-bis(halomethyl)pyridines (preferably Cl) by desymetrization using sodium azide as a source of azide moiety.

Cyclene derivatives of general formula (IV) are commercially available or may be prepared by reaction of cyclen or trans-N-bis-protcctcd cyclen (preferably carbamate protected) with alkyl haloacetates (alkylation), alkyl acrylates (Michael addition) or trialkylphosphites in the presence of (para)formaldehyde (Kabachnik- Fields reaction).

Steps iv-A), iv-B), v-A) and v-B) take place in a solvent selected from the group comprising MeCN (preferably), DMSO or DMF. The reaction takes place at room temperature for usually several hours up to several days. Step vi) of deprotecting pA groups is optional, for example if pA is -CH ₂ P(O)(OEt) ₂ , then if no deprotection takes place, the resulting A in general formula (I) equals pA. Specific conditions for deprotection of the protecting group depend on the chemical nature of the protecting group, and are known to the person skilled in the art. Typically, terc-butyl ester protecting groups and Boc protecting group are hydrolyzed under acidic conditions (TEA) or thermally, methyl or isopropyl protecting groups are hydrolyzed under alkaline conditions, ethyl phosphonate ester are converted to corresponding phosphonic acids by transesterification using trimethylsilylbromide in presence of pyridine base.

Another subject of the present invention is a coordination compound of the compound of the general formula (I) as defined above with a metal cation, selected from the group consisting of lanthanide(III) cations, Na ⁺ , Ba ²⁺ , Pb ²⁺ , Sr ²⁺ , Ca ²⁺ , Cd ²⁺ , Zn ²⁺ , Mn ²⁺ , Pt ²⁺ , Cu ²⁺ , Ni ²⁺ , Sc ³⁺ , Y ³⁺ , Bi ³⁺ , In ³⁺ , Ru ³⁺ , Ir ³⁺ , Ga ³⁺ , Tl ³⁺ , Pd ²⁺ ; preferably the metal cation is selected from the group consisting of La ³⁺ , Ce ³⁺ , Pr ³⁺ , Nd ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ , Dy ³⁺ , Ho ³⁺ , Er ³⁺ , Tm ³⁺ , Yb ³⁺ , Lu ³⁺ , Y ³⁺ , Sc ³⁺ , Bi ³⁺ , In ³⁺ , Tl ³⁺ , Pb ²⁺ , Ca ²⁺ , Cd ²⁺ , Zn ²⁺ , Cu ²⁺ , Ni ²⁺ , Mn ²⁺ , Pd ²⁺ , Na ⁺ .

The metal ions shall be undestood as comprising any izotope of the particular metal, including stable isotopes such as ⁴⁰ Ca, ⁴² Ca, ⁴³ Ca, ⁴⁴ Ca, ⁴⁶ Ca, ⁴⁸ Ca, ⁴⁵ Sc, ⁸⁹ Y, ¹³⁸ La, ¹³⁹ La, ¹³⁶ Ce, ¹³⁸ Ce, ¹⁴⁰ Ce, ¹⁴² Ce, ¹⁴¹ Pr, ¹⁴² Nd, ¹⁴³ Nd, 1 ⁴⁴ Nd, ¹⁴⁵ Nd, ¹⁴⁶ Nd, ¹⁴⁸ Nd, ¹⁵⁰ Nd, ¹⁴⁴ Sm, ¹⁴⁷ Sm, ¹⁴⁸ Sm, ¹⁴⁹ Sm, ¹⁵⁰ Sm, ¹⁵² Sm, ¹⁵⁴ Sm, ¹⁵¹ Eu, ¹⁵³ Eu, ¹⁵² Gd, ¹⁵⁴ Gd, ¹⁵⁵ Gd, 1 ⁵⁶ Gd, ¹⁵⁷ Gd, ¹⁵⁸ Gd, ¹⁶⁰ Gd, ¹⁵⁹ Tb, ¹⁵⁶ Dy, ¹⁵⁸ Dy, ¹⁶⁰ Dy, ¹⁶¹ Dy, ¹⁶² Dy, ¹⁶³ Dy, ¹⁶⁴ Dy, ¹⁶⁵ Ho, ¹⁶² Er, ¹⁶⁴ Er, ¹⁶⁶ Er, ¹⁶⁷ Er, 1 ⁶⁸ Er, ¹⁷⁰ Er, ¹⁶⁹ Tm, ¹⁶⁸ Yb, ¹⁷⁰ Yb, ¹⁷¹ Yb, ¹⁷² Yb, ¹⁷³ Yb, ¹⁷⁴ Yb, ¹⁷⁶ Yb, ¹⁷⁵ Lu, ¹⁷⁶ Lu, and radioisotopes such as ⁴⁴ Sc, 4 ⁷ Sc, ⁶⁴ Cu, ⁶⁷ Cu, ⁸⁶ Y, ⁹⁰ Y, ¹⁴⁰ Nd, ¹⁴⁹ Pm, ¹⁵¹ Pm, ¹⁵³ Sm, ¹⁵⁹ Gd, ¹⁴⁹ Tb, ¹⁶¹ Tb, ¹⁶⁵ Dy, ¹⁶¹ Ho, ¹⁶⁶ Ho, ¹⁶⁹ Er, ¹⁶⁷ Tm, ¹⁷⁵ Yb, 1 ⁷⁷ Lu.

Lanthanides (Ln) are defined as chemical elements comprising 15 metallic chemical elements with atomic numbers in the range of from 57 to 71 (from lanthanum through lutetium).

Preferably, the coordination compound has a general formula (VIII)

(VIII); wherein M is the metal cation, R ¹ , R ⁴ , R ⁵ and A are as defined above, and n is selected from 1, 2, 3 and 4; more preferably, the coordination compound has a general formula (Villa)

(VIlla).

The coordination compounds according to the present invention comprise also solvates and salts of pharmaceutically acceptable acids. The positive charge of the metal cation is counterbalanced by two negative charges arising from A pendant arms (e.g. acetates). Therefore, the overall charge of the coordination compound is -1 (for monovalent metal ions), 0 (for divalent metal ions) or +1 (trivalent metal ions). The counterion, compensating for the overall charge of the coordination compound, is selected from the group, comprising anions derived from the following pharmaceutically acceptable acids:

1 -hydroxy -2 -naphthoic acid; 2,2-dichloroacetic acid; 2 -hydroxyethanesulfonic acid; 2-oxoglutaric acid; 4- acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid; ascorbic acid (L); aspartic acid (L); benzenesulfonic acid; benzoic acid; camphoric acid (+); camphor- 10-sulfonic acid (+); capric acid (decanoic acid); caproic acid (hexanoic acid); caprylic acid (octanoic acid); carbonic acid; cinnamic acid; citric acid; cyclamic acid; dodecylsulfuric acid; ethane- 1,2-disulfonic acid; ethanesulfonic acid; formic acid; fumaric acid; galactaric acid; gentisic acid; glucoheptonic acid (D); gluconic acid (D); glucuronic acid (D); glutamic acid; glutaric acid; glycerophosphoric acid; glycolic acid; hippuric acid; hydrobromic acid; hydrochloric acid; isobutyric acid; lactic acid (DL); lactobionic acid; lauric acid; maleic acid; malic acid (- L); malonic acid; mandelic acid (DL); methanesulfonic acid; naphthalene-1,5-disulfonic acid; naphthalene-2-sulfonic acid; nicotinic acid; nitric acid; oleic acid; oxalic acid; palmitic acid; pamoic acid; phosphoric acid; proprionic acid; pyroglutamic acid (- L); salicylic acid; sebacic acid; stearic acid; succinic acid; sulfuric acid; tartaric acid (+ L); thiocyanic acid; toluenesulfonic acid (p ); undecylenic acid; trifluoroacetic acid.

The coordination compounds can be prepared according to Scheme 1 above from the free ligand of general formula (I) (preferably the non-caged, therefore preferably without the trazole bridge) and a metal salt (typically water soluble metal salt, preferably selected from a group comprising chloride, nitrate, acetate, formate, trifluoroacetate, trifluoromethylsulfonate, more preferably chloride or nitrate salt). By stirring of these reactants in an aqueous environment (pH 5-7) at temperature in the range of from 25 °C to 100 °C, the metal cation coordinates into the compound of general formula (I) and the R ² and R ³ substituents then “click-zip” the metal cation inside the cage by forming the triazole bridge (reaction temperatures and times are strongly dependent on the choice of ligand and metal cation).

However, the suitable ligands are not limited to the non-caged compounds of general formula (I), eventhough they are preferred because wider range of metal cations (such as lanthanides) may form the caged coordination compounds. The bridged (caged) compounds of general formula (I) with 1,5-triazole bridge are capable of forming coordination compounds with metal cations, typically selected from the group comprising Tl ³⁺ , Pb ²⁺ , Bi ³⁺ , In ³⁺ , Cd ²⁺ , Ca ²⁺ , Cu ²⁺ , Ni ²⁺ , Mn ²⁺ , Pd ²⁺ , Na ⁺ . The bridged (caged) compounds of general formula (I) with 1,4-triazole bridge are capable of forming coordination compounds with metal cations, typically selected from the group comprising La ³⁺ , Ce ³⁺ , Pr ³⁺ , Nd ³⁺ , Sm ³⁺ , Eu ³⁺ , Gd ³⁺ , Tb ³⁺ , Dy ³⁺ , Ho ³⁺ , Er ³⁺ , Tm ³⁺ , Yb ³⁺ , Lu ³⁺ , Y ³⁺ , Tl ³⁺ , Pb ²⁺ , Bi ³⁺ , In ³⁺ , Cd ²⁺ , Ca ²⁺ , Cu ²⁺ , Ni ²⁺ , Mn ²⁺ , Pd ²⁺ , Na ⁺ .

The resulting coordination compounds are very inert and stable, therefore suitable for various applications, such as MRI contract agents, radiodiagnostics or radiotherapy, peptide or protein containing drug tracing.

The coordination of the compound of general formula (I) to a metal cation takes place via the macrocyclic nitrogen atoms of the cyclene moiety, oxygen atoms present in groups A (pendant arms) and Y group (when Y is N-oxide), and via nitrogen atoms of Y group (when Y is nitrogen) and nitrogen atom present in Z group.

In one embodiment, the coordination compounds according to the present invention may undergo a post- clickzip transformation. It means that after the metal cation is coordinated within the cage of the compound of general formula (I) by either following the Scheme 1 or coordinating with the caged compound of general formula (I), some functional groups, if present, may undergo a further reaction. Typically, such functional group is a halogen, preferably Cl, NO ₂ or SH, present within substituent R ¹ or R ⁵ of the coordination compound, however, post-clickzip transformations may include reactions of R ¹ , R ⁴ , R ⁵ and/or A groups (such as amidic coupling reactions of non-coordinated carboxylic or amino groups).

For example, when R ¹ is halogen, preferably Cl; or R ¹ is C ₆ , to C ₁₀ aryl, substituted with -CH ₂ CI, then the coordination compound of general formula (VIII) may undergo post-click transformation using Pd(0) catalyzed Suzuki cross-coupling reaction with phenylboronic acids (3 -borono-5 -nitrobenzoic acid or 2-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid or 2-(4-boronophenyl)acetic acid), during which the halogen is replaced, thus the resulting coordination compound of general formula (VIII) would have R ¹ = COOH or C ₆ to C ₁₀ aryl, substituted with -COOH or -CH ₂ COOH. The resulting carboxylate moiety can be then utilized in amide coupling reaction for synthesis of peptide conjugates. Conjugates with oligoarginines are capable of crossing cell membrane, allowing metal cages to be incorporated to the cells. Another possible post-click transformation is the replacement of halogen present within R ¹ , R ⁴ and/or R ⁵ substituent by -N ₃ group by reaction with NaN ₃ . The resulting azide can be used for coupling of the metal cage to another alkyne-bearing moiety using copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction.

Another possible post-click transformation is the hydrolysis of TIPS protecting group present in R ¹ , R ⁴ and/or

R ⁵ substituent and protecting the triple bond (R ¹ , R ³ and/or R ⁵ is ). The hydrolysis is performed using aqueous K ₂ CO ₃ , and results in R ¹ , R ³ and/or R ⁵ being . The resulting deprotected triple bond is suitable for further conjugations via reaction with the alkyne, for example click reactions with azides and forming triazole bridges (e.g. CuAAC reaction).

In another embodiment, the post-click transformation may be addition reaction of methanol to R ¹ , R ⁴ and/or

R ⁵ , wherein R ¹ , R ³ and/or R ⁵ is thus transforming the triple bond to dimethyl acetal

(protected version of an aldehyde). This demonstrates conversion of one functional group (alkyne) to another (aldehyde). Aldehydes are usable for conjugation reactions based on formation of Schiff bases with amines, hydrazines and acid hydrazides.

In yet another embodiment, the post-click transformation may be deuteration reaction of CH ₂ groups of the pendant arms in D ₂ O in presence of DBU, transforming them into CD ₂ groups. This conversion does not alter the physico-chemical properties of the molecule (in terms of stability or reactivity), but changes the overall mass of the molecule, to be entirely distinguishable from the parent non-deuterated molecule using mass spectrometry. This means, that the metal ion cage with one particular metal can be used as two different mass tags.

In yet another embodiment, the post-click transformation may be a selective reduction of pyridyl cycle of

Z substituent, wherein Z is and R ³ and R ⁵ are as defined above, using NaBH ₄ or NaBD ₄ as the reducing agent, thus transforming the Z group into respectively. Similiarly to the deuteration of CH ₂ groups, this conversion changes the mass of the molecule for metal tags purposes.

In yet another embodiment, the post-click transformation may be reaction of NH ₂ group, if present, of R ¹ and/or R ⁴ and/or R ⁵ and/or A, wherein R ¹ and/or R ⁴ and/or R ⁵ contains -NH ₂ or -(CH ₂ ) _n NH ₂ , with FmocCl, resulting in transformation of-NH ₂ group into -NHFmoc group. Fmoc group is the most commonly encountered amine protecting group used in solid-phase peptide synthesis (SPPS). Introducing of Fmoc group therefore facilitates use of the metal cages for SPPS.

In yet another embodiment, the post-click transformation may be reaction of NH ₂ group, if present, of R ¹ and/or R ⁴ and/or R ⁵ and/or A, with a carboxyl group of another molecule of general formula (I) or of its metal complex as defined above, resulting in conjugation of two or more compounds of general formula (I) or of their metal complexes into conjugates bound via a peptide (amide) bond.

In yet another embodiment, the post-click transformation may be reaction of non-coordinating -COOH group, if present, in R ¹ and/or R ⁴ and/or R ⁵ and/or A, with an amino group of an aminoacid or peptide, thus forming a peptide bond for conjugation purposes.

In yet another embodiment, the post-click transformation may be S -alkylation reaction of a halogen, preferably Cl, of R ¹ , R ⁴ and/or R ⁵ substituent with a thiol, resulting in trasforming the halogen into sulfide. The thiol may be e.g. Na ₂ S, NaSH, N-Boc-cysteine or a cysteine-containing peptide and the reaction may take place in presence of DIPEA. Incorporating cysteine (aminoacid) into the structure of the coordination compound according to the present invention opens futher possibilities for amide bonds (e.g. peptide attachment).

In yet another embodiment, the post-click transformation may be reaction of group of R ¹ , R ³ and/or R ⁵ , wherein R ¹ , R ³ and/or R ⁵ contains , with an azide, preferably with alkyl- or arylazide, thereby forming a triazole bridge connecting the alkyl- or aryl- to R ¹ , R ³ and/or R ⁵ group. The arylazide is preferably C6 to C10 arylazide, e.g. benzyl azide, optionally substituted with -COOH or -CH ₂ COOH. The alkyl azide is preferably C1 to C7 alkyl azide, wherein the alkyl may be linear or branched. In yet another embodiment, the post-click transformation may be reaction of-N ₃ group of R ¹ or R ⁵ , wherein R ¹ or R ⁵ contains -N ₃ group, with a substituent comprising a carbon-carbon triple bond, thereby forming a triazole bridge connecting the substituent with the coordination compound. The substituent comprising a triple bond may be for example C7 to C10 arylalkynyl, optionally substituted with -COOH or -CH ₂ COOH, e.g. phenylacetylene, wherein the phenyl moiety may optionally be substituted with -COOH or -CH ₂ COOH.

In yet another embodiment, the post-clickzip transformation may be reaction of -SH group of R ¹ and/or R ⁵ , with a substituent comprising maleimide, thereby forming thiosuccinimide linkage connecting the substituent with the coordination compound; or reaction of -SH group of R ¹ and/or R ⁵ , with a substituent comprising another -SH group, thereby forming a disulfide bridge connecting the substituent with the coordination compound; or reaction of-SH group of R ¹ and/or R ⁵ , with alkyl- or arylhalogenide, thereby forming a thioether linkage connecting the alkyl- or aryl- to the coordination compound.

In yet another embodiment, the post-clickzip transformation may be reaction of -NO ₂ group of R ¹ and/or R ⁵ , with a substituent comprising -SH group, thereby forming a thioether linkage connecting the substituent with the coordination compound.

In one embodiment, the post-click transformation may include reaction with another coordination compound of the present invention, thereby forming a chain or a dimer. The coordination compound chain or dimer may contain the same metal cation in both click -zipped cages or it may contain different metal cations in each of the chelates. The advantage of the chains and dimers lies in the possibility to combine properties of the two caged chelates, such as their unique weights to produce mass tags with higher variability of weights.

Typically, the coordination compounds are bound into the chain by forming a triazole bridge between R ¹ or R ⁵ group of the first coordination compound and R ¹ or R ⁵ group of the following coordination compound (the use of R ⁵ group is only possible for Z being

The general basic structure of the coordination compound chain is thus (IXa) or (IXb)

(IXa)

(IXb).

In one embodiment, the coordination compounds are bound into the chain by amide bonds formed between a substituent of one coordination compound containing an amine group (R ¹ and/or R ⁴ and/or R ⁵ and/or A) and a substituent of another coordination compound containing a carboxyl group (R ¹ and/or R ⁴ and/or R ⁵ and/or A).

The chain usually contains two coordination compounds according to the present invention, however it may contain three, four or more coordination compounds.

In yet another embodiment the two types of linkage, described above, are possible in one chain, for example two neighbouring coordination compounds may be linked by one triazole bridge, leaving R ⁵ or R ¹ substituent available for linking another coordination compound according to the present invention, either via a triazole bridge or, if amino or carboxyl groups are present, via an amide bond.

In one embodiment, the coordination compounds are bound into the chain by disulfide bonds (-S-S-) formed between a substituent R ¹ or R ⁵ of one coordination compound containing -SH group, and a substituent R ¹ or R ⁵ of another coordination compound containing -SH group. The coordination compound dimer contains two coordination compounds according to the present invention, bound together by forming a triazole bridge between R ¹ group of the first coordination compound and R ⁵ group of the second coordination compound, and, at the same time, by forming a triazole bridge between R ⁵ group of the first coordination compound and R ¹ group of the second coordination compound.

The general structure of the coordination compound dimer is thus (X)

(X).

The synthesis of the coordination compound chain or dimer is based on a click reaction between an azido group of the first coordination compound and a triple bond of the second coordination compound, thereby forming a triazole bridge, linking the two coordination compound into a dimer. The triazole bridge is selected from the group comprising:

1,2,3 -triazole group of formula formed between -N ₃ group of R ¹ or R ⁴ or R ⁵ of first coordination compound and the triple bond of R ¹ or R ⁴ or R ⁵ of the second coordination compound. Preferably, the metal cations are different, for example the metal cations are selected from Tb ³⁺ and ¹⁷⁶ Yb ³⁺ .

Yet another object of the present invention is a conjugate suitable for use as markers for drug tracing. Many drugs are based on peptides or proteins, and their biodistribution can be traced by attachment of a fluorescent or radioactive marker to the peptide or protein structure. The coordination compounds and dimers of the present invention are suitable for their attachment to the peptide or protein of a drug to be traced. The isolated cell culture or a tissue can then be analysed for the presence of the metal complex using conventional methods, such as LC-MS, which is commonly used and relatively inexpensive instrument. The cells or tissues can be entirely hydrolyzed in a strong acid without any decomposition of the coordination compound according to the present invention. The coordination compound can then be detected in a hydrolyzed sample. Such method is unexpensive and reliable thanks to the extremely high stability of the coordination compounds. LC-MS method also allows for using a plurality of different coordination compounds with different metal isotops (multiplexing), which may then be all analyzed during one LC-MS analysis.

The conjugate according to the present invention contains the coordination compound according to the present invention as defined above or the coordination compound dimer or chain as defined above, conjugated to a peptide or to a protein. The conjugation takes place via an amide bond, formed between the amino group of the peptide or the protein and a carboxyl group of the coordination compound or of the chain or dimer or vice versa. Thus, the coordination compound or the chain or dimer need to contain either -NH ₂ or -COOH group prior to peptide or protein conjugation. Preferably, the -NH ₂ or -COOH group is part of the R ¹ and/or R ⁴ and/or R ⁵ group, therefore the conjugates are formed from coordination compounds or coordination compound dimers, which have R ¹ and/or R ⁴ and/or R ⁵ group selected from the group comprising -NH ₂ ; -(CH ₂ ) _n NH ₂ ; -COOH; - (CH ₂ ) _n COOH; C ₆ to C ₁₀ aryl, substituted with -NH ₂ , -COOH, -(CH ₂ ) _n NH ₂ , or -(CH ₂ ) _n COOH; wherein n is an integer in the range of from 1 to 3.

The conjugation reaction conditions are known to the person skilled in the art, typically the reaction takes place at 25 °C in DMSO, using commonly used peptide coupling agents (preferebaly HATU, PyAOP) in the presence of organic base (triethylamine, ethyldiisopropylamine). Reaction are usually completed within several minutes. The peptide is preferably selected from the group comprising oligopeptides of 3 to 20 aminoacids;

The protein is preferably selected from the group comprising antibodies, preferably monoclonal antibodies.

Another object of the present invention is a method of drug tracing, preferably of tracing of peptide-based or protein-based drugs, which comprises the following steps: i) providing a cell culture or a tissue to be analyzed, containing at least one conjugate defined above, wherein the peptide or the protein is of the peptide-based or protein-based drug to be traced; ii) hydrolyzing the cell culture or tissue from step i) using a strong acid, preferably non-oxidizing aq. HCl, obtaining a hydrolyzate; iii) qualitative and/or quantitative analysis of the hydrolyzate of step ii) for the presence of the coordination compound or of the coordination compound dimer according to the present invention, preferably using LC- MS.

Further object of the present invention is the in vitro use of the coordination compound or of the coordination compound dimer or of the conjugate according to the present invention in pharmacy, preferably for development and testing of new drugs, more preferably for drug marking and tracing.

Another object of the present invention is the use of the coordination compounds or of the coordination compound dimers according to the present invention in medical diagnostics, preferably as MRI contrast agents. Preferably, Gd ³⁺ coordination compounds or dimers shall be used as MRI contrast agents, as Gd has a very high relaxivity. The extremely high kinetic inertness of the coordination compounds (approximately WOx higher than for GdDOTA, a commonly used MRI contrast agent) allows for using even higher dosages and no free gadolinium, which itself is toxic for humans or animals, is released from the coordination compounds according to the present invention. The claimed coordination compounds are thus expected to be safe for use in human or animal beings.

Another object of the present invention is the use of the coordination compound or the coordination compound chain or the coordination compound dimer according to the present invention, wherein M is a radionuclide, preferably selected from the group comprising ⁴⁴ Sc, ⁴⁷ Sc, ⁶⁴ Cu, ⁶⁷ Cu, ⁸⁶ Y, ⁹⁰ Y, ¹⁴⁰ Nd, ¹⁴⁹ Pm, ¹⁵¹ Pm, ¹⁵³ Sm, ¹⁵⁹ Gd, 1 ⁴⁹ Tb, ¹⁶¹ Tb, ¹⁶⁵ Dy, ¹⁶¹ Ho, ¹⁶⁶ Ho, ¹⁶⁹ Er, ¹⁶⁷ Tm, ¹⁷⁵ Yb, ¹⁷⁷ Lu, in medicine as radiodiagnostic and/or radiopharmaceutic agents. Alternatively, a radionuclide may also be present in the side chain of the coordination compound such as a radioizotope of a halogen, e.g. R ¹ and/or R ⁵ may be ¹⁸ F.

The present invention is further demostrated by the following examples.

Examples

Example 1 : Synthesis of intermediates of alkyne pendant arms Synthesis of TD701 : Pear-shape glass flask (50 mL) was charged with (6-Bromopyridin-2- yl)methanol (2.47 g; 13. 1 mmol; 1.0 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (149 mg; 782 μmol; 6.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (225 mg; 321 μmol; 2.4 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (25 mL) through septum followed by addition of Ethynyltrimethylsilane (2.0 mL; 14.5 mmol; 1.1 equiv.) and TEA (5.5 mL; 39.5 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 3 h at RT. The mixture was then transferred to a separatory funnel with EtOAc (150 mL) and H ₂ O (100 mL). After shaking, the dark colored (and not entirely homogenous) organic layer was separated and the aqueous layer was further extracted with EtOAc (5 x 50 mL). Combined organic layers were filtered through cotton plug and the filtrate was further dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Resulting dark brown oily residue was purified on flash chromatography (330 g SiO ₂ . 100% DCM to 10% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as dark yellow oil. Yield: 2. 16 g (80%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 0.24 (CH ₃ , s, 9H); 4.52 (CH ₂ , d, 2H, ³ J _HH = 6); 5.48 (OH, t, 1H, ³ J _HH = 6); 7.39 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.46 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.80 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} δ _C -0.3 (CH ₃ , s); 63.9 (CH ₂ , s); 93.4 and 104.5 (C≡C; 2 x _s ); 120.2 (arom., s); 125.4 (arom., s); 137.2 (arom., s); 140.8 (arom., s); 162.7 (arom., s). ESI-HRMS: 206.0995 [M+H] ⁺ (theor. [C ₁₁ H ₁₆ N ₁ O ₁ Si ₁ ] ⁺ = 206.0996).

Synthesis of TD557: In a round-bottom glass flask (100 mL), TD701 (2. 16 g; 10.5 mmol; 1.0 equiv.) was dissolved in DCM (40 mL). Freshly prepared solution of SOCl ₂ (1.50 mL; 20.7 mmol; 2.0 equiv.) in DCM (10 mL) was then added and the open flask was stirred 1 h at RT. Dil. aq. solution of NaHCO ₃ (50 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved.

Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The brown residue (already pure according to ¹ H NMR) was purified on flash chromatography (330 g SiO ₂ , 60% P.E. in DCM to 20% P.E. in DCM) to remove the intensively colored impurities. Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residual nearly colorless oil was left in a freezer to solidify. Resulting solid was crushed and further dried on high vacuum overnight to give product in the form of free base as fine white powder. Yield: 2. 14 g (87%; 1 step; based on TD701). NMR (DMSO-d ₆ ): ¹ H δ _H 0.25 (CH ₃ , s, 9H); 4.76 (CH ₂ , s, 2H); 7.50 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.55 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.86 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} δ _C -0.4 (CH ₃ , s); 46.3 (CH ₂ , s); 94.3 and 103.8 (C≡C; 2 × s); 123.3 (arom., s); 126.7 (arom., s); 138.1 (arom., s); 141.5 (arom., s); 157.0 (arom., s). ESI-HRMS: 224.0657 [M+H] ⁺ (theor. [C ₁₁ H ₁₅ N ₁ Cl ₁ Si ₁ ] ⁺ = 224.0657).

Synthesis of TD558: In a pear-shaped glass flask (100 mL), TD557 (1.05 g; 4.69 mmol; 1.0 equiv.) was dissolved in MeCN (40 mL). Freshly prepared solution of KF (406 mg; 7.0 mmol; 1.5 equiv.) in H ₂ O (7 mL) was then added and the flask was vigorously stirred 2 h at RT. The mixture was concentrated to ~10 mL and then diluted with DCM (50 mL) and dil. aq. NaHCO ₃ (50 mL). The mixture was transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as pale yellow oil. Yield: 702 mg (99%; 1 step; based on TD557) NMR (DMSO-d ₆ ): ¹ H δ _H 4.37 (C≡CH, s, 1H); 4.76 (CH ₂ , s, 2H); 7.53 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.57 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.87 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} 46.3 (CH ₂ , s); 80.6 and 82.6 (C≡CH; 2 × s); 123.4 (arom., s); 126.8 (arom., s); 138.1 (arom., s); 141.3 (arom., s); 157.0 (arom., s). ESI-HRMS: 152.0262 [M+H] ⁺ (theor. [C ₈ H ₇ N ₁ Cl ₁ ] ⁺ = 152.0262). Synthesis of TD712: Pear-shape glass flask (10 mL) was charged with (6-Bromopyridin-2- yl)methanol (284 mg; 1.51 mmol; 1.0 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (14.5 mg; 76 μmol; 5.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (21 mg; 30 μmol; 2.0 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (4 mL) through septum followed by addition of Ethynyltriisopropylsilane (370 μL; 1.65 mmol; 1.1 equiv.) and TEA (630 μL; 4.52 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 16 h at RT. The mixture was then transferred to a separatory funnel with EtOAc (30 mL) and H ₂ O (30 mL). After shaking, the dark colored (and not entirely homogenous) organic layer was separated and the aqueous layer was further extracted with EtOAc (5 x 25 mL). Combined organic layers were filtered through cotton plug and the filtrate was further dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Resulting dark brown oily residue was purified on flash chromatography (120 g SiO ₂ , 100% DCM to 10% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 387 mg (89%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 0.92-1.26 (i-Pr, m, 21H); 4.53 (CH ₂ , d, 2H, ³ J _HH = 6); 5.48 (OH, t, 1H, ³ J _HH = 6); 7.40 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.47 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.80 (arom., t, 1H, ³ J _HH = 8). 1 ³ C{ ¹ H} δ _C 10.7 (i-Pr, s); 18.5 (i-Pr, s); 64.0 (CH ₂ , s); 89.4 and 106.6 (C≡C; 2 x s); 120.2 (arom., s); 125.8 (arom., s); 137.2 (arom., s); 140.9 (arom., s); 162.7 (arom., s). ESI-HRMS: 290.1932 [M+H] ⁺ (theor. [C ₁₇ H ₂₈ N ₁ O ₁ Si ₁ ] ⁺ = 290. 1935).

Synthesis of TD723: In a round-bottom glass flask (25 mL), TD712 (384 g; 1.33 mmol; 1.0 equiv.) was dissolved in DCM (5 mL). Freshly prepared solution of SOCI ₂ (200 μL; 2.75 mmol; 2. 1 equiv.) in DCM (1 mL) was then added and the open flask was stirred 1 h at RT. Dil. aq. solution of NaHCCO ₃ (10 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The brown residue (already pure according to ¹ H NMR) was purified on flash chromatography (120 g SiO ₂ , 20% DCM in P.E. to 30% DCM in P.E.) to remove the intensively colored impurities. Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residual colorless oil was further dried on high vacuum overnight to give product in the form of free base as colourless solid. Yield: 356 mg (87%; 1 step; based on TD712). NMR (DMSO-d ₆ ): ¹ H δ _H 0.91-1.28 (i-Pr, m, 21H); 4.78 (CH ₂ , s); 7.52 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.57 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.86 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 308.1593 [M+H] ⁺ (theor. [C ₁₇ H ₂₇ N ₁ Cl ₁ Si ₁ ] ⁺ = 308.1596). Synthesis of TD530: Pear-shape glass flask (50 mL) was charged with (6-Bromopyridin- 2-yl)methanol (1.00 g; 5.35 mmol; 1.0 equiv.), N-Boc-propargylamine (1.00 g; 6.44 mmol; 1.2 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (102 mg; 536 μmol; 10.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (187 mg; 266 μmol; 5.0 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (27 mL) through septum followed by addition of TEA (2.24 mL; 16. 1 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 18 h at RT. The mixture was then transferred to a separatory funnel with EtOAc (30 mL) and H ₂ O (50 mL). After shaking, the dark colored (and not entirely homogenous) organic layer was separated and the aqueous layer was further extracted with EtOAc (3 x 30 mL). Combined organic layers were fdtered through cotton plug and the filtrate was further dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Resulting dark brown oily residue was purified on flash chromatography (220 g SiO ₂ , 100% DCM to 100% EtOAc). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 610 mg (43%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 1.40 (CH ₃ , s, 9H); 3.99 (CH ₂ , d, 2H, ³ J _HH = 6); 4.51 (CH ₂ , d, 2H, ³ J _HH = 6); 5.47 (OH, t, 1H, ³ J _HH = 6); 7.32 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.40 (NH, t, 1H, ³ J _HH = 6); 7.44 (arom., dd, 1H, 3J _HH = 8; ⁴ J _HH = 1); 7.79 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} δ _C 28.2 (CH ₃ , s); 29.9 (CH ₂ , s); 64.0 (CH ₂ , s); 78.4 (C-CH ₃ , S); 81.3 and 86.9 (C=C; 2 * s); 119.8 (arom., s); 125.0 (arom., s); 137.2 (arom., s); 141.1 (arom., s); 155.3 (CO, s); 162.5 (arom., s). ESI-HRMS: 263.1390 [M+H] ⁺ (theor. [C ₁₄ H ₁₉ N ₂ O ₃ ] ⁺ = 263. 1390).

Synthesis of TD538: In a round-bottom glass flask (250 mL), TD530 (568 mg; 2.17 mmol; 1.0 equiv.) was dissolved in DCM (20 mL) followed by addition of TEA (900 μL; 6.46 mmol; 3.0 equiv.). Freshly prepared solution of MsCl (355 μL; 4.33 mmol; 2.0 equiv.) in DCM (5 mL) was then added. Resulting solution was stirred 20 min at RT. Mixture was then diluted with DCM (50 mL) followed by addition of dil. aq. solution of NaHCO ₃ (50 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 341.1 [M+H] ⁺ (theor. [C ₁₅ H ₂₁ N ₂ O ₅ S ₁ ] ⁺ = 341.1). All of TD538 obtained in this way was directly used for TD539 without further purification or characterization. Synthesis of TD1045: Pear-shaped glass flask (25 mL) was charged with (6-Bromopyridin- 2-yl)methanol (500 mg; 2.67 mmol; 1.0 equiv.), 1,1 -Dimethylpropargylamine (420 μL; 3.99 mmol; 1.5 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (21 mg; 110 μmol; 4.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (19 mg; 27 μmol; 1.0 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (10 mL) through septum followed by addition of TEA (1.10 mL; 7.89 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 18 h at RT. The mixture was filtered with syringe microfilter (PTFE) and the solid phase was further washed with MeCN. Filtrate was evaporated to dryness and the resulting dark brown solid residue was purified on flash chromatography (120 g SiO ₂ , 100% EtOAc to 40% EtOAc in MeOH). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow solidified oil. Yield: 283 mg (56%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 1.38 (CH ₃ , s, 6H); 3.17 (NH ₂ , s, 2H); 4.51 (CH ₂ , s, 2H); 5.44 (OH, bs, 1H); 7.26 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.40 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.76 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 191.1180 [M+H] ⁺ (theor. [C ₁₁ H ₁₅ N ₂ O ₁ ] ⁺ = 191.1180).

Synthesis of TD1048: Pear-shaped glass flask (25 mL) was charged with TD1045 (280 mg; 1.47 mmol; 1.0 equiv.) followed by addition of MeCN (10 mL) and solution of Boc ₂ O (2.0 M in dry THF; 1.0 mL; 2.00 mmol; 1.4 equiv.). The resulting mixture was stirred 16 h at RT. Mixture was then evaporated to dryness and the resulting yellow residue was purified on flash chromatography (120 g SiO ₂ . 100% DCM to 100% EtOAc). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless solid. Yield: 242 mg (57%; 1 step; based on TD1045) NMR (DMSO-d ₆ ): ¹ H δ _H 1.40 (CH ₃ , s, 9H), 1.53 (CH ₃ , s, 6H); 4.51 (CH ₂ , d, 2H, ³ J _HH = 4); 5.44 (OH, t, 1H, ³ J _HH = 4); 7. 12 (NH, bs, 1H); 7.25 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.41 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.77 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 291.1704 [M+H] ⁺ (theor. [C ₁₆ H ₂₃ N ₂ O ₃ ] ⁺ = 291.1703).

Synthesis of TD1050: In a glass vial (20 mL), TD1048 (19 mg; 65 μmol; 1.0 equiv.) was dissolved in DCM (3 mL) followed by addition of TEA (28 μL; 201 μmol; 3.1 equiv.). Freshly prepared solution of MsCl (10 μL; 129 μmol; 2.0 equiv.) in DCM (1 mL) was then added. Resulting solution was stirred 20 min at RT. Mixture was then diluted with DCM (15 mL) followed by addition of dil. aq. solution of NaHCO ₃ (15 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 20 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 369. 1 [M+H] ⁺ (theor. [C ₁₇ H ₂₅ N ₂ O ₅ S ₁ ] ⁺ = 369.1). All of TD1050 obtained in this way was directly used for TD1054 (and analogically for TD1105) without further purification or characterization.

Synthesis of TD966: Pear-shape glass flask (100 mL) was charged with (6-Bromopyridin-2-yl)methanol

(1.00 g; 5.35 mmol; 1.0 equiv.), N-Boc-4-ethynylpiperidine (1.23 g; 5.88 mmol; 1.1 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (41 mg; 215 μmol; 4.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (75 mg; 107 μmol; 2.0 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (40 mL) through septum followed by addition of TEA (2.20 mL; 15.7 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 2 d at RT. The mixture was then transferred to a separatory funnel with EtOAc (30 mL) and H ₂ O (50 mL). After shaking, the dark colored (and not entirely homogenous) organic layer was separated and the aqueous layer was further extracted with EtOAc (3 x 30 mL). Combined organic layers were filtered through cotton plug and the filtrate was further dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Resulting dark brown oily residue was purified on flash chromatography (220 g SiO ₂ , 100% DCM to 100% EtOAc). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 1.47 g (87%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 1.40 (CH ₃ , s, 9H); 1.44-1.57 (CH ₂ , m, 2H); 1.75-1.89 (CH ₂ , m, 2H); 2.87 (CH-C ≡C tt, 1H, ³ J _HH = 8, ³ J _HH = 4); 3.01-3. 17 (CH ₂ , m, 2H); 3.59-3.73 (CH ₂ , m, 2H); 4.51 (CH ₂ -O, d, 2H, ³ J _HH = 6); 5.44 (OH, t, 1H, ³ J _HH = 6); 7.32 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.41 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.76 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 317.1860 [M+H] ⁺ (theor. [C ₁₈ H ₂₅ N ₂ O ₃ ] ⁺ = 317.1860).

Synthesis of TD1117: In a glass vial (20 mL), TD952 (50.0 mg; 158 μmol; 1.0 equiv.) was dissolved in DCM (6 mL) followed by addition of TEA (66 μL; 473 μmol; 3.0 equiv.) and neat MsCl (25 μL; 323 μmol; 2.0 equiv.). Resulting solution was stirred 20 min at RT followed by addition of DCM (10 mL) dil. aq. solution of NaHCO ₃ (10 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 395.2 [M+H] ⁺ (theor. [C ₁₉ H ₂₇ N ₂ O ₅ S ₁ ] ⁺ = 395.2). All of TD1117 obtained in this way was directly used for TD1118 without further purification or characterization. Synthesis of TD936: Glass vial (4 mL) was charged with (6-Bromopyridin-2-yl)methanol (135 mg; 722 μmol; 1.0 equiv.), CuI (5.5 mg; 29 μmol; 4.0 mol%), [Pd(PPh ₃ ) ₂ Cl ₂ ] (10.0 mg; 14 μmol; 2.0 mol%) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added dry THF (3 mL) through septum followed by addition of phenylacetylene (95 μL; 865 μmol; 1.2 equiv.) and TEA (300 μL; 2. 15 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The vial was left stirring under septum (but without external argon) for 16 h at RT. The mixture was then filtered through syringe microfilter (PTFE) followed by washing with MeCN. Filtrate was evaporated to dryness, re-dissolved in MeCN (3 mL) and directly purified by preparative HPLC (C18; H ₂ O-MeCN gradient with TFA additive). Fractions containing product were neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in a mixture of DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (4 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residual solid was briefly dried on high vacuum to give product in the form of free base as a yellow oil. Yield: 141 mg (93%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): δ _H 4.57 (CH ₂ , d, 2H, ³ J _HH = 6); 5.50 (OH, t, 1H, ³ J _HH = 6); 7.42-7.54 (arom., Ph, m, 2+3H); 7.57-7.64 (Ph, m, 2H); 7.85 (arom., t, 1H, ³ J _HH = 8). ESI- HRMS: 210.0913 [M+H] ⁺ (theor. [C ₁₄ H ₁₂ N ₁ O ₁ ] ⁺ = 210.0913).

Synthesis of TD939: In a glass vial (20 mL), TD936 (22 mg; 105 μmol; 1.0 equiv.) was dissolved in DCM (6 mL) followed by addition of TEA (44 μL; 316 μmol; 3.0 equiv.). and neat MsCl (16 μL; 207 μmol; 2.0 equiv.). Resulting solution was stirred 20 min at RT followed by addition of dil. aq. solution of NaHCO ₃ (5 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 288. 1 [M+H] ⁺ (theor. [C ₁₅ H ₁₄ N ₁ O ₃ S ₁ ] ⁺ = 288.1). All of TD939 obtained in this way was directly used for TD944 without further purification or characterization.

Synthesis of TD937: Glass vial (4 mL) was charged with (6-Bromopyridin-2-yl)methanol (135 mg; 722 μmol; 1.0 equiv.), CuI (5.5 mg; 29 μmol; 4.0 mol%), [Pd(PPh ₃ ) ₂ Cl ₂ ] (10.0 mg; 14 μmol; 2.0 mol%) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added dry THF (3 mL) through septum followed by addition of Cyclopropylacetylene (75 μL; 886 μmol; 1.2 equiv.) and TEA (300 μL; 2. 15 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The vial was left stirring under septum (but without external argon) for 16 h at RT. The mixture was then filtered through syringe microfilter (PTFE) followed by washing with MeCN. Filtrate was evaporated to dryness, re-dissolved in MeCN (3 mL) and directly purified by preparative HPLC (C18; H ₂ O-MeCN gradient with TFA additive). Fractions containing product were neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in a mixture of DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (4 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residual solid was briefly dried on high vacuum to give product in the form of free base as a yellow oil. Yield: 98 mg (78%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 0.69-0.83 (CH ₂ -CH. m, 2H); 0.83-0.99 (CH ₂ -CH. m, 2H); 1.56 (CH, tt, ³ J _HH = 8, ³ J _HH = 5); 4.49 (CH ₂ , d, 2H, ³ J _HH = 6); 5.42 (OH, t, 1H, ³ J _HH = 6); 7.27 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.38 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.74 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 174.0913 [M+H] ⁺ (theor. [C ₁₁ H ₁₂ N ₁ O ₁ ] ⁺ = 174.0913).

Synthesis of TD940: In a glass vial (20 mL), TD937 (26 mg; 150 μmol; 1.0 equiv.) was dissolved in DCM (9 mL) followed by addition of TEA (63 μL; 452 μmol; 3.0 equiv.) and neat MsCl (23 μL; 297 μmol; 2.0 equiv.). Resulting solution was stirred 20 min at RT followed by addition of dil. aq. solution of NaHCO ₃ (5 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 252.0 [M+H] ⁺ (theor. [C ₁₂ H ₁₄ N ₁ O ₃ S ₁ ] ⁺ = 252.1). All of TD940 obtained in this way was directly used for TD943 without further purification or characterization.

Synthesis of TD952: Glass vial (4 mL) was charged with (6-Bromopyridin-2-yl)methanol (150 mg; 802 μmol; 1.0 equiv.), CuI (6.1 mg; 32 μmol; 4.0 mol%), [Pd(PPh ₃ ) ₂ Cl ₂ ] (11.5 mg; 16 μmol; 2.0 mol%) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added dry THF (3 mL) through septum followed by addition of tert- butylacetylene (200 μL; 1.62 mmol; 2.0 equiv.) and TEA (340 μL; 2.44 mmol; 3.0 equiv.) after which the mixture changed color to dark brown. The vial was left stirring under septum (but without external argon) for 24 h at RT. The mixture was then fdtered through syringe microfdter (PTFE) followed by washing with MeCN. Filtrate was evaporated to dryness, re-dissolved in MeCN (3 mL) and directly purified by preparative HPLC (C18; H ₂ O-MeCN gradient with TFA additive). Fractions containing product were neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in a mixture of DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (4 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residual solid was briefly dried on high vacuum to give product in the form of free base as a yellow oil. Yield: 146 mg (96%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 1.30 (CH... s, 9H); 4.51 (CH. d, 2H, 3J _HH = 6); 5.43 (OH, t, 1H, ³ J _HH = 6); 7.26 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.39 (arom., dd, 1H, ³ J _HH = 8, 4J _HH 1); 7.74 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 190.1227 [M+H] ⁺ (theor. [C ₁₂ H ₁₆ N ₁ O ₁ ] ⁺ = 190.1226).

Synthesis of TD956: In a glass vial (20 mL), TD952 (8 mg; 42 μmol; 1.0 equiv.) was dissolved in DCM (3 mL) followed by addition of TEA (18 μL; 129 μmol; 3.0 equiv.) and neat MsCl (6.5 μL: 84 μmol; 2.0 equiv.). Resulting solution was stirred 20 min at RT followed by addition of DCM (5 mL) dil. aq. solution of NaHCO ₃ (5 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 x 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , fdtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 268.1 [M+H] ⁺ (theor. [C ₁₃ H ₁₈ N ₁ O ₃ S ₁ ] ⁺ = 268.1). All of TD956 obtained in this way was directly used for TD959 without further purification or characterization.

Synthesis of TD965: Glass vial (4 mL) was charged with (6-Bromopyridin-2-yl)methanol (53 mg; 283 μmol; 1.0 equiv.), 7-Ethynyladamantane (50 mg; 312 μmol; 1.1 equiv.), CuI (2.7 mg; 14 μmol; 5.0 mol%), [Pd(PPh ₃ ) ₂ Cl ₂ ] (5.0 mg; 7 μmol; 2.5 mol%) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added dry THF (1.5 mL) through septum followed by addition of TEA (120 μL; 861 μmol; 3.0 equiv.) after which the mixture changed color to dark brown. The vial was left stirring under septum

(but without external argon) for 2 d at RT. The mixture was then filtered through syringe microfilter (PTFE) followed by washing with MeCN. Filtrate was evaporated to dryness, re-dissolved in MeCN (3 mL) and directly purified by preparative HPLC (C18; H ₂ O-MeCN gradient with TFA additive). Fractions containing product were neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in a mixture of DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (4 x 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ . filtered through glass frit (S3) and evaporated to dryness. The residual solid was briefly dried on high vacuum to give product in the form of free base as a colourless oil. Yield: 67 mg (89%; 1 step; based on (6-Bromopyridin-2-yl)methanol). NMR (DMSO-d ₆ ): ¹ H δ _H 1.61-1.76 (Adm., m, 6H); 1.82-1.93 (Adm., m, 6H); 1.94-2.00 (Adm., m, 3H); 4.50 (CH ₂ , d, 2H, ³ J _HH = 6); 5.43 (OH, t, 1H, ³ J _HH = 6); 7.25 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.38 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.74 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 268. 1694 [M+H] ⁺ (theor. [C ₁₈ H ₂₂ N ₁ O ₁ ] ⁺ = 268. 1696). Synthesis of TD990: In a glass vial (20 mL), TD965 (21 mg; 79 μmol; 1.0 equiv.) was dissolved in DCM (3 mL) followed by addition of TEA (33 μL; 237 μmol; 3.0 equiv.) and neat MsCl (12 μL; 155 μmol; 2.0 equiv.). Resulting solution was stirred 20 min at RT followed by addition of DCM (10 mL) dil. aq. solution of NaHCO ₃ (10 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 15 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , fdtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 346.1 [M+H] ⁺ (theor. [C ₁₉ H ₂₄ N ₁ O ₃ S ₁ ] ⁺ = 346.1). All of TD990 obtained in this way was directly used for TD992 without further purification or characterization.

Synthesis of TD1194: In a glass vial (4 mL), TD558 (110 mg; 726 μmol; 1.0 equiv.) was dissolved in MeCN (3.3 mL) followed by addition of NIS (180 mg; 800 μmol; 1.1 equiv.) and AcOH (50 μL; 875 μmol; 1.2 equiv.) and the resulting mixture was stirred 3 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O-MeCN gradient with FA additive). Fractions containing product were joined and diluted with DCM (50 mL). The resulting biphasic mixture was transferred to a separatory funnel followed by addition of dil. aq. NaHCO ₃ and aq. Na ₂ S ₃ O ₃ . After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was briefly dried on high vacuum to give product in the form of free base as a pale red solid. Yield: 61.5 mg (31%; 1 step; based on TD558) NMR (DMSO-d ₆ ): ¹ H δ _H 4.74 (CH ₂ , s, 2H); 7.48 (arom., dd, 1H, 3J _HH = 8, ⁴ J _HH = 1); 7.54 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 277.9230 [M+H] ⁺ (theor. [C ₈ H ₆ N ₁ I ₁ Cl ₁ ] ⁺ = 277.9228).

Synthesis of TD1178: Glass vial (20 mL) was charged with CuI (60.0 mg; 315 μmol; 40 mol%), Phen (114 mg; 633 μmol; 80.0 mol%), KHCO ₃ (159 mg; 1.59 mmol; 2.0 equiv.) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added solution of TD558 (120 mg; 792 μmol; 1.0 equiv.) and Togni I (288 mg; 872 μmol; 1.1 equiv.) in dry DCM (8 mL) through septum and the resulting mixture was stirred 2 d at RT. Mixture was then filtered through syringe microfilter (PTFE) and the solid phase was further washed with DCM. Filtrate was evaporated to dryness and the residue was resuspended in MeCN (3 mL). Mixture was again filtered through syringe microfilter (PTFE) and the filtrate was purified by preparative HPLC (C18; H ₂ O-McCN gradient with FA additive). Fractions containing product were joined and diluted with DCM (50 mL). The resulting biphasic mixture was transferred to a separatory funnel followed by addition of dil. aq. NaHCO ₃ . After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The resulting yellow oil was briefly dried on high vacuum (until the oil crystallized) to give product in the form of free base as pale yellow solid (portion of the product sublimed as colourless crystals on the upper part of the flask). Yield: 48.5 mg (28%; 1 step; based on TD558) NMR (DMSO-d ₆ ): ¹ H δ _H 4.83 (CH ₂ , s, 2H); 7.78 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.04 (arom., t, 1H, ³ J _HH = 8). 1 ⁹ F{ ¹ H} δ _F -49.2 (s). ESI-HRMS: 220.0140 [M+H] ⁺ (theor. [C ₉ H ₆ N ₁ F ₃ Cl ₁ ] ⁺ = 220.0135).

Synthesis of TD797: In a round-bottom glass flask (50 mL), Methyl 4,6- dibromopicolinate (200 mg; 678 μmol; 1.0 equiv.) was dissolved in a mixture of THF (4 mL) and MeOH (2 mL). To the resulting slightly yellow solution was added portion wise

(over course of 10 min, with no stopper on the flask) solid NaBH ₄ (205 mg; 5.42 mmol; 8.0 equiv.) during which hydrogen gas evolved intensively and the color of the mixture changed to nearly colorless. Mixture was then transferred to a separatory funnel and diluted with DCM (100 mL) and H ₂ O (100 mL). After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as white solid. Yield: 179 mg (99%; 1 step; based on Methyl 4,6-dibromopicolinate). NMR (DMSO-d ₆ ): ¹ H δ _H 4.53 (CH ₂ , s, 2H); 5.68 (OH, bs, 1H); 7.67 (arom., m, 1H); 7.89 (arom., m, 1H). ESI-HRMS: 265.8809 [M+H] ⁺ (theor. [C ₆ H ₆ N ₁ O ₁ Br ₂ ] ⁺ = 265.8811).

Synthesis of TD804: Glass vial (4 mL) was charged with TD797 (100 mg; 375 μmol; 1.0 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI (4.3 mg; 23 μmol; 6.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (8.0 mg; 11 μmol; 3.0 mol%) were subsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (1.5 mL) through septum followed by addition of Ethynyltrimethylsilane (160 μL; 1.16 mmol; 3.1 equiv.) and TEA (160 μL; 1.15 mmol; 3.1 equiv.) after which the mixture changed color to dark brown. The flask was left stirring under septum (but without external argon) for 16 h at RT. The mixture was then transferred to a separatory funnel with EtOAc (50 mL) and H ₂ O (50 mL). After shaking, the dark colored organic layer was separated and the aqueous layer was further extracted with EtOAc (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Resulting dark brown oily residue was purified on flash chromatography (120 g SiO ₂ . 100% DCM to 20% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as dark brown oil. Yield: 99 mg (88%; 1 step; based on TD797). NMR (DMSO-d ₆ ): ¹ H δ _H 0.24 (CH ₃ , s, 9H); 0.25 (CH ₃ , s, 9H); 4.51 (CH ₂ , d, 2H, ³ J _HH = 6); 5.53 (OH, t, 1H, ³ J _HH = 6); 7.40 (arom., d, 1H, ⁴ J _HH 2); 7.42 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 302.1389 [M+H] ⁺ (theor. [C ₁₆ H ₂₄ N ₁ O ₁ Si ₂ ] ⁺ = 302.1391).

Synthesis of TD806: In a pear-shaped glass flask (50 mL), TD804 (98 mg; 325 μmol; 1.0 equiv.) was dissolved in DCM (3 mL). Freshly prepared solution of SOCl ₂ (47 μL; 647 μmol; 2.0 equiv.) in DCM (1 mL) was then added and the open flask was stirred 1 h at RT. Reaction mixture was diluted with DCM (16 mL) and dil. aq. solution of NaHCO ₃ (20 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 20 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as brown oil. Yield: 102 mg (98%; 1 step; based on TD804) NMR (DMSO-d ₆ ): ¹ H δ _H 0.25 (CH ₃ , s, 18H); 4.74 (CH ₂ , s, 2H); 7.53 (arom., d, 1H, ⁴ J _HH 2); 7.60 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 320.1051 [M+H] ⁺ (theor. [C ₁₆ H ₂₃ N ₁ O ₁ Cl ₁ Si ₂ ] ⁺ = 320. 1052).

Synthesis of TD807: In a round-bottom glass flask (50 mL), TD806 (101 mg; 316 μmol; 1.0 equiv.) was dissolved in MeCN (5 mL). Freshly prepared solution of KF (46.4 mg; 800 μmol; 2.5 equiv.) in H ₂ O (800 μL) was then added and the flask was stirred 5 h at RT. The mixture was concentrated to ~1 ml and diluted with DCM (50 mL) and dil. aq. NaHCO ₃ (50 mL). The mixture was transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , fdtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as brown solid. Yield: 48 mg (87%; 1 step; based on TD806) NMR (DMSO-d ₆ ): ¹ H δ _H 4.48 (C≡CH, s, 1H); 4.75 (C≡CH, s, 1H); 4.76 (CH ₂ , s, 2H); 7.61 (arom., d, 1H, ⁴ J _HH = 1); 7.65 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 176.0267 [M+H] ⁺ (theor. [C ₁₀ H ₇ N ₁ Cl ₁ ] ⁺ = 176.0267).

Synthesis of TD662: In a glass vial (4 mL), Dipropargylamine (116 μL; 1.12 mmol; 1.0 equiv.) was dissolved in MeCN (2.5 mL) followed by addition of neat 1,2-Dibromoethane (965 μL; 11.2 mmol; 10 equiv.) and NaHCO ₃ (113 mg; 1.35 mmol; 1.2 equiv.) and the resulting mixture was stirred 2 days at 80 °C. Mixture was then diluted with DCM (50 mL) followed by addition of dil. aq. solution of NaHCO ₃ (50 mL). The resulting biphasic mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was further purified by column chromatography (SiO2; 25 g; DCM). Combined fractions with product were evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 69 mg (31%; 1 step; based on Dipropargylamine). NMR (DMSO-d ₆ ): ¹ H δ _H 2.86 (CH ₂ , t, 2H, ³ J _HH = 7); 3.21 (C≡CH, t, 2H, ⁴ J _HH = 2); 3.21 (CH ₂ , t, 4H, ⁴ J _HH = 2); 3.55 (CH ₂ , t, 2H, ³ J _HH = 7). ¹³ C{ ¹ H} δ _C 30.3 (CH ₂ , s); 41.6 (CH ₂ , s); 53.9 (CH ₂ , s); 76.4 and 78.5 (C≡CH, 2 x s). ESI-HRMS: 200.0070 [M+H] ⁺ (theor. [C ₈ H ₁₁ N ₁ Br ₁ ] ⁺ = 200.0070).

Example 2: Synthesis of intermediates of azide pendant arms

Synthesis of TD406: In aa round-bottom glass flask (250 mL), 2,6- Bis(chloromethyl)pyridine (6. 17 g; 35.0 mmol; 1.2 equiv.) was dissolved in MeCN (80 mL) followed by addition of solid NaN ₃ (1.90 g; 29.2 mmol; 1.0 equiv.) and anhydrous K ₂ CO ₃ (4.04 g; 29.2 mmol; 1.0 equiv.) and the resulting suspension was stirred 5 days at 50 °C. The mixture was filtered on glass frit S3 and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and the orange oily residue was purified by column chromatography (SiO ₂ , 30% P.E. in DCM to 100% DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as faint yellow oil. Yield: 2.62 g (49%; 1 step; based on NaN ₃ ). Recovery: 2.21 g of 2,6-Bis(chloromethyl)pyridine (36% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 4.53 (CH ₂ , s, 2H); 4.78 (CH ₂ , s, 2H); 7.40 (arom., d, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.52 (arom., d, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.89 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} δ _C 46.6 (CH ₂ , s); 54.2 (CH ₂ , s); 121.9 (arom., s); 122.6 (arom., s); 138.5 (arom., s); 155.7 (arom., s); 156.3 (arom., s). ESI-HRMS: 183.0433 [M+H] ⁺ (theor. [C ₇ H ₈ N ₄ Cl ₁ ] ⁺ = 183.0432).

Synthesis of TD595: In a glass vial (20 mL), TD406 (30 mg; 162 μmol; 1.0 equiv.) was dissolved in DCM (5 mL) followed by addition of freshly prepared solution of MCPBA (77%; 72 mg; 320 μmol; 2.0 equiv.) in DCM (1 mL). The resulting solution was stirred 3 h at RT. Mixture was then diluted with DCM (20 mL) and dil. aq. NaHCO ₃ (25 mL) and transferred to a separatory funnel. After shaking, the bottom layer was separated and aqueous layer was further extracted with DCM (3 x 20 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. ESI-MS (LC-MS): 199.0 [M+H] ⁺ (theor. [C ₇ H ₈ N ₄ O ₁ Cl ₁ ] ⁺ = 199.0). All of TD595 obtained in this way was directly used for TD596 without further purification or characterization.

Synthesis of TD726: In a round-bottom glass flask (1000 mL), Dimethyl 4- chloropyridine-2,6-dicarboxylate (15.0 g; 65.3 mmol; 1.0 equiv.) was gradually dissolved in a mixture of THF (540 mL) and MeOH (120 mL). The resulting slightly yellow solution was cooled with an ice bath (~5 °C) followed by portion wise additions (over course of 1 h, with no stopper on the flask) of solid NaBH ₄ (12.4 g; 328 mmol; 5.0 equiv.) during which hydrogen gas evolved intensively and the color of the mixture changed to red, orange and eventually yellow. After the addition, the flask was allowed to warm up to RT and was further stirred 16 h at RT. Resulting faint yellow opalescent solution was filtered on glass frit (S3), the filtrate was evaporated to dryness and further co-evaporated with DCM (as a suspension). Residue was dissolved in boiling H ₂ O (~600 mL) and the resulting highly alkaline solution was continuously extracted by DCM overnight. The organic layer (containing partly crystallized product) was evaporated to dryness. The residue was mechanically crushed and further dried on high vacuum (till constant mass) to give product in the form of free base as nearly colorless microcrystalline powder. Yield: 10.84 g (96%; 1 step; based on Dimethyl 4-chloropyridine-2,6-dicarboxylate). NMR (DMSO-d ₆ ): ¹ H δ _H 4.53 (CH ₂ , d, 4H, ³ J _HH = 6); 5.54 (OH, t, 2H, ³ J _HH = 6); 7.36 (arom., s, 2H). ¹³ C{ ¹ H} δ _C 63.7 (CH ₂ , s); 118.0 (arom., s); 144.0 (arom., s); 163.5 (arom., s). ESI-HRMS: 174.0317 [M+H] ⁺ (theor. [C ₇ H ₉ N ₁ O ₂ Cl ₁ ] ⁺ = 174.0316). EA (C ₇ H ₈ N ₁ O ₂ Cl ₁ , M _R = 173.6): C 48.4 (48.5); H 4.7 (4.5); N 7.7 (8. 1); Cl 20.4 (21.2).

Synthesis of TD759: In a round-bottom glass flask (100 mL), TD726 (626 mg; 3.61 mmol; 1.0 equiv.) was suspended in DCM (20 mL). Freshly prepared solution of SOCI ₂ (780 μL; 10.7 mmol; 3.0 equiv.) in DCM (10 mL) was then added and the open flask was stirred 90 min at RT, producing clear solution. Dil. aq. solution of NaHCO ₃ (40 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The resulting crystalized residue was crushed and further dried on high vacuum overnight to give product in the form of free base as nearly colorless microcrystalline powder. Yield: 711 mg (94%; 1 step; based on TD726). NMR (DMSO-d ₆ ): 1H δ _H 4.79 (CH ₂ , s, 4H); 7.70 (arom., s, 2H). ¹³ C{ ¹ H} δ _C 45.7 (CH ₂ , s); 122.8 (arom., s); 144.4 (arom., s); 158.2 (arom., s). ESI-HRMS: 209.9638 [M+H] ⁺ (theor. [C ₇ H ₇ N ₁ Cl ₃ ] ⁺ = 209.9639).

Synthesis of TD760: In a glass vial (20 mL), TD759 (708 mg; 3.36 mmol; 1.3 equiv.) was dissolved in MeCN (20 mL) followed by addition of solid NaN ₃ (168 mg; 2.58 mmol; 1.0 equiv.) and dried K ₂ CO ₃ (360 mg; 2.61 mmol; 1.0 equiv.) and the resulting suspension was stirred 24 h at 80 °C. The mixture was filtered on through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and yellow oily residue was purified by column chromatography (SiO ₂ , 40% P.E. in DCM to 10% P.E. in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum 1 h to give product in the form of free base as faint yellow oil. Yield: 323 mg (58%; 1 step; based on NaN ₃ ). Recovery: 218 mg of TD759 (31% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 4.56 (CH ₂ , s, 2H); 4.78 (CH ₂ , s, 2H); 7.58 (arom., d, 1H, ⁴ J _HH = 2); 7.69 (arom., d, 1H, ⁴ J _HH = 8). ¹³ C{ ¹ H} δ _C 45.8 (CH ₂ , s); 53.6 (CH ₂ , s); 121.9 (arom., s); 122.5 (arom., s); 144.4 (arom., s); 157.9 (arom., s); 158.2 (arom., s). ESI-HRMS: 217.0040 [M+H] ⁺ (theor. [C ₇ H ₇ N ₄ Cl ₂ ] ⁺ = 217.0042).

Synthesis of TD1146: In a glass vial (20 mL), TD726 (495 mg; 2.85 mmol; 1.0 equiv.) was dissolved in DMF (11.0 mL; 143 mmol; 50 equiv.) followed by addition of freshly ground KOH (1.6 g; 28.5 mmol; 10 equiv.). The resulting suspension was stirred 3 days at 100 °C in the presence of air (vial septum was punctured by two thick needles). The mixture was then filtered through syringe microfilter (PTFE; the solids were washed with

DMF). Filtrate was evaporated to dryness and purified by preparative HPLC (C18; H ₂ O-MeCN gradient with TFA additive). Fractions with product were combined and directly lyophilized to give product in the form of trifluoroacetate salt as white foam. Yield: 187 mg (22%; 1 step; based on TD726). NMR (DMSO-d ₆ ): ¹ H δ _H 3.18 (CH ₃ , s, 6H); 4.59 (CH ₂ , d, 4H, ³ J _HH = 6); 5.91 (OH, t, 2H, ³ J _HH = 6); 6.84 (arom., s, 2H). ESI-HRMS: 183.1128 [M+H] ⁺ (theor. [C ₉ H ₁₅ N ₂ O ₂ ] ⁺ = 183.1128). EA (C ₉ H ₁₄ N ₂ O ₂ · 1.0TFA, M _R = 296.2): C 44.6 (44.1); H 5.1 (4.9); N 9.5 (9. 1); F 19.2 (18.2).

Synthesis of TD1154: In a round-bottom glass flask (100 mL), TD1146 1.0TFA (173.3 mg; 585 μmol; 1.0 equiv.) was suspended in DCM (17 mL) followed by addition of neat SOCI ₂ (780 μL; 2.34 mmol; 4.0 equiv.). The resulting mixture was stirred 90 min at RT, producing clear solution. Dil. aq. solution of NaHCO ₃ (20 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , fdtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as white solid. Yield: 105.6 mg (82%; 1 step; based on TD726) NMR (DMSO-d ₆ ): ¹ H δ _H 2.98 (CH ₃ , s, 6H); 4.60 (CH ₂ , s, 4H); 6.73 (arom., s, 2H). ESI-HRMS: 219.0450 [M+H] ⁺ (theor. [C ₉ H ₁₃ N ₂ Cl ₂ ] ⁺ = 219.0450).

Synthesis of TD1163: In a glass vial (20 mL), TD1154 (103.9 mg; 474 μmol; 1.3 equiv.) was dissolved in MeCN (7 mL) followed by addition of solid NaN ₃ (23.7 mg; 365 μmol; 1.0 equiv.) and dried K ₂ CO ₃ (50.3 mg; 364 μmol; 1.0 equiv.) and the resulting suspension was stirred 24 h at 70 °C. The mixture was fdtered on through syringe microfdter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and the residue was purified by column chromatography (SiO ₂ , 5% EtOAc in DCM to 10% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum 1 h to give product in the form of free base as colourless oil. Yield: 33.8 mg (41%; 1 step; based on NaN ₃ ). Recovery: 11.0 mg of TD1154 (11% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 2.99 (CH ₃ , s, 6H); 4.32 (CH ₂ , s, 2H); 4.60 (CH ₂ , s, 2H); 6.60 (arom., d, 1H, ⁴ J _HH = 2); 6.73 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 226.0853 [M+H] ⁺ (theor. [C ₉ H ₁₃ N ₅ Cl ₁ ] ⁺ = 226.0854).

Synthesis of TD1024: Glass vial (100 mL) was charged with CuI (70 mg; 0.37 mmol; 4.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (125 mg; 0.18 mmol; 2.0 mol%) and magnetic stirrer and three times secured with argon. Solution of Dimethyl 4- iodopyridine-2,6-dicarboxylate (2.93 g; 9.13 mmol; 1.0 equiv.) in mixture of dry THF (40 ml), dry Toluene (40 ml) and dry DMF (2 mL) was subsequently added through septum followed by addition of Ethynyltriisopropylsilane (2.25 mL; 10.0 mmol; 1.1 equiv.) and TEA (3.80 mL; 27.3 mmol; 3.0 equiv.) after which the mixture changed color to pale red. The flask was left stirring under septum (but without external argon) for 20 h at RT. The resulting dark mixture was filtered through syringe microfilter (PTFE) and the filtrate was evaporated to dryness. Residue was dissolved in DCM (250 mL) and the resulting red solution was washed once with aq. solution of Na ₂ S ₂ O ₃ . The organic layer was separated, dried with Na ₂ SO ₄ . filtered through glass frit (S3) and evaporated to dryness. Residue was purified on flash chromatography (220 g SiO ₂ , 100% DCM to 20% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give pre-purified product in the form of free base as orange oil. Yield: 3.16 g (92%; 1 step; based on Dimethyl 4-iodopyridine-2,6-dicarboxylate). NMR (DMSO-d ₆ ): ¹ H δ _H 0.92-1.27 (i-Pr, m, 21H); 3.92 (CH ₃ , s, 6H); 8.16 (arom., s, 2H). ¹³ C{ ¹ H} δc 10.6 (i-Pr, s); 18.4 (i-Pr, s); 52.9 (CH ₃ , s); 99.0 (C≡C- Si, s); 102.5 (C≡C-arom.; s); 129.3 (arom., s); 132.7 (arom., s); 148.4 (arom., s); 164.0 (CO, s). ESI-HRMS: 376.1939 [M+H] ⁺ (theor. [C ₂₀ H ₃₀ N ₁ O ₄ Si ₁ ] ⁺ = 376.1939).

Synthesis of TD808: In a round-bottom glass flask (250 mL), TD1024 (3.15 g; 8.39 mmol; 1.0 equiv.) was dissolved in a mixture of THF (60 mL) and MeOH (30 mL). Then, solid NaBH ₄ (2.55 g; 67.4 mmol; 8 equiv.) was added portion wise over the course of 1 h (during which hydrogen gas evolved intensively) and the color of the mixture changed to dark red. After the addition, the flask was further stirred 1 h at RT. The mixture was evaporated to dryness. Residue was resuspended in DCM (200 mL) and H ₂ O (200 mL) and transferred to a separatory funnel. After shaking, the bottom phase (as a suspension) was separated. Aqueous phase was further extracted with DCM (3 x 100 mL). Combined organic layers were diluted with EtOAc (500 mL). The resulting brown solution was then dried with anhydrous Na ₂ SO ₄ . filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as pale brown solid. Yield: 2.61 g (97%; 1 step; based on TD1024). NMR (DMSO-d ₆ ): ¹ H δ _H 1.04-1.17 (i-Pr, m, 21H); 4.51 (CH ₂ , d, 4H, ³ J _HH = 6); 5.48 (OH, t, 2H, ³ J _HH = 6); 7.31 (arom., s, 2H). 1 ³ C{ ¹ H} δ _C 10.6 (i-Pr, s); 18.5 (i-Pr, s); 63.9 (CH ₂ , s); 94.6 (C≡C-Si, s); 105.1 (C≡C-arom.: s); 119.8 (arom., s); 130.8 (arom., s); 161.9 (arom., s). ESI-HRMS: 320.2036 [M+H] ⁺ (theor. [C ₁₈ H ₃₀ N ₁ O ₂ ] ⁺ = 320.2040).

Synthesis of TD815: In a round-bottom glass flask (250 mL), pre-purified TD808 (2.61 g; 8.17 mmol; 1.0 equiv.) was suspended in DCM (100 mL). Freshly prepared solution of SOCl ₂ (1.80 mL; 24.8 mmol; 3.0 equiv.) inDCM (10 mL) was then added and the open flask was stirred 1 h at RT. Dil. aq. solution of NaHCO ₃ (100 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 x 75 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 2.87 g (99%; 1 step; based on TD808) NMR (DMSO-d ₆ ): ¹ H δ _H 0.97-1.20 (i-Pr, m, 21H); 4.78 (CH ₂ , s, 4H); 7.59 (arom., s, 2H). ¹³ C{ ¹ H} δ _C 10.6 (i-Pr, s); 18.4 (i-Pr, s); 45.9 (CH ₂ , s); 96.6 (C≡C-Si, s); 103.5 (C≡C-arom.: s); 124.6 (arom., s); 132.0 (arom., s); 157.1 (arom., s). ESI-HRMS: 356.1368 [M+H] ⁺ (theor. [C ₁₈ H ₂₈ N ₁ Cl ₂ Si ₁ ] ⁺ = 356.1368).

Synthesis of TD817: In a round-bottom glass flask (250 mL), TD815 (2.86 g; 8.02 mmol; 1.2 equiv.) was dissolved in MeCN (130 mL) followed by addition of solid NaN ₃ (435 mg; 6.69 mmol; 1.0 equiv.) and dried K ₂ CO ₃ (920 mg; 6.67 mmol; 1.0 equiv.) and the resulting suspension was stirred 16 h at 80 °C. The mixture was filtered through syringe microfilter (PTFE) and the solid residue was washed with

MeCN. Filtrate was evaporated to dryness and orange oily residue was purified by column chromatography (220 g SiO ₂ . 30% P.E. in DCM to 10% P.E. in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum 1 h to give product in the form of free base as faint yellow oil. Yield: 1.23 g (51%; 1 step; based on NaN ₃ ). Recovery: 709 mg of TD815 (25% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 1.01-1.21 (i-Pr, m, 21H); 4.55 (CH ₂ , s, 2H); 4.78 (CH ₂ , s, 2H); 7.47 (arom., d, 1H, ⁴ J _HH = 1); 7.58 (arom., d, 1H, ⁴ J _HH = 1). ¹³ C{ ¹ H} δ _C 10.6 (i-Pr, s); 18.4 (i-Pr, s); 46.0 (CH ₂ , s); 53.7 (CH ₂ , S); 96.5 (C≡C-Si, s); 103.7 (C≡C-arom.: s); 123.7 (arom., s); 124.3 (arom., s); 131.8 (arom., s); 156.6 (arom.. s); 157.1 (arom., s). ESI-HRMS: 363.1763 [M+H] ⁺ (theor. [C ₁₈ H ₂₈ N ₄ Cl ₁ Si ₁ ] ⁺ = 363. 1766). Synthesis of TD1052: In a glass vial (20 mL), Dimethyl 4-iodopyridine-2,6- dicarboxylate (500 mg; 1.56 mmol; 1.0 equiv.), CuI (600 mg; 3.15 mmol, 2.0 equiv.) and [(dppf)PdCl ₂ ] (7.0 mg, 10 μmol; 0.6 mol%) were dissolved in dry DMF (8 mL) followed by addition of Methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (600 mg; 3.12 mmol; 2.0 equiv.) in dry DMF (2 mL). The resulting dark mixture was stirred 16 h at

100 °C. After cooling down, the mixture was diluted with DCM (10 mL) and filtered through syringe microfilter (PTFE). The solids were further washed with DCM. Filtrate was further diluted with DCM (50 mL) and washed with dil. aq. NaHCO ₃ (5 x 25 mL). Organic layer was dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified by column chromatography (120 g SiO ₂ , 100 % DCM to 15% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless solid. Yield: 366 mg (89%; 1 step; based on Dimethyl 4-iodopyridine-2,6-dicarboxylate). NMR (DMSO-d ₆ ): ¹ H δ _H 3.97 (CH ₃ , s, 6H); 8.49 (arom., q, 2H, ⁴ J _HF = 1). { ¹ H} δ _F -63.4 (s). ESI-HRMS: 264.0480 [M+H] ⁺ (theor. [C ₁₀ H ₉ N ₁ O ₄ F ₃ ] ⁺ = 264.0478).

Synthesis of TD1053: In a round-bottom glass flask (100 mL), TD1052 (365 mg; 1.39 mmol; 1.0 equiv.) was dissolved in a mixture of MeOH (5 mL) and THF (10 mL). The resulting colourless solution was cooled with an ice bath (~5 °C) followed by portion wise additions (over course of 30 min, with no stopper on the flask) of solid NaBFL (420 mg; 11.1 mmol; 8.0 equiv.) during which hydrogen gas evolved intensively and the color of the mixture changed to red and orange. After the addition, the flask was allowed to warm up to RT and was further stirred 30 min at RT. Resulting yellow solution was evaporated to dryness. Residue was purified by column chromatography (120 g SiO ₂ , solid load technique, 100 % EtOAc to 15% MeOH in EtOAc). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 171 mg (60%; 1 step; based on TD1052). NMR (DMSO-d ₆ ): ¹ H δ _H 4.62 (CH ₂ , s, 4H); 5.65 (OH, s, 2H); 7.60 (arom., q, 2H, ⁴ J _HF = 1). 19{ ¹ H} δ _F -63.6 (s). ESI-HRMS: 208.0580 [M+H] ⁺ (theor. [C ₈ H ₉ N ₁ O ₂ F ₃ ] ⁺ = 208.0580).

Synthesis of TD1055: In a round-bottom glass flask (100 mL), TD1053 (169 mg; 816 μmol; 1.0 equiv.) was dissolved in DCM (20 mL). Freshly prepared solution of SOCl ₂ (237 μL; 3.26 mmol; 4.0 equiv.) in DCM (5 mL) was then added and the resulting mixture was stirred 16 h at RT. Dil. aq. solution of NaHCO ₃ (25 mL) was then added and resulting biphasic mixture was vigorously stirred for additional 10 min at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 168 mg (84%; 1 step; based on TD1053). NMR (DMSO-d6): ¹ H δH 4.90 (CH ₂ , s, 4H); 7.94 (arom., s, 2H). ¹⁹ F{ ¹ H} δ _F −63.4 (s). APCI-HRMS: 243.9902 [M+H] ⁺ (theor. [C ₈ H ₇ N ₁ F ₃ Cl ₂ ] ⁺ = 243.9902). Synthesis of TD1057: In a glass vial (4 mL), TD1055 (143 mg; 586 µmol; 1.8 equiv.) was dissolved in MeCN (3.5 mL) followed by addition of solid NaN3 (21.5 mg; 331 µmol; 1.0 equiv.) and dried K ₂ CO ₃ (46 mg; 333 µmol; 1.0 equiv.) and the resulting suspension was stirred 3 d at 70 °C. The mixture was filtered through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and orange oily ed by column chromatography (80 g SiO ₂ , 30% P.E. in DCM to 40% DCM in P.E.). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum 1 h to give product in the form of free base as colourless oil. Yield: 43.9 g (53%; 1 step; based on NaN ₃ ). Recovery: 32.1 mg of TD1055 (22% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 4.69 (CH ₂ , s, 2H); 4.90 (CH ₂ , s, 2H); 7.81 (arom., d, 1H, ⁴ J _HH = 1); 7.93 (arom., d, 1H, ⁴ JHH = 1). ¹⁹ F{ ¹ H} δF −63.4 (s). APCI-HRMS: 251.0306 [M+H] ⁺ (theor. [C ₈ H ₇ N ₄ F ₃ Cl ₁ ] ⁺ = 251.0306). Synthesis of TD549: Pear-shape glass flask (250 mL) was charged with Dimethyl 4-chloropyridine-2,6- 20 dicarboxylate (5.00 g; 21.8 mmol; 1.0 equiv.), Phenylboronic acid (3.20 g; 26.2 mmol; 1.2 equiv.) and XPhos Pd G2 (510 mg; 648 µmol; 3.0 mol%) and was then three times secured with argon. Under constant flow of argon was then added dry DMF (110 mL) through septum followed by addition of freshly dried (using heat gun m) Cs ₂ CO ₃ (15.6 g; 47.9 mmol; 2.2 equiv.; the flask was briefly opened for addition). The mixture was then stirred 20 h under septum (but without external argon) at 80 °C. Resulting dark mixture was filtered through glass frit (S3) and the filtrate was poured to a stirred beaker with H ₂ O (500 mL). Precipitate was collected on glass frit (S2), washed with H ₂ O and further dried on high vacuum overnight to give product in the form of free base as off white solid. Yield: 3.01 g (51%; 1 step; based on Dimethyl 4-chloropyridine- 2,6-dicarboxylate). NMR (DMSO-d ₆ ): ¹ H δ _H 3.95 (CH ₃ , s, 6H); 7.45‒7.57 (Ph, m, 3H); 7.82‒8.00 (Ph, m, 2H); 8.48 (arom., s, 2H); ¹³ C{ ¹ H} δ _C 52.7 (CH ₃ , s); 125.0 (arom., s); 127.2 (Ph., s); 129.5 (Ph., s); 130.2 (Ph., s); 135.5 (Ph., s); 148.6 (arom., s); 150.0 (arom., s); 164.7 (CO., s). ESI-HRMS: 272.0916 [M+H] ⁺ (theor. [C ₁₅ H ₁₄ N ₁ O ₄ ] ⁺ = 272.0917). Synthesis of TD563: In a round-bottom glass flask (500 mL), TD549 (2.98 g; 11.0 mmol; 1.0 equiv.) was dissolved in a mixture of MeOH (100 mL) and THF (100 mL). The resulting slightly yellow solution was cooled with an ice bath (~5 °C) followed by ortion wise additions (over course of 30 min, with no stopper on the flask) of solid NaBH ₄ (2.90 g; 76.7 mmol; 9.0 equiv.) during which hydrogen gas evolved intensively mixture changed to red and orange. After the addition, the flask was allowed to warm up to RT and was further stirred 30 min at RT. Resulting faint yellow opalescent solution was filtered through syringe microfilter (PTFE). The filtrate was evaporated to dryness and further co-evaporated with DCM (as a suspension). Residue was dissolved in a mixture of H ₂ O (300 mL) and DCM (300 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (8 × 75 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The resulting crystalized residue was crushed and further dried on high vacuum overnight to give product in the form of free base as nearly colorless solid. Yield: 2.29 g (97%; 1 step; based on TD549). NMR (DMSO-d ₆ ): ¹ H δ _H 4.59 (CH ₂ , s, 4H); 5.45 (OH, s, 2H); 7.45‒7.57 (Ph, m, 3H); 7.60 (arom., s, 2H); 7.68‒7.82 (Ph, m, 2H). ¹³ C{ ¹ H} δ _C 64.2 (CH ₂ , s); 115.7 (arom., s); 126.7 (Ph, s); 129.1 (Ph, s); 129.3 (Ph, s); 138.1 (Ph, s); 148.2 (arom., s); 161.7 (arom., s). ESI-HRMS: 216.1022 [M+H] ⁺ (theor. [C ₁₃ H ₁₄ N ₁ O ₂ ] ⁺ = 216.1019). Synthesis of TD564: In a round-bottom glass flask (500 mL), TD563 (2.25 g; 10.5 mmol; 1.0 equiv.) was dissolved (with gentle heating) in DCM (250 mL). Freshly repared solution of SOCl ₂ (2.27 mL; 31.3 mmol; 3.0 equiv.) in DCM (10 mL) was hen added, after which precipitate started to form. After 1 h of stirring at RT, all of the previously formed precipitate was dissolved again. Dil. aq. solution of NaHCO ₃ (150 ) d to the clear yellow solution and the resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 100 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as faint yellow solid. Yield: 2.59 g (98%; 1 step; based on TD563). NMR (DMSO-d6): ¹ H δH 4.88 (CH ₂ , s, 4H); 7.47‒7.58 (Ph, m, 3H); 7.77‒7.85 (Ph, m, 2H); 7.86 (arom., s, 2H). ¹³ C{ ¹ H} δC 46.6 (CH ₂ , s); 120.3 (arom., s); 126.9 (Ph, s); 129.3 (Ph, s); 129.7 (Ph, s); 136.5 (Ph, s); 149.5 (arom., s); 157.1 (arom., s); 157.1 (arom., s); ESI-HRMS: 252.0342 [M+H] ⁺ (theor. [C ₁₃ H ₁₂ N ₁ Cl ₂ ] ⁺ = 252.0341). Synthesis of TD566: In a pear-shaped glass flask (100 mL), TD564 (1.60 g; 6.35 mmol; 1.3 equiv.) was dissolved (with gentle heating) in MeCN (60 mL) followed by addition of solid NaN3 320 mg; 4.92 mmol; 1.0 equiv.) and dried K ₂ CO ₃ (680 mg; 4.93 mmol; 1.0 equiv.) and he resulting suspension was stirred 24 h at 80 °C. The mixture was filtered on glass frit S3 and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and t he orange oily residue was purified by column chromatography (SiO ₂ , 15% P.E. in DCM to 100% DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried 1 h on high vacuum to give product in the form of free base as white solid. Yield: 691 mg (54%; 1 step; based on NaN ₃ ). Recovery: 613 mg of TD564 (38% of the initial amount used). NMR (DMSO-d6): ¹ H δH 4.59 (CH ₂ , s, 2H); 4.84 (CH ₂ , s, 2H); 7.46‒7.60 (Ph, m, 3H); 7.74 (arom., d, 1H, ⁴ J _HH = 2); 7.77‒7.85 (Ph, m, 2H); 7.86 (arom., d, 1H, ⁴ J _HH = 2). ¹³ C{ ¹ H} δ _C 46.7 (CH ₂ , s); 54.2 (CH ₂ , s); 119.4 (arom., s); 120.0 (arom., s); 126.9 (Ph, s); 129.3 (Ph, s); 129.7 (Ph, s); 136.6 (Ph, s); 149.3 (arom., s); 156.6 (arom., s); 157.1 (arom., s). ESI-HRMS: 259.0747 [M+H] ⁺ (theor. [C ₁₃ H ₁₂ N ₄ Cl ₁ ] ⁺ = 259.0745). Synthesis of TD1083: In a round-bottom glass flask (100 mL), methyl isonicotinate 250 mg; 1.83 mmol; 1.0 equiv.) was dissolved in MeOH (10 mL) followed by ddition of conc. H ₂ SO ₄ (25 µL). The resulting mixture was stirred 30 min at 55 °C. After cooling down, solution of (NH ₄ ) ₂ S ₂ O ₈ (4.16 g; 18.2 mmol; 10 equiv.) in H ₂ O (10 mL) was added dropwise and the resulting mixture was then further stirred 16 h at 55 °C. Reaction was then carefully quenched by aq. NaHCO ₃ . Mixture was then transferred to a separatory funnel and extracted with EtOAc (5 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of free base as white fluffy solid. Yield: 99.5 mg (28%; 1 step; based on methyl isonicotinate). NMR (DMSO- d6): ¹ H δH 3.92 (CH ₃ , s, 3H); 4.60 (CH ₂ , d, 4H, ³ J _HH = 6); 5.58 (OH, t, 2H, ³ J _HH = 6); 7.80 (arom., s, 2H). ESI- HRMS: 198.0759 [M+H] ⁺ (theor. [C ₉ H ₁₂ N ₁ O4] ⁺ = 198.0761). EA (C ₉ H ₁₁ N ₁ O4, MR = 197.2): C 54.8 (54.8); H 5.6 (5.5); N 7.1 (7.0). Synthesis of TD1087: In a round-bottom glass flask (50 mL), TD1083 (96.2 mg; 488 µmol; 1.0 equiv.) was dissolved in DCM (20 mL) followed by addition of SOCl2 (106 µL; 1.46 mmol; 3.0 equiv.). The mixture was stirred 1 h at RT. Mixture was then quenched by addition of dil. aq. solution of NaHCO ₃ (20 mL). The resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 30 mL). Combined organic layers were dried with anhydrous Na2SO4, filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight (where product slowly crystallized) to give product in the form of free base as bright yellow solid. Yield: 112.8 mg (99%; 1 step; based on TD1083). NMR (DMSO-d6): ¹ H δ _H 3.92 (CH ₃ , s, 3H); 4.90 (CH ₂ , s, 4H); 7.98 (arom., s, 2H). ESI-HRMS: 234.0085 [M+H] ⁺ (theor. [C ₉ H10N ₁ O ₂ Cl ₂ ] ⁺ = 234.0083). Synthesis of TD1089: In a glass vial (4 mL), TD1087 (112.0 mg; 478 µmol; 1.2 equiv.) was dissolved in MeCN (2 mL) followed by addition of solid NaN ₃ (26.0 mg; 400 µmol; 1.0 equiv.) and dried K ₂ CO ₃ (55.0 mg; 400 µmol; 1.0 equiv.) and the resulting suspension was stirred 2 h at 70 °C. The mixture was filtered on through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and oily residue was purified by column chromatography (SiO ₂ , DCM to 10% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give pre-purified product (containing ~20% of bis azide byproduct) in the form of free base as yellow oil. Yield: 49.6 mg. ESI-HRMS: 241.0490 [M+H] ⁺ (theor. [C ₉ H ₁₀ N ₄ O ₂ Cl ₁ ] ⁺ = 241.0487). Part of TD1089 obtained in this way was directly used for TD1092 without further purification or characterization. Synthesis of TD1101: In a round-bottom glass flask (100 mL), isopropyl sonicotinate (600 mg; 3.63 mmol; 1.0 equiv.) was dissolved in MeOH (20 mL) ollowed by addition of conc. H ₂ SO ₄ (50 µL). Then, solution of (NH ₄ ) ₂ S ₂ O ₈ (8.32 g; 6.5 mmol; 10 ₂ equiv.) in H O (20 mL) was added dropwise and the resulting mixture was further stirred 16 h at 70 °C. Reaction was then carefully neutralized by aq. NaHCO ₃ . Mixture was then transferred to a separatory funnel and extracted with EtOAc (5 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of free base as white fluffy solid. Yield: 284 mg (35%; 1 step; based on isopropyl isonicotinate). NMR (DMSO-d6): ¹ H δ _H 1.34 (CH ₃ , d, 6H, ³ J _HH = 6); 4.59 (CH ₂ , d, 4H, ³ J _HH = 6); 5.19 (CH, hept, 1H, ³ J _HH = 6); 5.57 (OH, t, 2H, ³ J _HH = 6); 7.78 (arom., s, 2H). ESI-HRMS: 226.1076 [M+H] ⁺ (theor. [C ₁₁ H ₁₆ N ₁ O ₄ ] ⁺ = 226.1074). ynthesis of TD1109: In a round-bottom glass flask (100 mL), TD1101 (283 mg; 1.26 mmol; 1.0 equiv.) was dissolved in DCM (40 mL) followed by addition of SOCl ₂ (275 L; 3.79 mmol; 3.0 equiv.). The mixture was stirred 1 h at RT. Mixture was then quenched by addition of dil. aq. solution of NaHCO ₃ (40 mL). The resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight (where product slowly crystallized) to give product in the form of free base as pale yellow solid. Yield: 322 mg (98%; 1 step; based on TD1101). NMR (DMSO-d6): ¹ H δ _H 1.35 (CH ₃ , d, 6H, ³ J _HH = 6); 4.90 (CH ₂ , s, 4H); 5.20 (CH, hept, 1H, ³ J _HH = 6); 7.96 (arom., s, 2H). ESI-HRMS: 262.0399 [M+H] ⁺ (theor. [C ₁₁ H ₁₄ N ₁ O ₂ Cl ₂ ] ⁺ = 262.0396). Synthesis of TD1112: In a glass vial (20 mL), TD1109 (321 mg; 1.23 mmol; 1.2 equiv.) was dissolved in MeCN (6 mL) followed by addition of solid NaN ₃ (66.5 mg; 1.02 mmol; 1.0 equiv.) and dried K ₂ CO ₃ (141 mg; 1.02 mmol; 1.0 equiv.) and the esulting suspension was stirred 16 h at 70 °C. The mixture was filtered on through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and oily residue was purified by column chromatography (SiO ₂ , DCM to 3% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 116 mg (42%; 1 step; based on NaN ₃ ). Recovery: 124 mg of TD1109 (39% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 1.35 (CH ₃ , d, 6H, ³ J _HH = 6); 4.67 (CH ₂ , s, 2H); 4.89 (CH ₂ , s, 4H); 5.19 (CH, hept, 1H, ³ J _HH = 6); 7.83 (arom., d, 1H, ⁴ J _HH = 1).7.95 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 269.0800 [M+H] ⁺ (theor. [C ₁₁ H ₁₄ N ₄ O ₂ Cl ₁ ] ⁺ = 269.0800). Synthesis of TD1119: In a glass vial (40 mL), tert-butyl isonicotinate (486 mg; 2.71 mmol; 1.0 equiv.) was dissolved in MeOH (15 mL) followed by addition of conc. H ₂ SO ₄ (40 µL). Then, solution of (NH ₄ ) ₂ S ₂ O ₈ (6.20 g; 27.2 mmol; 10 equiv.) in H ₂ O (15 mL) was added dropwise and the resulting mixture was further stirred 30 min at 80 °C. Reaction was then carefully neutralized by aq. NaHCO ₃ . Mixture was then transferred to a separatory funnel and extracted with EtOAc (5 × 30 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of free base as white fluffy solid. Yield: 161 mg (25%; 1 step; based on tert-butyl isonicotinate). NMR (DMSO-d6): ¹ H δ _H 1.57 (CH ₃ , s, 9H); 4.58 (CH ₂ , d, 4H, ³ J _HH = 4); 5.54 (OH, t, 2H, ³ J _HH = 4); 7.73 (arom., s, 2H). ESI-HRMS: 240.1230 [M+H] ⁺ (theor. [C ₁₂ H ₁₈ N ₁ O ₄ ] ⁺ = 240.1230). Synthesis of TD1129: In a round-bottom glass flask (100 mL), TD1119 (159 mg; 664 µmol; 1.0 equiv.) was dissolved in DCM (20 mL) followed by addition of SOCl ₂ (145 µL; 2.00 mmol; 3.0 equiv.). The mixture was stirred 1 h at RT. Mixture was then quenched by addition of dil. aq. solution of NaHCO ₃ (20 mL). The resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight (where product slowly crystallized) to give product in the form of free base as faint yellow solid. Yield: 175 mg (95%; 1 step; based on TD1119). NMR (DMSO-d6): ¹ H δ _H 1.57 (CH ₃ , s, 9H); 4.89 (CH ₂ , s, 4H); 7.91 (arom., s, 2H). ESI-HRMS: 276.0552 [M+H] ⁺ (theor. [C ₁₂ H ₁₆ N ₁ O ₂ Cl ₂ ] ⁺ = 276.0553). Synthesis of TD1130: In a glass vial (4 mL), TD1129 (174.0 mg; 630 µmol; 1.2 equiv.) was dissolved in MeCN (3 mL) followed by addition of solid NaN ₃ (34.0 mg; 523 µmol; 1.0 equiv.) and dried K ₂ CO ₃ (72.0 mg; 522 µmol; 1.0 equiv.) and the resulting suspension was stirred 6 h at 70 °C. The mixture was filtered on through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and oily residue was purified by column chromatography (SiO ₂ , DCM to 3% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 58.2 mg (39%; 1 step; based on NaN ₃ ). Recovery: 90.5 mg of TD1129 (52% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 1.57 (CH ₃ , s, 9H); 4.66 (CH ₂ , s, 2H); 4.89 (CH ₂ , s, 2H); 7.79 (arom., d, 1H, ⁴ J _HH = 2).7.91 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 305.0772 [M+Na] ⁺ (theor. [C ₁₂ H ₁₅ N ₄ O ₂ Cl ₁ Na ₁ ] ⁺ = 305.0776). Synthesis of TD725: Glass vial (40 mL) was charged with TD726 (628 mg; 3.62 mmol; 1.0 equiv.), (4-(tert-Butoxycarbonyl)phenyl)boronic acid (880 mg; 3.96 mmol; 1.1 equiv.) and XPhos Pd G2 (57 mg; 7.2 µmol; 2.0 mol%) and was then three times secured with argon. Under constant flow of argon was then added dry 1,4-Dioxane (16 mL) through septum followed by addition of freshly prepared (and briefly washed with argon prior addition) solution of K3PO ₄ ·H ₂ O (920 mg; 4.00 mmol; 1.1 equiv.) in H ₂ O (8 mL). The mixture was then stirred 16 h under septum (but without external argon) at 80 °C. Resulting dark mixture was transferred to a separatory funnel and diluted with EtOAc (40 mL) and H ₂ O (50 ml). After shaking, upper layer was separated and aqueous layer was further extracted with EtOAc (5 × 30 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified on flash chromatography (120 g SiO ₂ , 100% EtOAc to 30% MeOH in EtOAc). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give pre-purified product in the form of free base as off-white powder. Yield: 1.04 g. NMR (DMSO-d6): ¹ H δ _H 1.57 (CH ₃ , s, 9H); 4.61 (CH ₂ , d, 4H, ³ J _HH = 6); 5.48 (OH, t, 2H, ³ J _HH = 6); 7.64 (arom., s, 2H); 7.88 (arom., dm, 2H, ³ J _HH = 9); 8.04 (arom., dm, 2H, ³ J _HH = 9). ¹³ C{ ¹ H} δ _C 27.8 (CH ₃ , s); 64.2 (CH ₂ , s); 81.0 (C‒CH ₃ , s); 115.8 (arom., s); 127.0 (arom., s); 129.9 (arom., s); 131.6 (arom., s); 142.2 (arom., s); 147.0 (arom., s); 162.0 (arom., s); 164.6 (CO, s). ESI-HRMS: 316.1539 [M+H] ⁺ (theor. [C ₁₈ H ₂₂ N ₁ O ₄ ] ⁺ = 316.1543). 5 Synthesis of TD730: In a round-bottom glass flask (250 mL), pre-purified TD725 (1.04 g; ≤3.30 mmol; 1.0 equiv.) was suspended in DCM (35 mL). Freshly prepared solution of SOCl ₂ (721 µL; 9.93 mmol; ≥3.0 equiv.) in DCM 5 mL) was then added. Clear solution was quickly formed and the open flask was stirred 1 h at RT. Mixture was then quenched by addition of dil. aq. solution of NaHCO ₃ (60 mL). The resulting biphasic mixture was vigorously stirred for additional 1 h at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (5 × 30 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was purified on flash chromatography (120 g SiO ₂ , 100% DCM to 20% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residual faint yellow oil slowly crystallized. The solid was crushed and further dried on high vacuum overnight to give product in the form of free base as off-white powder. Yield: 839 mg (66%; 2 steps; based on TD726). NMR (DMSO-d ₆ ): ¹ H δ _H 1.58 (CH ₃ , s, 9H); 4.86 (CH ₂ , s, 4H); 7.92 (arom., s, 2H); 7.94 (arom., dm, 2H, ³ J _HH = 9); 8.05 (arom., dm, 2H, ³ J _HH = 9). ¹³ C{ ¹ H} δ _C 27.8 (CH ₃ , s); 46.5 (CH ₂ , s); 81.2 (C‒CH ₃ , s); 120.6 (arom., s); 127.2 (arom., s); 129.9 (arom., s); 132.1 (arom., s); 140.6 (arom., s); 148.3 (arom., s); 157.3 (arom., s); 164.5 (CO, s). ESI-HRMS: 352.0866 [M+H] ⁺ (theor. [C ₁₈ H ₂₀ N ₁ O ₂ Cl ₂ ] ⁺ = 352.0866). Synthesis of TD733: In a glass vial (20 mL), TD730 (837 mg; 2.38 mmol; 1.3 equiv.) was dissolved in MeCN (18 mL) followed by addition of solid NaN ₃ (119 mg; 1.83 mmol; 1.0 equiv.) and dried K ₂ CO ₃ (253 mg; 1.83 mmol; 1.0 equiv.) and the resulting suspension was stirred 24 h at 80 °C. The mixture was filtered on through syringe microfilter (PTFE) and the solid residue was washed with MeCN. Filtrate was evaporated to dryness and oily residue was purified by column chromatography (SiO ₂ , 20% Pentane in DCM to 1% EtOAc in DCM). Fractions with product were combined and evaporated to dryness. The resulting nearly colorless oil was further dried on high vacuum overnight (where product slowly crystallized) to give product in the form of free base as colorless solid. Yield: 230 mg (35%; 1 step; based on NaN ₃ ). Recovery: 442 mg of TD730 (53% of the initial amount used). NMR (DMSO-d6): ¹ H δ _H 1.57 (CH ₃ , s, 9H); 4.62 (CH ₂ , s, 2H); 4.86 (CH ₂ , s, 2H); 7.80 (arom., d, 1H, ⁴ J _HH = 2); 7.91 (arom., d, 1H, ⁴ J _HH = 2); 7.94 (arom., dm, 2H, ³ J _HH = 9); 8.05 (arom., dm, 2H, ³ J _HH = 9). ¹³ C{ ¹ H} δ _C 27.8 (CH ₃ , s); 46.6 (CH ₂ , s); 54.2 (CH ₂ , s); 81.2 (C‒CH ₃ , s); 119.6 (arom., s); 120.3 (arom., s); 127.2 (arom., s); 129.9 (arom., s); 132.1 (arom., s); 140.7 (arom., s); 148.1 (arom., s); 156.8 (arom., s); 157.3 (arom., s); 164.5 (CO, s). ESI-HRMS: 359.1270 [M+H] ⁺ (theor. [C ₁₈ H ₂₀ N ₄ O ₂ Cl ₁ ] ⁺ = 359.1269). Synthesis of TD1425: Glass vial (40 mL) was charged methyl 2-bromo-6- methylisonicotinate (1.00 g; 4.35 mmol; 1.0 equiv.), NBS (recrystallized from boiling H ₂ O; 770 mg; 4.33 mmol; 1.0 equiv.), (BnO) ₂ (53 mg; 219 µmol; 5 mol%) and magnetic tirrer and three times secured with argon. Under constant flow of argon was then added CCl ₄ (21 mL) through septum. The vial was left stirring under septum (but without external argon) for 24 h at 75 °C. After cooling down, the mixture was filtered through syringe microfilter (PTFE) and the solids were washed with DCM. Filtrate was evaporated to dryness, re-suspended in c-Hex (25 ml) and filtered through syringe microfilter (PTFE). Filtrate was evaporated to dryness and the residue was purified by flash chromatography (120 g SiO ₂ , 100% c-Hex to 80% DCM in c-Hex). Combined fractions with product were evaporated to dryness. The residual oil was further dried on high vacuum overnight (where the product crystallized) to give product in the form of free base as faint yellow solid. Yield: 571 mg (43%; 1 step; based on methyl 2-bromo-6-methylisonicotinate). Recovery: 314 mg of methyl 2-bromo-6-methylisonicotinate (31% of the initial amount used). NMR (DMSO-d ₆ ): ¹ H δ _H 3.91 (CH ₃ , s, 3H); 4.79 (CH ₂ , s, 2H); 7.94 (arom., d, 1H, ⁴ J _HH = 1); 8.05 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 307.8916 [M+H] ⁺ (theor. [C ₈ H ₈ N ₁ O ₂ Br ₂ ] ⁺ = 307.8916). ynthesis of TD1428: Pear-shaped glass flask (25 mL) was charged with TD1425 (523 mg; 1.69 mmol; 1.0 equiv.), N-Boc-1,1-dimethylpropargylamine (310 mg; 1.69 mmol; 1.0 equiv.) and magnetic stirrer and three times secured with argon. Solid CuI 13.0 mg; 68 µmol; 4.0 mol%) and [Pd(PPh ₃ ) ₂ Cl ₂ ] (24 mg; 34 µmol; 2.0 mol%) were ubsequently added followed by another securing with argon (three times). Under constant flow of argon was then added dry THF (7.5 mL) through septum followed by addition of DIPEA (885 µL; 5.08 mmol; 3.0 equiv.). The flask was left stirring under septum (but without external argon) for 2 d at RT. The mixture was evaporated to dryness, re-suspended in DCM (15 mL) and filtered through syringe microfilter (PTFE) and the solid phase was further washed with DCM. Filtrate was purified on flash chromatography (120 g SiO ₂ , 10% EtOAc in c-Hex to 50% EtOAc in c-Hex). Combined fractions with product were evaporated to dryness and once re-purified on flash chromatography (80 g SiO ₂ , 100% DCM to 5% EtOAc in DCM). Combined fractions with product were evaporated to dryness and further co-evaporated once with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as faint yellow solidified oil. Yield: 175 mg (25%; 1 step; based on TD1425). NMR (DMSO- d6): ¹ H δ _H 1.42 (CH ₃ –C–O, s, 9H); 1.56 (CH ₃ –C–N, s, 6H); 3.91 (CH ₃ –O, s, 3H); 4.79 (CH ₂ , s, 2H); 7.23 (NH, bs, 1H); 7.71 (arom., d, 1H, ⁴ J _HH = 1); 7.97 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 411.0913 [M+H] ⁺ (theor. [C ₁₈ H ₂₄ N ₂ O ₄ Br ₁ ] ⁺ = 411.0914). Synthesis of TD1386: In a round-bottom glass flask (100 mL), pyridine-2,6- diyldimethanol (2.00 g; 14.4 mmol; 1.0 equiv.) and Imidazole (0.98 g; 14.4 mmol; .0 equiv.) were dissolved in DMF (20 mL) followed by addition of TBDMSCl (2.17 ; 14.4 mmol; 1.0 equiv.). The resulting solution was stirred 2 h at RT. Mixture was evaporated to dryness and the residue dissolved in a mixture of DCM (50 mL) and dil. aq. NaHCO ₃ (50 mL) and transferred to a separatory funnel. After brief shaking, the bottom phase was separated and the aq. layer was further extracted with DCM (5 × 30 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was purified by column chromatography (100 g SiO ₂ , DCM to 50% EtOAc in DCM). Fractions with product were combined and evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 1.54 g (42%; 1 step; based on pyridine-2,6- diyldimethanol). NMR (DMSO-d ₆ ): ¹ H δ _H 0.09 (CH ₃ , s, 6H); 0.92 (CH ₃ , s, 9H); 4.51 (CH ₂ , d, 2H, ³ J _HH = 5); 4.71 (CH ₂ , s, 2H); 5.37 (OH, t, 1H, ³ J _HH = 5); 7.28 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.34 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.81 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 254.1569 [M+H] ⁺ (theor. [C ₁₃ H ₂₄ N ₁ O ₂ Si ₁ ] ⁺ = 254.1571). Synthesis of TD1389: In a round-bottom glass flask (250 mL), TD1386 (1.54 g; 6.08 mmol; 1.0 equiv.) was dissolved in DCM (60 mL) followed by addition of SOCl ₂ (885 µL; 12.0 mmol; 2.0 equiv.). The mixture was stirred 1 h at RT. Mixture was then quenched by addition of dil. aq. solution of NaHCO ₃ (60 mL). The resulting biphasic mixture was vigorously stirred for additional 30 min at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 1.63 g (99%; 1 step; based on TD1386). NMR (DMSO-d ₆ ): ¹ H δ _H 0.10 (CH ₃ , s, 6H); 0.92 (CH ₃ , s, 9H); 4.74 (CH ₂ , s, 2H); 4.75 (CH ₂ , s, 2H); 7.40 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.42 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.87 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 272.1231 [M+H] ⁺ (theor. [C ₁₃ H ₂₃ N ₁ O ₁ Cl ₁ Si ₁ ] ⁺ = 272.1232). Synthesis of TD1390: In a glass flask (20 mL), KCN (390 mg; 5.99 mmol; 1.05 equiv.) was dissolved in H ₂ O (2 mL) followed by addition of TD1389 (1.55 g; 5.70 mmol; 1.0 quiv.) in DMF (6 mL). The resulting mixture was vigorously stirred for 70 min at 100 C. After cooling to RT, mixture was diluted with H ₂ O (4 mL) and MeCN (8 mL) and filtered through syringe microfilter (PTFE). Filtrate was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residual pale yellow oil was left in a freezer to solidify. Resulting solid was crushed and further dried on high vacuum overnight to give product in the form of free base as faint yellow powder. Yield: 1.23 g (82%; 1 step; based on TD1389). NMR (DMSO-d ₆ ): ¹ H δ _H 0.10 (CH ₃ , s, 6H); 0.92 (CH ₃ , s, 9H); 4.17 (CH ₂ , s, 2H); 4.75 (CH ₂ , s, 2H); 7.30 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.40 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.86 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 263.1573 [M+H] ⁺ (theor. [C ₁₄ H ₂₃ N ₂ O ₁ Si ₁ ] ⁺ = 263.1574). ynthesis of TD1393: In a pear-shaped glass flask (100 mL), TD1390 (700 mg; 2.67 mmol; 00 equiv.) was dissolved in MeOH (2.70 mL; 66.7 mmol; 25 equiv.) followed by addition TMSCl (2.37 mL; 18.7 mmol; 7.0 equiv.). The resulting mixture was vigorously stirred r 2 h at 60 °C. After cooling to RT, mixture was quenched with H ₂ O (4 mL) and partly neutralized (to pH 3–4) by slow addition of sat. aq. NaHCO ₃ (5 mL). Resulting biphasic mixture was carefully evaporated to dryness followed by addition of H ₂ O (10 mL) to the residue. Mixture was then filtered through syringe microfilter (RC) and the filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as faint yellow oil. Yield: 404 mg (84%; 1 step; based on TD1390). NMR (DMSO-d ₆ ): ¹ H δ _H 3.61 (CH ₃ , s, 3H); 3.81 (CH ₂ , s, 2H); 4.51 (CH ₂ , d, 2H, ³ J _HH = 5); 5.39 (OH, t, 1H, ³ J _HH = 5); 7.20 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.36 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.76 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 182.0811 [M+H] ⁺ (theor. [C ₉ H ₁₂ N ₁ O ₃ ] ⁺ = 182.0812). Synthesis of TD1395: In a round-bottom glass flask (50 mL), TD1393 (340 mg; 1.88 mmol; 1.0 equiv.) and Imidazole (190 mg; 2.79 mmol; 1.5 equiv.) were dissolved in DMF (6 mL) followed by addition of TBDMSCl (425 mg; 2.82 mmol; 1.5 equiv.). The resulting solution was stirred 16 h at RT. Mixture was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as faint yellow oil. Yield: 537 mg (97%; 1 step; based on TD1393). NMR (DMSO-d6): ¹ H δ _H 0.09 (CH ₃ , s, 6H); 0.91 (CH ₃ , s, 9H); 3.61 (CH ₃ , s, 3H); 3.81 (CH ₂ , s, 2H); 4.70 (CH ₂ , s, 2H); 7.23 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.32 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.79 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 296.1676 [M+H] ⁺ (theor. [C ₁₅ H ₂₆ N ₁ O ₃ Si ₁ ] ⁺ = 296.1677). Synthesis of TD1396: In a round-bottom glass flask (100 mL), TD1395 (537 mg; 1.82 mol; 1.0 equiv.) was dissolved in a mixture of THF (9 mL) and MeOH (9 mL). To the sulting colourless solution was added portion wise (over course of 10 min, with no opper on the flask) solid NaBH ₄ (2.06 g; 54.5 mmol; 30 equiv.) during which hydrogen gas evolved intensively. Mixture was further stirred 1 h at RT, during which was twice diluted with MeOH (9 mL each) to ensure stirring. Mixture was then diluted with DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colourless oil. Yield: 483 mg (99%; 1 step; based on TD1395). NMR (DMSO-d ₆ ): ¹ H δ _H 0.09 (CH ₃ , s, 6H); 0.92 (CH ₃ , s, 9H); 2.84 (CH ₂ , t, 2H, ³ J _HH = 7); 3.71 (CH ₂ , td, 2H, ³ J _HH = 7, ³ J _HH = 5); 4.62 (OH, t, 1H, ³ J _HH = 5); 4.71 (CH ₂ , s, 2H); 7.14 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.24 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.70 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 268.1726 [M+H] ⁺ (theor. [C14H ₂ 6N1O ₂ Si ₁ ] ⁺ = 268.1727). Synthesis of TD1401: In a round-bottom glass flask (50 mL), TD1396 (94 mg; 352 µmol; .0 equiv.) was dissolved in DCM (3.5 mL) followed by addition of SOCl ₂ (51 µL; 702 µmol; .0 equiv.). The mixture was stirred 3 h at RT. Mixture was then diluted with DCM (20 mL) nd quenched by addition of dil. aq. solution of NaHCO ₃ (10 mL). The resulting biphasic mixture was vigorously stirred for additional 30 min at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 15 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was dissolved in DMF (1.7 mL) followed by addition of solid NaN ₃ (46 mg; 708 µmol; 2.0 equiv.). The resulting mixture was stirred at 80 °C overnight. After cooling, the mixture was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless oil. Yield: 17.6 mg (28%; 2 steps; based on TD1396). NMR (DMSO-d6): ¹ H δ _H 2.98 (CH ₂ , t, 2H, ³ J _HH = 7); 3.69 (CH ₂ , td, 2H, ³ J _HH = 7, ³ J _HH = 5); 4.53 (CH ₂ , d, 2H, ³ J _HH = 6); 5.37 (OH, t, 1H, ³ J _HH = 6); 7.18 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.32 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.73 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 201.0746 [M+Na] ⁺ (theor. [C ₈ H ₁₀ N ₄ O ₁ Na ₁ ] ⁺ = 201.0747). Synthesis of TD1406: In a round-bottom glass flask (25 mL), TD1401 (16.5 mg; 92.6 µmol; 1.0 equiv.) was dissolved in DCM (1.85 mL) followed by addition of SOCl ₂ (13.5 µL; 186 µmol; 2.0 equiv.). The mixture was stirred 1 h at RT. Mixture was then diluted with DCM (10 mL) and quenched by addition of dil. aq. solution of NaHCO ₃ (10 mL). The resulting biphasic mixture was vigorously stirred for additional 30 min at RT, during which bubbles of gas slowly evolved. Mixture was then transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless solid. Yield: 17.7 mg (97%; 1 step; based on TD1401). NMR (DMSO-d ₆ ): ¹ H δ _H 3.02 (CH ₂ , t, 2H, ³ J _HH = 7); 3.71 (CH ₂ , td, 2H, ³ J _HH = 7, ³ J _HH = 5); 4.75 (CH ₂ , s, 2H); 7.32 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.41 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.79 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 197.0589 [M+H] ⁺ (theor. [C ₈ H ₁₀ N ₄ Cl ₁ ] ⁺ = 197.0589). Synthesis of TD1339: Pear-shaped glass flask (250 mL) was charged with ethyl l-lactate (3.54 30.0 mmol; 1.00 equiv.) and magnetic stirrer and three times briefly secured with argon. nder constant flow of argon was then added dry DCM (100 mL) through septum and the mixture was cooled with an ice bath (5 °C) followed by dropwise addition of triflic anhydride (5.3 mL; 31.5 mmol; 1.05 equiv.) and immediately followed by dropwise addition of dry pyridine (2.54 ml; 31.5 mmol; 1.05 equiv.). The resulting mixture was stirred at 5 °C for 30 min. Resulting suspension was then directly purified by column chromatography (140 g SiO ₂ , DCM). Combined fractions with product were evaporated to dryness and briefly dried on high vacuum to give product as faintly pinkish oil. Yield: 5.90 g (79%; 1 step; based on ethyl l-lactate). NMR (DMSO-d ₆ ): ¹ H δ _H 1.26 (CH ₃ ‒CH ₂ , t, 3H, ³ J _HH = 7); 1.51 (CH ₃ ‒CH, d, 3H, ³ J _HH = 7); 4.19–4.31 (CH ₂ , m, 2H); 5.27 (CH, q, 1H, ³ J _HH = 7). ¹⁹ F{ ¹ H} δ _F −77.7 (s). CI-HRMS: 251.0193 [M+H] ⁺ (theor. [C ₆ H ₁₀ O ₅ S ₁ F ₃ ] ⁺ = 251.0196). ynthesis of TD1488: Pear-shaped glass flask (25 mL) was charged with dimethyl L- malate (200 mg; 1.23 mmol; 1.00 equiv.) and magnetic stirrer and three times briefly ecured with argon. Under constant flow of argon was then added dry DCM (4 mL) through septum and the mixture was cooled with an ice bath (5 °C) followed by dropwise addition of triflic anhydride (220 µL; 1.31 mmol; 1.06 equiv.) and immediately followed by dropwise addition of dry pyridine (105 µL; 1.30 mmol; 1.06 equiv.). The resulting mixture was stirred at RT for 30 min. Resulting suspension was then directly purified by column chromatography (30 g SiO ₂ , DCM). Combined fractions with product were evaporated to dryness and briefly dried on high vacuum to give product as colourless oil. Yield: 258 mg (77%; 1 step; based on dimethyl L- malate). NMR (DMSO-d6): ¹ H δ _H 3.08 (CH ₂ , dd, 1H, ² J _HH = 17, ³ J _HH = 5); 3.13 (CH ₂ , dd, 1H, ² J _HH = 17, ³ J _HH = 6); 4.65 (CH ₃ , s, 3H); 3.78 (CH ₃ , s, 3H); 5.48 (CH, dd, 1H, ³ J _HH = 6, ³ J _HH = 5). ¹⁹ F{ ¹ H} δ _F −77.7 (s). ESI-HRMS: 316.9910 [M+Na] ⁺ (theor. [C ₇ H ₉ O ₇ F ₃ S ₁ Na ₁ ] ⁺ = 316.9913). Example 3: Synthesis of protected macrocyclic intermediates Synthesis of TD680: In a pear-shape glass flask (250 mL), Cbz2cyclen (free base; 1.54 g; 3.50 mmol; 1.6 equiv.) was dissolved in MeCN (100 mL) followed by addition of dried K ₂ CO ₃ (300 mg; 2.17 mmol; 1.0 equiv.). To the vigorously stirred reaction mixture, olution of tert-Butyl bromoacetate (427 mg; 2.19 mmol; 1.0 equiv.) in dry MeCN (25 mL) was added dropwise (over the course of 2 h). Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (150 mL) and H ₂ O (150 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 75 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 624 mg (51%; 1 step; based on tert-Butyl bromoacetate). NMR (CD ₃ CN): ¹ H δ _H 1.32‒1.49 (CH ₃ , m, 9H); 2.57‒2.76 (mc, m, 4H); 2.81‒2.98 (mc, m, 4H); 3.23‒3.64 (mc, CH ₂ ‒CO, m, 8+2H); 5.00‒5.15 (CH ₂ ‒Ph, m, 4H); 7.19‒7.48 (Ph, m, 10H). ESI-HRMS: 555.3171 [M+H] ⁺ (theor. [C ₃₀ H ₄₃ N ₄ O ₆ ] ⁺ = 555.3177). Synthesis of TD686: In a glass vial (4 mL), TD680 (150 mg; 270 µmol; 1.0 equiv.) was dissolved in MeCN (3 mL) followed by addition of Boc ₂ O (2.0 M solution in THF; 200 µL; 400 µmol; 1.5 equiv.). Resulting mixture was stirred 16 h at RT. Reaction mixture was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, immediately neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless oil. Yield: 170 mg (96%; 1 step; based on TD680). NMR (CD ₃ CN): ¹ H δ _H 1.17‒1.56 (CH ₃ , m, 18H); 2.62‒2.99 (mc, m, 4H); 3.10‒3.53 (mc, CH ₂ ‒CO, m, 12+2H); 4.96‒5.16 (CH ₂ ‒Ph, m, 4H); 7.20‒7.47 (Ph, m, 10H). ESI-HRMS: 655.3691 [M+H] ⁺ (theor. [C ₃₅ H ₅₁ N ₄ O ₈ ] ⁺ = 655.3701). Synthesis of TD691: Pear-shape glass flask (25 mL) was charged with TD686 (170 mg; 260 mol) and magnetic stirrer and three times secured with argon. Solid Pd@C (17 mg) was then dded followed by another securing with argon (three times). Under constant flow of argon as then added MeOH (10 mL) through septum. Argon input was then removed and H ₂ gas rom balloon) was allowed to bubble through the mixture for 30 min at RT. Catalyst was then fil tered off using syringe microfilter (PTFE; filter was further washed with MeOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless oil. Yield: 100 mg (≥99%; 1 step; based on TD686). ESI-MS (LC- MS): 387.3 [M+H] ⁺ (theor. [C ₁₉ H ₃₉ N ₄ O ₄ ] ⁺ = 387.3). All of TD691 was directly used for TD692 without further characterization. ynthesis of TD1106: In a pear-shape glass flask (50 mL), Cbz2cyclen (free base; 500 mg; .14 mmol; 1.0 equiv.) was dissolved in MeCN (10 mL) followed by addition of dried K ₂ CO ₃ (870 mg; 5.69 mmol; 5.0 equiv.) and Methyl bromoacetate (235 µL; 2.51 mmol; .2 equiv.) in MeCN (5 mL). The resulting suspension was stirred 2 d at RT. Solids were ltered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless oil. Yield: 422 mg (64%; 1 step; based on Cbz2cyclen). NMR (CD ₃ CN): ¹ H δ _H 2.63‒2.88 (mc, m, 8H); 3.19‒- 3.49 (mc, CH ₂ ‒CO, m, 8+4H); 3.59 (CH ₃ , s, 6H); 5.07 (CH ₂ ‒Ph, s, 4H); 7.21‒7.41 (Ph, m, 10H). ESI-LCMS: 585.3 [M+H] ⁺ (theor. [C ₃₀ H ₄₁ N ₄ O ₈ ] ⁺ = 585.3). Synthesis of TD1116: Pear-shape glass flask (50 mL) was charged with Pd@C (42 mg) and magnetic stirrer and three times secured with argon. Under constant flow of argon was then added olution of TD1106 (418 mg; 715 µmol) in MeOH (25 mL) through septum. Argon input was hen removed and H ₂ gas (from balloon) was allowed to bubble through the mixture for 1 h at RT. Catalyst was then filtered off using syringe microfilter (PTFE; filter was further washed with MeOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was urther dried on high vacuum overnight to give product in the form of free base as colorless oil that crystallized on standing. Yield: 223 mg (99%; 1 step; based on TD1106). NMR (CD ₃ CN): ¹ H δ _H 2.48‒- 2.57 (mc, m, 8H); 2.63‒2.74 (mc, m, 8H); 3.36 (CH ₂ ‒CO, s, 4H); 3.64 (CH ₃ , s, 6H). ESI-MS (LC-MS): 317.2 [M+H] ⁺ (theor. [C ₁₄ H ₂₉ N ₄ O ₄ ] ⁺ = 317.2). Synthesis of TD687: In a glass vial (2 mL), TD680 (150 mg; 270 µmol; 1.0 equiv.) and P(OEt) ₃ (232 µL; 1.35 mmol; 5.0 equiv.) were mixed together followed by addition of solid (CH ₂ O) _n (12 mg; 400 µmol; 1.5 equiv.). The resulting suspension was stirred 3 d at RT. Reaction mixture was then diluted with MeCN (700 µL) and filtered through syringe microfilter (PTFE). Filter was further washed with MeCN. Filtrate was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, immediately neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as slightly yellow oil. Yield: 167 mg (87%; 1 step; based on TD680). ESI-MS (LC-MS): 705.4 [M+H] ⁺ (theor. [C ₃₅ H ₅₄ N ₄ O ₉ P ₁ ] ⁺ = 705.4). All of TD687 was directly used for TD695 without further characterization. Synthesis of TD695: Pear-shape glass flask (25 mL) was charged with TD687 (167 mg; 237 mol) and magnetic stirrer and three times secured with argon. Solid Pd@C (17 mg) was then ded followed by another securing with argon (three times). Under constant flow of argon s then added MeOH (10 mL) through septum. Argon input was then removed and H ₂ gas om balloon) was allowed to bubble through the mixture for 30 min at RT. The reaction xture was further stirred under hydrogen atmosphere (from balloon) 16 h at RT. Catalyst was then filtered off using syringe microfilter (PTFE; filter was further washed with MeOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as slightly yellow oil. Yield: 100 mg (97%; 1 step; based on TD686). ESI-MS (LC-MS): 437.2 [M+H] ⁺ (theor. [C ₁₉ H ₄₁ N ₄ O ₅ P ₁ ] ⁺ = 437.3). All of TD695 was directly used for TD700 without further characterization. Synthesis of TD913: In a glass vial (20 mL), Cbz2cyclen (free base; 242 mg; 549 µmol; 1.0 equiv.) was dissolved in MeCN (12 mL) followed by addition of solid (CH ₂ O)n (50 mg; 1.67 mmol; 3.0 equiv.) and PhP(OMe) ₂ (350 µL; 2.2 mmol; 4.0 equiv.). The resulting uspension was stirred 24 h at 80°C. Reaction mixture was then filtered through syringe microfilter (PTFE) and the filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (75 mL) and H ₂ O (75 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colourless oil. Yield: 259 mg (61%; 1 step; based on Cbz2cyclen). NMR (CD ₃ CN): ¹ H δ _H 2.30‒3.38 (mc, CH ₂ ‒P, m, 16+4H); 3.47 (CH ₃ , d, 6H, ³ J _HP = 11); 5.00‒5.12 (CH ₂ ‒Ph, m, 4H); 7.27‒7.40 (Ph, m, 10H); 7.40‒7.51 (Ph, m, 4H); 7.51‒ 7.60 (Ph, m, 2H); 7.60‒7.82 (Ph, m, 4H). ³¹ P δ _P 42.8 (m). ESI-HRMS: 777.3178 [M+H] ⁺ (theor. [C ₄₀ H ₅₁ N ₄ O ₈ P ₂ ] ⁺ = 777.3177). Synthesis of TD910: Pear-shape glass flask (50 mL) was charged with TD913 (250 mg; 322 µmol) and magnetic stirrer and three times secured with argon. Solid Pd@C (50 mg) was hen added followed by another securing with argon (three times). Under constant flow of argon was then added MeOH (25 mL) through septum. Argon input was then removed and H ₂ gas (from balloon) was allowed to bubble through the mixture for 2 h at RT. Catalyst was hen filtered off using syringe microfilter (PTFE; filter was further washed with MeOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colourless oil. Yield: 161 mg (98%; 1 step; based on TD913). NMR (CD ₃ CN): ¹ H δ _H 2.28‒3.14 (mc, CH ₂ ‒P, m, 16+4H); 3.53 (CH ₃ , d, 3H, ³ JHP = 11); 3.54 (CH ₃ , d, 3H, ³ JHP = 11); 7.46‒7.63 (Ph, m, 6H); 7.71‒7.83 (Ph, m, 4H). ³¹ P δP 43.3 (m). ESI-HRMS: 509.2438 [M+H] ⁺ (theor. [C24H ₃ 9N4O ₄ P ₂ ] ⁺ = 509.2441). Synthesis of TD571: In a glass vial (4 mL), Cbz2cyclen (free base; 1.00 g; 2.27 mmol; 1.0 quiv.) and P(OEt) ₃ (2.00 mL; 11.7 mmol; 5.1 equiv.) were mixed together followed by ddition of solid (CH ₂ O)n (164 mg; 5.47 mmol; 2.4 equiv.). The resulting suspension was tirred 24 h at RT. Reaction mixture was then evaporated to dryness and the residue was urified by column chromatography (SiO ₂ ; 80 g; DCM‒MeOH‒aq. NH ₃ 150:10:1). Fractions with product were combined and evaporated to dryness. The residue was further ried on high vacuum overnight to give product in the form of free base as slightly yellow oil. Yield: 1.29 g (77%; 1 step; based on Cbz2cyclen). ESI-MS (LC-MS): 741.3 [M+H] ⁺ (theor. [C ₃₄ H ₅₅ N ₄ O ₁₀ P ₂ ] ⁺ = 741.3). All of TD571 was directly used for TD573 without further characterization. Synthesis of TD573: Pear-shape glass flask (100 mL) was charged with TD571 (1.29 g; .74 mmol) and magnetic stirrer and three times secured with argon. Solid Pd@C (129 mg) was then added followed by another securing with argon (three times). Under constant flow f argon was then added EtOH (96%, 70 mL) through septum. Argon input was then emoved and H ₂ gas (from balloon) was allowed to bubble through the mixture for 30 min t RT. The reaction mixture was further stirred under hydrogen atmosphere (from balloon) 6 h at RT. Catalyst was then filtered off using syringe microfilter (PTFE; filter was further washed with EtOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as slightly yellow oil. Yield: 776 mg (95%; 1 step; based on TD571). ESI-MS (LC-MS): 473.2 [M+H] ⁺ (theor. [C ₁₈ H ₄₃ N ₄ O ₄ P ₂ ] ⁺ = 473.3). Major portion of TD573 was directly used for TD579 without further characterization. ynthesis of TD423: In a pear-shape glass flask (25 mL), tBuDO2A (free base; 410 mg; .03 mmol; 1.4 equiv.) was dissolved in dry MeCN (8 mL) followed by addition of Cs2CO3 (840 mg; 2.58 mmol; 3.4 equiv.) and of KI (172 mg; 1.04 mmol; 1.4 equiv.). olution of 2-Chloro-N-(prop-2-yn-1-yl)acetamide (100 mg; 760 µmol; 1.0 equiv.) in ry MeCN (2 mL) was added and the resulting mixture was stirred 3 d at RT. Solids were ltered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness to give pre- purified product in the form of free base as yellow oil. Yield: 180 mg (~75% of TD423 in a mixture with ~25% of bis(substituted) by-product). ESI-MS (LC-MS): 496.4 [M+H] ⁺ (theor. [C25H46N5O ₅ ] ⁺ = 496.3). All of TD423 was directly used for TD425 without further purification and characterization. Synthesis of TD635: In a pear-shape glass flask (250 mL), tBuDO2A (free base; 1.21 ; 3.02 mmol; 2.3 equiv.) was dissolved in MeCN (150 mL). To the vigorously stirred eaction mixture, solution of TD558 (1202 mg; 1.33 mmol; 1.0 equiv.) in MeCN (100 mL) was added dropwise (over the course of 2 h). Resulting mixture was further stirred d at RT after which was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were ombined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as faint yellow oil that crystallized on standing. Yield: 453 mg (66%; 1 step; based on TD558). NMR (CD ₃ CN): ¹ H δ _H 1.39 (CH ₃ , s, 18H); 2.53 (mc, m, 4H); 2.61 (mc, m, 4H); 2.73 (mc, m, 4H); 2.77 (mc, m, 4H); 3.01 (CH ₂ ‒CO, s, 4H); 3.44 (C≡CH, s, 1H); 3.66 (CH ₂ ‒arom., s, 2H); 7.38 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.70 (arom., t, 1H, ³ J _HH = 8); 7.76 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1). ¹³ C{ ¹ H} δ _C 28.4 (CH ₃ , s); 48.2 (mc, s); 51.8 (mc, s); 52.6 (mc, s); 54.9 (mc, s); 57.6 (CH ₂ ‒CO, s); 59.3 (CH ₂ ‒arom., s); 78.0 (C≡CH, s); 81.3 (C‒CH ₃ , s); 84.0 (C≡CH, s); 124.9 (arom., s); 126.5 (arom., s); 137.8 (arom., s); 141.6 (arom., s); 162.8 (arom., s); 172.0 (CO, s). ESI-HRMS: 516.3542 [M+H] ⁺ (theor. [C ₂₈ H ₄₆ N ₅ O ₄ ] ⁺ = 516.3544). ynthesis of TD539: In a pear-shape glass flask (100 mL), tBuDO2A (free base; .73 g; 4.32 mmol; ≥2.0 equiv.) was dissolved in dry MeCN (15 mL) followed by ddition of dried K ₂ CO ₃ (900 mg; 6.52 mmol; ≥3.0 equiv.). To the vigorously tirred reaction mixture, solution of freshly prepared and isolated TD538 (≤2.17 mmol; 1.0 equiv.) in dry MeCN (10 mL) was added dropwise (over the course of 5 min). Resulting mixture was further stirred 20 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (150 mL) and H ₂ O (150 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 100 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow solidified oil. Yield: 653 mg (47%; 2 steps; based on TD530). NMR (CD ₃ CN): ¹ H δ _H 1.39 (CH ₃ , s, 18H); 1.43 (CH ₃ , s, 9H); 2.51–2.84 (mc, m, 16H); 3.01 (CH ₂ ‒CO, s, 4H); 3.64 (CH ₂ ‒arom., s, 2H); 4.05 (CH ₂ ‒C≡C, bd, 2H, ³ J _HH = 5); 5.97 (NH‒CO, bt, 1H, ³ J _HH = 5); 7.27 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.66–7.75 (arom., m, 2H). ¹³ C{ ¹ H} δ _C 28.4 (CH ₃ , s); 28.6 (CH ₃ , s); 31.2 (CH ₂ ‒C≡C, bs); 48.1 (mc, s); 51.8 (mc, s); 52.8 (mc, s); 55.1 (mc, s); 57.6 (CH ₂ ‒CO, s); 59.6 (CH ₂ ‒arom., s); 81.3 (C‒CH ₃ , 2 × s); 82.6 and 87.0 (C≡C, 2 × s); 124.3 (arom., s); 126.0 (arom., s); 137.7 (arom., s); 142.3 (arom., s); 162.7 (arom., s); 172.0 (CO, s). ESI-HRMS: 645.4331 [M+H] ⁺ (theor. [C ₃₄ H ₅₇ N ₆ O ₆ ] ⁺ = 645.4334). Synthesis of TD1118: In a pear-shape glass flask (50 mL), tBuDO2A (free base; 160 mg; 399 µmol; ≥2.5 equiv.) was dissolved in MeCN (10 mL) followed by addition of ried K ₂ CO ₃ (65 mg; 470 µmol; ≥3 equiv.). To the vigorously stirred reaction mixture, olution of freshly prepared and isolated TD1117 (≤470 mmol; 1.0 equiv.) in MeCN (10 mL) was added dropwise (over the course of 5 min). Resulting mixture was further irred 16 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 30 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless solidified oil. Yield: 62.2 mg (57%; 2 steps; based on TD966). NMR (CD ₃ CN): ¹ H δ _H 1.40 (CH ₃ , s, 18H); 1.43 (CH ₃ , s, 9H); 1.53–1.64 (CH ₂ , m, 2H); 1.82–1.91 (CH ₂ , m, 2H); 2.47–2.79 (mc, m, 16H); 2.79–2.88 (CH‒C≡C, m, 1H); 3.01 (CH ₂ ‒CO, s, 4H); 3.06–3.18 (CH ₂ , m, 2H); 3.63 (CH ₂ ‒arom., s, 2H); 3.71–3.82 (CH ₂ , m, 2H); 7.27 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.62–7.72 (arom., m, 2H). ESI-HRMS: 699.4801 [M+H] ⁺ (theor. [C ₃₈ H63N6O ₆ ] ⁺ = 699.4804). Synthesis of TD692: In a pear-shape glass flask (250 mL), TD681 (100 mg; 259 µmol; .5 equiv.) was dissolved in MeCN (25 mL). To the vigorously stirred reaction mixture, solution of TD558 (26 mg; 172 µmol; 1.0 equiv.) in MeCN (25 mL) was dded dropwise (over the course of 1 h). Resulting mixture was further stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, immediately neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 38 mg (44%; 1 step; based on TD558). ESI-MS (LC-MS): 502.4 [M+H] ⁺ (theor. [C ₂₇ H ₄₄ N ₅ O ₄ ] ⁺ = 502.3). All of TD692 was directly used for TD703 without further characterization. Synthesis of TD700: In a pear-shape glass flask (100 mL), TD695 (100 mg; 229 µmol; 1.5 equiv.) was dissolved in MeCN (25 mL) followed by addition of dried K ₂ CO ₃ (21 mg; 152 µmol; 1.0 equiv.). To the vigorously stirred reaction mixture, olution of TD558 (23 mg; 152 µmol; 1.0 equiv.) in MeCN (25 mL) was added ropwise (over the course of 1 h). Resulting mixture was further stirred 16 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (75 mL) and H ₂ O (75 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 20 mg (24%; 1 step; based on TD558). ESI-MS (LC-MS): 552.3 [M+H] ⁺ (theor. [C ₂₇ H ₄₇ N ₅ O ₅ P ₁ ] ⁺ = 552.3). All of TD700 was directly used for TD705 without further characterization. Synthesis of TD579: In a pear-shape glass flask (25 mL), TD573 (600 mg; 1.27 mmol; 2.0 equiv.) was dissolved in MeCN (10 mL). To the vigorously stirred reaction mixture, solution of TD558 (30 mg; 488 µmol; 1.0 equiv.) in MeCN (10 mL) was dded dropwise (over the course of 30 min). Resulting mixture was further stirred 16 at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was vaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (125 mL), H ₂ O (125 mL) and aq. NaOH (1%; 20 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as yellow oil. Yield: 137 mg (48%; 1 step; based on TD558). ESI-MS (LC-MS): 588.3 [M+H] ⁺ (theor. [C26H48N5O ₆ P ₂ ] ⁺ = 588.3). TD579 was directly used for TD575 and TD580 and without further characterization. Synthesis of TD799: In a pear-shape glass flask (100 mL), tBuDO2Prop (free base; 65 mg; 385 µmol; 2.0 equiv.) was dissolved in MeCN (30 mL). To the vigorously irred reaction mixture, solution of TD558 (29 mg; 191 µmol; 1.0 equiv.) in MeCN (30 mL) was added dropwise (over the course of 6 h). Resulting mixture was further stirred 0 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was vaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN radient with FA additive). Fractions with product were combined, neutralized with dil. q. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as slightly yellow oil. Yield: 47 mg (45%; 1 step; based on TD558). NMR (CD ₃ CN): ¹ H δ _H 1.38 (CH ₃ , s, 18H); 2.19‒2.25 (CH ₂ ‒CO, m, 4H); 2.44‒2.64 (mc, CH ₂ ‒CH ₂ ‒CO, m, 16+4H); 3.41 (C≡CH, s, 1H); 3.66 (CH ₂ ‒arom., s, 2H); 7.36 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.70 (arom., t, 1H, ³ J _HH = 8); 7.77 (arom., bd, 1H, ³ J _HH = 8). ESI-HRMS: 544.3854 [M+H] ⁺ (theor. [C ₃₀ H ₅₀ N ₅ O ₄ ] ⁺ = 544.3857). ynthesis of TD663: In a pear-shape glass flask (50 mL), tBuDO2A (free base; 10 mg; 524 µmol; 2.7 equiv.) was dissolved in MeCN (15 mL) followed by ddition of dried K ₂ CO ₃ (27 mg; 195 µmol; 1.0 equiv.). To the vigorously irred reaction mixture, solution of TD566 (50 mg; 193 µmol; 1.0 equiv.) in MeCN (15 mL) was added dropwise (over the course of 15 min). Resulting ixture was further stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 83 mg (69%; 1 step; based on TD566). NMR (CD ₃ CN): ¹ H δ _H 1.33 (CH ₃ , s, 18H); 2.62 (mc, m, 4H); 2.66 (mc, m, 4H); 2.74 (mc, m, 4H); 2.80 (mc, m, 4H); 2.82 (CH ₂ ‒CO, s, 4H); 3.74 (CH ₂ ‒arom., s, 2H); 4.46 (CH ₂ ‒N ₃ , s, 2H); 2.46–7.58 (Ph, arom., m, 3+1H); 7.78–7.87 (Ph, m, 2H); 8.18 (arom., bs, 1H). ESI-HRMS: 623.4022 [M+H] ⁺ (theor. [C ₃₃ H51N8O ₄ ] ⁺ = 623.4028). Synthesis of TD711: In a pear-shape glass flask (100 mL), tBuDO2A (free base; 564 mg; 1.41 mmol; 2.5 equiv.) was dissolved in MeCN (40 mL). To the vigorously stirred eaction mixture, solution of TD406 (103 mg; 564 µmol; 1.0 equiv.) in MeCN (40 mL) was added dropwise (over the course of 2 h). Resulting mixture was further stirred 3 d t RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was vaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN radient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colourless oil. Yield: 217 mg (70%; 1 step; based on TD406). NMR (CD ₃ CN): ¹ H δ _H 1.39 (CH ₃ , s, 18H); 2.55 (mc, m, 4H); 2.60 (mc, m, 4H); 2.76 (mc, m, 8H); 3.03 (CH ₂ ‒CO, s, 4H); 3.70 (CH ₂ ‒arom., s, 2H); 4.39 (CH ₂ ‒N ₃ , s, 2H); 7.21 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.67 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.73 (arom., t, 1H, ³ J _HH = 8). ¹³ C{ ¹ H} δ _C 28.4 (CH ₃ , s); 48.3 (mc, s); 51.8 (mc, s); 52.7 (mc, s); 54.7 (mc, s); 56.1 (CH ₂ ‒N ₃ , s); 57.7 (CH ₂ ‒CO, s); 59.0 (CH ₂ ‒arom., s); 81.2 (C‒CH ₃ , s); 121.2 (arom., s); 124.1 (arom., s); 138.2 (arom., s); 155.6 (arom., s); 161.9 (arom., s); 172.0 (CO, s). ESI-HRMS: 547.3716 [M+H] ⁺ (theor. [C ₂₇ H ₄₇ N ₈ O ₄ ] ⁺ = 547.3715). ynthesis of TD596: In a pear-shape glass flask (25 mL), tBuDO2A (free base; 162 g; 405 µmol; ≥2.5 equiv.) was dissolved in MeCN (10 mL). To the vigorously stirred action mixture, solution of crude TD633 (≤162 µmol; 1.0 equiv.) in MeCN (10 mL) as added dropwise (over the course of 15 min). Resulting mixture was further stirred d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was vaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated and the aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 44 mg (48%; 2 steps; based on TD406). ESI-MS (LC-MS): 563.4 [M+H] ⁺ (theor. [C ₂₇ H47N8O ₅ ] ⁺ = 563.4). All of TD596 was directly used for TD604 without further characterization. Synthesis of TD1340: In a pear-shaped glass flask (50 mL), Cbz2cyclen (free base; 1.32 ; 3.0 mmol; 1.0 equiv.) was dissolved in dry MeCN (15 mL) followed by addition of dried K ₂ CO ₃ (1.65 g; 12.0 mmol; 4.0 equiv.). Then, solution of TD1339 (1.50 g; 6.0 mmol; 2.0 quiv.) in dry MeCN (5 mL) was added and the resulting suspension was stirred 8 h at RT. olids were filtered off using syringe microfilter (PTFE) and the filtrate was evaporated to ryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA a dditive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (150 mL) and H ₂ O (150 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 1.57 g (82%; 1 step; based on Cbz2cyclen). NMR (CD ₃ CN): ¹ H δ _H 1.09 (CH ₃ ‒CH, d, 6H, ³ J _HH = 7); 1.19 (CH ₃ ‒CH ₂ , t, 6H, ³ J _HH = 7); 2.58‒2.70 (mc, m, 4H); 2.76‒2.98 (mc, m, 4H); 3.23‒3.52 (mc, m, 8H); 3.52‒3.79 (CH, m, 2H); 4.06 (CH ₂ ‒CH ₃ , q, 4H, ³ J _HH = 7); 5.00‒5.13 (CH ₂ ‒Ph, m, 4H); 7.24‒7.41 (Ph, m, 10H). ESI-HRMS: 641.3539 [M+H] ⁺ (theor. [C ₃₄ H ₄₉ N ₄ O ₈ ] ⁺ = 641.3545). Synthesis of TD1341: Pear-shaped glass flask (100 mL) was charged with Pd@C (127 mg) nd magnetic stirrer and three times secured with argon. Solution of TD1340 (1.27 g; 1.98 mmol) in MeOH (50 mL) was then added through septum. Argon input was then removed nd H ₂ gas (from balloon) was allowed to bubble through the mixture for 1 h at RT. Catalyst as then filtered off using syringe microfilter (PTFE; filter was further washed with MeOH). iltrate was evaporated to dryness and once co-evaporated with DCM. The residue was urther dried on high vacuum overnight to give product in the form of free base as nearly colourless oil. Yield: 723 mg (98%; 1 step; based on TD1340). NMR (CD ₃ CN): ¹ H δ _H 1.16–1.33 (CH ₃ , m, 12H); 2.35‒2.45 (mc, m, 4H); 2.56‒2.65 (mc, m, 4H); 2.65‒2.76 (mc, m, 4H); 2.76‒2.85 (mc, m, 4H); 3.54 (CH, q, 2H, ³ J _HH = 7); 4.00–4.24 (CH ₂ ‒CH ₃ , q, 4H, ³ J _HH = 7). ESI-HRMS: 372.2808 [M+H] ⁺ (theor. [C ₁₈ H ₃₇ N ₄ O ₄ ] ⁺ = 373.2809). ynthesis of TD1343: In a pear-shaped glass flask (50 mL), TD1341 (143 mg; 384 mol; 2.0 equiv.) was dissolved in MeCN (15 mL) followed by addition of dried K ₂ CO ₃ (26.3 mg; 191 µmol; 1.0 equiv.). To the vigorously stirred reaction mixture, olution of TD558 (29.0 mg; 191 µmol; 1.0 equiv.) in MeCN (15 mL) was added ropwise (over the course of 15 min). Resulting mixture was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as nearly colourless oil. Yield: 46.0 mg (49%; 1 step; based on TD558). NMR (CD ₃ CN): ¹ H δ _H 1.14 (CH ₃ ‒CH, d, 6H, ³ J _HH = 7); 1.19 (CH ₃ ‒CH ₂ , t, 6H, ³ J _HH = 7); 2.28‒2.38 (mc, m, 4H); 2.45‒2.59 (mc, m, 4H); 2.59‒2.94 (mc, m, 8H); 3.23 (CH, q, 2H, ³ J _HH = 7); 3.41 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 3.45 (C≡CH, s, 1H); 3.88 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.06 (CH ₂ ‒CH ₃ , q, 4H, ³ J _HH = 7); 7.35–7.42 (arom., m, 1H); 7.66–7.79 (arom., m, 2H). ESI- HRMS: 488.3231 [M+H] ⁺ (theor. [C ₂₆ H ₄₂ N ₅ O ₄ ] ⁺ = 488.3231). 10 Synthesis of TD1345: In a pear-shaped glass flask (25 mL), TD1343 (45.0 mg; 92 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (51 mg; 196 µmol; 4.0 equiv.). Solution of TD406 (20.0 mg; 110 µmol; 1.2 equiv.) in MeCN (2 mL) was then added and the resulting uspension was stirred 7 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as nearly colourless oil. Yield: 52.9 mg (90%; 1 step; based on TD1343). ESI-HRMS: 634.3825 [M+H] ⁺ (theor. [C ₃₃ H ₄₈ N ₉ O ₄ ] ⁺ = 634.3824). All of TD1345 was directly used for TD1346 without further characterization. Synthesis of TD1447: In a pear-shaped glass flask (100 mL), TD1341 (722 mg; 1.94 mmol; 2.0 equiv.) was dissolved in MeCN (40 mL) followed by addition of dried K ₂ CO ₃ (133 mg; 964 µmol; 1.0 equiv.). To the vigorously stirred reaction mixture, solution of TD1057 (241 mg; 962 µmol; 1.0 equiv.) in MeCN (40 mL) was added dropwise (over the course of 2 h). Resulting mixture was further stirred 16 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O- ‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (100 mL) and H ₂ O (100 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of formate salt as faint yellow oil. Yield: 367 mg (60% assuming M·1.0FA; M _R = 632.7; 1 step; based on TD1057). Recovery: 352 mg of TD1341 (49% of the initial amount used). NMR (CD ₃ CN): ¹ H δ _H 1.18 (CH ₃ ‒ CH, d, 6H, ³ J _HH = 7); 1.21 (CH ₃ ‒CH ₂ , t, 6H, ³ J _HH = 7); 2.52‒2.62 (mc, m, 4H); 2.64‒2.76 (mc, m, 4H); 2.81‒ 2.94 (mc, m, 4H); 2.95‒3.06 (mc, m, 4H); 3.39 (CH‒CH ₃ , q, 2H, ³ J _HH = 7); 3.81 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 3.90 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.09 (CH ₂ ‒CH ₃ , q, 4H, ³ J _HH = 7); 4.62 (CH ₂ ‒N ₃ , s, 2H); 7.58 (arom., d, 1H, ⁴ J _HH = 2); 7.66 (arom., d, 1H, ⁴ J _HH = 2). ¹⁹ F δ _F −65.10 (s). ESI-HRMS: 587.3266 [M+H] ⁺ (theor. [C ₂₆ H ₄₂ N ₈ O ₄ F ₃ ] ⁺ = 587.3276). Synthesis of TD1449: In a pear-shaped glass flask (25 mL), TD1447 (assuming M·FA; 263.0 mg; 418 µmol; 1.0 equiv.) was dissolved in MeCN (5 mL) followed by addition of dried K ₂ CO ₃ 231 mg; 1.67 µmol; 4.0 equiv.). Solution of TD1428 (173.0 mg; 421 µmol; 1.0 equiv.) in MeCN (10 mL) was then added and the resulting suspension was stirred 1 d at 40 °C. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as yellow waxy oil. Yield: 309 mg (81%; 1 step; based on TD1447). NMR (CD ₃ CN): ¹ H δ _H 1.10 (CH ₃ ‒CH, d, 6H, ³ J _HH = 7); 1.13 (CH ₃ ‒CH ₂ , t, 6H, ³ J _HH = 7); 1.43 (CH ₃ –C–O, s, 9H); 1.61 (CH ₃ –C–N, s, 6H); 2.53‒2.80 (mc, m, 12H); 2.89‒3.03 (mc, m, 4H); 3.32 (CH‒CH ₃ , q, 2H, ³ J _HH = 7); 3.68 (CH ₂ ‒arom., s, 2H); 3.71 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 3.77 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 3.89 (CH ₃ –O, s, 3H); 3.99 (CH ₂ ‒CH ₃ , q, 4H, ³ J _HH = 7); 4.52 (CH ₂ ‒N ₃ , s, 2H); 5.56 (NH, bs, 1H); 7.50 (arom., d, 1H, ⁴ J _HH = 2); 7.71 (arom., d, 1H, ⁴ J _HH = 2); 8.00 (arom., d, 1H, ⁴ J _HH = 2); 8.16 (arom., d, 1H, ⁴ J _HH = 2). ¹⁹ F δ _F −64.98 (s). ESI-HRMS: 917.4851 [M+H] ⁺ (theor. [C ₄₄ H ₆₄ N ₁₀ O ₈ F ₃ ] ⁺ = 917.4855). Synthesis of rac-TD1489: In a glass vial (20 mL), Cbz2cyclen (free base; 178 mg; 404 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (225 mg; 1.63 mmol; 4.0 equiv.). Then, solution of TD1488 (250 mg; 850 µmol; 2.1 equiv.) in MeCN (2 mL) was added and the esulting suspension was stirred 4 d at 40 °C (racemization occurred during the course of the reaction). Solids were filtered off using syringe microfilter (PTFE) and further washed with MeCN. The filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and concentrated on rotary evaporator to remove most of MeCN. Mixture was diluted with DCM (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 172 mg (73%; 1 step; based on Cbz2cyclen). ESI-MS (LC-MS): 585.3 [M+H] ⁺ (theor. [C ₃₀ H ₄₁ N ₄ O ₈ ] ⁺ = 585.3). ynthesis of TD1493: In a glass vial (20 mL), rac-TD1489 (free base; 172 mg; 294 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by ddition of dried K ₂ CO ₃ (162 mg; 1.17 mmol; 4.0 equiv.). Then, solution of D1399 (148 mg; 592 µmol; 2.0 equiv.) in MeCN (2 mL) was added and the esulting suspension was stirred 70 min at 40 °C. Solids were filtered off using yringe microfilter (PTFE) and further washed with MeCN. The filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with pure product (the more hydrophobic diastereomer differing in chirality of the malate arm was successfully separated) were combined, neutralized with dil. aq. NaHCO ₃ and concentrated on rotary evaporator to remove most of MeCN. Mixture was diluted with DCM (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 88.1 mg (44%; 1 step; based on rac-TD1489). NMR (CD ₃ CN): ¹ H δ _H 1.09 (CH ₃ ‒CH, d, 3H, ³ J _HH = 7); 1.19 (CH ₃ ‒ CH ₂ , t, 3H, ³ J _HH = 7); 2.44 (CH ₂ ‒CH, dd, 1H, ² J _HH = 17, ³ J _HH = 6); 2.55‒2.70 (mc, CH ₂ ‒CH, m, 3+2H); 2.73‒7.43 (Ph, m, 10H). ESI-HRMS: 685.3439 [M+H] ⁺ (theor. [C ₃₅ H ₄₉ O ₁₀ N ₄ ] ⁺ = 685.3443). Synthesis of TD1495: Pear-shaped glass flask (25 mL) was charged with Pd@C (9 mg) and magnetic stirrer and three times secured with argon. Solution of TD1493 (88.0 mg; 129 µmol) in MeOH (6 mL) was then added hrough septum. Argon input was then removed and H ₂ gas (from balloon) was allowed to bubble through the mixture for 1 h at RT. Catalyst was then iltered off using syringe microfilter (PTFE; filter was further washed with MeOH). Filtrate was evaporated to dryness and once co-evaporated with DCM. The residue was further dried on high vacuum overnight to give product in the form of free base as colourless oil. Yield: 52.6 mg (98%; 1 step; based on TD1493). ESI-HRMS: 417.2706 [M+H] ⁺ (theor. [C ₁₉ H ₃₇ O ₆ N ₄ ] ⁺ = 417.2708). ynthesis of TD1497: In a pear-shaped glass flask (25 mL), TD1495 55 mg; 132 µmol; 1.7 equiv.) was dissolved in MeCN (5 mL) followed y addition of dried K ₂ CO ₃ (11.0 mg; 80 µmol; 1.0 equiv.). To the igorously stirred reaction mixture, solution of TD558 (12.0 mg; 79 mol; 1.0 equiv.) in MeCN (5 mL) was added dropwise (over the course f 15 min). Resulting mixture was stirred 4 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 10 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as nearly colourless oil. Yield: 12.1 mg (29%; 1 step; based on TD558). ESI-MS (LC-MS): 532.3 [M+H] ⁺ (theor. [C ₂₇ H ₄₂ N ₅ O ₆ ] ⁺ = 532.3). Synthesis of TD1500: In a glass vial (4 mL), TD1497 (12.1 mg; 23 mol; 1.0 equiv.) was dissolved in solution of TD406 (5.8 mg; 32 µmol; .4 equiv.) in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (17.5 mg; 127 µmol; 4.0 equiv.). The resulting suspension was stirred 1 d at 0 °C. Solids were filtered off using syringe microfilter (PTFE) and iltrate was diluted with H ₂ O (1 mL). Resulting solution was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (25 mL) and H ₂ O (25 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (4 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further briefly dried on high vacuum to give product in the form of free base as faint yellow oil. Yield: 11.9 mg (77%; 1 step; based on TD1497). ESI-MS (LC-MS): 678.3 [M+H] ⁺ (theor. [C ₃₄ H ₄₈ N ₉ O ₆ ] ⁺ = 678.4). Example 4: Synthesis of non-caged macrocyclic ligands Synthesis of TD425: In a pear-shape glass flask (50 mL), crude TD423 ~75% in a mixture with ~25% of bis(substituted) by-product; 180 mg; ≥1.0 equiv.) was dissolved in dry MeCN (10 mL) followed by addition of Cs ₂ CO ₃ (360 mg; 1.11 mmol; 3.8 equiv.). Solution of TD566 (75 mg; 290 µmol; 1.0 equiv.) in MeCN (5 mL) was then added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 129 mg (27%; 3 steps; based on 2-Chloro-N-(prop-2-yn-1-yl)acetamide). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.62 (C≡CH, t, 1H, ⁴ J _HH = 3); 2.89‒3.74 (mc, CH ₂ ‒CO, m, 16+6H); 3.79 (CH ₂ ‒C≡CH, t, 2H, ⁴ J _HH = 3); 4.03 (CH ₂ ‒arom., bs, 2H); 4.68 (CH ₂ ‒N ₃ , s, 2H); 7.55‒7.67 (Ph, arom., m, 3+1H); 7.78 (arom., d, 1H, ⁴ J _HH = 2); 7.85‒7.92 (Ph, m, 2H); 8.17 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 606.3151 [M+H] ⁺ (theor. [C ₃₀ H40N ₉ O ₅ ] ⁺ = 606.3147). EA (C ₃₀ H ₃₉ N ₉ O ₅ ·0.1FA·1.3H ₂ O, M _R = 633.7): C 57.0 (56.8); H 6.6 (6.3); N 19.9 (19.5). Synthesis of TD669: In a glass vial (4 mL), TD663 (30 mg; 48 µmol, 1.0 equiv.) was dissolved in dry MeCN (500 µL) followed by ddition of K ₂ CO ₃ (20 mg; 145 µmol; 3 equiv.). Solution of TD662 10 mg; 50 µmol; 1.0 equiv.) in MeCN (500 µL) was then added and he resulting suspension was stirred 2 d at RT. Another portion of TD662 (6 mg; 30 µmol; 0.6 equiv.) in MeCN (200 µL) was then dded and the mixture was further stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co- evaporated with MeOH to remove most of TFA. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 27 mg (≤88% assuming M·0.1FA·xH ₂ O; M _R = 634.4; 2 steps; based on TD663). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.59‒3.82 (mc, CH ₂ ‒CO, CH ₂ ‒CH ₂ ‒N(CH ₂ ‒C≡CH) ₂ , m, 16+4+10H); 4.00 (CH ₂ ‒arom., bs, 2H); 4.64 (CH ₂ ‒N ₃ , s, 2H); 7.55‒7.65 (Ph, m, 3H); 7.74 (arom., d, 1H, ⁴ J _HH = 2); 7.83‒7.91 (Ph, m, 2H); 8.17 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 630.3510 [M+H] ⁺ (theor. [C ₃₃ H ₄₄ N ₉ O ₄ ] ⁺ = 630.3511). Synthesis of TD604: In a glass vial (4 mL), TD596 (44 mg; 78 µmol; 1.0 quiv.) was dissolved in MeCN (3 mL) followed by addition of dried K ₂ CO ₃ 33 mg; 239 µmol; 3.0 equiv.). Solution of TD558 (13 mg; 86 µmol; 1.1 quiv.) in MeCN (600 µL) was then added and the resulting suspension was tirred 16 d at RT. Then additional portion of TD558 (2 mg; 13 µmol; 0.2 quiv.) in MeCN (400 µL). Reaction mixture was further stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 38 mg (81%; 2 steps; based on TD596). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.80‒ 3.68 (mc, CH ₂ ‒CO, m, 16+4H); 3.72 (C≡CH, s, 1H); 3.93 (CH ₂ ‒arom., bs, 2H); 4.17 (CH ₂ ‒arom., s, 2H); 4.74 (CH ₂ ‒N ₃ , s, 2H); 7.48‒7.67 (arom., m, 3H); 7.74‒7.95 (arom., m, 3H). ¹³ C{ ¹ H} δ _C 48.3 (mc, s); 48.9 (mc, s); 50.6 (CH ₂ ‒N ₃ , s); 51.4 (CH ₂ ‒arom., s); 51.5 (mc, s); 51.7 (mc, s); 56.7 (CH ₂ ‒CO, s); 58.8 (CH ₂ ‒arom., s); 80.7 and 82.2 (C≡CH; 2 × s); 126.0 (arom., s); 126.5 (arom., s); 127.9 (arom., s); 128.5 (arom., s); 131.5 (arom., s); 140.3 (arom., s); 141.2 (arom., s); 148.4 (arom., s); 148.7 (arom., s); 157.3 (arom., s); 169.5 (CO, s). ESI- HRMS: 566.2836 [M+H] ⁺ (theor. [C ₂₇ H ₃₆ N ₉ O ₅ ] ⁺ = 566.2834). EA (C ₂₇ H ₃ 5N ₉ O ₅ ·0.1FA·1.6H ₂ O, M _R = 599.1): C 54.3 (54.4); H 6.5 (6.1); N 21.0 (20.7). Synthesis of TD556: In a pear-shape glass flask (25 mL), TD635 (216 mg; 419 µmol; 1.0 equiv.) was dissolved in MeCN (12 mL) followed by addition of dried K ₂ CO ₃ (174 mg; 1.26 mmol; 3.0 equiv.). Solution of TD406 (92 mg; 504 µmol; 1.2 equiv.) in MeCN (3 mL) was then added and the resulting suspension was stirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 161 mg (66%; 2 steps; based on TD635). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.80‒3.60 (mc, CH ₂ ‒ CO, m, 16+4H); 3.74 (C≡CH, s, 1H); 3.86 (CH ₂ ‒arom., bs, 2H); 3.94 (CH ₂ ‒arom., bs, 2H); 4.72 (CH ₂ ‒N ₃ , s, 2H); 7.65 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.67 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.95–8.03 (arom., m, 3H); 8.12 (arom., t, 1H, ³ J _HH = 8); ¹³ C{ ¹ H} δ _C 48.3 (mc, s); 48.4 (mc, s); 51.4 (mc, s); 51.5 (mc, s); 54.3 (CH ₂ ‒ N ₃ , s); 56.6 (CH ₂ ‒CO, s); 58.0 (CH ₂ ‒arom., s); 58.9 (CH ₂ ‒arom., s); 80.9 and 82.0 (C≡CH; 2 × s); 124.5 (arom., s); 126.2 (arom., s); 126.3 (arom., s); 128.5 (arom., s); 140.5 (arom., s); 141.2 (arom., s); 142.7 (arom., s); 155.0 (arom., s); 155.5 (arom., s); 157.2 (arom., s); 169.2 (CO, s). ESI-HRMS: 550.2880 [M+H] ⁺ (theor. [C ₂₇ H ₃₆ N ₉ O ₄ ] ⁺ = 550.2885). EA (C ₂₇ H ₃₅ N ₉ O ₄ ·0.1FA·1.6H ₂ O, M _R = 583.1): C 55.8 (55.5); H 6.6 (6.1); N 21.6 (21.2). Synthesis of TD810: In a glass vial (20 mL), TD711 (103 mg; 188 µmol; 1.0 equiv.) was dissolved in MeCN (5 mL) followed by addition of dried K ₂ CO ₃ (130 mg; 942 µmol; 5.0 equiv.). Solution of TD807 (33 mg; 188 µmol; 1.0 equiv.) in MeCN (2 mL) was then added and the resulting suspension was stirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of mixed trifluoroacetate/formate salt as off white fluffy solid. Yield: 55 mg (43%; 2 steps; based on TD711). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.79‒3.63 (mc, CH ₂ ‒CO, m, 16+4H); 3.74 (C≡CH, s, 1H); 3.82 (CH ₂ ‒arom., bs, 2H); 3.87 (CH ₂ ‒arom., bs, 2H); 3.92 (C≡CH, s, 1H); 4.63 (CH ₂ ‒N ₃ , s, 2H); 7.55 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.72 (arom., d, 1H, ⁴ J _HH = 1); 8.10 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.16 (arom., t, 1H, ³ J _HH = 8); 8.26 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 574.2882 [M+H] ⁺ (theor. [C ₂₉ H ₃₆ N ₉ O ₄ ] ⁺ = 574.2885). EA (C ₂₉ H ₃₅ N ₉ O ₄ ·0.5TFA·0.1FA·2.1H ₂ O, M _R = 673.1): C 53.7 (53.8); H 6.0 (6.2); N 18.7 (18.7). Synthesis of TD827: In a glass vial (20 mL), TD635 (157 mg; 304 µmol; 1.0 equiv.) was dissolved in dry MeCN (7 mL) followed by ddition of dried K ₂ CO ₃ (210 mg; 1.52 mmol; 5.0 equiv.). Solution f TD817 (110 mg; 303 µmol; 1.0 equiv.) in dry MeCN (3 mL) was hen added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was vaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, concentrated to approx. half volume (to remove most of MeCN) and then diluted with DCM (125 mL). The resulting biphasic mixture was transferred to a separatory funnel. Aqueous phase was only then neutralized with dil. aq. NaHCO ₃ . After shaking, the bottom phase was separated and the aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and once co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as off white fluffy solid. Yield: 149 mg (62%; 2 steps; based on TD711). NMR (D ₂ O+FA, pD ~3): ¹ H δ _H 0.86‒1.33 (i-Pr, m, 21H); 2.58‒3.78 (mc, CH ₂ ‒CO, C≡CH, bm, 16+4+1H); 3.93 (CH ₂ ‒arom., bs, 2H); 4.06 (CH ₂ ‒arom., bs, 2H); 4.56 (CH ₂ ‒N ₃ , s, 2H); 7.37 (arom., s, 1H); 7.53 (arom., d, 1H, ³ J _HH = 8); 7.74 (arom., s, 1H); 7.80 (arom., d, 1H, ³ J _HH = 8); 7.96 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 730.4216 [M+H] ⁺ (theor. [C ₃₈ H56N ₉ O ₄ Si ₁ ] ⁺ = 730.4219). EA (C ₃₈ H ₅₅ N ₉ O ₄ Si ₁ ·0.8FA·1.6H ₂ O, M _R = 795.6): C 58.6 (58.7); H 7.6 (7.7); N 15.8 (15.7); Si 3.5 (3.2). Synthesis of TD718: In a pear-shape glass flask (10 mL), TD711 (31 mg; 57 µmol; 1.0 equiv.) was dissolved in dry MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (31 mg; 225 µmol; 4.0 equiv.). Solution of TD706 (13 mg; 58 µmol; 1.0 equiv.) in dry MeCN (2 mL) was then added and the resulting uspension was stirred 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, diluted with DCM (100 mL) and transferred to a separatory funnel. Aqueous phase was only then neutralized with dil. aq. NaHCO ₃ . After shaking, bottom phase was separated, dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and once co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as white fluffy solid. Yield: 23 mg (61%; 2 steps; based on TD706). NMR (D ₂ O, pD ~5): ¹ H δ _H 0.28 (CH ₃ , s, 9H); 2.28‒3.67 (mc, CH ₂ ‒CO, m, 16+4H); 3.89 (CH ₂ ‒arom., bs, 4H); 4.57 (CH ₂ ‒N ₃ , s, 2H); 7.49 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.58–7.64 (arom., m, 1H); 7.78–7.98 (arom., m, 4H). ESI-HRMS: 622.6277 [M+H] ⁺ (theor. [C ₃₀ H ₄₄ N ₉ O ₄ Si ₁ ] ⁺ = 622.3280). EA (C ₃₀ H ₄₃ N ₉ O ₄ Si ₁ ·2.6H ₂ O, M _R = 668.7): C 53.9 (53.9); H 7.3 (7.0); N 18.9 (18.7). Synthesis of TD728: In a pear-shape glass flask (10 mL), TD711 (66 mg; 121 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (67 mg; 486 µmol; 4.0 equiv.). Solution of TD723 (37 mg; 120 µmol; 1.0 equiv.) in MeCN (2 mL) was then added and the resulting suspension was stirred 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, diluted with DCM (150 mL) and the resulting biphasic mixture was transferred to a separatory funnel. Aqueous phase was only then neutralized with dil. aq. NaHCO ₃ . After shaking, the bottom phase was separated and the aqueous phase was further extracted with DCM (2 × 50 mL). Combined organic layers were with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and once co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as white fluffy solid. Yield: 64 mg (71%; 2 steps; based on TD723). NMR (D ₂ O, pD ~5): ¹ H δ _H 0.84‒1.34 (i-Pr, m, 21H); 2.41‒3.78 (mc, CH ₂ ‒CO, m, 16+4H); 3.89 (CH ₂ ‒arom., bs, 2H); 3.95 (CH ₂ ‒arom., bs, 2H); 4.52 (CH ₂ ‒N ₃ , s, 2H); 7.42 (arom., d, 1H, ³ J _HH = 8); 7.46 (arom., d, 1H, ³ J _HH = 8); 7.74 (arom., d, 1H, ³ J _HH = 8); 7.78 (arom., d, 1H, ³ J _HH = 8); 7.85 (arom., t, 1H, ³ J _HH = 8); 7.87 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 706.4221 [M+H] ⁺ (theor. [C ₃₆ H ₅₆ N ₉ O ₄ Si ₁ ] ⁺ = 706.4219). EA (C ₃₆ H ₅₅ N ₉ O ₄ Si ₁ ·2.6H ₂ O, M _R = 752.8): C 57.4 (57.7); H 8.1 (8.0); N 16.7 (16.5); Si 3.7 (3.8). Synthesis of TD1204: In a glass vial (20 mL), TD711 (35.0 mg; 64.0 µmol; 1.0 equiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ (44.2 mg; 320 µmol; 5.0 equiv.). Solution of TD1194 (21.4 mg; 77.1 µmol; 1.2 equiv.) in MeCN (2 mL) was then added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 23.3 mg (49%; 2 steps; based on TD711). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.83‒3.67 (mc, CH ₂ ‒ CO, m, 16+4H); 3.88 (CH ₂ ‒arom., bs, 2H); 3.92 (CH ₂ ‒arom., bs, 2H); 4.56 (CH ₂ ‒N ₃ , s, 2H); 7.49 (arom., d, 1H, ³ J _HH = 8); 7.54 (arom., d, 1H, ³ J _HH = 8); 7.87–8.00 (arom., m, 4H). ESI-HRMS: 676.1855 [M+H] ⁺ (theor. [C ₂₇ H ₃₅ N ₉ O ₄ I ₁ ] ⁺ = 676.1851). EA (C ₂₇ H ₃₄ N ₉ O ₄ I ₁ ·0.3FA·2.7H ₂ O, M _R = 738.0): C 44.4 (44.6); H 5.5 (5.1); N 17.1 (16.7). Synthesis of TD944: In a pear-shape glass flask (10 mL), TD711 (58 mg; 106 mol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of ried K ₂ CO ₃ (87 mg; 629 µmol; 6.0 equiv.). Solution of freshly prepared and solated TD939 (≤105 µmol; ≤1.0 equiv.) in MeCN (2 mL) was then added nd the resulting suspension was stirred 2 d at RT. Solids were filtered off sing syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with A additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as faint yellow solid. Yield: 38 mg (55%; 3 steps; based on TD936). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.82‒3.67 (mc, CH ₂ ‒CO, m, 16+4H); 3.91 (CH ₂ ‒arom., bs, 2H); 3.95 (CH ₂ ‒arom., bs, 2H); 4.58 (CH ₂ ‒N ₃ , s, 2H); 7.40‒8.07 (Ph, arom., m, 5+6H). ESI-HRMS: 626.3197 [M+H] ⁺ (theor. [C ₃₃ H ₄₀ N ₉ O ₄ ] ⁺ = 626.3198). EA (C ₃₀ H ₃₉ N ₉ O ₄ ·1.5H ₂ O, M _R = 652.8): C 60.7 (61.0); H 6.5 (6.3); N 19.3 (18.8). 5 Synthesis of TD943: In a pear-shape glass flask (10 mL), TD711 (82 mg; 150 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (125 mg; 904 µmol; 6.0 equiv.). Solution of freshly prepared and solated TD940 (≤150 µmol; ≤1.0 equiv.) in MeCN (2 mL) was then added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as faint yellow solid. Yield: 66 mg (71%; 3 steps; based on TD937). NMR (D ₂ O, pD ~7): ¹ H δ _H 0.74‒1.06 (CH ₂ ‒CH, m, 4H); 1.35‒1.66 (CH ₂ ‒CH, m, 1H); 2.69‒3.65 (mc, CH ₂ ‒CO, m, 16+4H); 3.86 (CH ₂ ‒arom., bs, 2H); 3.92 (CH ₂ ‒arom., bs, 2H); 4.57 (CH ₂ ‒N ₃ , s, 2H); 7.42‒7.53 (arom., m, 2H); 7.83‒8.01 (arom., m, 4H). ESI-HRMS: 590.3196 [M+H] ⁺ (theor. [C ₃₀ H ₄₀ N ₉ O ₄ ] ⁺ = 590.3198). EA (C ₃₀ H ₃₉ N ₉ O ₄ ·1.5H ₂ O, M _R = 616.7): C 58.4 (58.6); H 6.9 (6.9); N 20.4 (20.3). Synthesis of TD959: In a pear-shape glass flask (10 mL), TD711 (23 mg; 42 µmol; 1.0 equiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ (35 mg; 253 µmol; 6.0 equiv.). Solution of freshly prepared and solated TD956 (≤42 µmol; ≤1.0 equiv.) in MeCN (1 mL) was then added and he resulting suspension was stirred 2 d at RT. Solids were filtered off using yringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as nearly colourless solid. Yield: 18 mg (67%; 3 steps; based on TD952). NMR (D ₂ O, pD ~6): ¹ H δ _H 1.34 (CH ₃ , s, 9H); 2.72‒3.69 (mc, CH ₂ ‒CO, m, 16+4H); 3.88 (CH ₂ ‒arom., bs, 2H); 3.92 (CH ₂ ‒arom., bs, 2H); 4.57 (CH ₂ ‒N ₃ , s, 2H); 7.46‒7.55 (arom., m, 2H); 7.84‒8.03 (arom., m, 4H). ESI-HRMS: 606.3513 [M+H] ⁺ (theor. [C ₃₁ H ₄₄ N ₉ O ₄ ] ⁺ = 606.3511). EA (C ₃₁ H ₄₃ N ₉ O ₄ ·1.8H ₂ O, M _R = 638.2): C 58.3 (58.7); H 7.4 (7.0); N 19.8 (19.4 5 Synthesis of TD992: In a glass vial (4 mL), TD711 (43 mg; 79 µmol; 1.0 equiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ (44 mg; 318 µmol; 4.1 equiv.). Solution of freshly prepared and isolated TD990 (≤79 µmol; ≤1.0 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 16 h at 40 °C. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as off white fluffy solid. Yield: 42.0 mg (73%; 3 steps; based on TD965). NMR (D ₂ O, pD ~5): ¹ H δ _H 1.62–1.83 (Adm., m, 6H); 1.86–2.04 (Adm., m, 9H); 2.77‒3.70 (mc, CH ₂ ‒ CO, m, 16+4H); 3.90 (CH ₂ ‒arom., bs, 2H); 3.94 (CH ₂ ‒arom., bs, 2H); 4.57 (CH ₂ ‒N ₃ , s, 2H); 7.44‒7.56 (arom., m, 2H); 7.82‒8.00 (arom., m, 4H). ESI-HRMS: 684.3982 [M+H] ⁺ (theor. [C ₃₇ H ₅₀ N ₉ O ₄ ] ⁺ = 684.3980). EA (C ₃₇ H ₄₉ N ₉ O ₄ ·0.3FA·1.9H ₂ O, M _R = 731.9): C 61.2 (61.2); H 7.1 (7.1); N 17.2 (17.0). Synthesis of TD703: In a glass vial (20 mL), TD692 (38 mg; 76 µmol; 1.0 equiv.) was dissolved in MeCN (3 mL) followed by addition of dried K ₂ CO ₃ 31 mg; 217 µmol; 3.0 equiv.). Solution of TD406 (14 mg; 77 µmol; 1.0 equiv.) in MeCN (2 mL) was then added and the resulting suspension was tirred 16 h at RT. Then, another portion of dried K ₂ CO ₃ (31 mg; 217 µmol; 3.0 equiv.) and of TD406 (10 mg; 55 µmol; 0.7 equiv.) in MeCN (1 mL) was added and the resulting suspension was further stirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with protected product were combined, evaporated to dryness and further two-times co-evaporated with MeOH. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and three-times co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of mixed trifluoroacetate/formate salt as slightly yellow viscous oil. Yield: 16 mg (34%; 2 steps; based on TD692). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.59‒3.73 (mc, CH ₂ ‒CO, m, 16+2H); 3.75 (C≡CH, s, 1H); 3.84 (CH ₂ ‒ arom., bs, 2H); 4.29‒4.62 (CH ₂ ‒arom., CH ₂ ‒N ₃ , m, 2+2H); 7.37 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.45 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.52 (arom., t, 1H, ³ J _HH = 8); 7.56 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.59 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 492.2829 [M+H] ⁺ (theor. [C ₂₅ H ₃₄ N ₉ O ₂ ] ⁺ = 492.2830). EA (C ₂₅ H ₃₃ N ₉ O ₂ ·0.3TFA·0.7FA·3.5H ₂ O, M _R = 621.1): C 50.9 (51.1); H 6.8 (6.8); N 20.3 (20.0). Synthesis of TD705: In a glass vial (20 mL), TD700 (20 mg; 36 µmol; 1.0 quiv.) was dissolved in MeCN (3 mL) followed by addition of dried K ₂ CO ₃ 20 mg; 145 µmol; 4.0 equiv.). Solution of TD406 (9 mg; 49 µmol; 1.4 equiv.) n MeCN (1 mL) was then added and the resulting suspension was stirred 2 d t RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 22 mg (87%; 1 step; based on TD406). ESI-MS (LC-MS): 698.4 [M+H] ⁺ (theor. [C ₃₄ H ₅₃ N ₉ O ₅ P ₁ ] ⁺ = 698.4). All of TD705 was directly used for TD714 without further characterization. Synthesis of TD714: In a glass vial (4 mL), TD705 (22 mg; 32 µmol; 1.0 equiv.) was dissolved in dry Pyridine (1 mL) followed by addition of neat TMSBr (50 µL; 379 µmol; 12.0 equiv.) and the resulting mixture was stirred 16 h at RT. Reaction was then quenched with 50% aq. MeOH (1 mL) and the mixture was further stirred 1 h at RT. The mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and further two-times co-evaporated with MeOH. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 12 mg (≤64% assuming M·0.1FA·xH ₂ O; M _R = 590.2; 2 steps; based on TD705). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.73‒3.71 (mc, CH ₂ ‒CO, CH ₂ ‒P, m, 16+2+1H); 3.74 (C≡CH, s, 1H); 3.84 (CH ₂ ‒arom, bs, 1H); 3.99 (CH ₂ ‒arom., bs, 1H); 4.17 (CH ₂ ‒arom., bs, 2H); 4.47 (CH ₂ ‒P; bd, ² JH = 13); 4.67 (CH ₂ ‒N ₃ , s, 1H); 4.68 (CH ₂ ‒N ₃ , s, 1H); 7.54 (arom., d, 1H, ³ J _HH = 8); 7.61 (arom., d, 1H, ³ J _HH = 8); 7.62 (arom., d, 1H, ³ J _HH = 8); 7.64 (arom., d, 1H, ³ J _HH = 8); 7.90 (arom., t, 1H, ³ J _HH = 8); 7.93 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 586.2649 [M+H] ⁺ (theor. [C ₂₆ H ₃₇ N ₉ O ₅ P ₁ ] ⁺ = 586.2650). Synthesis of TD921: In a pear-shape glass flask (25 mL), TD910 (160 mg; 315 µmol; 2.0 equiv.) was dissolved in MeCN (10 mL) followed by addition of solution of dried K ₂ CO ₃ (22 mg; 160 µmol; 1.0 equiv.). Solution of TD558 24 mg; 158 µmol; 1.0 equiv.) in MeCN (5 mL) was then added dropwise over the course of 15 min and the resulting suspension was stirred for 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O- ‒MeCN gradient with TFA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was s dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The resulting alkyne bearing intermediate (together with partially N- methylated/demethylated by-products as a consequence of ongoing self-methylation; 49 mg; ≤78 µmol; ≤1.0 equiv.) was dissolved in MeCN (7 mL) followed by addition of TD406 (18 mg; 119 µmol; ≥1.5 equiv.) and K ₂ CO ₃ (54 mg; 391 µmol; ≥5.0 equiv.) and the resulting suspension was stirred 16 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was s dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The resulting methyl ester of product (together with partially N- methylated/demethylated by-products as a consequence of ongoing self-methylation; 37 mg; ≤48 µmol; ≤1.0 equiv.) was dissolved in dry Pyridine (2 mL) followed by addition of neat TMSBr (65 µL; 492 µmol; ≥12.0 equiv.) and the resulting mixture was stirred 16 h at RT. Reaction was then quenched with 50% aq. MeOH (1 mL) and the mixture was further stirred 1 h at RT. The mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as white fluffy solid. Yield: 25.6 mg (20%; 3 steps; based on TD558). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.56‒3.75 (mc, CH ₂ ‒P, C≡CH, m, 16+4+1H); 4.20 (CH ₂ ‒arom., bs, 2H); 4.29 (CH ₂ ‒ arom., bs, 2H); 4.45 (CH ₂ ‒N ₃ , s, 2H); 7.23–7.77 (Ph, arom., m, 10+4H); 7.96 (arom., t, 1H, ³ J _HH = 8); 7.97 (arom., t, 1H, ³ J _HH = 8). ³¹ P{ ¹ H} δP 25.1 (bs). ESI-HRMS: 796.2334 [M+H] ⁺ (theor. [C ₄₄ H ₃₄ N ₁₀ O ₂ P ₂ ] ⁺ = 796.2336). EA (C ₃₇ H ₄₅ N ₉ O ₄ P ₂ ·4.6H ₂ O, M _R = 824.6): C 53.9 (54.5); H 6.6 (6.3); N 15.3 (14.7). Synthesis of TD580: In a glass vial (20 mL), TD579 (137 mg; 233 µmol; 1.0 equiv.) was dissolved in MeCN (7 mL) followed by addition of dried K ₂ CO ₃ 141 mg; 1.02 mmol; 4.4 equiv.). Solution of TD406 (50 mg; 274 µmol; 1.2 equiv.) in MeCN (3 mL) was then added and the resulting suspension was tirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and iltrate was evaporated to dryness. Residue was purified by preparative HPLC C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 50 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as colorless oil. Yield: 125 mg (73%; 1 step; based on TD579). NMR (CD ₃ CN): ¹ H δ _H 1.21 (CH ₃ , t, 12H, ³ J _HH = 7); 2.90 (mc, m, 8H); 2.97 (CH ₂ ‒P, d, 4H, 2J _HP = 10); 2.99 (mc, m, 4H); 3.24 (mc, m, 8H); 3.55 (C≡CH, s, 1H); 4.01 (CH ₂ ‒O‒P, m, 8H); 4.21 (CH ₂ ‒ arom., s, 2H); 4.48 (CH ₂ ‒N ₃ , s, 2H); 4.55 (CH ₂ ‒arom., s, 2H); 7.37 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.49 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.51 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.54 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.80 (arom., t, 1H, ³ J _HH = 8); 7.84 (arom., t, 1H, ³ J _HH = 8). ³¹ P{ ¹ H} δ _P 24.8 (s). ESI-MS (LC-MS): 734.5 [M+H] ⁺ (theor. [C ₃₃ H ₅₄ N ₉ O ₆ P ₂ ] ⁺ = 734.4). ynthesis of TD582: In a glass vial (4 mL), TD580 (25 mg; 34 µmol; 1.0 quiv.) was dissolved in a mixture of aq. NaOH (10%; 1 mL) and EtOH (300 L) and the resulting solution was stirred 2 d at RT. Reaction was then uenched with AcOH (200 µL) and the mixture was directly purified by reparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 9 mg (≤39% assuming M·0.1FA·xH ₂ O; M _R = 682.3; 1 step; based on TD580). ESI-MS (LC-MS): 678.4 [M+H] ⁺ (theor. [C ₂₉ H ₄₆ N ₉ O ₆ P ₂ ] ⁺ = 678.3). Synthesis of TD581: In a glass vial (4 mL), TD580 (25 mg; 34 µmol; 1.0 equiv.) was dissolved in dry Pyridine (1 mL) followed by addition of neat TMSBr (110 µL; 833 µmol; ~25 equiv.) and the resulting mixture was stirred 16 h at RT. Reaction was then quenched with 50% aq. MeOH (1 mL) and the mixture was further stirred 1 h at RT. The mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as slightly yellow fluffy solid. Yield: 6 mg (≤28% assuming M·0.1FA·xH ₂ O; M _R = 626.2; 1 step; based on TD580). ESI-MS (LC-MS): 622.3 [M+H] ⁺ (theor. [C ₂₅ H ₃₈ N ₉ O ₆ P ₂ ] ⁺ = 622.2). Synthesis of TD575: In a glass vial (20 mL), TD579 (51 mg; 87 µmol; .2 equiv.) was dissolved in MeCN (3 mL) followed by addition of ried K ₂ CO ₃ (30 mg; 217 µmol; 3.0 equiv.). Solution of TD566 (20 mg; 73 µmol; 1.0 equiv.) in MeCN (2 mL) was then added and the esulting suspension was stirred 16 h at RT. Solids were filtered off sing syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were combined, neutralized with dil. aq. NaHCO ₃ and evaporated to dryness. Residue was dissolved in DCM (50 mL) and H ₂ O (50 mL) and transferred to a separatory funnel. After shaking, the bottom phase was separated. Aqueous phase was further extracted with DCM (3 × 25 mL). Combined organic layers were dried with anhydrous Na ₂ SO ₄ , filtered through glass frit (S3) and evaporated to dryness. The residue was further dried on high vacuum overnight to give product in the form of free base as nearly colorless oil. Yield: 46 mg (90%; 1 step; based on TD566). ESI-MS (LC-MS): 810.4 [M+H] ⁺ (theor. [C ₃₉ H ₅₈ N ₉ O ₆ P ₂ ] ⁺ = 810.4). TD575 was directly used for TD576 and without further characterization. ynthesis of TD576: In a glass vial (4 mL), TD575 (23 mg; 28 µmol; .0 equiv.) was dissolved in dry Pyridine (1 mL) followed by addition f neat TMSBr (220 µL; 1.67 mmol; ~60 equiv.) and the resulting mixture was stirred 16 h at RT. Reaction was then quenched with 50% q. MeOH (1 mL) and the mixture was further stirred 1 h at RT. The mixture was then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 15 mg (≤75% assuming M·0.1FA·xH ₂ O; M _R = 702.3; 1 step; based on TD575). NMR (D ₂ O+NaOD, pD ~8): ¹ H δ _H 2.54‒ 3.76 (mc, CH ₂ ‒P, m, 16+4H); 3.93 (CH ₂ ‒arom., bs, 2H); 4.10 (CH ₂ ‒arom., bs, 2H); 4.60 (CH ₂ ‒N ₃ , s, 2H); 7.44 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.46‒7.51 (Ph, m, 3H); 7.53 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.66‒7.70 (Ph, m, 2H); 7.71 (arom., d, 1H, ⁴ J _HH = 2); 7.77 (arom., d, 1H, ⁴ J _HH = 2); 7.81 (arom., t, 1H, ³ J _HH = 8). ³¹ P{ ¹ H} δ _P 8.2 (bs). ESI-HRMS: 696.2575 [M−H] ⁻ (theor. [C ₃₁ H ₄₀ N ₉ O ₆ P ₂ ] ⁻ = 696.2582). 5 Synthesis of TD801: In a glass vial (20 mL), TD799 (46 mg; 85 µmol; 1.0 quiv.) was dissolved in MeCN (5 mL) followed by addition of dried K ₂ CO ₃ 8 mg; 348 µmol; 4.1 equiv.). Solution of TD406 (20 mg; 110 µmol; 1.3 quiv.) in MeCN (1 mL) was then added and the resulting suspension was irred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and ltrate was evaporated to dryness. Residue was purified by preparative HPLC C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 33 mg (48%; 2 steps; based on TD799). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.41‒ 3.78 (mc, CH ₂ ‒CO, CH ₂ ‒P, m, 16+2+2H); 3.89 (CH ₂ ‒arom., bs, 2H); 3.95 (CH ₂ ‒arom., bs, 2H); 4.52 (CH ₂ ‒ N ₃ , s, 2H); 7.42 (arom., d, 1H, ³ J _HH = 8); 7.46 (arom., d, 1H, ³ J _HH = 8); 7.74 (arom., d, 1H, ³ J _HH = 8); 7.78 (arom., d, 1H, ³ J _HH = 8); 7.85 (arom., t, 1H, ³ J _HH = 8); 7.87 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 578.3208 [M+H] ⁺ (theor. [C ₂₉ H ₄₀ N ₉ O ₄ ] ⁺ = 578.3203). EA (C ₂₉ H ₃₉ N ₉ O ₄ ·2.0TFA, M _R = 805.7): C 49.2 (49.3); H 5.1 (5.4); N 15.6 (15.7). Synthesis of TD764: In a glass vial (20 mL), TD635 (304 mg; 589 µmol; .1 equiv.) was dissolved in MeCN (7 mL) followed by addition of dried K ₂ CO ₃ (305 mg; 2.21 mmol; 4.0 equiv.). Solution of TD760 (120 mg; 553 mol; 1.0 equiv.) in MeCN (3 mL) was then added and the resulting uspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 196 mg (51%; 2 steps; based on TD635). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.86‒3.60 (mc, CH ₂ ‒CO, m, 16+4H); 3.77 (C≡CH, s, 1H); 3.79‒4.06 (CH ₂ ‒arom., bm, 4H); 4.62 (CH ₂ ‒ N ₃ , s, 2H); 7.62 (arom., d, 1H, ⁴ J _HH = 2); 7.67‒7.73 (arom., m, 1H); 8.07‒8.14 (arom., m, 2H); 8.17 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 582.2344 [M−H] ⁻ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Cl ₁ ] ⁻ = 582.2350). EA (C ₂₇ H ₃₄ N ₉ O ₄ Cl ₁ ·0.7TFA·1.7H ₂ O, M _R = 694.5): C 49.1 (49.0); H 5.5 (5.4); N 18.2 (18.4); Cl 5.1 (5.3). Synthesis of TD1063: In a glass vial (4 mL), TD635 (50 mg; 97 µmol; 1.0 equiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ (67 mg; 485 µmol; 5.0 equiv.). Solution of TD1057 (24 mg; 96 µmol; 1.0 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 33.4 mg (55%; 2 steps; based on TD635). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.81‒ 3.68 (mc, CH ₂ ‒CO, m, 16+4H); 3.72 (C≡CH, s, 1H); 3.82 (CH ₂ ‒arom., bs, 2H); 4.05 (CH ₂ ‒arom., bs, 2H); 4.70 (CH ₂ ‒N ₃ , s, 2H); 7.62–7.69 (arom., m, 1H); 7.82 (arom., s, 1H); 7.92–7.99 (arom., m, 2H); 8.38 (arom., s, 1H). ¹⁹ F{ ¹ H} δ _F −64.2 (s). ESI-HRMS: 618.2759 [M+H] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ F ₃ ] ⁺ = 618.2759). EA (C ₂₈ H ₃₄ N ₉ O ₄ F ₃ ·0.1FA·1.2H ₂ O, M _R = 643.8): C 52.4 (52.8); H 5.7 (5.4); N 19.6 (19.4); F 8.8 (7.8). Synthesis of TD1092: In a glass vial (4 mL), TD635 (35 mg; 68 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (44 mg; 318 µmol; 4.7 equiv.). Solution of pre-purified TD1089 (containing ~20% of the bis azide byproduct; 20 mg; <83 µmol; <1.2 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 24 h at RT. Solids were filtered off using syringe 30 microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 31.9 mg (74%; 2 steps; based on TD635). NMR (D ₂ O, pD ~6): ¹ H δ _H 2.76‒3.62 (mc, CH ₂ ‒CO, m, 16+4H); 3.73 (C≡CH, s, 1H); 3.83 (CH ₂ ‒arom., bs, 2H); 3.99 (CH ₃ , s, 3H); 4.05 (CH ₂ ‒arom., bs, 2H); 4.69 (CH ₂ ‒N ₃ , s, 2H); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.02 (arom., d, 1H, ⁴ J _HH = 1); 8.05 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.15 (arom., t, 1H, ³ J _HH = 8); 8.58 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 608.2939 [M+H] ⁺ (theor. [C ₂₉ H ₃₈ N ₉ O ₆ ] ⁺ = 608.2940). EA (C ₂₉ H ₃₇ N ₉ O ₆ ·0.1FA·1.1H ₂ O, M _R = 632.1): C 55.3 (55.1); H 6.3 (6.0); N 19.9 (19.6). Synthesis of TD1148: In a glass vial (4 mL), TD635 (44 mg; 85 µmol; 1.0 equiv.) was dissolved in MeCN (2.5 mL) followed by addition of dried K ₂ CO ₃ (47 mg; 340 µmol; 4.0 equiv.). Solution of TD1112 (23 mg; 86 µmol; 1.0 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co- evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 30.7 mg (55%; 2 steps; based on TD635). NMR (D ₂ O, pD ~6): ¹ H δ _H 1.40 (CH ₃ , d, 6H, ³ J _HH = 6); 2.77‒3.63 (mc, CH ₂ ‒CO, m, 16+4H); 3.70 (C≡CH, s, 1H); 3.80 (CH ₂ ‒arom., bs, 2H); 4.06 (CH ₂ ‒arom., bs, 2H); 4.65 (CH ₂ ‒N ₃ , s, 2H); 5.26 (CH, hept, 1H, ³ J _HH = 6); 7.65 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.93–8.00 (arom., m, 2H); 8.12 (arom., t, 1H, ³ J _HH = 8); 8.45 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 636.3247 [M+H] ⁺ (theor. [C ₃₁ H ₄₂ N ₉ O ₆ ] ⁺ = 636.3253). EA (C ₃₁ H ₄₁ N ₉ O ₆ ·0.1FA·1.0H ₂ O, M _R = 658.3): C 56.7 (56.4); H 6.6 (6.4); N 19.1 (18.8). ynthesis of TD1160: In a pear-shape glass flask (100 mL), TD1116 50 mg; 158 µmol; 2.0 equiv.) was dissolved in MeCN (20 mL) ollowed by addition of dried K ₂ CO ₃ (11 mg; 80 µmol; 1.0 equiv.). olution of TD558 (12 mg; 79 µmol; 1.0 equiv.) in MeCN (20 mL) as then added dropwise over the course of 2 h and the resulting uspension was stirred 7 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with mono alkylated intermediate were combined and directly lyophilized. Resulting solid (15.4 mg; ≤36 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (25 mg; 181 µmol; ≥5.0 equiv.). Solution of TD1130 (15 mg; 53 µmol; ≥1.5 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 7 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with methyl protected product were joined and directly lyophilized. Residue was re-dissolved in a mixture of MeOH (2 mL) and H ₂ O (1 mL) followed by addition of solid LiOH·H ₂ O (15 mg; 360 µmol; >10 equiv.). The resulting mixture was stirred 15 min at RT, quenched with FA (15 µL) and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white solid. Yield: 1.7 mg (<5%; 3 steps; based on TD558). ESI-HRMS: 650.3407 [M+H] ⁺ (theor. [C ₃₂ H ₄₄ N ₉ O ₆ ] ⁺ = 650.3409). Synthesis of TD1176: In a glass vial (4 mL), TD635 (43.5 mg; 84.4 µmol; 1.1 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (42.5 mg; 308 µmol; 4.0 equiv.). Solution of TD1163 (17.3 mg; 76.7 µmol; 1.0 equiv.) in MeCN (1 mL) was then added and the resulting suspension was stirred 2 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co- evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 43.6 mg (80%; 2 steps; based on TD1163). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.74‒ 3.62 (mc, CH ₂ ‒CO, CH ₃ , m, 16+4+6H); 3.70 (C≡CH, s, 1H); 3.76 (CH ₂ ‒arom., bs, 2H); 3.84 (CH ₂ ‒arom., bs, 2H); ~4.7‒4.8 (CH ₂ ‒N ₃ , obscured by HOD signal); 6.85 (arom., bs, 1H); 7.02 (arom., bs, 1H); 7.64 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., bt, 1H, ³ J _HH = 8); 7.94 (arom., bd, 1H, ³ J _HH = 8). ESI-HRMS: 593.3310 [M+H] ⁺ (theor. [C ₂₉ H ₄₁ N ₁₀ O ₄ ] ⁺ = 593.3307). EA (C ₂₉ H ₄₀ N ₁₀ O ₄ ·0.8FA·4.4H ₂ O, M _R = 708.8): C 50.5 (50.8); H 7.2 (7.1); N 19.8 (19.5). Synthesis of TD647: In a pear-shape glass flask (50 mL), TD635 (375 mg; 727 µmol; 1.0 equiv.) was dissolved in dry MeCN (20 mL) ollowed by addition of dried K ₂ CO ₃ (300 mg; 2.17 mmol; 3.0 equiv.). Solution of TD566 (189 mg; 731 µmol; 1.0 equiv.) in dry MeCN (5 mL) was then added and the resulting suspension was stirred 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and iltrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 342 mg (72%; 2 steps; based on TD635). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.70‒3.59 (mc, CH ₂ ‒CO, m, 16+4H); 3.66 (CH ₂ ‒arom., bs, 2H); 3.69 (C≡CH, s, 1H); 3.90 (CH ₂ ‒arom., bs, 2H); 4.64 (CH ₂ ‒N ₃ , s, 2H); 7.46‒7.60 (Ph, arom., m, 3+1H); 7.64 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 2); 7.68 (arom., t, 1H, ³ J _HH = 8); 7.69 (arom., d, 1H, ⁴ J _HH = 2); 7.79‒7.88 (Ph, m, 2H); 8.28 (arom., d, 1H, ⁴ J _HH = 2). ¹³ C{ ¹ H} δ _C 48.2 (mc, s); 48.3 (mc, s); 51.2 (mc, s); 51.3 (mc, s); 54.7 (CH ₂ ‒N ₃ , s); 56.4 (CH ₂ ‒CO, s); 57.8 (CH ₂ ‒arom., s); 59.1 (CH ₂ ‒arom., s); 80.3 and 82.4 (C≡CH; 2 × s); 121.9 (arom., s); 124.4 (arom., s); 125.6 (arom., s); 128.2 (Ph, s); 128.5 (Ph, s); 130.0 (Ph, s); 130.8 (arom., s); 137.7 (Ph, s); 140.3 (arom., s); 141.2 (arom., s); 153.6 (arom., s); 155.4 (arom., bs); 156.2 (arom., s); 157.6 (arom., s); 168.7 (CO, s). ESI-HRMS: 626.3195 [M+H] ⁺ (theor. [C ₃₃ H ₄₀ N ₉ O ₄ ] ⁺ = 626.3198). EA (C ₃₃ H ₃₉ N ₉ O ₄ ·0.2FA·0.9H ₂ O, M _R = 651.2): C 61.2 (61.6); H 6.4 (6.1); N 19.4 (19.1). Synthesis of TD722: In a glass vial (20 mL), TD539 (350 mg; 543 µmol; 1.0 equiv.) was dissolved in MeCN (15 mL) followed by ddition of dried K ₂ CO ₃ (375 mg; 2.72 mmol; 5.0 equiv.). Solution of TD566 (140 mg; 541 µmol; 1.0 equiv.) in MeCN (3 mL) was then dded and the resulting suspension was stirred 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was 30 evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl/Boc protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (5 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as slightly yellow solid. Yield: 295 mg (69%; 2 steps; based on TD566). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.74‒3.64 (mc, CH ₂ ‒CO, m, 16+4H); 3.72 (CH ₂ ‒arom., bs, 2H); 3.98 (CH ₂ ‒arom., bs, 2H); 4.10 (CH ₂ ‒C≡C, s, 2H); 4.65 (CH ₂ ‒N ₃ , s, 2H); 7.47‒7.69 (Ph, arom., m, 3+3H); 7.72 (arom., d, 1H, ⁴ J _HH = 2); 7.85‒7.96 (Ph, m, 2H); 8.41 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 655.3460 [M+H] ⁺ (theor. [C ₃₄ H ₄₃ N ₁₀ O ₄ ] ⁺ = 655.3463). EA (C ₃₄ H ₄₂ N ₁₀ O ₄ ·0.7TFA·2.0H ₂ O, M _R = 770.6): C 55.2 (54.9); H 6.1 (5.8); N 18.2 (18.3); F 5.2 (5.3). Synthesis of TD1054: In a glass vial (4 mL), TD663 (30.0 mg; 45.3 µmol; 1.0 equiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ (37.5 mg; 271 µmol; 5.0 equiv.). Solution of freshly prepared and isolated TD1050 (≤65.3 µmol; ≤1.5 equiv.) n MeCN (1 mL) was then added and the resulting suspension was stirred 3 d at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl/Boc protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of mixed trifluoroacetate/formate salt as colourless solid. Yield: 23.0 mg (65%; 2 steps; based on TD663). NMR (D ₂ O, pD ~8): ¹ H δ _H 1.72 (CH ₃ , s, 6H); 2.67‒ 3.61 (mc, CH ₂ ‒CO, m, 16+4H); 3.70 (CH ₂ ‒arom., bs, 2H); 3.97 (CH ₂ ‒arom., bs, 2H); 4.64 (CH ₂ ‒N ₃ , s, 2H); 7.45‒7.67 (Ph, arom., m, 3+3H); 7.72 (arom., d, 1H, ⁴ J _HH = 2); 7.86‒7.93 (Ph, m, 2H); 8.40 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 683.3775 [M+H] ⁺ (theor. [C ₃₆ H ₄₇ N ₁₀ O ₄ ] ⁺ = 683.3776). EA (C ₃₆ H ₄₆ N ₁₀ O ₄ ·0.3TFA·0.8FA·2.3H ₂ O, M _R = 777.3): C 57.8 (58.0); H 6.5 (6.5); N 18.0 (17.7). ynthesis of TD1105: In a glass vial (4 mL), TD711 (101 mg; 185 µmol; .0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (102 mg; 738 µmol; 4.0 equiv.). Solution of freshly prepared and solated TD1050 (≤222 µmol; ≤1.2 equiv.) in MeCN (1 mL) was then dded and the resulting suspension was stirred 24 h at 40 °C. Solids were ltered off using syringe microfilter (PTFE) and filtrate was evaporated o dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with tert-butyl/Boc protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co- evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with fully deprotected intermediate were joined and directly lyophilized. The resulting solid was dissolved in a mixture of H ₂ O (6 mL), MeCN (6 mL) and THF (2 mL) followed by addition of Boc2O (2.0 ^M in dry THF; 315 µL; 630 µmol; ≥3.4 equiv.) and NaHCO ₃ (210 mg; 2.50 mmol; ≥13.5 equiv.) The resulting mixture was stirred 2 d at RT after which another portion of Boc ₂ O (2.0 M in dry THF; 315 µL; 630 µmol; ≥3.4 equiv.) was added. The mixture was further stirred 16 h at RT. Mixture was evaporated to dryness and the residue was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined to give product in nearly zwitterionic form as white fluffy solid. Yield: 36.8 mg (27%; 3 steps; based on TD711). NMR (D ₂ O, pD ~7): ¹ H δ _H 1.47 (CH ₃ , s, 9H); 1.65 (CH ₃ , s, 6H); 2.85‒3.65 (mc, CH ₂ ‒CO, m, 16+4H); 3.91 (CH ₂ ‒arom., bs, 2H); 3.95 (CH ₂ ‒ arom., bs, 2H); 4.59 (CH ₂ ‒N ₃ , s, 2H); 7.51 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.59 (arom., dd, 1H, ³ J _HH = 7, 4J _HH = 2); 7.89‒8.05 (arom., m, 4H). ESI-HRMS: 707.3988 [M+H] ⁺ (theor. [C ₃₅ H ₅₁ N ₁₀ O ₆ ] ⁺ = 707.3988). EA (C ₃₅ H ₅₀ N ₁₀ O ₆ ·0.1FA·2.0H ₂ O, M _R = 747.5): C 56.4 (56.7); H 7.3 (7.0); N 18.7 (18.5). Synthesis of TD1127: In a glass vial (20 mL), TD1118 (56.9 mg; 81.4 µmol; 1.0 equiv.) was dissolved in MeCN (2 mL) followed by addition of dried K ₂ CO ₃ (45.0 mg; 326 µmol; 4.0 equiv.) and TD406 (16.0 mg; 87.6 µmol; 1.1 quiv.) in MeCN (1 mL). The resulting suspension was stirred 16 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA dditive). Fractions with tert-butyl/Boc protected product were combined, vaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of mixed trifluoroacetate/formate salt as colourless solid. Yield: 49.0 mg (71%; 2 steps; based on TD1118). NMR (D ₂ O, pD ~7): ¹ H δ _H 1.96‒2.11 (CH ₂ , m, 2H); 2.14‒2.29 (CH ₂ , m, 2H); 2.86‒3.63 (mc, CH ₂ ‒CO, CH ₂ , CH, m, 16+4+4+1H); 3.90 (CH ₂ ‒arom., bs, 2H); 3.94 (CH ₂ ‒arom., bs, 2H); 4.59 (CH ₂ ‒N ₃ , s, 2H); 7.49‒7.55 (arom., m, 1H); 7.60 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 2); 7.92‒8.04 (arom., m, 4H). ESI-HRMS: 633.3612 [M+H] ⁺ (theor. [C ₃₂ H ₄₅ N ₁₀ O ₄ ] ⁺ = 633.3620). EA (C ₃₂ H ₄₄ N ₁₀ O ₄ ·1.8TFA·0.1FA, M _R = 878.6): C 50.9 (50.7); H 5.5 (5.9); N 16.6 (16.9). Synthesis of TD742: In a glass vial (20 mL), TD635 (90 mg; 63 µmol; 1.1 equiv.) was dissolved in MeCN (6 mL) followed y addition of dried K ₂ CO ₃ (85 mg; 616 µmol; 4.0 equiv.). olution of TD733 (55 mg; 153 µmol; 1.0 equiv.) in MeCN (2 mL) was then added and the resulting suspension was stirred 18 at RT. Solids were filtered off using syringe microfilter PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 87 mg (80%; 2 steps; based on TD733). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.76‒3.64 (mc, CH ₂ ‒CO, m, 16+4H); 3.69 (C≡CH, s, 1H); 3.72 (CH ₂ ‒arom., bs, 2H); 3.99 (CH ₂ ‒arom., bs, 2H); 4.77 (CH ₂ ‒N ₃ , s, 2H); 7.54‒7.70 (arom., m, 3H); 7.85 (arom., d, 1H, ⁴ J _HH = 2); 7.96 (arom., d, 2H, ³ J _HH = 8); 8.11 (arom., d, 2H, ³ J _HH = 8); 8.38 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 670.3094 [M+H] ⁺ (theor. [C ₃₄ H ₄₀ N ₉ O ₆ ] ⁺ = 670.3096). EA (C ₃₄ H ₄₀ N ₉ O ₆ ·0.2FA·1.6H ₂ O, M _R = 707.8): C 58.0 (58.4); H 6.1 (5.9); N 17.8 (17.5). Synthesis of TD744: In a glass vial (20 mL), TD539 (80 mg; 124 µmol; 1.1 equiv.) was dissolved in MeCN (3 mL) followed by addition of dried K ₂ CO ₃ (65 mg; 471 µmol; 4.0 equiv.). Solution of TD733 (42 mg; 117 µmol; 1.0 equiv.) in MeCN (3 mL) was then added and the resulting suspension was stirred 24 h at RT. Solids were filtered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of mixed trifluoroacetate/formate salt as off white fluffy solid. Yield: 44 mg (45%; 2 steps; based on TD733). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.71‒3.64 (mc, CH ₂ ‒ CO, m, 16+4H); 3.70 (CH ₂ ‒arom., bs, 2H); 3.98 (CH ₂ ‒arom., bs, 2H); 4.12 (CH ₂ ‒C≡C, s, 2H); 4.70 (CH ₂ ‒N ₃ , s, 2H); 7.50‒7.59 (arom., m, 2H); 7.63 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.78 (arom., d, 1H, ⁴ J _HH = 2); 7.95 (arom., d, 2H, ³ J _HH = 9); 8.07 (arom., d, 2H, ³ J _HH = 9); 8.42 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 699.3358 [M+H] ⁺ (theor. [C ₃₅ H ₄₃ N ₁₀ O ₆ ] ⁺ = 699.3362). EA (C ₃₅ H ₄₂ N ₁₀ O ₆ ·1.0TFA·1.3H ₂ O, M _R = 836.2): C 53.1 (52.8); H 5.5 (5.8); N 16.8 (16.9). Synthesis of TD750: In a glass vial (2 mL), TD744·1.0TFA·1.3H ₂ O (1.5 mg; ~1.8 µmol; 1.0 equiv.) was dissolved in aq. Borate/NaOH buffer (200 m ^M ; pH 9.0; 900 µL; 180 mmol; ~100 equiv.). followed by addition of freshly prepared solution of FmocCl (0.6 mg; ~2.3 µmol; 1.3 equiv.) in MeCN (900 µL). The resulting clear solution was stirred 2 h at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 0.8 mg (≤48% assuming M·0.2FA·xH ₂ O; M _R = 930.2; 1 step; based on TD744·1.0TFA·1.3H ₂ O). ESI-HRMS: 921.4044 [M+H] ⁺ (theor. [C ₅₀ H ₅₃ N ₁₀ O ₈ ] ⁺ = 921.4042). Synthesis of TD779: In a glass vial (4 mL), TD647·0.2FA·0.9H ₂ O (10 mg; 15 µmol; 1.0 equiv.) and Ammonium chloride (2 mg; 38 µmol; .5 equiv.) were dissolved in DMSO (2 mL) followed by addition of DIPEA (22 µL; 126 µmol; 8.2 equiv.) and solid HATU (18 mg; 47 mol; 3.1 equiv.). The resulting yellow solution was stirred 15 min at RT. Mixture was then quenched with FA (6 µL; 169 µmol; 10 equiv.) nd directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 7 mg (≤73% assuming M·0.1FA·xH ₂ O; M _R = 628.4; 1 step; based on TD647·0.2FA·0.9H ₂ O). NMR (D ₂ O+FA, pD ~3): ¹ H δ _H 2.83‒3.74 (mc, CH ₂ ‒CO, bm, 16+4H); 3.65 (C≡CH, s, 1H); 4.13‒4.68 (CH ₂ ‒arom., bm, 4H); 4.69 (CH ₂ ‒N ₃ , s, 2H); 7.52‒7.66 (Ph, arom., m, 3+1H); 7.71 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.80‒7.88 (Ph, m, 2H); 7.90 (arom., d, 1H, ⁴ J _HH = 2); 7.91 (arom., t, 1H, ³ J _HH = 8); 8.00 (arom., bs, 1H). ESI-HRMS: 624.3503 [M+H] ⁺ (theor. [C ₃₃ H ₄₂ N ₁₁ O ₂ ] ⁺ = 624.3504). Synthesis of TD778: In a glass vial (4 mL), TD647·0.2FA·0.9H ₂ O (12 mg; 18 µmol; 1.0 equiv.) and Glycine tert-butyl ester hydrochloride (8 mg; 48 µmol; 2.6 equiv.) were dissolved in DMSO (2 mL) followed by addition of DIPEA (26 µL; 149 µmol; 8.1 equiv.) and solid HATU (21 mg; 55 µmol; 3.0 equiv.). The resulting yellow solution was stirred 20 min at RT. Mixture was then quenched with FA (7 µL; 186 µmol; 10 equiv.) and directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 9 mg (62%; 2 steps; based on TD647·0.2FA·0.9H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.83–3.93 (mc, CH ₂ –CO, C≡CH, bm, 16+8+1H); 4.35–4.69 (CH ₂ ‒arom., CH ₂ ‒N ₃ ., bm, 4+2H); 7.49 (arom., d, 1H, ³ J _HH = 8); 7.56–7.73 (Ph, arom., m, 3+1H); 7.75–7.92 (Ph, arom., m, 2+2H); 8.06 (arom., s, 1H). ESI-HRMS: 738.3471 [M−H] ⁻ (theor. [C ₃₇ H ₄₄ N ₁₁ O ₆ ] ⁻ = 738.3482). EA (C ₃₇ H ₄₅ N ₁₁ O ₆ ·0.1FA·2.4H ₂ O, M _R = 787.7): C 56.6 (55.9); H 6.4 (5.8); N 19.6 (20.3). ynthesis of TD1408: In a glass vial (25 mL), TD635 (51 mg; 99 µmol; 1.1 quiv.) was dissolved in MeCN (1 mL) followed by addition of dried K ₂ CO ₃ 54 mg; 391 µmol; 4.4 equiv.). Solution of TD1406 (17.5 mg; 89 µmol; 1.0 quiv.) in MeCN (1 mL) was then added and the resulting suspension was tirred 16 h at 40 °C. Solids were filtered off using syringe microfilter (PTFE) nd filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with tert-butyl protected product were combined, evaporated to dryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 41.7 mg (77%; 2 steps; based on TD1406). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.74‒4.16 (mc, CH ₂ ‒CO, CH ₂ -arom., CH ₂ -CH ₂ -N ₃ , C≡CH, m, 16+4+4+4+1H); 7.37–7.45 (arom., m, 1H); 7.65 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85–7.93 (arom., m, 2H); 7.96 (arom., t, 1H, ³ J _HH = 8); 8.06 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1). ESI-HRMS: 564.3044 [M+H] ⁺ (theor. [C ₂₈ H ₃₈ N ₉ O ₄ ] ⁺ = 564.3041). EA (C ₂₈ H ₃₇ N ₉ O ₄ ·0.1FA·2.4H ₂ O, M _R = 611.5): C 55.2 (56.0); H 6.9 (6.7); N 20.6 (19.8). ynthesis of TD1346: In a pear-shaped glass flask (25 mL), TD1345 (52.7 mg; 83 µmol; 1.0 equiv.) was dissolved in 60 % aq. MeCN (2.7 mL) followed y addition of freshly prepared aq. LiOH (1.0 M; 830 µL; 830 µmol; 10 quiv.). Resulting solution was stirred at RT for 5 h. Mixture was quenched y addition of FA (31 µL; 822 µmol; 10 equiv.). The resulting solution was riefly concentrated to remove most of MeCN and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of free base as white fluffy solid. Yield: 35.4 mg (71%; 1 step; based on TD1345). NMR (D ₂ O, pD ~7): ¹ H δ _H 1.24–1.42 (CH ₃ , m, 6H); 2.44‒ 3.81 (mc, CH ₂ ‒arom., C≡CH, m, 16+4+1H); 4.41–4.53 (CH–CH ₃ , m, 2H); 4.56 (CH ₂ ‒N ₃ , s, 2H); 7.49 (arom., d, 1H, ³ J _HH = 8); 7.63 (arom., d, 1H, ³ J _HH = 8); 7.93 (arom., t, 1H, ³ J _HH = 8); 7.96 (arom., t, 1H, ³ J _HH = 8); 8.05 (arom., d, 1H, ³ J _HH = 8); 8.10 (arom., d, 1H, ³ J _HH = 8). ESI-HRMS: 578.3197 [M+H] ⁺ (theor. [C ₂₉ H ₄₀ N ₉ O ₄ ] ⁺ = 578.3198). EA (C ₂₉ H ₃₉ N ₉ O ₄ ·1.2H ₂ O, M _R = 599.3): C 58.1 (58.0); H 7.0 (6.5); N 21.0 (20.6). Synthesis of TD1451: In a pear-shaped glass flask (25 mL), TD1449 (302 mg; 330 µmol; 1.0 equiv.) was dissolved in 60 % aq. MeCN (17 mL) followed by addition of freshly prepared aq. LiOH (1.0 M; 3.3 mL; 3.3 mmol; 10 equiv.). Resulting solution was stirred at RT for 2 h. Mixture was briefly concentrated to remove most of MeCN and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in nearly zwitterionic form as white fluffy solid. Yield: 257 mg (87%; 1 step; based on TD1449). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.37–1.60 (CH ₃ –C–O, CH ₃ ‒ CH, m, 9+6H); 1.67 (CH ₃ –C–N, s, 6H); 2.66–4.30 (mc, CH ₂ ‒arom., CH‒CH ₃ , m, 16+4+2H); 4.68 (CH ₂ ‒N ₃ , s, 2H); 7.80 (arom., s, 1H); 7.92 (arom., s, 1H); 7.98 (arom., s, 1H); 8.02 (arom., s, 1H). ¹⁹ F δ _F −64.44 (s). ESI- HRMS: 847.4070 [M+H] ⁺ (theor. [C ₃₉ H ₅₄ N ₁₀ O ₈ F ₃ ] ⁺ = 634.3824). EA (C ₃₉ H ₅₃ N ₁₀ O ₈ F ₃ ·0.1FA·2.7H ₂ O, M _R = 900.1): C 52.2 (53.1); H 6.6 (6.2); N 15.6 (15.5); 6.3 (5.4). ynthesis of TD1504: In a glass vial (25 mL), TD1500 (11.9 mg; 18 mol; 1.0 equiv.) was dissolved in MeCN (800 µL) and H ₂ O (550 µL) ollowed by addition of freshly prepared aq. LiOH (1.0 M; 263 µL; 263 mol; 15 equiv.). Resulting solution was stirred at RT for 3 h. Mixture was quenched by addition of FA (8 µL; 212 µmol; 12 equiv.). The esulting solution was diluted with H ₂ O (2 mL) and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of free base as white fluffy solid. Yield: 8.9 mg (~77 % assuming M·2H ₂ O; M _R = 657.7; 2 steps; based on TD1500). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.28–1.45 (CH ₃ , m, 3H); 2.49–3.70 (mc, CH‒CH ₃ , CH‒CH ₂ , CH ₂ ‒arom., m, 16+1+3+4H); 3.76 (C≡CH, s, 1H); 4.35–4.51 (CH ₂ ‒N ₃ , m, 2H); 7.69 (arom., dd, 2H, ³ J _HH = 8, ⁴ J _HH = 1); 7.98 (arom., t, 1H, ³ J _HH = 8); 8.05–8.21 (arom., m, 3H). ESI-MS (LC-MS): 622.3 [M+H] ⁺ (theor. [C ₃₀ H ₄₀ N ₉ O ₆ ] ⁺ = 622.3). Example 5: Synthesis of caged macrocyclic ligands (bridged with a triazole group) Synthesis of cz-TD425: Obtained as side product during synthesis of TD425 n nearly zwitterionic form as white fluffy solid. Yield: 3 mg (≤1% assuming M·0.1FA·xH ₂ O; M _R = 609.9; 3 steps; based on 2-Chloro-N-(prop-2-yn-1- yl)acetamide). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.52–5.20 (mc, CH ₂ –CO, CH ₂ – NH–CO–CH ₂ , CH ₂ –arom., bm, 16+4+4+2H); 6.24 (CH ₂ ‒N ₃ ., bs, 2H); 7.56– 7.72 (Ph, m, 3H); 7.88 (CH–N ₃ , s, 1H); 7.88–7.94 (Ph, m, 2H); 8.33 (arom., d, 1H, ⁴ J _HH = 2); 8.73 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 606.3143 [M+H] ⁺ (theor. [C ₃₀ H ₄₀ N ₉ O ₅ ] ⁺ = 606.3147). Synthesis of cz-TD556: Obtained as side product during synthesis of TD556 in the form of trifluoroacetate salt as white fluffy solid. Yield: 9 mg (~2%; 2 steps; based on TD635). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.54‒4.06 (mc, CH ₂ ‒CO, bm, 16+4H); 4.59 (CH ₂ ‒arom., bs, 2H); 5.02 (CH ₂ ‒arom., bs, 2H); 5.86 (CH ₂ ‒N ₃ , bs, 2H); 7.67 (arom., bd, 1H, ³ J _HH = 8); 7.70 (arom., bd, 1H, ³ J _HH = 8); 7.83 (arom., bd, 1H, ³ J _HH = 8); 7.87 (arom., bd, 1H, ³ J _HH = 8); 8.14 (arom., bt, 1H, ³ J _HH = 8); 8.16 (CH‒N ₃ , bs, 1H); 8.17 (arom., bt, 1H, ³ J _HH = 8). ESI-HRMS: 550.2889 [M+H] ⁺ (theor. [C ₂₇ H ₃₆ N ₉ O ₄ ] ⁺ = 550.2885). EA (C ₂₇ H ₃₅ N ₉ O ₄ ·2.7TFA·0.5H ₂ O, M _R = 866.4): C 44.9 (44.8); H 4.5 (4.8); N 14.5 (14.8). ynthesis of cz-TD764: Obtained as side product during synthesis of TD764 in he form of trifluoroacetate salt as white fluffy solid. Yield: 9 mg (~2%; 2 steps; ased on TD635). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.48‒3.94 (mc, CH ₂ ‒CO, bm, 6+4H); 4.57 (CH ₂ ‒arom., bs, 2H); 5.00 (CH ₂ ‒arom., bs, 2H); 5.94 (CH ₂ ‒N ₃ , bs, H); 7.64 (arom., d, 1H, ³ J _HH = 8); 7.79 (arom., s, 1H); 7.84 (arom., d, 1H, ³ J _HH 8); 7.92 (arom., s, 1H); 8.14 (arom., t, 1H, ³ J _HH = 8); 8.15 (CH‒N ₃ , s, 1H). ESI- HRMS: 582.2344 [M−H] ⁻ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Cl ₁ ] ⁻ = 582.2350). EA (C ₂₇ H ₃₄ N ₉ O ₄ Cl ₁ ·1.8TFA·3.3H ₂ O, M _R = 848.7): C 43.3 (43.3); H 5.0 (4.5); N 14.9 (14.5); Cl 4.2 (4.2); F 12.1 (12.0). Synthesis of cz-TD1063: Obtained as side product during synthesis of TD1113 in the form of trifluoroacetate salt as white fluffy solid. Yield: 1.7 mg. NMR (D ₂ O, pD ~3): ¹ H δ _H 2.57‒3.84 (mc, CH ₂ ‒CO, m, 16+4H); 4.70 CH ₂ ‒arom., s, 2H); 4.99 (CH ₂ ‒arom., bs, 2H); 6.03 (CH ₂ ‒N ₃ , bs, 2H); 7.65 arom., d, 1H, ³ J _HH = 8); 7.86 (arom., d, 1H, ³ J _HH = 8); 8.05 (arom., s, 1H); 8.12‒8.18 (arom., CH–N ₃ , m, 1+1H); 8.19 (arom., s, 1H). ¹⁹ F δ _F −65.82 (s). NMR (~0.5 mM cz-TD1063 in ~50 mM MOPS/NaOH buffer in 10% H ₂ O, pH 7.0): ¹⁹ F δ _F −65.66 (s; ΔH½ = 4.6 Hz). ESI-HRMS: 618.2754 [M+H] ⁺ (theor. [C ₂₉ H ₃₅ N ₉ O ₄ F ₃ ] ⁺ = 618.2759). 10 Synthesis of TD1188: In a glass vial (4 mL), TD711 (70.0 mg; 128 µmol; 1.0 equiv.) as dissolved in MeCN (1.5 mL) followed by addition of dried K ₂ CO ₃ (71 mg; 514 mol; 4.0 equiv.). Solution of TD1178 (31 mg; 141 µmol; 1.1 equiv.) in MeCN (1.5 mL) was then added and the resulting suspension was stirred 7 d at RT. Solids were ltered off using syringe microfilter (PTFE) and filtrate was evaporated to dryness. esidue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA dditive). Fractions with tert-butyl protected product were combined, evaporated to ryness and twice co-evaporated with MeOH to remove most of MeCN. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and twice co-evaporated with MeOH to remove most of TFA. Residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in zwitterionic form as white fluffy solid. Yield: 9.5 mg (10%; 2 steps; based on TD711). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.11‒4.00 (mc, CH ₂ ‒CO, bm, 16+4H); 4.52 (CH ₂ ‒arom., bs, 2H); 4.88‒6.58 (CH ₂ ‒arom., CH ₂ ‒N ₃ , bm, 4H); 7.66 (arom., bd, 1H, ³ J _HH = 8); 7.68 (arom., d, 1H, ³ J _HH = 8); 7.75 (arom., bd, 1H, ³ J _HH = 8); 7.85 (arom., d, 1H, ³ J _HH = 8); 8.08 (arom., bt, 1H, ³ J _HH = 8); 8.16 (arom., t, 1H, ³ J _HH = 8). ¹⁹ F δ _F −59.35 (s). ESI-HRMS: 618.2756 [M+H] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ F ₃ ] ⁺ = 618.2759). EA (C ₂₈ H ₃₄ N ₉ O ₄ F ₃ ·0.2TFA·0.4FA·4.3H ₂ O, M _R = 736.3): C 47.0 (46.6); H 6.0 (5.6); N 17.1 (16.8); F 9.3 (10.1). ynthesis of TD650: In a glass vial (40 mL), TD647·0.2FA·0.9H ₂ O (130 mg; 200 µmol; 1.0 equiv.) was dissolved in H ₂ O (20 mL) followed by ddition aq. Citric acid (100 mM; 20 mL; 2.0 mmol; 10 equiv.) to reach pH .4. Resulting mixture was then stirred 2 d at 80 °C. Mixture was then ltered through syringe microfilter (RC). The filtrate was concentrated on otary evaporator and then directly purified by preparative HPLC (C18; 2O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 109 mg (77%; 1 step; based on TD647·0.2FA·0.9H ₂ O). NMR (D ₂ O, pD ~5, 95 °C): ¹ H δ _H 2.69‒3.63 (mc, CH ₂ ‒CO, m, 16+4H); 4.22 (CH ₂ ‒arom., s, 2H); 4.58 (CH ₂ ‒arom., s, 2H); 6.22 (CH ₂ ‒N ₃ , s, 2H); 7.61 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.60‒7.67 (Ph, m, 3H); 7.83 (arom., s, 1H); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86‒7.92 (Ph, m, 2H); 8.00 (arom., s, 1H); 8.11 (arom., t, 1H, ³ J _HH = 8); 8.21 (CH–N ₃ , s, 1H). ¹³ C{ ¹ H} δ _C 48.5 (mc, s); 49.9 (mc, s); 50.2 (mc, s); 50.4 (mc, s); 53.4 (CH ₂ ‒N ₃ , s); 55.6 (CH ₂ ‒CO, s); 57.8 (CH ₂ ‒arom., s); 59.2 (CH ₂ ‒ arom., s); 122.6 (arom., s); 124.2 (arom., s); 125.4 (arom., s); 125.9 (arom., s); 127.8 (Ph, s); 129.9 (Ph, s); 130.7 (Ph, s); 134.5 (CH–N ₃ , s); 137.0 (Ph, s); 138.0 (arom., s); 139.9 (arom., s); 147.1 (arom., s); 152.3 (arom., bs); 153.6 (arom., bs); 153.8 (arom., bs); 156.8 (arom., s); 172.6 (CO, s). ESI-HRMS: 626.3200 [M+H] ⁺ (theor. [C ₃₃ H ₄₀ N ₉ O ₄ ] ⁺ = 626.3198). EA (C ₃₃ H ₃₉ N ₉ O ₄ ·0.9FA·2.0H ₂ O, M _R = 703.2): C 57.9 (58.3); H 6.4 (5.9); N 17.9 (17.5). Synthesis of TD871: In a glass vial (40 mL), TD647·1.3TFA (78.0 mg; 103 µmol; 1.0 equiv.) was dissolved in H ₂ O (34 mL) followed by addition aq. Borate/CsOH buffer (200 mM; pH 9.0; 6.0 mL; 1.2 mmol; ~12 equiv.). Resulting mixture was then stirred 6 d at 80 °C. Mixture was then filtered hrough syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 49.3 mg (70%; 1 step; based on TD647·1.3TFA). NMR (D ₂ O, pD ~5, 95 °C): ¹ H δ _H 2.93‒3.56 (mc, CH ₂ ‒CO, m, 16+4H); 4.41 (CH ₂ ‒arom., s, 2H); 4.49 (CH ₂ ‒arom., s, 2H); 6.00 (CH ₂ ‒N ₃ , s, 2H); 7.54 (arom., dd, 1H, ³ J _HH = 7, ⁴ J _HH = 2); 7.56‒7.66 (Ph, m, 3H); 7.77 (arom., d, 1H, ⁴ J _HH = 1); 7.79‒7.87 (Ph, m, 2H); 7.94 (arom., d, 1H, ⁴ J _HH = 1); 8.05 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 2); 8.07 (arom., dd, 1H, ³ J _HH = 8, ³ J _HH = 7); 8.93 (CH–N ₃ , s, 1H). ¹³ C{ ¹ H} δ _C 50.0 (mc, s); 50.7 (mc, bs); 52.0 (mc, s); 52.3 (mc, s); 54.8 (CH ₂ ‒N ₃ , s); 56.6 (CH ₂ ‒CO, s); 59.9 (CH ₂ ‒arom., s); 60.2 (CH ₂ ‒arom., bs); 121.2 (arom., s); 121.7 (arom., s); 123.3 (arom., s); 124.5 (arom., s); 127.0 (CH–N ₃ , s); 127.7 (Ph, s); 129.9 (Ph, s); 130.5 (Ph, s); 137.1 (Ph, s); 140.2 (arom., s); 148.0 (arom., s); 150.3 (arom., s); 151.7 (arom., s); 152.5 (arom., bs); 154.9 (arom., s); 155.0 (arom., s); 174.4 (CO, s). ESI-HRMS: 626.3199 [M+H] ⁺ (theor. [C ₃₃ H ₄₀ N ₉ O ₄ ] ⁺ = 626.3198). EA (C ₃₃ H ₃₉ N ₉ O ₄ ·0.6FA·2.3H ₂ O, M _R = 696.8): C 58.1 (57.9); H 6.5 (6.2); N 18.1 (18.2). Example 6: Synthesis of coordination compounds Synthesis of TD734: In a glass vial (20 mL), TD714·0.1FA·xH ₂ O (6 mg; ~10 µmol; 0 equiv.) was dissolved in H ₂ O (4 mL) followed by addition aq. MOPS/NaOH uffer (500 m ^M ; pH 7.0; 1.00 mL; 500 µmol; ~50 equiv.) and aq. LuCl ₃ (100 m ^M ; 10 µL; 11 µmol; ~1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture as then filtered through syringe microfilter (RC). The filtrate was concentrated on tary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN adient with FA additive). Fractions with product were joined and directly lyo philized to give product as a mixture of two diastereoisomer (~11:1) in the form of formate salt as white fluffy solid. Yield: 5 mg (≤61% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 803.6; 1 step; based on TD714·0.1FA·xH ₂ O). NMR (D ₂ O, pD ~4, signals of major isomer): ¹ H δ _H 2.50–3.82 (mc, CH ₂ –CO, CH ₂ –P, m, 16+2+1H); 3.85–4.00 (CH ₂ ‒arom., CH ₂ –P, m, 1+1H); 4.10 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.23 (CH ₂ ‒ arom., d, 1H, ² J _HH = 15); 4.99 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 5.53 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.56 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.67 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 2); 7.83 (CH–N ₃ , s, 1H); 7.98 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 2); 7.18 (arom., t, 1H, 3J _HH = 8); 8.20 (arom., t, 1H, ³ J _HH = 8); 8.35 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 48.9 (mc, s); 51.3 (mc, s); 51.6 (CH ₂ –P, d, ¹ J _CP = 73); 52.0 (mc, s); 52.3 (mc, s); 53.4 (mc, s); 53.5 (CH ₂ ‒N ₃ , s); 53.6 (mc, s); 55.0 (mc, s); 56.3 (mc, s); 59.7 (CH ₂ ‒arom., s); 60.0 (CH ₂ ‒arom., s); 61.0 (CH ₂ ‒CO, s); 125.9 (arom., s); 127.6 (arom., s); 128.9 (arom., s); 130.4 (arom., s); 136.4 (CH–N ₃ , s); 138.7 (arom., s); 142.0 (arom., s); 142.9 (arom., s); 146.2 (arom., s); 156.8 (arom., s); 157.6 (arom., s); 158.6 (arom., s); 169.5 (FA, s); 178.2 (CO, s). ³¹ P{ ¹ H} δ _P 17.8 (s). ESI- HRMS: 758.1822 [M] ⁺ (theor. [C ₂₆ H ₃₄ N ₉ O ₅ P ₁ Lu ₁ ] ⁺ = 758.1823). ynthesis of TD925: In a glass vial (20 mL), TD921·4.6H ₂ O (6.1 mg; 7.4 µmol; 1.0 quiv.) was dissolved in H ₂ O (18 mL) and i-PrOH (1 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 400 µL; 200 µmol; 27 equiv.) and aq. GdCl ₃ (100 mM; 95 µL; 9.5 µmol; 1.3 equiv.) and the mixture was stirred 7 d at 80 C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 2.5 mg (≤33% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1010.0; 1 step; based on TD921·4.6H ₂ O). ESI-HRMS: 897.2158 [M] ⁺ (theor. [C ₃₇ H ₄₃ N ₉ O ₄ P ₂ Gd ₁ ] ⁺ = 897.2149). Synthesis of TD560: In a glass vial (20 mL), TD556·0.1FA·1.6H ₂ O (39 mg; 69 mol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 3.40 mL; 1.70 mmol; 25 equiv.) and aq. uCl ₃ (100 m ^M ; 745 µL; 75 µmol; 1.1 equiv.) and the mixture was stirred 4 d at 80 C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined nd directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 24 mg (43%; 1 step; based on TD556·0.1FA·1.6H ₂ O). ESI-HRMS: 700.1867 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Eu ₁ ] ⁺ = 700.1862). EA ([C ₂₇ H ₃₃ N ₉ O ₄ Eu ₁ ] ⁺ [FA] ⁻ ·4.5H ₂ O, M _R = 825.7): C 40.7 (40.7); H 5.2 (4.8); N 15.3 (15.0); Eu 18.4 (17.7). ynthesis of TD561: In a glass vial (20 mL), TD556·0.1FA·1.6H ₂ O (40 mg; 69 mol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 3.40 mL; 1.70 mmol; 25 equiv.) and aq. dCl ₃ (100 mM; 745 µL; 75 µmol; 1.1 equiv.) and the mixture was stirred 4 d at 80 C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 24 mg (42%; 1 step; based on TD556·0.1FA·1.6H ₂ O). ESI-HRMS: 705.1893 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Gd ₁ ] ⁺ = 705.1891). EA ([C ₂₇ H ₃₃ N ₉ O ₄ Gd ₁ ] ⁺ [FA] ⁻ ·4.6H ₂ O, M _R = 832.8): C 40.4 (40.8); H 5.2 (4.9); N 15.1 (15.5); Gd 18.9 (18.1). Synthesis of TD562: In a glass vial (20 mL), TD556·0.1FA·1.6H ₂ O (40 mg; 69 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 3.40 mL; 1.70 mmol; 25 equiv.) and aq. TbCl ₃ (100 mM; 745 µL; 75 µmol; 1.1 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 27 mg (47%; 1 step; based on TD556·0.1FA·1.6H ₂ O). ESI-HRMS: 706.1906 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Tb ₁ ] ⁺ = 706.1903). EA ([C ₂₇ H ₃ 3N ₉ O ₄ Tb1] ⁺ [FA] ⁻ ·4.7H ₂ O, M _R = 836.2): C 40.2 (40.5); H 5.2 (4.9); N 15.1 (14.7); Tb 19.0 (18.7). Synthesis of TD1069: In a glass vial (20 mL), TD556·0.1FA·1.6H ₂ O (20.8 mg; 35.7 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 1.80 mL; 900 µmol; 25 equiv.) and aq. LuCl ₃ (100 m ^M ; 400 µL; 40.0 µmol; 1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 26.6 mg (82%; 1 step; based on TD556·0.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.64‒3.82 (mc, CH ₂ ‒CO, m, 16+4H); 3.95 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.29 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.85 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.60 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.10 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.02 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.25 (arom., t, 1+1H, ³ J _HH = 8). ESI-HRMS: 722.2060 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ Lu ₁ ] ⁺ = 722.2058). EA ([C ₂₇ H ₃₃ N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.3TFA·2.4H ₂ O, M _R = 913.0): C 38.9 (38.7); H 4.2 (3.8); N 13.8 (13.7); Lu 19.2 (16.5). Synthesis of TD751: In a glass vial (20 mL), TD718·2.6H ₂ O (14 mg; 21 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MES/NaOH buffer 500 mM; pH 5.2; 1.30 mL; 650 µmol; 31 equiv.) and aq. LuCl ₃ (100 mM; 236 µL; 24 µmol; 1.1 equiv.) and the mixture was stirred 3 h at 80 °C. Mixture was then iltered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 13 mg (65%; 1 step; based on TD718·2.6H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 0.10 (CH ₃ , s, 9H); 2.61–3.83 (mc, CH ₂ –CO, m, 16+4H); 3.94 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.24 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.24 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.54 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.92 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.75 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.98 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.22 (arom., t, 1H, ³ J _HH = 8); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.45 (FA, s, 1H). ¹³ C{ ¹ H} δ _C −1.85 (CH ₃ , s); 48.4 (mc, s); 48.7 (mc, s); 50.7 (mc, s); 51.9 (mc, s); 52.0 (CH ₂ ‒N ₃ , s); 53.2 (mc, s); 53.8 (mc, s); 54.4 (mc, s); 55.5 (mc, s); 58.4 (CH ₂ ‒CO, s); 59.0 (CH ₂ ‒arom., s); 59.1 (CH ₂ ‒arom., s); 60.9 (CH ₂ ‒CO, s); 125.9 (arom., s); 126.7 (arom., s); 128.3 (arom., s); 130.4 (arom., s); 141.4 (arom., s); 142.3 (arom., s); 142.6 (arom., s); 146.3 (arom., s); 147.5 (arom., s); 155.1 (arom., s); 157.7 (arom., s); 158.7 (arom., s); 171.0 (FA, s); 176.8 (CO, s); 178.6 (CO, s). ESI-HRMS: 794.2445 [M] ⁺ (theor. [C ₃₀ H ₄₁ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ = 794.2453). EA ([C ₃₀ H ₄₁ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ [FA] ⁻ ·6.6H ₂ O, M _R = 958.7): C 38.8 (39.0); H 5.8 (5.3); N 13.1 (13.0); Si 2.9 (3.0); Lu 18.2 (17.4). Synthesis of TD737: In a glass vial (20 mL), TD728·2.6H ₂ O (15 mg; 20 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.00 mL; 1.00 mmol; 50 equiv.) and aq. LuCl ₃ (100 m ^M ; 220 µL; 22 µmol; 1.1 equiv.) and the mixture was stirred 5 days at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 12 mg (58%; 1 step; based on TD728·2.6H ₂ O). NMR (D ₂ O, pD ~5): δ _H 0.96 (i-Pr, d, 9H, ³ J _HH = 8); 0.99 (i-Pr, d, 9H, ³ J _HH = 8); 1.26 (i- Pr, hept, 3H, ³ J _HH = 8); 2.62–3.84 (mc, CH ₂ –CO, m, 16+4H); 4.05 (CH ₂ ‒arom., s, 2H); 4.29 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 4.88 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.43 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.74 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.67 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.94 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.20 (arom., t, 1H, ³ J _HH = 8); 8.22 (arom., t, 1H, ³ J _HH = 8); 8.43 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 12.1 (i-Pr, s); 18.8 (i-Pr, 2 × s); 47.9 (mc, bs); 50.0 (mc, bs); 50.4 (mc, bs); 52.2 (mc, bs); 53.0 (CH ₂ ‒N ₃ , s); 54.0 (mc, s); 55.2 (mc, s); 57.2 (mc, s); 57.6 (mc, s); 59.3 (CH ₂ ‒CO, s); 60.0 (CH ₂ ‒arom., s); 62.3 (CH ₂ ‒arom., bs); 64.0 (CH ₂ ‒CO, s); 126.1 (arom., s); 127.4 (arom., s); 128.9 (arom., s); 130.8 (arom., s); 141.6 (arom., s); 143.3 (arom., s); 143.8 (arom., s); 144.6 (arom., s); 147.1 (arom., s); 156.1 (arom., s); 158.4 (arom., s); 159.6 (arom., s); 171.5 (FA, s); 178.0 (CO, s); 179.1 (CO, s). ESI-HRMS: 878.3396 [M] ⁺ (theor. [C ₃₆ H ₅₃ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ = 878.3392). EA ([C ₃₆ H ₅₃ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ [FA] ⁻ ·5.9H ₂ O, M _R = 1030.2): C 43.1 (43.4); H 12.2 (11.8); N 12.2 (11.8); Si 2.7 (2.9); Lu 17.0 (16.9). Synthesis of TD946: In a glass vial (20 mL), TD943·1.5H ₂ O (28.1 mg; 45.6 µmol; 1.0 equiv.) was dissolved n H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 3.00 mL; 1.50 mmol; 33 equiv.) and aq. LuCl ₃ (100 mM; 540 µL; 54 µmol; 1.2 quiv.) and the mixture was stirred 3 days at 80 °C. Mixture was then filtered through yringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA dditive). Fractions with product were joined and directly lyophilized to give product n the form of trifluoroacetate salt as white fluffy solid. Yield: 32.6 mg (77%; 1 step; based on TD943·1.5H ₂ O). NMR (D ₂ O, pD ~5): δ _H 0.69‒0.94 (CH ₂ ‒CH, m, 2H); 0.94–1.07 (CH ₂ ‒CH, m, 2H); 1.65 (CH ₂ ‒CH, tt, 1H, ³ J _HH = 8, ³ J _HH = 5); 2.58‒3.86 (mc, CH ₂ –CO, m, 16+4H); 3.97 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.19 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.29 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.53 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.99 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.93 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.99 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.24 (arom., t, 1H, ³ J _HH = 8); 8.29 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 762.2375 [M] ⁺ (theor. [C ₃₀ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ = 762.2371). EA ([C ₃₀ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·1.8H ₂ O, M _R = 930.8): C 41.8 (42.2); H 4.4 (4.2); N 13.5 (13.1); F 7.3 (7.0). Synthesis of TD961: In a glass vial (20 mL), TD959·1.5H ₂ O (14.7 mg; 23.0 µmol; 1.0 equiv.) was dissolved in H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 1.50 mL; 0.75 mmol; 33 equiv.) and aq. LuCl ₃ (100 m ^M ; 280 µL; 28 µmol; 1.2 equiv.) and the mixture was stirred 3 days at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on otary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly yophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 20.1 mg (90%; 1 step; based on TD959·1.8H ₂ O). NMR (D ₂ O, pD ~4): δ _H 1.18 (CH ₃ , s, 9H); 2.64‒3.86 (mc, CH ₂ –CO, m, 16+4H); 4.01 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.35 (CH ₂ ‒ arom., d, 1H, ² J _HH = 17); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.48 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.66 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.93 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.22 (arom., t, 1H, ³ J _HH = 8); 8.26 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 778.2685 [M] ⁺ (theor. [C ₃₁ H ₄₁ N ₉ O ₄ Lu ₁ ] ⁺ = 778.2684). EA ([C ₃₁ H ₄₁ N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·3.0H ₂ O, M _R = 968.5): C 41.4 (41.5); H 4.9 (4.6); N 13.0 (12.7); F 7.1 (7.4). Synthesis of TD951: In a glass vial (20 mL), TD944·1.5H ₂ O (14.4 mg; 22.1 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.20 mL; 600 µmol; 27 equiv.) and aq. LuCl ₃ (100 mM; 265 µL; 26.5 µmol; 1.2 equiv.) and the mixture was stirred 4 days at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on otary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly 30 yophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 17.4 mg (80%; 1 step; based on TD944·1.5H ₂ O). NMR (D ₂ O, pD ~2): δ _H 2.69‒3.88 (mc, CH ₂ –CO, m, 16+4H); 3.97 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16‒4.36 (CH ₂ ‒arom., m, 2H); 4.88 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.51 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.97 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.16‒7.25 (Ph, m, 2H); 7.28‒7.41 (Ph, m, 3H); 7.49 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.03 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.06 (arom., t, 1H, ³ J _HH = 8); 8.25 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 798.2379 [M] ⁺ (theor. [C ₃₃ H ₃ 7N ₉ O ₄ Lu ₁ ] ⁺ = 798.2371). EA ([C ₃₃ H ₃ 7N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·3.0H ₂ O, M _R = 988.5): C 43.0 (43.0); H 4.4 (4.3); N 12.8 (12.6); F 6.9 (6.9). Synthesis of TD994: In a glass vial (20 mL), TD992·0.3FA·1.9H ₂ O (41.6 mg; 56.8 µmol; 1.0 equiv.) was 5 dissolved in H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; H 7.0; 2.85 mL; 1.43 mmol; 25 equiv.) and aq. LuCl ₃ (100 m ^M ; 625 µL; 62.5 µmol; .1 equiv.) and the mixture was stirred 8 days at 80 °C. Mixture was then filtered hrough syringe microfilter (RC). The filtrate was concentrated on rotary evaporator nd then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give roduct in the form of trifluoroacetate salt as white fluffy solid. Yield: 52.3 mg 86%; 1 step; based on TD992·0.3FA·1.9H ₂ O). NMR (D ₂ O, pD ~4): δ _H 1.52–1.78 (Adm., m, 9H); 1.80–1.95 (Adm., m, 6H); 2.60‒3.83 (mc, CH ₂ –CO, m, 16+4H); 3.99 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.11 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.33 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.43 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.58 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.66 (arom., d, 1H, ³ J _HH = 8); 7.80 (arom., d, 1H, ³ J _HH = 8); 7.88‒7.92 (arom., m, 2H); 8.18 (arom., t, 1H, ³ J _HH = 8); 8.22 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 856.3154 [M] ⁺ (theor. [C ₃₇ H ₄₇ N ₉ O ₄ Lu ₁ ] ⁺ = 856.3153). EA ([C ₃₇ H ₄₇ N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.4TFA·3.0H ₂ O, M _R = 1069.4): C 44.7 (44.3); H 5.0 (4.6); N 11.8 (11.5); F 7.5 (7.4); Lu 16.4 (14.0). ynthesis of TD1221: In a glass vial (20 mL), TD1204·0.3FA·2.7H ₂ O (22.5 mg; 0.5 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.57 mL; 785 µmol; 26 equiv.) and aq. uCl ₃ (100 mM; 375 µL; 37.5 µmol; 1.2 equiv.) and the mixture was stirred 24 h at 0 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 24.5 mg (74%; 1 step; based on TD1204·0.3FA·2.7H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.59‒3.83 (mc, CH ₂ ‒CO, m, 16+4H); 3.95 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.23 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 4.27 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.85 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.62 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.01 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.72 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (arom., d, 1H, ⁴ J _HH = 2); 7.90 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.97 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.23 (arom., t, 1H, ³ J _HH = 8); 8.29 (arom., t, 1H, ³ J _HH = 8). ESI- HRMS: 848.1020 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₉ O ₄ I1Lu ₁ ] ⁺ = 848.1024). EA ([C ₂₇ H ₃₂ N ₉ O ₄ I ₁ Lu ₁ ] ⁺ [TFA] ⁻ ·0.5TFA·4.1H ₂ O, M _R = 1092.3): C 33.0 (33.8); H 3.8 (3.6); N 11.5 (11.8); I 11.6 (10.9); F 7.8 (7.0). Synthesis of TD782: In a glass vial (40 mL), TD764·0.7TFA·1.7H ₂ O (190 mg; 274 µmol; 1.0 equiv.) was dissolved in H ₂ O (21 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 15.4 mL; 7.70 mmol; 28 equiv.) and q. LuCl ₃ (100 mM; 3.30 mL; 330 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 224 mg (85%; 1 step; based on TD764·0.7TFA·1.7H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.61‒ 3.84 (mc, CH ₂ ‒CO, m, 16+4H); 3.94 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.29 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.58 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.10 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., d, 1H, ⁴ J _HH = 2); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.13 (arom., d, 1H, ⁴ J _HH = 2); 8.24 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 756.1664 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₉ O ₄ Cl ₁ Lu ₁ ] ⁺ = 756.1668). EA ([C ₂₇ H ₃₂ N ₉ O ₄ Cl ₁ Lu ₁ ] ⁺ [TFA] ⁻ ·5.1H ₂ O, M _R = 961.9): C 36.2 (36.4); H 4.4 (4.0); N 13.1 (12.9); Cl 3.7 (3.7); F 5.9 (6.4); Lu 18.2 (16.8). Synthesis of TD819: Glass vial (4 mL) was charged with [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O (10.0 mg; 10.4 µmol; 1.0 equiv.), 3- borono-5-nitrobenzoic acid (4.4 mg; 21 µmol; 2.0 equiv.) and XPhos Pd G2 (0.5 mg; ~0.6 µmol; 6 mol%) and was then three times secured with argon. Under constant flow of argon was then added dry DMF (420 µL) through septum followed by addition of freshly prepared (and briefly washed with argon prior addition) aq. solution of K ₃ PO ₄ ·H ₂ O (326 mM; 160 µL; 52 µmol; 5.0 equiv.). The mixture was then stirred 16 h under septum (but without external argon) at 80 °C. Resulting heterogenous mixture was diluted with H ₂ O (2 mL) and the resulting slightly opalescent pale- yellow solution was filtered through syringe microfilter (RC). Filtrate was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 10 mg (≤96% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1000.7; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.66‒3.84 (mc, CH ₂ ‒CO, m, 16+4H); 4.07 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.17 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.39 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 5.72 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.19 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.14 (arom., d, 1H, ⁴ J _HH = 2); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.45 (arom., d, 1H, ⁴ J _HH = 2); 8.82 (arom., dm, 1H, 4J _HH = 2); 8.92 (arom., dd, 1H, ⁴ J _HH = 2, ⁴ J _HH = 1); 8.97 (arom., dm, 1H, ⁴ J _HH = 2). ESI-HRMS: 887.2121 [M] ⁺ (theor. [C ₃₄ H ₃₆ N ₁₀ O ₈ Lu ₁ ] ⁺ = 887.2120). Synthesis of TD891: Glass vial (4 mL) was charged with [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O (15.0 mg; 15.6 µmol; 1.0 equiv.), 2-(4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid (8.0 mg; 30.5 µmol; 2.0 equiv.) and XPhos Pd G2 (0.7 mg; ~0.9 µmol; 6 mol%) and was then three times secured with argon. Under constant flow of argon was then added dry DMF (600 µL) through septum followed by addition of freshly prepared (and briefly washed with argon prior addition) aq. solution of K ₃ PO ₄ ·H ₂ O (391 mM; 200 µL; 78 µmol; 5.0 equiv.). The mixture was then stirred 16 h under septum (but without external argon) at 80 °C. Resulting heterogenous mixture was diluted with H ₂ O (2 mL) and the resulting slightly opalescent pale-yellow solution was filtered through syringe microfilter (RC). Filtrate was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 7.2 mg (41%; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.60‒3.82 (mc, CH ₂ ‒CO, m, 16+4H); 3.86 (OC‒CH ₂ ‒ arom., s, 2H); 3.99 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.32 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.65 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.13 (CH ₂ ‒N ₃ , d, 1H, 2J _HH = 15); 7.54 (arom., dm, 2H, ³ J _HH = 8); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 7.92 (arom., dm, 2H, ³ J _HH = 8); 7.99 (arom., d, 1H, ⁴ J _HH = 1); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.30 (arom., d, 1H, ⁴ J _HH = 1). ESI-HRMS: 856.2418 [M] ⁺ (theor. [C ₃₅ H ₃₉ N ₉ O ₆ Lu ₁ ] ⁺ = 856.2426). EA ([C ₃₅ H ₃₉ N ₉ O ₆ Cl ₁ Lu ₁ ] ⁺ [TFA] ⁻ ·0.7TFA·4.6H ₂ O, M _R = 1132.4): C 40.7 (40.6); H 4.4 (4.3); N 11.1 (11.3). Synthesis of TD891-OH: TD891-OH was obtained (in the form of rifluoroacetate salt as white fluffy solid) as by-product during synthesis TD891. Yield: 5.7 mg. NMR (D ₂ O, pD ~3): ¹ H δ _H 2.60‒3.83 (mc, CH ₂ ‒CO, CH ₂ ‒arom., m, 16+4+1H); 4.13 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.20 (CH ₂ ‒ arom., d, 1H, ² J _HH = 15); 4.82 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.43 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.97 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.09 (arom., d, 1H, ⁴ J _HH = 2); 7.40 (arom., d, 1H, ⁴ J _HH = 2); 7.79 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (CH–N ₃ , s, 1H); 8.23 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 738.2003 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₅ Lu ₁ ] ⁺ = 738.2007). Synthesis of TD786: In a glass vial (4 mL), [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O (37 mg; 8 µmol; 1.0 equiv.) was dissolved in DMSO (3 mL) followed by addition solid NaN ₃ (54 mg; 831 µmol; 20 equiv.) and the mixture was stirred 2 h at 80 °C. Mixture was then concentrated to remove most of DMSO. Residue was issolved in H ₂ O and lyophilized. Crude product was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of rifluoroacetate salt as white fluffy solid. Yield: 21 mg (55%; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.62‒3.81 (mc, CH ₂ ‒CO, m, 16+4H); 3.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.14 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.25 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.83 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.52 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.05 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.38 (arom., d, 1H, ⁴ J _HH = 2); 7.71 (arom., d, 1H, ⁴ J _HH = 2); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.24 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 763.2075 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₁₂ O ₄ Lu ₁ ] ⁺ = 763.2072). EA ([C ₂₇ H ₃₂ N ₁₂ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·5.2H ₂ O, M _R = 993.0): C 35.6 (35.6); H 4.3 (4.0); N 16.9 (16.6); F 6.9 (6.8). Synthesis of TD787: Obtained as side product during synthesis of TD786 in he form of trifluoroacetate salt as white fluffy solid. Yield: 5 mg (~10%; 1 tep; based on TD782·5.1H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.59‒3.79 (mc, CH ₂ ‒CO, CH ₂ ‒arom., m, 16+4+1H); 4.02−4.19 (CH ₂ ‒arom., m, 2H); 4.25 CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.79 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 5.27 (CH ₂ ‒ N ₃ , d, 1H, ² J _HH = 15); 6.74 (arom., d, 1H, ⁴ J _HH = 2); 6.83 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.03 (arom., d, 1H, ⁴ J _HH = 2); 7.78 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (CH–N ₃ , s, 1H); 8.22 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 737.2165 [M] ⁺ (theor. [C ₂₇ H ₃₄ N ₁₀ O ₄ Lu ₁ ] ⁺ = 737.2167). Synthesis of TD830: In a glass vial (20 mL), TD764·0.7TFA·1.7H ₂ O (60 mg; 86 µmol; 1.0 equiv.) was dissolved in H ₂ O (5 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 5.0 mL; 2.50 mmol; 29 equiv.). and freshly prepared aq. ¹⁷⁶ YbCl ₃ (~90 µmol; ~1.0 eq.; obtained by dissolving 18.1 mg of ¹⁷⁶ Yb2O in 0.5 mL of 6 M HCl at 80 °C for several hours, followed by evaporation of the acid and adding 10 mL of H ₂ O to the residue). Mixture was hen stirred 6 h at 80 °C after which was filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 71 mg (≤94% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 871.0; 1 step; based on TD764·0.7TFA·1.7H ₂ O). ESI-HRMS: 757.1680 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₉ O ₄ Cl ₁ ¹⁷⁶ Yb ₁ ] ⁺ = 757.1686). Synthesis of TD836: In a glass vial (4 mL), [TD830] ⁺ [TFA] ⁻ ·xH ₂ O (12.1 mg; ~14 µmol; 1.0 equiv.) was dissolved in DMSO (500 µL) followed by addition olid NaN ₃ (9.0 mg; 138 µmol; ~10 equiv.) and the mixture was stirred 30 min t 80 °C. Mixture was then diluted with H ₂ O (3 mL) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy olid. Yield: 9.9 mg (≤81% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 877.6; 1 step; b ased on [TD830] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 764.2085 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₁₂ O ₄ ¹⁷⁶ Yb ₁ ] ⁺ = 764.2090). Synthesis of TD888: In a glass vial (20 mL), TD764·0.6TFA·1.0H ₂ O (56.5 mg; 84.3 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 4.0 mL; 2.00 mmol; 24 equiv.). and aq. TmCl ₃ (100 mM; 1.00 mL; 100 µmol; 1.2 equiv.) and the mixture was stirred 6 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; ₂ H O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 68.0 mg (86%, 1 step; based on TD764·0.6TFA·1.0H ₂ O). ESI-HRMS: 750.1608 [M] ⁺ (theor. [C ₂₇ H ₃₂ N ₉ O ₄ Cl ₁ Tm ₁ ] ⁺ = 750.1602). EA ([C ₂₇ H ₃₂ N ₉ O ₄ Cl ₁ Tm ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·2.6H ₂ O, M _R = 933.6): C 37.8 (37.7); H 4.0 (3.8); N 13.5 (13.4); Cl 3.8 (3.9); F 7.3 (7.3); Tm 18.1 (17.8). Synthesis of TD899: Glass vial (4 mL) was charged with [TD888] ⁺ [TFA] ⁻ ·0.2TFA·2.6H ₂ O (15.0 mg; 16.1 µmol; 1.0 equiv.), 2-(4-boronophenyl)acetic acid (4.2 mg; 23.3 µmol; 1.5 equiv.) and XPhos Pd G2 (0.7 mg; ~0.9 µmol; 6 mol%) and was then three times secured with argon. Under constant flow of argon was then added dry 1,4-Dioxane (600 µL) through septum followed by addition of freshly prepared (and briefly washed with argon prior addition) aq. solution of K3PO ₄ ·H ₂ O (391 mM; 200 µL; 78 µmol; 4.9 equiv.). The mixture was then stirred 16 h under septum (but without external argon) at 80 °C. Resulting heterogenous mixture was evaporated to dryness. Residue was re-dissolved in H ₂ O (3 mL), filtered through syringe microfilter (RC) and purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 10.1 mg (57%; 1 step; based on [TD888] ⁺ [TFA] ⁻ ·0.2TFA·2.6H ₂ O). ESI-HRMS: 850.2362 [M] ⁺ (theor. [C ₃₅ H ₃₉ N ₉ O ₆ Tm ₁ ] ⁺ = 850.2360). EA ([C ₃₅ H ₃₉ N ₉ O ₆ Tm ₁ ] ⁺ [TFA] ⁻ ·0.2TFA·7.0H ₂ O, M _R = 1112.6): C 40.4 (40.6); H 4.8 (4.7); N 11.3 (11.1); F 6.1 (6.4). 5 Synthesis of TD822: In a glass vial (20 mL), TD810·0.5TFA·0.1FA·2.1H ₂ O (26 mg; 39 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. AcOH/NaOH buffer (500 mM; pH 5.8; 2.1 mL; 1.05 mmol; 27 equiv.) and aq. EuCl ₃ (100 mM; 510 µL; 51 µmol; 1.3 equiv.) and the mixture was stirred 3 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 19 mg (≤59% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 836.6; 1 step; based on TD810·0.5TFA·0.1FA·2.1H ₂ O). ESI-HRMS: 724.1861 [M] ⁺ (theor. [C ₂₉ H ₃₃ N ₉ O ₄ Eu ₁ ] ⁺ = 724.1862). Synthesis of TD823: In a glass vial (20 mL), TD810·0.5TFA·0.1FA·2.1H ₂ O (28 mg; 42 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. AcOH/NaOH buffer (500 mM; pH 5.8; 2.3 mL; 1.15 mmol; 28 equiv.) and aq. TbCl ₃ (100 mM; 530 µL; 53 µmol; 1.3 equiv.) and the mixture was stirred 2 d at 0 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were oined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 22 mg (≤63%assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 843.6; 1 step; based on TD810·0.5TFA·0.1FA·2.1H ₂ O). ESI-HRMS: 730.1899 [M] ⁺ (theor. [C ₂₉ H ₃₃ N ₉ O ₄ Tb1] ⁺ = 730.1903). Synthesis of TD831: In a glass vial (20 mL), TD827·0.8FA·1.6H ₂ O (50 mg; 63 µmol; 1.0 equiv.) was dissolved in a mixture of abs. EtOH (8 mL) nd H ₂ O (7.5 mL) followed by addition aq. AcOH/NaOH buffer (500 mM; pH 5.8; 3.3 mL; 1.65 mmol; 26 equiv.) and aq. EuCl ₃ (100 mM; 740 µL; 74 µmol; 1.2 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then diluted with EtOH (100 mL) and filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator. The residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 36 mg (≤58% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 993.0; 1 step; based on TD827·0.8FA·1.6H ₂ O). ESI-HRMS: 880.3189 [M] ⁺ (theor. [C ₃₈ H ₅₃ N ₉ O ₄ Si ₁ Eu ₁ ] ⁺ = 880.3197). Synthesis of TD885: In a glass vial (4 mL), [TD831] ⁺ [TFA] ⁻ ·xH ₂ O (30.5 mg; 30.7 µmol; 1.0 equiv.) was dissolved in a H ₂ O (3.4 mL) followed by addition q. K ₂ CO ₃ (1.0 ^M ; 155 µL; 155 µmol; ~5 equiv.) and the mixture was stirred 40 min at 80 °C. The resulting orange-brown (and not entirely homogenous) mixture was then filtered through syringe microfilter (RC) and the filtrate was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 15.4 mg (≤60% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 836.6; 1 step; based on [TD831] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 724.1858 [M] ⁺ (theor. [C ₂₉ H ₃₃ N ₉ O ₄ Eu ₁ ] ⁺ = 724.1862). Synthesis of TD832: In a glass vial (20 mL), TD827·0.8FA·1.6H ₂ O (47 mg; 59 µmol; 1.0 equiv.) was dissolved in a mixture of abs. EtOH (8 mL) nd H ₂ O (8 mL) followed by addition aq. AcOH/NaOH buffer (500 mM; H 5.8; 3.1 mL; 1.55 mmol; 26 equiv.) and aq. EuCl ₃ (100 mM; 720 µL; 2 µmol; 1.2 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then diluted with EtOH (100 mL) and filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator. The residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 46 mg (≤78% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 999.9; 1 step; based on TD827·0.8FA·1.6H ₂ O). ESI-HRMS: 886.3229 [M] ⁺ (theor. [C ₃₈ H ₅₃ N ₉ O ₄ Si ₁ Tb ₁ ] ⁺ = 886.3238). Synthesis of TD886: In a glass vial (4 mL), [TD832] ⁺ [TFA] ⁻ ·xH ₂ O (46.2 mg; 46.2 µmol; 1.0 equiv.) was dissolved in a H ₂ O (3.3 mL) followed by addition aq. K ₂ CO ₃ (1.0 M; 230 µL; 230 µmol; ~5 equiv.) and the mixture was stirred 40 min at 80 °C. The resulting orange-brown (and not entirely homogenous) mixture was then filtered through syringe microfilter (RC) and the filtrate was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 29.3 mg (≤75% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 843.6; 1 step; based on [TD832] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 730.7901 [M] ⁺ (theor. [C ₂₉ H ₃₃ N ₉ O ₄ Tb1] ⁺ = 730.1903). Synthesis of TD829: In a glass vial (20 mL), TD827·0.8FA·1.6H ₂ O (31 mg; 39 µmol; 1.0 equiv.) was dissolved in a mixture of abs. EtOH (11 mL) and H ₂ O (6 mL) followed by addition aq. AcOH/NaOH buffer (500 m ^M ; pH 5.8; 2.0 mL; 1.00 mmol; 26 equiv.) and aq. YbCl ₃ (100 m ^M ; 400 µL; 40 µmol; 1.0 equiv.) and the mixture was stirred 8 h at 80 °C. Mixture was then diluted with MeOH (20 mL) and filtered through syringe microfilter (RC). The filtrate was concentrated on rotary e vaporator. The residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 38 mg (≤96% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1014.0; 1 step; based on TD827·0.8FA·1.6H ₂ O). ESI-HRMS: 901.3372 [M] ⁺ (theor. [C ₃₈ H ₅₃ N ₉ O ₄ Si ₁ Yb ₁ ] ⁺ = 901.3373). Synthesis of TD834: In a glass vial (4 mL), [TD829] ⁺ [TFA] ⁻ ·xH ₂ O (37.9 mg; 37.4 µmol; 1.0 equiv.) was dissolved in a 50% aq. MeOH (18 mL) followed by addition aq. K ₂ CO ₃ (100 mM; 2.0 mL µL; 200 µmol; ~5 equiv.) and the mixture was stirred 1 h at 80 °C. The resulting mixture was then concentrated to ~3 mL and then purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 22.5 mg (≤65% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 921.8; 1 step; based on [TD829] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 809.2570 [M] ⁺ (theor. [C ₃₁ H ₄₁ N ₉ O ₆ Yb ₁ ] ⁺ = 809.2563). Synthesis of TD833: In a glass vial (20 mL), TD827·0.8FA·1.6H ₂ O 64.8 mg; 81 µmol; 1.0 equiv.) was dissolved in a mixture of i-PrOH (10 mL) and H ₂ O (5 mL) followed by addition aq. MOPS/NaOH buffer 500 mM; pH 7.0; 4.1 mL; 2.05 mmol; 25 equiv.) and aq. LuCl ₃ (100 mM; 900 µL; 90 µmol; 1.1 equiv.) and the mixture was stirred 20 h at 80 C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator. The residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 76.3 mg (78%; 1 step; based on TD827·0.8FA·1.6H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.06–1.32 (i-Pr, m, 21H); 2.63–3.81 (mc, CH ₂ –CO, m, 16+4H); 3.90 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.28 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.55 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.09 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.76 (arom., d, 1H, ⁴ J _HH = 1); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.06 (arom., d, 1H, ⁴ J _HH = 1); 8.24 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 902.3386 [M] ⁺ (theor. [C ₃₈ H ₅₃ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ = 902.3392). EA ([C ₃₈ H ₅₃ N ₉ O ₄ Si ₁ Lu ₁ ] ⁺ [TFA] ⁻ ·1.0TFA·4.0H ₂ O, M _R = 1202.0): C 42.0 (41.7); H 5.2 (5.0); N 10.5 (10.4); Si 2.3 (1.9); F 9.5 (9.4). Synthesis of MIS007: In a glass vial (40 mL), TD833] ⁺ [TFA] ⁻ ·1.0TFA·4.0H ₂ O (19 mg; 16 µmol; 1.0 equiv.) was dissolved n a 50% aq. MeCN (20 mL) followed by addition aq. K ₂ CO ₃ (100 mM; 2.0 mL; 200 µmol; ~10 equiv.) and the mixture was stirred 1 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated to ~3 mL and then purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and dir ectly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 13 mg (≤81% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1016.0; 1 step; based on [TD833] ⁺ [TFA] ⁻ ·1.0TFA·4.0H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.68–3.84 (mc, CH ₂ –CO, m, 16+4H); 3.96 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.17 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.18 (C≡CH, s, 1H); 4.30 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.61 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.11 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.82 (arom., d, 1H, ⁴ J _HH = 2); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.11 (arom., d, 1H, ⁴ J _HH = 2); 8.27 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 746.2059 [M] ⁺ (theor. [C ₂₉ H ₃₃ N ₉ O ₄ Lu ₁ ] ⁺ = 746.2058). Synthesis of TD1113: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (4.0 mg; 6.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 mM; pH 7.0; 310 µL; 155 µmol; 25 equiv.) and q. PrCl ₃ (100 mM; 67 µL; 6.7 µmol; 1.1 equiv.) and the mixture was stirred 0 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The ltrate was concentrated on rotary evaporator and then directly purified by reparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions ith product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 0.6 mg (≤10% assuming [M] ⁺ [TFA] ⁻ ·1.0TFA·xH ₂ O; M _R = 985.9; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~3): ¹⁹ F δ _F −66.45 (bs). NMR (~0.5 mM TD1113 in ~50 m ^M MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.49 (bs; ΔH½ = 135.2 Hz). ESI- HRMS: 756.1593 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Pr ₁ ] ⁺ = 756.1600). Synthesis of TD1114: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (4.0 mg; 6.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 310 µL; 155 µmol; 25 equiv.) and q. NdCl ₃ (100 m ^M ; 67 µL; 6.7 µmol; 1.1 equiv.) and the mixture was stirred 0 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The ltrate was concentrated on rotary evaporator and then directly purified by reparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 2.0 mg (≤33% assuming [M] ⁺ [TFA] ⁻ ·0.9TFA·xH ₂ O; M _R = 975.5; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~3): ¹⁹ F δ _F −66.75 (s). NMR (~0.5 mM TD1114 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.76 (s; ΔH½ = 47.4 Hz). ESI- HRMS: 757.1595 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Nd ₁ ] ⁺ = 757.1601). Synthesis of TD1115: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (4.0 mg; 6.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 310 µL; 155 µmol; 25 equiv.) and q. SmCl ₃ (100 m ^M ; 67 µL; 6.7 µmol; 1.1 equiv.) and the mixture was stirred 10 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 3.6 mg (≤63% assuming [M] ⁺ [TFA] ⁻ ·0.3TFA·xH ₂ O; M _R = 913.2; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −66.03 (s). NMR (~0.5 mM TD1115 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.06 (s; ΔH½ = 1.9 Hz). ESI- HRMS: 767.1713 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Sm ₁ ] ⁺ = 767.1721). Synthesis of TD1072: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and aq. EuCl ₃ (100 m ^M ; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 8 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 2.7 mg (≤66% assuming [M] ⁺ [TFA] ⁻ ·0.3TFA·xH ₂ O; M _R = 914.8; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −62.77 (s). NMR (~0.5 mM TD1072 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −62.79 (s; ΔH _½ = 3.3 Hz). ESI- HRMS: 768.1738 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Eu ₁ ] ⁺ = 768.1736). Synthesis of TD1179: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (4.0 mg; 6.5 µmol; 1.0 equiv.) was dissolved in H ₂ O (13 mL) followed by addition q. MOPS/NaOH buffer (500 mM; pH 7.0; 326 µL; 163 µmol; 25 equiv.) nd aq. GdCl ₃ (100 mM; 78 µL; 7.8 µmol; 1.2 equiv.) and the mixture was tirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter RC). The filtrate was concentrated on rotary evaporator and then directly urified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 2.2 mg (≤36% assuming [M] ⁺ [TFA] ⁻ ·0.9TFA·xH ₂ O; M _R = 988.5; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −62.98 (bs). NMR (~0.5 mM TD1179 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −62.97 (bs; ΔH _½ = 342.9 Hz). ESI-HRMS: 773.1779 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Gd ₁ ] ⁺ = 773.1765). Synthesis of TD1073: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 mM; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and q. TbCl ₃ (100 mM; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by reparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 2.8 mg (≤64% assuming [M] ⁺ [TFA] ⁻ ·0.7TFA·xH ₂ O; M _R = 967.3; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −107.22 (bs). NMR (~0.5 mM TD1073 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −107.50 (bs; ΔH _½ = 708.6 Hz). ESI- HRMS: 774.1779 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Tb ₁ ] ⁺ = 774.1777). Synthesis of TD1074: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and aq. DyCl ₃ (100 m ^M ; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 5 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 3.3 mg (≤75% assuming [M] ⁺ [TFA] ⁻ ·0.7TFA·xH ₂ O; M _R = 970.9; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −142.86 (s). NMR (~0.5 mM TD1074 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −143.22 (s; ΔH½ = 47.2 Hz). ESI-HRMS: 779.1816 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Dy ₁ ] ⁺ = 779.1816). Synthesis of TD1075: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and q. HoCl ₃ (100 m ^M ; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 5 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 4.0 mg (≤90% assuming [M] ⁺ [TFA] ⁻ ·0.8TFA·xH ₂ O; M _R = 984.7; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −85.69 (bs). NMR (~0.5 mM TD1075 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −85.79 (bs; ΔH½ = 185.8 Hz). ESI- HRMS: 780.1829 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Ho ₁ ] ⁺ = 780.1827). Synthesis of TD1076: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition q. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and q. ErCl ₃ (100 m ^M ; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 4.1 mg (≤92% assuming [M] ⁺ [TFA] ⁻ ·1.0TFA·xH ₂ O; M _R = 987.1; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −47.48 (s). NMR (~0.5 mM TD1076 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −47.42 (s; ΔH _½ = 19.3 Hz). ESI-HRMS: 781.1824 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Er ₁ ] ⁺ = 781.1827). Synthesis of 1077: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and aq. TmCl ₃ (100 mM; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 4.2 mg (≤92% assuming [M] ⁺ [TFA] ⁻ ·1.0TFA·xH ₂ O; M _R = 1011.6; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −57.57 (bs). NMR (~0.5 mM TD1077 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −57.51 (bs; ΔH _½ = 138.72 Hz). ESI- HRMS: 784.1863 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Tm ₁ ] ⁺ = 784.1866). Synthesis of 1078: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and aq. YbCl ₃ (100 mM; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 3.7 mg (≤82% assuming [M] ⁺ [TFA] ⁻ ·0.9TFA·xH ₂ O; M _R = 1004.3; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹⁹ F δ _F −59.01 (s). NMR (~0.5 mM TD1078 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −59.00 (s; ΔH _½ = 18.4 Hz). ESI-HRMS: 789.1913 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Yb ₁ ] ⁺ = 789.1912). Synthesis of TD1079: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (14.7 mg; 22.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 1150 µL; 575 µmol; 25 equiv.) and aq. LuCl ₃ (100 m ^M ; 250 µL; 25.0 µmol; 1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). F ractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 16.1 mg (70%; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): 1H δ _H 2.69–3.85 (mc, CH ₂ –CO, m, 16+4H); 4.12 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.19 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.38 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.88 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.75 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.23 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8, 4J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.12 (arom., d, 1H, ⁴ J _HH = 2); 8.28 (arom., t, 1H, ³ J _HH = 8), 8.43 (arom., d, 1H, 4J _HH = 2). ¹⁹ F δ _F −66.10 (s). NMR (~0.5 m ^M TD1079 in ~50 m ^M MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): 1 ⁹ F δ _F −66.13 (s; ΔH½ = 2.4 Hz). ESI-HRMS: 790.1931 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Lu ₁ ] ⁺ = 790.1932). EA ([C ₂₈ H ₃₂ N ₉ O ₄ Lu ₁ F ₃ ] ⁺ [TFA] ⁻ ·0.2TFA·4.1H ₂ O, M _R = 1000.2): C 36.5 (36.2); H 4.1 (3.6); N 12.6 (12.3); F 12.5 (12.0). Synthesis of TD1080: In a glass vial (20 mL), TD1063·0.1FA·1.2H ₂ O (2.9 mg; 4.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (10 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 225 µL; 113 µmol; 25 equiv.) and aq. YCl ₃ (100 mM; 55 µL; 5.5 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The iltrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 3.6 mg (≤94% assuming [M] ⁺ [TFA] ⁻ ·0.3TFA·xH ₂ O; M _R = 851.7; 1 step; based on TD1063·0.1FA·1.2H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.66–3.87 (mc, CH ₂ –CO, m, 16+4H); 4.11 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.18 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.42 (CH ₂ ‒arom., d, 1H, 2J _HH = 15); 4.89 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.80 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.16 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.13 (arom., d, 1H, ⁴ J _HH = 2); 8.28 (arom., t, 1H, ³ J _HH = 8), 8.43 (arom., d, 1H, ⁴ J _HH = 2). ¹⁹ F δ _F −66.10 (s). NMR (~0.5 m ^M TD1080 in ~50 m ^M MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.12 (s; ΔH½ = 2.1 Hz). ESI-HRMS: 704.1583 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ Y ₁ ] ⁺ = 704.1582). Synthesis of TD651: In a glass vial (20 mL), TD647·0.2FA·0.9H ₂ O (30 mg; 46 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.30 mL; 1.15 mmol; 25 equiv.) and aq. LaCl ₃ (100 m ^M ; 500 µL; 50 µmol; 1.1 equiv.) and the mixture was stirred 14 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 15 mg (36%; 1 step; based on TD647·0.2FA·0.9H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.54–3.63 (mc, CH ₂ –CO, m, 16+3H); 3.96 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.00 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 4.09 (CH ₂ –CO, 1H, d, ² J _HH = 17); 4.23 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.25 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 5.72 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 6.62 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.58–7.66 (Ph, m, 3H); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83–7.95 (Ph, arom., m, 2+1H); 8.06 (arom., d, 1H, ⁴ J _HH = 2); 8.16 (CH–N ₃ , s, 1H); 8.22 (arom., t, 1H, ³ J _HH = 8); 8.42 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 53.5 (CH ₂ ‒N ₃ , s); 56.3 (mc, s); 58.7 (mc, s); 58.9 (mc, s); 59.2 (mc, s); 59.3 (mc, s); 60.0 (mc, s); 61.9 (mc, s); 62.5 (CH ₂ ‒CO, s); 63.5 (mc, s); 65.1 (CH ₂ ‒CO, s); 65.2 (CH ₂ ‒arom., s); 66.6 (CH ₂ ‒arom., s); 124.1 (arom., s); 124.6 (arom., s); 127.1 (arom., s); 127.9 (arom., s); 128.1 (Ph, s); 130.2 (Ph, s); 131.5 (Ph, s); 136.1 (arom, s); 136.2 (Ph., s); 136.8 (CH–N ₃ , s); 142.0 (arom., s); 144.9 (arom., s); 153.6 (arom., s); 157.0 (arom., s); 157.5 (arom., s); 159.0 (arom., s); 171.0 (FA, s); 179.0 (CO, s); 180.4 (CO, s). ESI-HRMS: 762.2024 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ La ₁ ] ⁺ = 762.2027). EA ([C ₃₃ H ₃₇ N ₉ O ₄ La ₁ ] ⁺ [FA] ⁻ ·4.8H ₂ O, M _R = 894.1): C 45.7 (46.1); H 5.4 (4.7); N 14.1 (13.6); La 15.5 (15.0). ynthesis of TD870: In a glass vial (20 mL), TD647·1.3TFA (30.5 mg; 39.4 mol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.30 mL; 1.15 mmol; 29 equiv.) nd aq. CeCl ₃ (100 mM; 545 µL; 54.5 µmol; 1.4 equiv.) and the mixture was irred 14 d at 80 °C. Mixture was then filtered through syringe microfilter RC). The filtrate was concentrated on rotary evaporator and then directly urified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA dditive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 21.2 mg (58%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 763.2012 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Ce ₁ ] ⁺ = 763.2017). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Ce ₁ ] ⁺ [FA] ⁻ ·6.5H ₂ O, M _R = 925.9): C 44.1 (44.7); H 5.6 (5.1); N 13.6 (13.1); Ce 15.1 (14.5). Synthesis of TD869: In a glass vial (20 mL), TD647·1.3TFA (26.4 mg; 34.1 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.40 mL; 1.20 mmol; 35 equiv.) and aq. PrCl ₃ (100 m ^M ; 500 µL; 50.0 µmol; 1.5 equiv.) and the mixture was stirred 14 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 17.7 mg (56%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 764.2035 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Pr ₁ ] ⁺ = 764.2040). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Pr ₁ ] ⁺ [FA] ⁻ ·6.4H ₂ O, M _R = 924.9): C 44.2 (44.7); H 5.5 (5.0); N 13.6 (13.1); Pr 15.2 (14.8). Synthesis of TD868: In a glass vial (20 mL), TD647·1.3TFA (25.7 mg; 33.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.30 mL; 1.15 mmol; 35 equiv.) and aq. NdCl ₃ (100 mM; 460 µL; 46.0 µmol; 1.4 equiv.) and the mixture was stirred 12 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 19.8 mg (65%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 765.2039 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Nd ₁ ] ⁺ = 765.2040). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Nd ₁ ] ⁺ [FA] ⁻ ·5.6H ₂ O, M _R = 913.9): C 44.7 (45.0); H 5.4 (4.6); N 13.8 (13.4); Nd 15.8 (15.2). Synthesis of TD867: In a glass vial (20 mL), TD647·1.3TFA (25.6 mg; 33.1 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.30 mL; 1.15 mmol; 35 equiv.) and aq. SmCl ₃ (100 mM; 460 µL; 46.0 µmol; 1.4 equiv.) and the mixture was stirred 12 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 22.3 mg (73%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 775.2158 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Sm ₁ ] ⁺ = 775.2160). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Sm ₁ ] ⁺ [FA] ⁻ ·5.8H ₂ O, M _R = 923.6): C 44.2 (44.7); H 5.4 (4.9); N 13.6 (13.3); Nd 16.3 (15.8). Synthesis of TD599: In a glass vial (20 mL), TD647·1.3H ₂ O (50 mg; 77 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 3.75 mL; 1.88 mmol; 24 equiv.) and aq. EuCl ₃ (100 m ^M ; 825 µL; 83 µmol; 1.1 equiv.) and the mixture was stirred 3 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 44 mg (63%; 1 step; based on TD647·1.3H ₂ O). ESI-HRMS: 776.2171 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Eu ₁ ] ⁺ = 776.2175). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Eu ₁ ] ⁺ [FA] ⁻ ·4.6H ₂ O, M _R = 903.6): C 45.2 (45.3); H 5.3 (5.1); N 14.0 (13.7); Eu 16.8 (16.5). Synthesis of TD451: In a glass vial (2 mL), TD647·2.2H ₂ O (2.0 mg; 3.1 µmol; 1.0 equiv.) was dissolved in aq. MOPS/NaOH buffer (500 mM; pH 7.0; 155 µL; 77.5 µmol; 25 equiv.) and aq. GdCl ₃ (100 mM; 34 µL; 120 µmol; 1.1 equiv.) and the mixture was stirred 2 d at RT. Mixture was then diluted with H ₂ O and filtered through syringe microfilter (RC). The filtrate was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 0.3 mg. Synthesis of TD527: In a glass vial (40 mL), TD647·2.2H ₂ O (75 mg; 113 µmol; 1.0 equiv.) was dissolved in H ₂ O (32 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 4.60 mL; 2.30 mmol; 20 equiv.) and aq. GdCl ₃ (100 mM; 1.20 mL; 120 µmol; 1.1 equiv.) and the mixture was stirred 2 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 58 mg (56%; 1 step; based on TD647·2.2H ₂ O). ESI-HRMS: 781.2218 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Gd ₁ ] ⁺ = 781.2204). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Gd ₁ ] ⁺ [FA] ⁻ ·5.3H ₂ O, M _R = 921.5): C 44.3 (44.7); H 5.3 (4.7); N 13.7 (13.4); Gd 17.1 (16.2). Synthesis of TD600: In a glass vial (20 mL), TD647·1.3H ₂ O (50 mg; 77 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 3.75 mL; 1.88 mmol; 24 equiv.) and aq. TbCl ₃ (100 m ^M ; 825 µL; 83 µmol; 1.1 equiv.) and the mixture was stirred 3 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 49 mg (69%; 1 step; based on TD647·1.3H ₂ O). ESI-HRMS: 782.2211 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Tb ₁ ] ⁺ = 781.2217). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Tb ₁ ] ⁺ [FA] ⁻ ·4.9H ₂ O, M _R = 915.9): C 44.6 (44.7); H 5.3 (5.1); N 13.8 (13.6); Tb 17.4 (17.1). Synthesis of TD866: In a glass vial (20 mL), TD647·1.3TFA (20.0 mg; 25.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.84 mL; 920 µmol; 36 equiv.) and aq. DyCl ₃ (100 mM; 370 µL; 37.0 µmol; 1.4 equiv.) and the mixture was stirred 46 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 22.2 mg (89%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 787.2248 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Dy ₁ ] ⁺ = 787.2255). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Dy ₁ ] ⁺ [FA] ⁻ ·7.7H ₂ O, M _R = 970.0): C 42.1 (42.5); H 5.5 (5.0); N 13.0 (12.6); Dy 16.8 (16.1). Synthesis of TD648: In a glass vial (20 mL), TD647·0.2FA·0.9H ₂ O (22 mg; 34 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.72 mL; 860 µmol; 25 equiv.) and aq. HoCl ₃ (100 mM; 375 µL; 38 µmol; 1.1 equiv.) and the mixture was stirred 20 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 24 mg (76%; 1 step; based on TD647·0.2FA·0.9H ₂ O). ESI-HRMS: 788.2265 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Ho1] ⁺ = 788.2266). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Ho1] ⁺ [FA] ⁻ ·5.0H ₂ O, M _R = 923.7): C 44.2 (44.2); H 5.2 (4.8); N 13.6 (13.3); Ho 17.9 (17.3). Synthesis of TD865: In a glass vial (20 mL), TD647·1.3TFA (20.5 mg; 26.5 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 1.84 mL; 920 µmol; 35 equiv.) and aq. ErCl ₃ (100 m ^M ; 370 µL; 37.0 µmol; 1.4 equiv.) and the mixture was stirred 22 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 22.8 mg (90%; 1 step; based on TD647·1.3TFA). ESI-HRMS: 791.2280 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Er ₁ ] ⁺ = 791.2302). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Er ₁ ] ⁺ [FA] ⁻ ·6.9H ₂ O, M _R = 960.3): C 42.5 (42.4); H 5.4 (4.9); N 13.1 (12.7); Er 17.4 (16.8). Synthesis of TD601: In a glass vial (20 mL), TD647·1.3H ₂ O (49 mg; 75 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 3.75 mL; 1.88 mmol; 25 equiv.) and aq. TmCl ₃ (100 mM; 825 µL; 83 µmol; 1.1 equiv.) and the mixture was stirred 20 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 51 mg (73%; 1 step; based on TD647·1.3H ₂ O). ESI-HRMS: 792.2299 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Tm ₁ ] ⁺ = 792.2305). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Tm ₁ ] ⁺ [FA] ⁻ ·4.7H ₂ O, M _R = 922.3): C 44.3 (44.4); H 5.2 (5.1); N 13.7 (13.5); Tm 18.3 (18.3). Synthesis of TD602: In a glass vial (20 mL), TD647·1.3H ₂ O (49 mg; 75 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 3.75 mL; 1.88 mmol; 25 equiv.) and aq. YbCl ₃ (100 mM; 825 µL; 83 µmol; 1.1 equiv.) and the mixture was stirred 20 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 53 mg (77%; 1 step; based on TD647·1.3H ₂ O). ESI-HRMS: 797.2347 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Yb ₁ ] ⁺ = 797.2352). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Yb ₁ ] ⁺ [FA] ⁻ ·4.2H ₂ O, M _R = 917.4): C 44.5 (44.1); H 5.1 (5.1); N 13.7 (13.3); Yb 18.4 (18.7). Synthesis of TD522: In a glass vial (20 mL), TD647·1.3TFA (30.0 mg; 38.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.30 mL; 1.15 mmol; 30 equiv.) and aq. LuCl ₃ (100 m ^M ; 500 µL; 50.0 µmol; 1.3 equiv.) and the mixture was stirred 4 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 32.6 mg (89%; 1 step; based on TD647·1.3TFA). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.62–3.83 (mc, CH ₂ –CO, m, 16+4H); 3.99 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.32 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.66 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.13 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.60–7.67 (Ph, m, 3H); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 7.91–7.97 (Ph, m, 2H); 7.99 (arom., d, 1H, ⁴ J _HH = 2); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.31 (arom., d, 1H, ⁴ J _HH = 2); 8.38 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 48.9 (mc, bs); 49.1 (mc, bs); 51.8 (mc, bs); 51.9 (mc, bs); 52.9 (CH ₂ ‒N ₃ , s); 53.8 (mc, s); 53.9 (mc, bs); 54.9 (mc, s); 56.0 (mc, s); 59.2 (CH ₂ ‒CO, s); 59.6 (CH ₂ ‒arom., s); 59.7 (CH ₂ ‒arom., s); 61.0 (CH ₂ ‒CO, s); 123.7 (arom., s); 126.5 (arom., s); 127.7 (arom., s); 128.3 (Ph, s); 130.3 (Ph, s); 130.5 (arom., s); 131.8 (Ph, s); 136.0 (Ph, s); 136.4 (CH–N ₃ , s); 138.4 (arom., s); 142.6 (arom., s); 146.4 (arom., s); 154.7 (arom., s); 156.0 (arom., s); 158.7 (arom., s); 158.8 (arom., s); 170.0 (FA, s); 177.9 (CO, s); 179.4 (CO, s). ESI-HRMS: 798.2377 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ = 798.2371). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ [FA] ⁻ ·5.5H ₂ O, M _R = 942.8): C 43.3 (43.7); H 5.2 (4.6); N 13.4 (13.1); Lu 18.6 (18.0). Synthesis of TD776: In a glass vial (4 mL), [TD522] ⁺ [FA] ⁻ ·5.5H ₂ O (9.0 mg; 9.5 µmol; 1.0 equiv.) was dissolved in D ₂ O (500 µL) and evaporated o dryness. Residue was re-dissolved in D ₂ O (500 µL) followed by addition of neat DBU (29 µL; 194 µmol; 20 equiv.) and the resulting solution was stirred 2 d at 80 °C. Mixture was then evaporated to dryness. Residue was re-dissolved in D ₂ O (500 µL) followed by addition of another portion of neat DBU (15 µL; 100 µmol; ~10 equiv.) and the resulting solution was further stirred 16 h at 80 °C. Mixture was then quenched by addition of FA (75 µL; 2.92 mmol; ~300 equiv.) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give crude product in the form of formate salt as white fluffy solid ( ¹ H NMR analysis found ~1 equiv. of DBU or its byproducts apart from otherwise pure deka-deuterated chelate). Bulk of the material was therefore re- purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 7.6 mg (≤87% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 921.7; 1 step; based on [TD522] ⁺ [FA] ⁻ ·5.5H ₂ O). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.64–3.83 (mc, m, 16H); 7.59–7.67 (Ph, m, 3H); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (CH–N ₃ , s, 1H); 7.90–7.96 (Ph, m, 2H); 7.98 (arom., d, 1H, ⁴ J _HH = 2); 8.24 (arom., t, 1H, ³ J _HH = 8); 8.30 (arom., d, 1H, ⁴ J _HH = 2); 8.39 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 48.9 (mc, bs); 49.2 (mc, bs); 51.8 (mc, bs); 51.9 (mc, bs); 52.0‒52.9 (CD ₂ ‒N ₃ , bm); 53.8 (mc, s); 53.9 (mc, bs); 54.8 (mc, s); 55.9 (mc, s); 58.2‒59.7 (CD ₂ ‒CO, 2 × CD ₂ ‒arom., bm); 59.7‒60.9 (CD ₂ ‒CO, s); 123.8 (arom., s); 126.5 (arom., s); 127.8 (arom., s); 128.3 (Ph, s); 130.3 (Ph, s); 130.5 (arom., s); 131.8 (Ph, s); 136.1 (Ph, s); 136.4 (CH–N ₃ , s); 138.5 (arom., s); 142.6 (arom., s); 146.4 (arom., s); 154.8 (arom., s); 156.0 (arom., s); 158.7 (arom., s); 158.8 (arom., s); 170.5 (FA, s); 178.0 (CO, s); 179.4 (CO, s). ESI-HRMS: 808.3004 [M] ⁺ (theor. [C ₃₃ H ₂₇ D ₁₀ N ₉ O ₄ Lu ₁ ] ⁺ = 808.2998). Synthesis of TD688: In a glass vial (2 mL), [TD522] ⁺ [FA] ⁻ ·5.5H ₂ O (1 mg; ~1 µmol; 1.0 equiv.) was dissolved in MeOH (1 mL) followed by addition of solid NaBH ₄ (4 mg; ~100 mmol; ~100 equiv.). The resulting open vial was stirred 1 h at RT after which further portions of NaBH ₄ were added until all starting material was consumed (analyzed by LC-MS). The mixture was hen diluted with H ₂ O (2 mL), neutralized with neat FA (200 µL) and filtered hrough syringe microfilter (RC). Filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: <1 mg. NMR (D ₂ O, pD ~6): ¹ H δ _H 1.42–2.23 (Pip., m, 6H); 2.52–3.70 (mc, CH ₂ –CO, CH ₂ –Pip., m, 16+3+2H); 3.76 (Pip., m, 1H); 4.16 (CH ₂ –CO, d, ² J _HH = 17); 4.22 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.32 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.78 (Pip., m, 1H); 5.66 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 6.88 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.68–7.74 (Ph, m, 3H); 7.91 (CH–N ₃ , s, 1H); 7.98 (arom., d, 1H, ⁴ J _HH = 2); 7.98–8.02 (Ph, m, 2H); 8.25 (arom., d, 1H, ⁴ J _HH = 2); 8.52 (FA, s). ¹³ C{ ¹ H} δ _C 22.8 (Pip., s); 27.0 (Pip., s); 29.5 (Pip., s); 50.1 (Pip., s); 51.4 (CH ₂ ‒N ₃ , s); 52.1 (mc, s); 53.4 (mc, s); 54.4 (mc, s); 54.5 (Pip., s); 55.4 (mc, s); 55.6 (mc, s); 56.0 (mc, s); 56.1 (mc, s); 56.8 (mc, s); 56.0 (CH ₂ ‒Pip., s); 64.7 (CH ₂ ‒CO, s); 64.8 (CH ₂ ‒arom., s); 65.4 (CH ₂ ‒Pip., s); 119.8 (arom., s); 123.7 (arom., s); 126.9 (Ph, s); 129.0 (Ph, s); 130.5 (Ph, s); 131.6 (CH–N ₃ , s); 135.7 (Ph, s); 138.9 (arom., s); 153.1 (arom., s); 155.9 (arom., s); 159.0 (arom., s); 170.5 (FA, s); 178.8 (CO, s); 179.5 (CO, s). ESI-HRMS: 804.2841 [M] ⁺ (theor. [C ₃₃ H ₄₃ N ₉ O ₄ Lu ₁ ] ⁺ = 804.2840). Synthesis of TD739: In a glass vial (2 mL), [TD522] ⁺ [FA] ⁻ ·5.5H ₂ O (10 mg; 11 µmol; 1.0 equiv.) was dissolved in CD ₃ OD (1 mL) followed by addition of solid NaBD4 (44 mg; 1.05 mmol; ~100 equiv.). The resulting open vial was stirred 1 h at RT after which another portion of NaBD4 (28 mg; 0.67 mmol; ~60 equiv.) was added. Mixture was further stirred with 1 h at RT. The mixture was then diluted with H ₂ O (2 mL), neutralized with neat FA (160 µL; ~400 equiv.) and filtered through syringe microfilter (RC). Filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product (major diastereoisomer) were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 6 mg (~60%; 1 step; based on [TD522] ⁺ [FA] ⁻ ·5.5H ₂ O). NMR (D ₂ O, pD ~5): 1.33–1.77 (Pip., m, 1H); 1.93–2.09 (Pip., m, 2H); 2.42–3.62 (mc, CH ₂ –CO, CH ₂ –Pip. m, 16+3H+1H); 4.07 (CH ₂ –CO, d, 1H, ² J _HH = 17); 4.19 (CHD–arom., s, 1H); 5.56 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 6.78 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.59–7.65 (Ph, m, 3H); 7.82 (CH–N ₃ , s, 1H); 7.87 (arom., d, 1H, ⁴ J _HH = 2); 7.88–7.93 (Ph, m, 2H); 8.14 (arom., d, 1H, ⁴ J _HH = 2); 8.43 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 23.4 (Pip., bs); 27.7 (Pip., bs); 30.3 (Pip., bs); 50.9 (Pip., bs); 52.7 (CH ₂ ‒N ₃ , s); 53.4 (mc, s); 54.7 (mc, s); 55.3 (Pip., bs); 55.7 (mc, s); 56.7 (mc, s); 56.8 (mc, s); 57.3 (mc, s); 57.4 (mc, s); 58.1 (mc, s); 61.2 (CH ₂ ‒CO, s); 65.8 (CHD–arom., bs); 66.0 (CH ₂ ‒Pip., s); 66.8 (CH ₂ ‒CO, s); 121.1 (arom., s); 125.0 (arom., s); 128.2 (Ph, s); 130.3 (Ph, s); 131.8 (Ph, s); 132.9 (arom., s); 135.9 (Ph, s); 140.2 (arom., s); 154.3 (arom., s); 157.2 (arom., s); 160.3 (arom., s); 171.4 (FA, s); 180.1 (CO, s); 180.8 (CO, s). ESI-HRMS: 810.3215 [M] ⁺ (theor. [C ₃₃ H ₃₇ D ₆ N ₉ O ₄ Lu ₁ ] ⁺ = 810.3217). Synthesis of TD649: In a glass vial (20 mL), TD647·0.2FA·0.9H ₂ O (38 mg; 59 µmol; 1.0 equiv.) was dissolved in H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.96 mL; 1.48 mmol; 25 equiv.) and aq. YCl ₃ (100 mM; 650 µL; 65 µmol; 1.1 equiv.) and the mixture was stirred 20 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 32 mg (65%; 1 step; based on TD647·0.2FA·0.9H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.58–3.86 (mc, CH ₂ –CO, m, 16+4H); 3.99 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.37 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.85 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.71 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.07 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.58–7.68 (Ph, m, 3H); 7.78–7.86 (arom., m, 2H); 7.89 (CH–N ₃ , s, 1H); 7.91–7.97 (Ph, m, 2H); 7.99 (arom., d, 1H, ⁴ J _HH = 2); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.31 (arom., d, 1H, ⁴ J _HH = 2); 8.42 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 49.0 (mc, s); 49.2 (mc, s); 51.4 (mc, s); 51.7 (mc, s); 53.0 (CH ₂ ‒N ₃ , s); 53.9 (mc, s); 54.1 (mc, s); 54.7 (mc, s); 55.7 (mc, s); 59.5 (CH ₂ ‒ CO, s); 59.6 (CH ₂ ‒arom., s); 59.8 (CH ₂ ‒arom., s); 61.4 (CH ₂ ‒CO, s); 123.9 (arom., s); 126.5 (arom., s); 127.6 (arom., s); 128.4 (Ph, s); 130.1 (arom., s); 130.3 (Ph, s); 131.8 (Ph, s); 136.2 (Ph, s); 136.8 (CH–N ₃ , s); 138.2 (arom., s); 142.8 (arom., s); 146.0 (arom., s); 155.0 (arom., s); 155.6 (arom., s); 158.6 (arom., s); 158.7 (arom., s); 171.2 (FA, s); 177.7 (CO, s); 179.0 (CO, s). ESI-HRMS: 712.2017 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Y ₁ ] ⁺ = 712.2022). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Y ₁ ] ⁺ [FA] ⁻ ·4.5H ₂ O, M _R = 838.7): C 48.7 (48.6); H 5.6 (5.2); N 15.0 (14.7); Y 10.6 (10.3). Synthesis of TD890: In a glass vial (4 mL), TD650·1.1FA·1.6H ₂ O (15.2 mg; 21.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (2 mL) followed by ddition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.10 mL; 550 µmol; 25 equiv.) and aq. Zn(NO ₃ ) ₂ (51.7 mM; 460 µL; 23.8 µmol; 1.1 equiv.) and he mixture was stirred 2 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with no additive). Fractions with product were joined and directly lyophilized to give product as white luffy solid. Yield: 15.5 mg (91%; 1 step; based on TD650·1.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~8): ¹ H δ _H 2.43–3.38 (mc, CH ₂ –CO, bm, 16+4H); 4.14 (CH ₂ ‒arom., s, 2H); 4.25 (CH ₂ ‒arom., bs, 2H); 6.48 (CH ₂ ‒N ₃ , bs, 2H); 7.60 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.62–7.68 (Ph, m, 3H); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., d, 1H, ⁴ J _HH = 2); 7.91–7.98 (Ph, m, 2H); 8.09 (arom., t, 1H, ³ J _HH = 8); 8.21 (CH–N ₃ , s, 1H); 8.31 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 688.2339 [M+H] ⁺ (theor. [C ₃₃ H ₃₈ N ₉ O ₄ Zn ₁ ] ⁺ = 688.2333). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Zn ₁ ]·5.5H ₂ O, M _R = 788.2): C 50.3 (50.2); H 6.1 (5.8); N 16.0 (15.7); Zn 8.3 (8.5). Synthesis of TD1195: In a glass vial (4 mL), TD650·1.1FA·1.6H ₂ O (9.0 mg; 12.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (780 µL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 650 µL; 325 µmol; 25 equiv.) and aq. MnCl ₂ (25.0 mM; 570 µL; 14.3 µmol; 1.1 equiv.) and the mixture was stirred 1 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white luffy solid. Yield: 7.5 mg (74%; 1 step; based on TD650·1.1FA·1.6H ₂ O). ESI-HRMS: 679.2423 [M+H] ⁺ (theor. [C ₃₃ H ₃₈ N ₉ O ₄ Mn ₁ ] ⁺ = 679.2422). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Mn ₁ ]·6.4H ₂ O, M _R = 794.0): C 49.9 (49.5); H 6.3 (5.9); N 15.9 (15.7); Mn 6.9 (6.2). Synthesis of TD880: In a glass vial (4 mL), TD650·1.1FA·1.6H ₂ O (35.0 mg; 49.8 µmol; 1.0 equiv.) was dissolved in aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.50 mL; 1.25 mmol; 25 equiv.) and aq. CdCl ₂ (62.6 m ^M ; 875 µL; 54.8 µmol; 1.1 equiv.) and the mixture was stirred 1 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with no additive). Fractions with product were joined and directly yophilized to give product as white fluffy solid. Yield: 37.1 mg (90%; 1 tep; based on TD650·1.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.24– 3.54 (mc, CH ₂ –CO, m, 16+4H); 3.60–3.79 (CH ₂ ‒arom., m, 2H); 4.03 (CH ₂ ‒arom., d, 1H, ² J _HH = 13); 4.75 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 5.51 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.95 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.58–7.67 (Ph, m, 3H); 7.71 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.80 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (arom., d, 1H, ⁴ J _HH = 2); 7.93–7.98 (Ph, m, 2H); 8.04 (CH–N ₃ , s, 1H); 8.15 (arom., t, 1H, ³ J _HH = 8); 8.21 (arom., d, 1H, ⁴ J _HH = 2); ¹³ C{ ¹ H} δ _C 47.8 (mc, s); 48.3 (mc, s); 49.3 (mc, s); 50.3 (mc, s); 50.9 (mc, s); 51.1 (mc, s); 51.2 (mc, s); 51.5 (mc, s); 53.4 (CH ₂ ‒N ₃ , s); 56.6 (CH ₂ ‒CO, s); 57.4 (CH ₂ ‒arom., s); 57.6 (CH ₂ ‒CO, s); 58.6 (CH ₂ ‒arom., s); 124.3 (arom., s); 125.2 (arom., s); 128.2 (Ph, s); 128.3 (arom., s); 128.9 (arom., s); 130.2 (Ph, s); 131.3 (Ph, s); 135.3 (CH–N ₃ , s); 136.6 (Ph, s); 138.8 (arom., s); 141.3 (arom., s); 147.4 (arom., s); 153.6 (arom., s); 156.9 (arom., s); 157.9 (arom., s); 158.3 (arom., s); 175.7 (CO, s); 177.4 (CO, s). ESI-HRMS: 738.2079 [M+H] ⁺ (theor. [C ₃₃ H ₃₈ N ₉ O ₄ Cd ₁ ] ⁺ = 738.2075). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Cd ₁ ]·5.1H ₂ O, M _R = 828.0): C 47.9 (47.6); H 5.7 (5.0); N 15.2 (14.6); Cd 13.6 (13.5). Synthesis of TD863: In a glass vial (20 mL), TD650·1.1FA·1.6H ₂ O (8.2 mg; 11.7 µmol; 1.0 equiv.) was dissolved in H ₂ O (2 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.35 mL; 675 µmol; 58 equiv.) and aq. Ca(NO ₃ ) ₂ (100 mM; 200 µL; 20 µmol; 1.7 equiv.) and the mixture was stirred 24 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with no additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 7.4 mg (81%; 1 step; based on TD650·1.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 2.20–3.58 (mc, CH ₂ –CO, m, 16+4H); 3.62 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 3.76 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.09 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 4.54 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 5.56 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.02 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.57–7.65 (Ph, m, 3H); 7.66 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.72 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., d, 1H, ⁴ J _HH = 2); 7.89 (CH–N ₃ , s, 1H); 7.90–7.95 (Ph, m, 2H); 8.09 (arom., t, 1H, ³ J _HH = 8); 8.12 (arom., d, 1H, ⁴ J _HH = 2); ¹³ C{ ¹ H} δ _C 48.4 (mc, s); 48.5 (mc, s); 50.6 (mc, s); 50.7 (mc, s); 52.6 (mc, s); 52.7 (mc, s); 53.0 (mc, s); 53.3 (CH ₂ ‒N ₃ , s); 53.6 (mc, s); 57.9 (CH ₂ ‒CO, s); 59.1 (CH ₂ ‒arom., s); 59.2 (CH ₂ ‒arom., s); 59.3 (CH ₂ ‒CO, s); 123.3 (arom., s); 124.7 (arom., s); 127.0 (arom., s); 128.1 (Ph, s); 128.2 (arom., s); 130.1 (Ph, s); 130.9 (Ph, s); 136.7 (CH–N ₃ , s); 137.3 (Ph, s); 139.4 (arom., s); 140.9 (arom., s); 146.7 (arom., s); 153.1 (arom., s); 155.5 (arom., s); 159.3 (arom., s); 159.5 (arom., s); 178.4 (CO, s); 179.7 (CO, s). ESI-HRMS: 664.2663 [M+H] ⁺ (theor. [C ₃₃ H ₃ 8N ₉ O ₄ Ca1] ⁺ = 664.2667). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Ca ₁ ]·6.7H ₂ O, M _R = 784.5): C 50.5 (50.5); H 6.5 (6.0); N 16.1 (15.6); Ca 5.1 (4.8). 5 Synthesis of TD1214: In a glass vial (20 mL), TD650·1.1FA·1.6H ₂ O (9.0 mg; 12.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (780 µL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 650 µL; 325 µmol; 25 equiv.) and aq. Na ₂ [PdCl ₄ ] (25 mM; 570 µL; 14.3 µmol; 1.1 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter (RC) and directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 6.4 mg (58%; 1 step; based on TD650·1.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~5): 1.54–3.82 (mc, CH ₂ –CO, bm, 16+4H); 4.21–5.10 (CH ₂ –arom., bm, 4H overlapped with water signal); 5.69 (CH ₂ ‒N ₃ , bs, 1H); 7.42–7.54 (Ph, arom., m, 3+1H); 7.60 (arom., d, 1H, ³ J _HH = 8); 7.65 (CH ₂ ‒N ₃ , bs, 1H); 7.69–7.76 (Ph, m, 2H); 8.01 (arom., d, 1H, ³ J _HH = 8); 8.08–8.15 (arom., m, 2H); 8.47 (CH–N ₃ , s, 1H). ESI-HRMS: 730.2088 [M+H] ⁺ (theor. [C ₃₃ H ₃₈ N ₉ O ₄ Pd ₁ ] ⁺ = 730.2076). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Pd ₁ ]·0.2FA·7.0H ₂ O, M _R = 865.2): C 46.1 (46.4); H 6.0 (5.7); N 14.6 (14.4); Pd 12.3 (9.6). Synthesis of TD876: In a glass vial (20 mL), TD650·1.1FA·1.6H ₂ O (8.2 mg; 11.7 µmol; 1.0 equiv.) was dissolved in H ₂ O (2.5 mL) followed by ddition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 580 µL; 290 µmol; 25 quiv.) and aq. Pb(NO ₃ ) ₂ (52.4 mM; 300 µL; 15.7 µmol; 1.3 equiv.) and the mixture was stirred 5 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with no additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 10.4 mg (94%; 1 step; based on TD650·1.1FA·1.6H ₂ O). NMR (D ₂ O, pD ~6): δ _H 2.40–3.62 (mc, CH ₂ –CO, bm, 16+4H); 4.20 (CH ₂ ‒arom., bm, 4H); 5.72 (CH ₂ ‒N ₃ , bd, 1H, ² J _HH = 15); 6.18 (CH ₂ ‒N ₃ , bd, 1H, ² J _HH = 15); 7.56–7.67 (Ph, m, 3H); 7.74 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.79 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86–7.90 (Ph, m, 2H); 7.91 (arom., d, 1H, ⁴ J _HH = 2); 7.99 (CH–N ₃ , s, 1H); 8.08 (arom., d, 1H, ⁴ J _HH = 2); 8.16 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 832.2806 [M+H] ⁺ (theor. [C ₃₃ H ₃ 8N ₉ O ₄ Pb ₁ ] ⁺ = 832.2808). EA ([C ₃₃ H ₃₇ N ₉ O ₄ Pb ₁ ]·6.4H ₂ O, M _R = 946.2): C 41.9 (42.6); H 5.3 (4.7); N 13.3 (12.6); Pb 21.9 (21.4). Synthesis of TD1238: Synthesis: In a glass vial (20 mL), TD1188·0.2TFA·0.4FA·4.3H ₂ O (6.5 mg; 8.6 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 950 µL; 475 µmol; 56 equiv.) and solid Tl(NO3)3·3H ₂ O (4.2 mg; 9.5 µmol; 1.1 equiv.) and the mixture was stirred 2 h at 80 °C. Then, another portion of Tl(NO3)3·3H ₂ O (19.0 mg; 43 µmol; 5.0 equiv.) was added and the mixture was further stirred 20 h at 80 °C. Mixture was then filtered through syringe microfilter (RC) and the filtrate was evaporated to dryness. Residue was re-dissolved in H ₂ O and directly purified by preparative (HPLC C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white solid. Yield: 1.4 mg (≤18% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 933.0; 1 step; based on TD1188·0.2TFA·0.4FA·4.3H ₂ O). NMR (D ₂ O, pD ~4, two set of signals on ¹ H, but one on ¹⁹ F): δ _H 2.17–5.34 (mc, CH ₂ –CO, CH ₂ ‒arom., m, 16+4H+4H); 5.54–5.70 (CH ₂ ‒N ₃ , m, 1H); 6.93–7.07 (CH ₂ ‒N ₃ , m, 1H); 7.69–8.44 (arom., m, 6H). ¹⁹ F δ _F −58.70 (s). ESI-HRMS: 820.2265 [M] ⁺ (theor. [C ₂₈ H ₃₂ N ₉ O ₄ F ₃ T _l 1] ⁺ = 820.2264). 1 ₅ Synthesis of TD735: In a glass vial (20 mL), TD722·0.7TFA·2.0H ₂ O (100 mg; 130 µmol; 1.0 equiv.) was dissolved in H ₂ O (30 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 7.00 mL; 3.50 mmol; 27 equiv.) and aq. LuCl ₃ (100 mM; 1.50 mL; 150 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 134.2 mg (91%; 1 step; based on TD722·0.7TFA·2.0H ₂ O). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.65–3.84 (mc, CH ₂ –CO, m, 16+4H); 4.01 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.04 (CH ₂ ‒NH ₂ , d, 1H, ² J _HH = 15); 4.23 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.31 (CH ₂ ‒NH ₂ , d, 1H, ² J _HH = 15); 4.33 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.68 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.08 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.60‒7.69 (Ph, m, 3H); 7.72 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.91 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.92‒7.99 (Ph, m, 2H); 8.03 (arom., d, 1H, ⁴ J _HH = 2); 8.31 (arom., t, 1H, ³ J _HH = 8); 8.33 (arom., d, 1H, ⁴ J _HH = 2). ¹³ C{ ¹ H} δ _C 34.8 (CH ₂ ‒C≡C, s); 48.9 (mc, s); 49.2 (mc, s); 51.8 (mc, s); 52.0 (mc, s); 53.4 (CH ₂ ‒N ₃ , s); 53.9 (mc, s); 54.1 (mc, s); 55.2 (mc, s); 56.1 (mc, s); 59.2 (CH ₂ ‒CO, s); 59.7 (CH ₂ ‒arom., s); 60.0 (CH ₂ ‒arom., s); 61.1 (CH ₂ ‒CO, s); 124.0 (arom., s); 126.8 (arom., s); 128.2 (arom., s); 128.4 (Ph, s); 130.3 (Ph, s); 130.8 (arom., s); 131.9 (Ph, s); 136.0 (Ph, s); 136.2 (arom, s); 140.5 (arom., s); 142.8 (arom., s); 144.4 (arom., s); 155.0 (arom., s); 156.0 (arom., s); 158.9 (arom., s); 160.0 (arom., s); 170.7 (FA, s); 178.8 (CO, s); 179.3 (CO, s). ESI-HRMS: 827.2637 [M] ⁺ (theor. [C ₃₄ H ₄₀ N ₁₀ O ₄ Lu ₁ ] ⁺ = 827.2636). EA ([C ₃₄ H40N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.2TFA·3.1H ₂ O, M _R = 1133.3): C 40.7 (40.9); H 4.2 (3.9); N 12.4 (12.1); Lu 11.1 (11.0). Synthesis of TD1059: In a glass vial (20 mL), TD1054·0.3TFA·0.8FA·2.3H ₂ O (10.0 mg; 12.9 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition aq. MOPS/NaOH buffer 500 m ^M ; pH 7.0; 800 µL; 400 µmol; 31 equiv.) and aq. LuCl ₃ (100 m ^M ; 150 µL; 15.0 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 10.8 mg (71%; 1 step; based on TD1054·0.3TFA·0.8FA·2.3H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 1.18 (CH ₃ , s, 3H); 1.79 (CH ₃ , s, 3H); 2.64–3.85 (mc, CH ₂ –CO, m, 16+4H); 4.03 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.30 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.36 (CH ₂ ‒arom., d, 1H, ² J _HH = 18); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 18); 5.62 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.83 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.60‒7.68 (Ph, m, 3H); 7.83 (arom., d, 1H, ³ J _HH = 8); 7.89 (arom., d, 1H, ³ J _HH = 8); 7.91‒7.98 (Ph, m, 2H); 8.03 (arom., d, 1H, ⁴ J _HH = 2); 8.28 (arom., t, 1H, ³ J _HH = 8); 8.30 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 855.2951 [M] ⁺ (theor. [C ₃₆ H ₄₄ N ₁₀ O ₄ Lu ₁ ] ⁺ = 855.2949). EA ([C ₃₇ H ₄₅ N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.0TFA·4.6H ₂ O, M _R = 1178.6): C 41.8 (41.4); H 4.7 (4.2); N 11.9 (11.7); Lu 14.8 (13.2). 20 Synthesis of TD1124: In a glass vial (20 mL), TD1105·0.1FA·2.0H ₂ O (35.2 mg; 47.1 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.35 mL; 1.18 mmol; 25 equiv.) and aq. LuCl ₃ (100 mM; 520 µL; 52.0 µmol; 1.1 equiv.) and the mixture was stirred 4 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 41.2 mg (77%; 1 step; based on TD1105·0.1FA·2.0H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.17 (CH ₃ , s, 3H); 1.78 (CH ₃ , s, 3H); 2.64–3.84 (mc, CH ₂ –CO, m, 16+4H); 3.97 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.25 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.35 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.56 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.80 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.73 (arom., d, 1H, ³ J _HH = 8); 7.82 (arom., d, 1H, 3J _HH = 8); 7.88 (arom., d, 1H, ³ J _HH = 8); 7.99 (arom., d, 1H, ³ J _HH = 8); 8.24 (arom., t, 1H, ³ J _HH = 8); 8.27 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 779.2636 [M] ⁺ (theor. [C ₃₀ H40N ₁₀ O ₄ Lu ₁ ] ⁺ = 779.2636). EA ([C ₃₀ H40N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.5TFA·3.9H ₂ O, M _R = 1133.9): C 37.1 (37.3); H 4.4 (3.9); N 12.4 (12.0); F 12.6 (12.1). Synthesis of TD1137: In a glass vial (20 mL), TD1127·1.8TFA·0.1FA (45.9 mg; 52.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 3.15 mL; 1.58 mmol; 30 equiv.) and aq. LuCl ₃ (100 m ^M ; 690 µL; 69.0 µmol; 1.3 equiv.) and the mixture was stirred 2 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were oined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 58.2 mg (98%; 1 step; based on TD1127·1.8TFA·0.1FA). NMR (D ₂ O, pD ~4): ¹ H δ _H 1.92–2.13 (CH ₂ , m, 3H); 2.17–2.33 (CH ₂ , m, 1H); 2.63–3.83 (mc, CH ₂ –CO, CH ₂ , CH, m, 16+4+4+1H); 3.98 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.22 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.34 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 17); 5.50 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.93 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.67– 7.76 (arom., m, 2H); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.98 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.23 (arom., t, 1H, ³ J _HH = 8); 8.27 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 805.2786 [M] ⁺ (theor. [C ₃₂ H ₄₂ N ₁₀ O ₄ Lu ₁ ] ⁺ = 805.2793). EA ([C ₃₂ H ₄₂ N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.0TFA·5.5H ₂ O, M _R = 1131.8): C 38.2 (38.7); H 4.8 (4.5); N 12.4 (11.9); F 10.1 (9.9). Synthesis of TD1182: In a glass vial (20 mL), TD1176·0.8FA·4.4H ₂ O (39.3 mg; 55.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (16 mL) followed by addition q. MOPS/NaOH buffer (500 mM; pH 7.0; 2.77 mL; 1.39 mmol; 25 equiv.) nd aq. LuCl ₃ (100 mM; 610 µL; 61.0 µmol; 1.1 equiv.) and the mixture was tirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 44.8 mg (77%; 1 step; based on TD1176·0.8FA·4.4H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.55–3.78 (mc, CH ₂ –CO, CH ₃ , CH ₂ ‒arom., m, 16+4+6+2H); 4.11 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.13 (CH ₂ ‒arom., d, 1H, ² J _HH = 14); 5.31 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.73 (arom., d, 1H, ⁴ J _HH = 2); 6.83 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.07 (arom., d, 1H, ⁴ J _HH = 2); 7.78 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (CH–N ₃ , s, 1H); 8.22 (arom., t, 1H, ³ J _HH = 8). ESI-HRMS: 765.2487 [M] ⁺ (theor. [C ₂₉ H ₃ 9N ₁₀ O ₄ Lu ₁ ] ⁺ = 765.2486). EA ([C ₂₉ H ₃ 8N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.0TFA·3.4H ₂ O, M _R = 1053.9): C 37.6 (37.5); H 4.4 (4.1); N 13.3 (13.1); F 10.8 (10.5). Synthesis of TD1152: In a glass vial (20 mL), TD1148·0.1FA·1.0H ₂ O (27.0 mg; 41.0 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.05 mL; 1.03 mmol; 25 equiv.) and aq. LuCl ₃ (100 m ^M ; 450 µL; 45.0 µmol; 1.1 equiv.) and the mixture was stirred 3 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 24.5 mg (60%; 1 step; based on TD1148·0.1FA·1.0H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.43 (CH ₃ , d, 6H, ³ J _HH = 6); 2.65–3.85 (mc, CH ₂ –CO, m, 16+4H); 4.06 (CH ₂ ‒ arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.34 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.86 (CH ₂ ‒ arom., d, 1H, ² J _HH = 16); 5.34 (CH, hept, 1H, ³ J _HH = 6); 5.69 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.17 (CH ₂ ‒N ₃ , d, 1H, 2J _HH = 15); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.22 (arom., d, 1H, ⁴ J _HH = 2); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.53 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 808.2425 [M] ⁺ (theor. [C ₃₁ H ₃₉ N ₉ O ₆ Lu ₁ ] ⁺ = 808.2426). EA ([C ₃₁ H ₃₉ N ₉ O ₆ Lu ₁ ] ⁺ [TFA] ⁻ ·0.3TFA·2.5H ₂ O, M _R = 1000.9): C 40.3 (40.7); H 4.5 (4.2); N 12.6 (12.2); F 7.4 (7.6). Synthesis of TD1123: In a glass vial (20 mL), TD1092·0.1FA·1.1H ₂ O (25.9 mg; 41.0 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.05 mL; 1.03 mmol; 25 equiv.) and aq. LuCl ₃ (100 mM; 450 µL; 45.0 µmol; 1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 24.7 mg (60%; 1 step; based on TD1092·0.1FA·1.1H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.65–3.86 (mc, CH ₂ –CO, m, 16+4H); 4.09 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.18 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.36 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.73 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.19 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.21 (arom., d, 1H, ⁴ J _HH = 2); 8.27 (arom., t, 1H, ³ J _HH = 8); 8.50 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 766.1948 [M] ⁺ (theor. [C ₂₈ H ₃₃ N ₉ O ₆ Lu ₁ ] ⁺ = 766.1956). EA ([C ₂₈ H ₃₃ N ₉ O ₆ Lu ₁ ] ⁺ [TFA] ⁻ ·0.6TFA·3.6H ₂ O, M _R = 1012.8): C 37.0 (36.7); H 4.1 (3.6); N 12.4 (12.0); F 9.0 (8.6). Synthesis of TD897: In a glass vial (20 mL), TD742·0.1FA.3.2H ₂ O (48.6 mg; 66.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (15 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 3.4 mL; 1.70 mmol; 26 equiv.) and aq. TmCl ₃ (100 m ^M ; 800 µL; 80.0 µmol; 1.2 equiv.) and the mixture was stirred 8 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 65.2 mg (88%; 1step; based on TD742·0.1FA.3.2H ₂ O). ESI-HRMS: 836.2206 [M] ⁺ (theor. [C ₃₄ H ₃₇ N ₉ O ₆ Tm ₁ ] ⁺ = 836.2203). EA ([C ₃₄ H ₄₀ N ₁₀ O ₄ Tm ₁ ] ⁺ [TFA] ⁻ ·1.1TFA·2.6H ₂ O, M _R = 1121.9): C 40.9 (40.9); H 3.9 (3.8); N 11.2 (11.2); Tm 15.1 (15.2); F 10.7 (10.7). Synthesis of TD748: In a glass vial (20 mL), TD742·0.2FA·1.6H ₂ O (85 mg; 120 µmol; 1.0 equiv.) was dissolved in H ₂ O (12 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 6.00 mL; 3.00 mmol; 25 equiv.) and aq. LuCl ₃ (100 mM; 1.3 mL; 130 µmol; 1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 105 mg (75%; 1step; based on TD742·0.1FA·2.9H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.64–3.86 (mc, CH ₂ –CO, m, 16+4H); 3.98 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.18 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.34 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.71 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.17 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.92 (arom., d, 1H, ⁴ J _HH = 2); 7.94 (CH–N ₃ , s, 1H); 7.97 (arom., dm, 2H, ³ J _HH = 9); 8.15 (arom., dm, 2H, ³ J _HH = 9); 8.27 (arom., t, 1H, ³ J _HH = 8); 8.43 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 842.2259 [M] ⁺ (theor. [C ₃₄ H ₃₇ N ₉ O ₆ Lu ₁ ] ⁺ = 842.2269).EA ([C ₃₄ H40N ₁₀ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O, M _R = 1172.9): C 39.7 (40.0); H 3.9 (3.5); N 10.7 (10.3); Lu 14.9 (14.9); F 11.7 (11.8). Synthesis of TD785: In a glass vial (20 mL), TD742·0.1FA·2.9H ₂ O (13 mg; 18 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 1.20 mL; 600 µmol; 31 equiv.) and aq. YCl ₃ (100 m ^M ; 197 µL; 20 µmol; 1.1 equiv.) and the mixture was stirred 22 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 13 mg (71%; 1step; based on TD742·0.1FA·2.9H ₂ O). NMR (D ₂ O, pD ~2): ¹ H δ _H 2.60–3.88 (mc, CH ₂ –CO, m, 16+4H); 3.98 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.38 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.94 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.09 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.91 (CH–N ₃ , s, 1H); 7.98 (arom., d, 1H, ⁴ J _HH = 2); 8.00 (arom., dm, 2H, ³ J _HH = 9); 8.02 (arom., dm, 2H, ³ J _HH = 9); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.40 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 756.1925 [M] ⁺ (theor. [C ₃₄ H ₃₇ N ₉ O ₆ Y ₁ ] ⁺ = 756.1920). EA ([C ₃₄ H ₃₇ N ₉ O ₆ Y ₁ ] ⁺ [TFA] ⁻ ·0.6TFA·4.8H ₂ O, M _R = 1024.5): C 43.6 (43.9); H 4.6 (4.2); N 12.3 (12.0); Y 8.7 (7.9); F 8.9 (8.5). Synthesis of TD904: In a glass vial (20 mL), TD744·1.0TFA·1.3H ₂ O (38.6 mg; 46.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (16 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 2.80 mL; 1.40 mmol; 30 equiv.) and aq. LuCl ₃ (100 mM; 550 µL; 55.0 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator 25 and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 42.2 mg (75%; 1 step; based on TD744·1.0TFA·1.3H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.62–3.87 (mc, CH ₂ –CO, m, 16+4H); 4.03 (CH ₂ ‒NH ₂ , d, 1H, ² J _HH = 15); 4.05 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.24 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.32 (CH ₂ ‒NH ₂ , d, 1H, ² J _HH = 15); 4.35 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.71 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.10 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.92 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.03 (arom., dm, 2H, ³ J _HH = 9); 8.07 (arom., d, 1H, ⁴ J _HH = 2); 8.21 (arom., dm, 2H, ³ J _HH = 9); 8.31 (arom., t, 1H, ³ J _HH = 8); 8.40 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 871.2536 [M] ⁺ (theor. [C ₃₅ H40N ₁₀ O ₆ Lu ₁ ] ⁺ = 471.2535). EA ([C ₃₅ H40N ₁₀ O ₆ Lu ₁ ] ⁺ [TFA] ⁻ ·1.1TFA·6.0H ₂ O, M _R = 1218.2): C 38.6 (38.6); H 4.4 (4.1); N 11.5 (11.2); F 9.8 (9.5). Synthesis of 905: In a glass vial (2 mL), [TD904] ⁺ [TFA] ⁻ ·1.1TFA·6.0H ₂ O (10.0 mg; 8.2 µmol; 1.0 equiv.) was dissolved in aq. Borate/NaOH buffer (200 m ^M ; pH 9.0; 2.00 mL; 400 mmol; 50 equiv.). followed by addition of freshly prepared solution of FmocCl (3.3 mg; 12.8 µmol; 1.6 equiv.) in MeCN (1.5 mL). The resulting clear solution was stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 9.8 mg (≤99% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1207.0; 1step; based on [TD904] ⁺ [TFA] ⁻ ·1.1TFA·6.0H ₂ O). NMR (CD ₃ CN; compound is soluble in D ₂ O but shows broad ¹ H signals): ¹ H δ _H 2.52–3.64 (mc, CH ₂ –CO, m, 16+4H); 3.89 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.03 (CH ₂ ‒NH‒Fmoc, dd, 1H, ² J _HH = 15, ³ J _HH = 3); 4.05 (CH ₂ ‒ arom., d, 1H, ² J _HH = 16); 4.18 (Fmoc, t, 1H, ³ J _HH = 7); 4.26‒4.35 (Fmoc, m, 2H); 4.36 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.52 (CH ₂ ‒NH‒Fmoc, dd, 1H, ² J _HH = 15, ³ J _HH = 7); 4.78 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.50 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.54 (NH‒Fmoc, dd, 1H, ³ J _HH = 7, ³ J _HH = 3); 7.27‒7.33 (Fmoc, m, 2H); 7.35‒7.43 (Fmoc, CH ₂ ‒N ₃ , m, 2+1H); 7.57‒7.65 (Fmoc, CH ₂ ‒arom., m, 2+1H); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.78‒ 7.84 (Fmoc, m, 2H); 7.91 (arom., d, 1H, ⁴ J _HH = 2); 7.97 (arom., dm, 2H, ³ J _HH = 9); 8.14 (arom., t, 1H, ³ J _HH = 8); 8.18 (arom., dm, 2H, ³ J _HH = 9); 8.26 (arom., d, 1H, ⁴ J _HH = 2). ESI-HRMS: 1093.3219 [M] ⁺ (theor. [C ₅₀ H ₅₀ N ₁₀ O ₈ Lu ₁ ] ⁺ = 1093.3215). Synthesis of TD757: In a glass vial (2 mL), [TD748] ⁺ [FA] ⁻ ·6.4H ₂ O (0.7 mg; 0.7 µmol; 1.0 equiv.) was dissolved in DMSO (75 µL) followed by addition of 4-Fluoro-L-phenylalanine hydrochloride (50 mM in DMSO; 22 µL; 1.1 µmol; 1.5 equiv.), DIPEA (100 mM in DMSO; 22 µL; 2.2 µmol; 3.1 equiv.) and HATU (freshly prepared 50 mM in DMSO; 24 µL; 1.2 µmol; 1.7 equiv.) and the resulting yellow solution was stirred 5 min at RT. Mixture was then diluted with H ₂ O (750 µL) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 0.7 mg (≤90% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 1066.9; 1 step; based on [TD748] ⁺ [FA] ⁻ ·6.4H ₂ O). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.56–3.79 (mc, CH ₂ –CO, CH ₂ –CH, m, 16+4+2H); 3.82 (CH ₃ , s, 3H); 4.02 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.35 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.96 (CH ₂ –CH, dd, 1H, ³ J _HH = 10, ³ J _HH = 5); 5.68 (CH ₂ ‒ N ₃ , d, 1H, ² J _HH = 15); 7.04‒7.20 (CH ₂ ‒N ₃ , arom., m, 1+2H); 7.27‒7.34 (arom., dd, 2H, ³ JHF = 9, ³ J _HH = 6); 7.78‒7.88 (arom., m, 4H); 7.90 (CH–N ₃ , s, 1H); 7.95‒8.06 (arom., m, 3H); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.35 (arom., d, 1H, ⁴ J _HH = 2); 8.46 (FA, s, 1H). ¹⁹ F δ _F −116.5 (tt, ³ JFH = 9, ⁴ JFH = 5). ESI-HRMS: 1021.3014 [M] ⁺ (theor. [C44H47N ₁₀ O7F1Lu ₁ ] ⁺ = 1021.3015). Synthesis of TD793: In a glass vial (2 mL), [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O (4.4 mg; 4.6 µmol; 1.0 equiv.) was dissolved in DMSO (460 µL) followed by addition of N-Boc- cysteine (50 m ^M in DMSO; 185 µL; 9.3 µmol; 2.0 equiv.) and DIPEA (8 µL; 46 µmol; 10 equiv.) and the resulting solution was stirred 16 h RT. Mixture was then diluted with H ₂ O (2 mL) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 2.0 mg (≤41% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1054.8; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.28–1.54 (CH ₃ , m, 9H); 2.63–3.95 (mc, CH ₂ –CO, CH ₂ –S, CH ₂ –arom., m, 16+4+2+1H); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.26 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.48–4.63 (NH–CH–COOH, m, 1H); 4.84 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.45–5.59 (CH ₂ ‒N ₃ , m, 1H); 7.03 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.59–7.65 (arom., m, 1H); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 7.90–7.95 (arom., m, 1H); 8.26 (arom., t, 1H, ³ J _HH = 8). ESI- HRMS: 941.2614 [M] ⁺ (theor. [C ₃₅ H ₄₆ N ₁₀ O ₈ S ₁ Lu ₁ ] ⁺ = 941.2623). Synthesis of TD875: In a glass vial (20 mL), TD871·0.6FA·2.3H ₂ O (10.0 mg; 14.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (2 mL) followed by addition of aq. MOPS/NaOH buffer (500 mM; pH 7.0; 750 µL; 375 µmol; 26 equiv.) and aq. GdCl ₃ (100 mM; 180 µL; 18.0 µmol; 1.3 equiv.). The resulting suspension was stirred 20 d at 80 °C. Then, the mixture was diluted with additional H ₂ O (16 mL) followed by another portion of aq. MOPS/NaOH buffer (500 mM; pH 7.0; 750 µL; 375 µmol; 26 equiv.) and aq. GdCl ₃ (100 mM; 180 µL; 18.0 µmol; 1.3 equiv.). The resulting suspension was further stirred 10 d at 80 °C. Mixture was the filtered through syringe microfilter (RC). The filtrate was evaporated to dryness and then resuspended in H ₂ O (3.6 mL). Mixture was once more filtered through syringe microfilter (RC) and the filtrate was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 2.1 mg (≤18% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 826.0; 1 step; based on TD871·0.6FA·2.3H ₂ O). ESI-HRMS: 781.2205 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Gd1] ⁺ = 781.2204). Synthesis of TD874: In a glass vial (20 mL), TD871·0.6FA·2.3H ₂ O (10.0 mg; 14.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (2 mL) followed by addition of aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 750 µL; 375 µmol; 26 equiv.) and aq. LuCl ₃ (100 m ^M ; 180 µL; 18.0 µmol; 1.3 equiv.). The resulting suspension was stirred 20 d at 80 °C. Then, the mixture was diluted with additional H ₂ O (16 mL) followed by another portion of aq. MOPS/NaOH buffer (500 mM; pH 7.0; 750 µL; 375 µmol; 26 equiv.) and aq. LuCl ₃ (100 mM; 180 µL; 18.0 µmol; 1.3 equiv.). The resulting suspension was further stirred 10 d at 80 °C. Mixture was the filtered through syringe microfilter (RC). The filtrate was evaporated to dryness and then resuspended in H ₂ O (3.6 mL). Mixture was once more filtered through syringe microfilter (RC) and the filtrate was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 8.6 mg (≤71% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 843.2; 1 step; based on TD871·0.6FA·2.3H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 2.13–3.76 (mc, CH ₂ –CO, CH ₂ –arom., m, 16+3+1H); 4.13 (CH ₂ –CO, d, 1H, ² J _HH = 18); 4.32 (CH ₂ –arom., d, 1H, ² J _HH = 16); 4.45 (CH ₂ –arom., d, 1H, ² J _HH = 16); 4.67 (CH ₂ –arom., d, 1H, ² J _HH = 13); 5.81 (CH ₂ – N ₃ , d, 1H, ² J _HH = 14); 6.08 (CH ₂ – N ₃ , d, 1H, ² J _HH = 14); 7.56–7.64 (Ph, arom., m, 3+1H); 7.67 (arom., d, 1H, ⁴ J _HH = 2); 7.79–7.85 (Ph, m, 2H); 7.90 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.09 (arom., d, 1H, ⁴ J _HH = 2); 8.16 (arom., t, 1H, ³ J _HH = 8); 8.45 (FA, s, 1H); 8.72 (CH–N ₃ , s, 1H). ESI-HRMS: 798.2376 [M] ⁺ (theor. [C ₃₃ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ = 798.2371). Synthesis of TD900: In a glass vial (4 mL), TD871·0.6FA·2.3H ₂ O (4.3 mg; 6.2 µmol; 1.0 equiv.) was dissolved in aq. MOPS/NaOH buffer (500 mM; pH 7.0; 640 µL; 320 µmol; 52 equiv.) and aq. CdCl ₂ (62.6 mM; 120 µL; 7.5 µmol; 1.2 equiv.) and the mixture was stirred 1 h at 80 °C. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with no additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 4.2 mg (≤92% assuming [M]·xH ₂ O; M _R = 736.1; 1 step; based on TD871·0.6FA·2.3H ₂ O). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.00–4.41 (mc, CH ₂ –CO, CH ₂ ‒arom., bm, 16+4+4H); 5.93 (CH ₂ ‒N ₃ , bs, 2H); 7.44 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.53–7.63 (Ph, m, 3H); 7.73–7.84 (Ph, arom., m, 2+1H); 7.88–7.96 (arom., m, 2H); 8.01 (arom., t, 1H, ³ J _HH = 8); 9.74 (CH–N ₃ , s, 1H). ESI-HRMS: 738.2081 [M+H] ⁺ (theor. [C ₃₃ H ₃ 8N ₉ O ₄ Cd1] ⁺ = 738.2075). Synthesis of TD685: In a glass vial (20 mL), TD669·0.1FA·xH ₂ O (17 mg; ~27 µmol; 1.0 equiv.) was dissolved in H ₂ O (17 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 2.10 mL; 1.05 mmol; ~40 equiv.) and aq. YCl ₃ (100 m ^M ; 290 µL; 29 µmol; ~1.1 equiv.) and the mixture was stirred 6 weeks at 80 °C. Mixture was then filtered hrough syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 4 mg (≤21% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 761.7; 1 step; based on TD669·0.1FA·xH ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 2.63–3.09 (mc, CH ₂ –CH ₂ –N–CH ₂ –C≡CH, m, 4+2H); 3.11 (C≡CH, t, 1H, ⁴ J _HH = 2); 3.13–3.75 (mc, CH ₂ –CH ₂ – N–CH ₂ –C≡CH, CH ₂ –CO, 12+2+2H); 3.78 (CH ₂ –CO, d, 1H, ² J _HH = 19); 3.79 (CH ₂ –C≡CH, dm, 1H, ² J _HH = 18); 3.91 (CH ₂ –C≡CH, dd, 1H, ² J _HH = 18, ⁴ J _HH = 2); 4.01 (CH ₂ –CO, d, 1H, ² J _HH = 19); 4.09 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.25 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.39 (CH ₂ ‒C‒N ₃ , d, 1H, ² J _HH = 15); 4.75 (CH ₂ ‒C‒N ₃ , d, 1H, ² J _HH = 15); 5.67 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.00 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.67–7.73 (Ph, m, 3H); 7.94 (arom., d, 1H, ⁴ J _HH = 2); 7.96–8.00 (Ph, m, 2H); 8.13 (CH‒N ₃ , s, 1H); 8.30 (arom., d, 1H, ⁴ J _HH = 2); 8.52 (FA, s, 1H). ¹³ C{ ¹ H} δ _C 41.2 (CH ₂ –C≡CH, s); 47.8 (CH ₂ ‒C‒N ₃ , s); 52.6 (CH ₂ –CH ₂ –N–CH ₂ –C≡CH, s); 54.1 (CH ₂ – CH ₂ –N–CH ₂ –C≡CH, s); 54.4 (CH ₂ ‒N ₃ , s); 55.1 (mc, s); 57.2 (mc, s); 58.0 (mc, s); 59.0 (mc, s); 59.4 (mc, s); 59.5 (mc, s); 59.9 (mc, s); 60.1 (mc, bs); 66.0 (CH ₂ ‒CO, s); 67.2 (CH ₂ ‒CO, s); 67.6 (CH ₂ ‒arom., s); 75.3 (C≡CH, s); 81.8 (C≡CH, s); 124.8 (arom., s); 127.7 (arom., s); 130.0 (Ph, s); 132.1 (Ph, s); 133.6 (Ph, s); 143.4 (arom., s); 137.5 (Ph, s); 138.1 (CH–N ₃ , s); 156.1 (arom., s); 158.6 (arom., s); 161.4 (arom., s); 173.3 (FA, s); 181.2 (CO, s); 181.5 (CO, s). ESI-HRMS: 716.2327 [M] ⁺ (theor. [C ₃₃ H ₄₁ N ₉ O ₄ Y ₁ ] ⁺ = 716.2335). Synthesis of TD780: In a glass vial (4 mL), [TD685] ⁺ [FA] ⁻ ·xH ₂ O (3 mg; ~4 µmol; 1.0 equiv.) was dissolved in aq. MES/NaOH buffer (500 mM; pH 5.2; 375 µL; 188 µmol; ~50 equiv.) followed by addition of t-BuOH ( 240 µL), Benzyl azide (500 mM in t-BuOH; 12 µL; 6 µmol; ~1.6 equiv.) and aq. solution of CuSO ₄ (500 mm; 3 µL; 1.5 µmol; ~0.4 equiv.). To the resulting faint light blue solution was added freshly prepared aq. solution of Sodium ascorbate (100 mM; 15 µL; 1.5 µmol; ~0.4 equiv.) and the color of the solution immediately changed to yellow- green. Mixture was stirred 1 h at RT after which was diluted with H ₂ O (2.4 mL) and filtered through syringe microfilter (RC). The filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 3 mg (≤74% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 962.8; 1 step; based on TD685·xH ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 2.46–4.59 (mc, CH ₂ –CO, CH ₂ –arom., CH ₂ –CH ₂ –N– (CH ₂ –C=C) ₂ , m, 16+4+2+8H); 5.60 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 5.71 (CH ₂ ‒Ph, s, 2H); 6.94 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.37–7.50 (Ph, m, 5H); 7.59–7.65 (Ph, m, 3H); 7.88 (arom., d, 1H, ⁴ J _HH = 2); 7.89–7.93 (Ph, m, 2H); 8.21 (arom., d, 1H, ⁴ J _HH = 2); 8.34 (CH‒N ₃ , s, 1H); 8.35 (CH‒N ₃ , s, 1H). ESI-HRMS: 849.2970 [M] ⁺ (theor. [C40H48N12O ₄ ] ⁺ = 849.2975). Synthesis of 1,4-TD1413: In a glass vial (20 mL), TD1408·0.1FA·2.4H ₂ O (10.0 mg; 16.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition of aq. MOPS/NaOH buffer (500 mM; pH 7.0; 820 µL; 410 µmol; 25 equiv.) and aq. LuCl ₃ (100 mM; 196 µL; 19.6 µmol; 1.2 equiv.). The resulting suspension was stirred 1 w at 80 °C. Mixture was the filtered through syringe microfilter (RC). The filtrate was evaporated to dryness and the residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 9.3 mg (≤73% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 781.6; 1 step; based on TD1408·0.1FA·2.4H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 1.73–3.16 (mc, CH ₂ –CO, m, 12+1H); 3.27 (CH ₂ –CO, d, ² J _HH = 13); 3.42–3.77 (mc, CH ₂ –CH ₂ –N ₃ , CH ₂ –CO, m, 4+2+1H); 4.03 (CH ₂ –CH ₂ –N ₃ , ddd, 1H, ² J _HH = 14, ³ J _HH = 12, ³ J _HH = 16); 4.10 (CH ₂ –arom., d, 1H, ² J _HH = 17); 4.19 (CH ₂ –arom., d, 1H, ² J _HH = 16); 4.34 (CH ₂ –arom., d, 1H, ² J _HH = 16); 4.56 (CH ₂ –CO, d, 1H, ² J _HH = 13); 4.92–5.03 (CH ₂ –CH ₂ –N ₃ , CH ₂ –arom., m, 1+1H); 7.18 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.54–7.60 (arom., m, 2H); 7.71–7.77 (arom., m, 2H); 8.11 (arom., t, 1H, ³ J _HH = 8); 8.13 (CH–N ₃ , s, 1H); 8.44 (FA, s, 1H). ESI-HRMS: 736.2217 [M] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ Lu ₁ ] ⁺ = 736.2214). Synthesis of 1,5-TD1413: Obtained as a side product during synthesis of 1,4- TD1413 in the form of formate salt as white fluffy solid. Yield: 4.0 mg (≤31% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 781.6; 1 step; based on TD1408·0.1FA·2.4H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 2.62–4.60 (mc, CH ₂ –CO, CH ₂ –arom., CH ₂ –CH ₂ –N ₃ , CH ₂ –CH ₂ –N ₃ , m, 16+4+3+2+1H); 4.85 (CH ₂ –arom., m, 1H); 5.45 (CH ₂ –CH ₂ –N ₃ , bs, 1H); 7.44 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.67–7.78 (arom., m, 2H); 7.81–7.90 (arom., CH–N ₃ , m, 1+1H); 8.02 (arom., t, 1H, ³ J _HH = 8); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.45 (FA, s, 1H). ESI-HRMS: 736.2218 [M] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ Lu ₁ ] ⁺ = 736.2214). Synthesis of 1,5-TD1414: In a glass vial (20 mL), TD1408·0.1FA·2.4H ₂ O (10.0 mg; 16.4 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition of aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 820 µL; 410 µmol; 25 equiv.) and aq. YCl ₃ (100 m ^M ; 196 µL; 19.6 µmol; 1.2 equiv.). The resulting suspension was stirred 1 w at 80 °C. Mixture was the filtered through syringe microfilter (RC). The filtrate was evaporated to dryness and the residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 6.6 mg (≤58% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 695.6; 1 step; based on TD1408·0.1FA·2.4H ₂ O). NMR (D ₂ O, pD ~6): ¹ H δ _H 2.56–4.00 (mc, CH ₂ –CO, CH ₂ –CH ₂ –N ₃ , CH ₂ –arom., m, 16+4+2+1H); 4.06 (CH ₂ –arom., d, 1H, ² J _HH = 15); 4.38 (CH ₂ –arom., d, 1H, ² J _HH = 16); 4.42–4.54 (CH ₂ –CH ₂ – N ₃ , m, 1H); 4.93 (CH ₂ –arom., d, 1H, ² J _HH = 15); 5.72–5.91 (CH ₂ –CH ₂ –N ₃ , m, 1H); 7.45 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.69–7.80 (arom., m, 2H); 7.84 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (CH–N ₃ , s, 1H); 8.01 (arom., t, 1H, ³ J _HH = 8); 8.26 (arom., t, 1H, ³ J _HH = 8); 8.46 (FA, s, 1H). ESI-HRMS: 650.1867 [M] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ Y ₁ ] ⁺ = 650.1865). Synthesis of 1,4-TD1414: Obtained as a side product during synthesis of 1,5- TD1414 in the form of formate salt as white fluffy solid. Yield: 4.0 mg (≤35% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 695.6; 1 step; based on TD1408·0.1FA·2.4H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 1.76–3.19 (mc, CH ₂ –CO, m, 12+1H); 3.23 (CH ₂ –CO, d, ² J _HH = 13); 3.43–3.79 (mc, CH ₂ –CH ₂ –N ₃ , CH ₂ –CO, m, 4+2+1H); 4.06–4.24 (CH ₂ –CH ₂ –N ₃ , CH ₂ –arom., m, 1+2H); 4.34 (CH ₂ –arom., d, 1H, ² J _HH = 15); 4.60 (CH ₂ –CO, d, 1H, ² J _HH = 12); 4.89–5.05 (CH ₂ –CH ₂ –N ₃ , CH ₂ – arom., m, 1+1H); 7.17 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.50–7.58 (arom., m, 2H); 7.72 (arom., t, 1H, ³ J _HH = 8); 7.74 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.09 (arom., t, 1H, ³ J _HH = 8); 8.14 (CH–N ₃ , s, 1H); 8.43 (FA, s, 1H). ESI-HRMS: 650.1868 [M] ⁺ (theor. [C ₂₈ H ₃₅ N ₉ O ₄ Y ₁ ] ⁺ = 650.1865). Synthesis of TD1350: In a glass vial (20 mL), TD1346·0.1FA·3.0H ₂ O (6.9 mg; 10.8 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 550 µL; 275 µmol; 25 equiv.) and aq. LuCl ₃ 100 mM; 120 µL; 12.0 µmol; 1.1 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was oncentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 41.4 mg (84%; 1 step; based on TD1346·0.1FA·3.0H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.03 (CH ₃ , d, 3H, ³ J _HH = 7); 1.12 (CH ₃ , d, 3H, ³ J _HH = 7); 2.69‒3.81 (mc, CH‒CH ₃ , m, 16+2H); 3.90 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.10 (CH ₂ ‒ arom., d, 1H, ² J _HH = 16); 4.23 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.78 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.58 (CH ₂ ‒ N ₃ , d, 1H, ² J _HH = 15); 7.11 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.70 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.78 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.84 (CH–N ₃ , s, 1H); 8.01 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.22 (arom., t, 1+1H, ³ J _HH = 8). ESI-HRMS: 750.2370 [M] ⁺ (theor. [C ₂₉ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ = 750.2371). EA ([C ₂₉ H ₃₇ N ₉ O ₄ Lu ₁ ] ⁺ [TFA] ⁻ ·0.3TFA·2.1H ₂ O, M _R = 935.6): C 40.6 (40.6); H 4.5 (4.2); N 13.5 (13.2); F 7.9 (8.1). Synthesis of TD1452: In a glass vial (40 mL), TD1451·0.1FA·2.7H ₂ O (101 mg; 112 µmol; 1.0 equiv.) was dissolved in H ₂ O (30 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 7.0 mL; 3.50 mmol; 31 equiv.) and aq. LuCl ₃ (100 mM; 1.40 mL; 140 µmol; 1.3 equiv.) and the mixture was stirred 18 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as faint yellow fluffy solid. Yield: 115 mg (76%; 1 step; based on TD1451·0.1FA·2.7H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.12 (CH ₃ – CH, d, 3H, ³ J _HH = 7); 1.18 (CH ₃ –C–NH ₂ , s, 3H); 1.19 (CH ₃ –CH, d, 3H, ³ J _HH = 7); 1.80 (CH ₃ –C–NH ₂ , s, 3H); 2.77–3.90 (mc, CH–CO, m, 16+2H); 4.08 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.31 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.44 (CH ₂ ‒arom., d, 1H, ² J _HH = 18); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 18); 5.71 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.97 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 8.05 (arom., d, 1H, ⁴ J _HH = 2); 8.11 (arom., d, 1H, ⁴ J _HH = 1); 8.16 (arom., d, 1H, ⁴ J _HH = 2); 8.41 (arom., d, 1H, ⁴ J _HH = 1); ¹⁹ F δ _F −66.1 (s). NMR (~0.5 mM TD1452 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.12 (s). ESI-HRMS: 919.2725 [M] ⁺ (theor. [C ₃₄ H ₄₃ N ₁₀ O ₆ F ₃ Lu ₁ ] ⁺ = 919.2721). EA ([C ₃₃ H ₄₃ N ₁₀ O ₆ Lu ₁ F ₃ ] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O, M _R = 1353.2): C 34.6 (35.4); H 4.6 (3.7); N 10.4 (9.7); F 14.7 (14.3). Synthesis of TD1453: In a glass vial (20 mL), TD1451·0.1FA·2.7H ₂ O (21.7 mg; 24.1 µmol; 1.0 equiv.) was dissolved in H ₂ O (18 mL) followed by addition aq. MOPS/NaOH buffer (500 mM; pH 7.0; 1.50 mL; 750 µmol; 31 equiv.) and aq. ErCl ₃ (100 mM; 300 µL; 30.0 µmol; 1.2 equiv.) and the mixture was stirred 10 d at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 22.6 mg (~70% assuming [M] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O; M _R = 1345; 1 step; based on TD1451·0.1FA·2.7H ₂ O). NMR (~0.5 m ^M TD1453 in ~50 m ^M MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −47.85 (s). ESI-HRMS: ^{910.2620 [M]+ (theor. [C} 34 ^H 43 ^N 10 ^O 6 ^F 3 ^Er 1 ^{]+ = 910.2617).} Synthesis of TD1472: In a glass vial (4 mL), [TD1452] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O (20.0 mg; 14.8 µmol; 1.0 equiv.) was dissolved in DMSO (1.5 mL) followed by addition of AcOH (42 µL; 735 µmol; 50 equiv.) and DIPEA (181 µL; 1.04 mmol; 70 equiv.). Freshly prepared solution of PyAOP (200 mM in DMSO; 368 µL; 73.7 µmol; 5.0 equiv.) was then added and the resulting mixture was stirred 5 min at RT. The resulting biphasic mixture was diluted with DMF (800 µL), and the resulting solution was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 11.5 mg (64%; 1 step; based on [TD1452] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O). NMR (~0.5 mM TD1472 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.10 (s). EA ([C ₃₆ H ₄₅ N ₁₀ O ₇ Lu ₁ F ₃ ] ⁺ [TFA] ⁻ ·0.8TFA·3.1H ₂ O, M _R = 1221.8): C 38.9 (39.1); H 4.3 (4.5); N 11.5 (11.3). Synthesis of TD1473: In a glass vial (4 mL), [TD1452] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O (16.2 mg; 12.0 µmol; 1.0 equiv.) was dissolved in a MeOH (1.20 mL) followed by addition of SOCl ₂ (8.8 µL; 121 µmol; 10 equiv.). The resulting clear solution was stirred 2 d at 50 °C. Mixture was then diluted with H ₂ O (2 mL) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 13.2 mg (91%; 1 step; based on [TD1452] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O). NMR (~0.5 mM TD1473 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.13 (s). EA ([C ₃₅ H45N ₁₀ O ₆ Lu ₁ F ₃ ] ⁺ [TFA] ⁻ ·0.2TFA·7.2H ₂ O, M _R = 1199.2): C 37.5 (37.1); H 5.0 (4.0); N 11.7 (10.7). Synthesis of TD1475: In a glass vial (4 mL), TD1453 (assuming [TD1453] ⁺ [TFA] ⁻ ·1.5TFA·8.3H ₂ O; M _R = 1345; 20.6 mg; 15.3 µmol; 1.0 equiv.) was dissolved in a MeOH (1.50 mL) followed by addition of SOCl ₂ (11.2 µL; 154 µmol; 10 equiv.). The resulting clear solution was stirred 2 d at 50 °C. Mixture was then diluted with H ₂ O (2 mL) and directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fl uffy solid. Yield: 15.5 mg (~85% assuming [M] ⁺ [TFA] ⁻ ·0.2TFA·7.2H ₂ O; M _R = 1192; 1 step; based on [TD1453]). NMR (~0.5 mM TD1475 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −48.45 (s). Synthesis of TD1506: In a glass vial (20 mL), TD1504 (assuming M·2.0H ₂ O; M _R = 657.7, 8.7 mg; 13.2 µmol; 1.0 equiv.) was dissolved in H ₂ O (19 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 595 µL; 398 µmol; 30 equiv.) and aq. LuCl ₃ (100 mM; 159 µL; 15.9 µmol; 1.2 equiv.) and the mixture was stirred 16 h at 80 °C. Mixture was then filtered through syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with products (both diastereoisomers were fully separated) were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 6.9+3.4 mg (≤62+31% assuming [M] ⁺ [FA] ⁻ ·xH ₂ O; M _R = 836.6; 1 step; based on TD1504·2.0H ₂ O). NMR (first isomer, D ₂ O, pD ~4): ¹ H δ _H 1.06 (CH ₃ , d, 3H, ³ J _HH = 7); 2.53‒2.65 (CH ₂ ‒CO, m, 2H); 2.76‒3.84 (mc, CH‒CH ₂ , CH‒CH ₃ , m, 16+1+1H); 3.96 (CH2‒arom., d, 1H, ² J _HH = 15); 4.13 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.27 (CH ₂ ‒ arom., d, 1H, ² J _HH = 15); 4.77 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.61 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.11 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.78 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.81 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.85 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.87 (CH–N ₃ , s, 1H); 8.03 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.28 (arom., t, 1H, ³ J _HH = 8); 8.40 (FA, s, 1H). NMR (second isomer, D ₂ O, pD ~5): ¹ H δ _H 1.14 (CH ₃ , d, 3H, ³ J _HH = 7); 2.38‒2.61 (CH ₂ ‒CO, m, 2H); 2.76‒ 3.82 (mc, CH‒CH ₂ , CH‒CH ₃ , m, 16+1+1H); 3.92 (CH2‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.25 (CH2‒arom., d, 1H, ² J _HH = 15); 4.80 (CH2‒arom., d, 1H, ² J _HH = 16); 5.61 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.14 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.73 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 8.03 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 8.24 (arom., t, 1H, ³ J _HH = 8); 8.27 (arom., t, 1H, ³ J _HH = 8); 8.45 (FA, s, 1H). ESI-MS (LC-MS): 794.2 [M] ⁺ (theor. [C ₃₀ H ₃₇ N ₉ O ₆ Lu ₁ ] ⁺ = 794.2). Synthesis of TD1512: In a glass vial (2 mL), [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O 0.5 mg; 0.52 µmol; 1.0 equiv.) was dissolved in solution of freshly prepared DIPEA (100 m ^M in DMSO; 104 µL; 10.4 µmol; 20 equiv.) ollowed by addition of freshly prepared solution of NaSH (500 mM in DMSO; 4.2 µL; 2.1 µmol; 4 equiv.) and the resulting mixture was stirred 15 min at RT. Mixture was diluted with H ₂ O (800 µL) and purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 0.2 mg (≤44% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 867.6; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~4): ¹ H δ _H 2.63‒3.79 (mc, CH ₂ ‒ CO, CH ₂ ‒arom., m, 16+4+1H); 4.05−4.17 (CH ₂ ‒arom., m, 2H); 4.79 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 5.28 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.83 (CH2‒N ₃ , d, 1H, ² J _HH = 15); 7.47 (arom., d, 1H, ⁴ J _HH = 2); 7.72 (arom., d, 1H, ⁴ J _HH = 2); 7.79 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.83 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.23 (arom., t, 1H, ³ J _HH = 8). ESI-MS (LC-MS): 754.2 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O ₄ S ₁ Lu ₁ ] ⁺ = 754.2). Synthesis of TD1512-SO3H: In a glass vial (2 mL), [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O (1.0 mg; 1.0 µmol; 1.0 equiv.) was dissolved in H ₂ O (156 µL) followed by addition of aq. solution of Na2S (100 mM; 52 µL; 5.2 µmol; 5 equiv.) and the resulting mixture was stirred at 80 °C overnight. Mixture was diluted with H ₂ O (800 µL) and purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 0.3 mg (≤32% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 915.6; 1 step; based on [TD782] ⁺ [TFA] ⁻ ·5.1H ₂ O). NMR (D ₂ O, pD ~7): ¹ H δ _H 2.60‒3.83 (mc, CH ₂ ‒CO, CH ₂ ‒arom., m, 16+4H); 4.09 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒ arom., d, 1H, ² J _HH = 16); 4.35 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.82 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.72 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.16 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.82 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.86 (arom., dd, 1H, ³ J _HH = 8, ⁴ J _HH = 1); 7.88 (CH–N ₃ , s, 1H); 8.06 (arom., d, 1H, ⁴ J _HH = 2); 8.25 arom., t, 1H, ³ J _HH = 8); 8.36 (arom., d, 1H, ⁴ J _HH = 2). ESI-MS (LC-MS): 802.1 [M] ⁺ (theor. [C ₂₇ H ₃₃ N ₉ O7S ₁ Lu ₁ ] ⁺ = 802.2). Example 7: Synthesis of chains of coordination compounds Synthesis of TD837: In a glass vial (4 mL), aq. solution of [TD836] ⁺ [TFA] ⁻ ·xH ₂ O (~20 mM; 274 µL; ~5.5 µmol; 1.0 equiv.) was mixed with aq. solution of [TD823] ⁺ [TFA] ⁻ ·xH ₂ O (~20 mM; 274 µL; ~5.5 µmol; 1.0 equiv.) followed by addition of aq. MES/NaOH buffer (500 mM; pH 5.2; 548 µL; 274 µmol; ~50 equiv.), t-BuOH (1.1 mL) and aq. solution of CuSO ₄ (100 mM; 11 µL; 1.1 µmol; ~0.2 equiv.). To the resulting solution was added freshly prepared aq. solution of sodium ascorbate (100 mM; 11 µL; 1.1 µmol; ~0.2 equiv.) and the mixture was stirred 2 h at RT. The mixture was then concentrated to ~1 mL and then purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 4.7 mg (≤50% assuming [M] ²⁺ [TFA] ₂ ²⁻ ·xH ₂ O; M _R = 1721; 1 step; based on [TD836] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 747.1998 [M] ²⁺ (theor. [C56H65N21O8Tb1 ¹⁷⁶ Yb1] ²⁺ = 747.1997). Synthesis of TD889: In a glass vial (4 mL), aq. solution of [TD836] ⁺ [TFA] ⁻ ·xH ₂ O (~20 mM; 274 µL; ~5.5 µmol; 1.0 equiv.) was mixed with aq. solution of [TD886] ⁺ [TFA] ⁻ ·xH ₂ O (~20 mM; 274 µL; ~5.5 µmol; 1.0 equiv.) followed by addition of aq. MES/NaOH buffer (500 mM; pH 5.2; 548 µL; 274 µmol; ~50 equiv.), t-BuOH (1.1 mL) and aq. solution of CuSO ₄ (100 mM; 28 µL; 2.8 µmol; ~0.5 equiv.). To the resulting solution was added freshly prepared aq. solution of sodium ascorbate (100 mM; 28 µL; 2.8 µmol; ~0.5 equiv.) and the mixture was stirred 30 min at RT. The mixture was then concentrated to ~1 mL and then purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 7.8 mg (≤82% assuming [M] ²⁺ [TFA]2 ²⁻ ·xH ₂ O; M _R = 1721; 1 step; based on [TD836] ⁺ [TFA] ⁻ ·xH ₂ O). ESI-HRMS: 747.2002 [M] ²⁺ (theor. [C56H65N21O8Tb1 ¹⁷⁶ Yb1] ²⁺ = 747.1997). Synthesis in TD1483: In a glass vial (4 mL), [TD1472] ⁺ [TFA] ⁻ ·0.8TFA·3.1H ₂ O (7.8 mg; 6.4 µmol; 1.0 equiv.) and [TD1473] ⁺ [TFA] ⁻ ·0.2TFA·7.2H ₂ O (7.5 mg; 6.4 µmol; 1.0 equiv.) were dissolved in DMSO (335 µL) followed by addition of DIPEA (400 mM in DMF; 240 µL; 96 µmol; 15 equiv.). Freshly prepared solution of PyAOP (200 mM in DMSO; 64 µL; 12.8 µmol; 2.0 equiv.) was then added and the resulting mixture was vortexed for 1 min and further left standing for 5 min at RT. Mixture was then diluted with H ₂ O (1 mL), vortexed for 1 min and further left standing for 5 min at RT. Reaction mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid. Yield: 10.8 mg (≤80% assuming [M] ²⁺ [TFA] ₂ ⁻ ·xH ₂ O; M _R = 2090; 1 step; based on [TD1472] ⁺ [TFA] ⁻ ·0.8TFA·3.1H ₂ O). NMR (~0.5 mM TD1483 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −66.10 (CF ₃ , s, 3F); −66.11 (CF ₃ , s, 3F).

Synthesis of TD1484: In a glass vial (4 mL), TD1483 (~20 m ^M in DMSO; 20 µL; 0.4 µmol; 1.0 equiv.), TD1473 (~20 m ^M in DMSO; 20 µL; 0.4 µmol; 1.0 equiv.), DIPEA (400 m ^M in DMF; 15 µL; 6.0 µmol; 15 equiv.) and DMSO (21 µL) were mixed together followed by addition of PyAOP (200 mM in DMSO; 4 µL; 0.8 µmol; 2.0 equiv.) and the resulting mixture was stirred 30 min at RT. Mixture was then diluted with H ₂ O (2 mL) and further stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized. All of the obtained product was used for ¹⁹ F NMR characterization. NMR (~0.5 mM TD1484 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −65.86 (CF ₃ , s, 3F); −66.09 (CF ₃ , s, 3F); −66.10 (CF ₃ , s, 3F). Synthesis of TD1512-SS: Obtained as a side product (in the form of trifluoroacetate salt) during synthesis and purification of TD1512. Yield: 0.1 mg. ESI-MS (LC-MS): 753.3 [M] ²⁺ (theor. [C ₅₄ H ₆₄ Lu ₂ N ₁₈ O ₈ S ₂ ] ²⁺ = 753.2). Synthesis: In a glass vial (4 mL), TD1483 (~20 m ^M in DMSO; 20 µL; 0.4 µmol; 1.0 equiv.), TD1475 (~20 m ^M in DMSO; 20 µL; 0.4 µmol; 1.0 equiv.), DIPEA (400 m ^M in DMF; 15 µL; 6.0 µmol; 15 equiv.) and DMSO (21 µL) were mixed together followed by addition of PyAOP (200 mM in DMSO; 4 µL; 0.8 µmol; 2.0 equiv.) and the resulting mixture was stirred 30 min at RT. Mixture was then diluted with H ₂ O (2 mL) and further stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized. All of the obtained product was used for ¹⁹ F NMR characterization. NMR (~0.5 mM TD1485 in ~50 mM MOPS/NaOH buffer in 10% D ₂ O, pH 7.0): ¹⁹ F δ _F −48.05 (CF ₃ , s, 3F); −65.13 (CF ₃ , s, 3F); −67.24 (CF ₃ , s, 3F). Example 8: Synthesis of dimers of coordination compounds Synthesis of sc-TD647: Obtained as side product during synthesis of TD647. Yield: ~8 mg. NMR (D ₂ O): ¹ H δ _H 2.69–3.65 (mc and CH ₂ –CO, 32+8H); 3.68 (C≡CH, s, 1H); 3.70 (CH ₂ –arom., bs, 2H); 3.75–4.12 (CH ₂ –arom., 6H); 4.59 (CH ₂ ‒N ₃ ., s, 2H); 5.89 (CH ₂ ‒N ₃ , s, 2H); 7.36–7.97 (Ph and arom., 10+8H); 8.15 (arom., bs, 1H); 8.32 (arom., bs, 1H); 8.64 (CH–N ₃ , s, 1H). ESI-HRMS: 1251.6313 [M+H] ⁺ (theor. [C66H79N18O8] ⁺ = 1251.6323). Synthesis of TD613: In a glass vial (20 mL), sc- TD647·xH ₂ O (5.0 mg; ~4 µmol; 1.0 equiv.) was dissolved in H ₂ O (14 mL) followed by addition aq. MOPS/NaOH buffer (500 m ^M ; pH 7.0; 800 µL; 400 mmol; ~100 equiv.) and aq. LuCl ₃ (100 m ^M ; 88 µL; 8.8 µmol; ~2.2 equiv.) and the mixture was tirred 1 h at 80 °C. Mixture was then filtered hrough syringe microfilter (RC). The filtrate was concentrated on rotary evaporator and then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with FA additive). Fractions with product were joined and directly lyophilized to give product in the form of formate salt as white fluffy solid. Yield: 4 mg (~60%; 1 step; based on sc-TD647·xH ₂ O). ESI-HRMS: 798.2368 [M] ²⁺ (theor. [C ₆₆ H ₇₄ N ₁₈ O ₈ Lu ₂ ] ²⁺ = 798.2371). Synthesis of TD598: Obtained as side product during synthesis of TD651 in the form of formate salt as white fluffy solid. Yield: 6 mg. NMR (D ₂ O, pD ~5): ¹ H δ _H 2.47–3.99 (mc, CH ₂ –CO, CH ₂ ‒arom, m, 32+8+4H); 4.42 (CH ₂ ‒arom., d, 2H, ² J _HH = 17); 4.75 (CH ₂ ‒arom., d, 2H, ² J _HH = 17); 5.90 (CH ₂ ‒N ₃ , d, 2H, ² J _HH = 16); 6.20 (CH ₂ ‒N ₃ , d, 2H, ² J _HH = 16); 7.07 (arom., d, 2H, ⁴ J _HH = 2); 7.44 (arom., d, 2H, ⁴ J _HH = 2); 7.47–7.63 (Ph, m, 10H); 7.66 (arom., dd, 2H, ³ J _HH = 8, ⁴ J _HH = 1); 7.89 (arom., dd, 2H, ³ J _HH = 8, ⁴ J _HH = 1); 8.15 (arom., t, 2H, 3J _HH = 8); 8.42 (FA, s); 8.74 (CH–N ₃ , s, 2H). ¹³ C{ ¹ H} δ _C 49.3 (mc, s); 49.4 (mc, s); 51.0 (mc, s); 51.6 (mc, s); 52.5 (mc, s); 53.9 (mc, s); 54.0 (mc, s); 54.3 (mc, s); 55.6 (CH ₂ ‒N ₃ , s); 59.2 (CH ₂ ‒arom., s); 59.8 (CH ₂ ‒CO, s); 61.2 (CH ₂ ‒arom., s); 61.9 (CH ₂ ‒CO, s); 120.7 (arom., s); 121.2 (arom., s); 122.2 (arom., s); 125.4 (arom., s); 126.7 (CH–N ₃ , s); 128.2 (Ph, s); 129.6 (Ph, s); 131.6 (Ph, s); 135.2 (Ph, s); 143.0 (arom., s); 145.5 (arom., s); 148.9 (arom., s); 150.2 (arom., s); 157.2 (arom., s); 157.3 (arom., s); 158.9 (arom., s); 170.8 (FA, s); 177.9 (CO, s); 180.5 (CO, s). ESI-HRMS: 762.2025 [M] ²⁺ (theor. [C66H74N18O8La2] ²⁺ = 762.2027). Example 9: Synthesis of conjugates of coordination compounds with peptides Synthesis of TD981: In a glass vial #1 (20 mL), HO-R(Nω-NO ₂ )-Fmoc (886 mg; .01 mmol; 1.1 equiv.) was dissolved (with the help of vortexing/gentle heating) n DMSO (6 mL) followed by addition of DBU (550 µL; 3.68 mmol; 2.0 equiv.) nd the resulting solution was briefly vortexed and further stirred 2 mins at RT. n a glass vial #2 (20 mL), HO- ^D R(Pbf)-Fmoc (1.20 g; 1.85 mmol; 1.0 equiv.) was dissolved (with the help of vortexing/gentle heating) in a mixture of DMSO 9 mL) and NMM (1.0 mL; 9.09 mmol; 4.9 equiv.) followed by addition of solid PyAOP (965 mg; 1.85 mmol; 1.0 equiv.). The mixture was briefly vortexed and he resulting slightly yellow solution was further stirred 2 mins at RT). Solution rom vial #1 was then added in one portion (via syringe) to the intensively stirred solution in vial #2. Resulting bright yellow solution was further gentle stirred 5 mins at RT after which neat TFA (430 µL; 5.62 mmol; 3.0 equiv.) was added. Mixture was then directly purified by flash chromatography (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with pure product were joined and directly lyophilized. Fractions containing impure product were joined, lyophilized and subsequently re-purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive) and re-lyophilized. Both solids were then joined and homogenized to give product as off-white solid. Yield: 1.21 g (63%; 2 steps; based on HO- ^D R(Pbf)- H). ESI-MS (LC-MS): 850.4 [M+H] ⁺ (theor. [C ₄₀ H ₅₂ N ₉ O ₁₀ S ₁ ] ⁺ = 850.3). EA (C ₄₀ H ₅₁ N ₉ O ₁₀ S ₁ ·1.4TFA·1.4H ₂ O, M _R = 1034.8): C 49.7 (50.0); H 5.4 (5.1); N 12.2 (11.8); F 7.7 (7.8). Synthesis of TD982: In a glass vial (20 mL), TD981·1.4TFA·1.4H ₂ O (360 mg; 348 µmol; 1.1 equiv.) and NH ₄ Cl (27 mg; 505 µmol; 1.5 equiv.) were dissolved (with the help of vortexing/gentle heating) in DMSO (2 mL) followed by addition of NMM (140 µL; 1.27 mmol; 3.0 equiv.) and of solid PyAOP (264 mg; 506 µmol; 1.5 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 5 mins at RT followed by addition of DBU (380 µL; 2.54 mmol; 7.3 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 2 mins at RT after which neat TFA (160 µL; 2.09 mmol; 6.0 equiv.) was added. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with pure product were joined and directly lyophilized to give product as white fluffy solid. Yield: 237 mg (74%; 2 steps; based on TD981·1.4TFA·1.4H ₂ O). ESI-MS (LC-MS): 627.4 [M+H] ⁺ (theor. [C25H42N ₁₀ O7S ₁ ] ⁺ = 627.3). EA (C25H42N ₁₀ O7S ₁ ·2.3TFA·1.9H ₂ O, M _R = 923.2): C 38.5 (38.7); H 5.3 (4.9); N 15.2 (14.8); F 14.2 (14.0). Synthesis of TD986: In a glass vial (20 mL), TD981·1.4TFA·1.4H ₂ O (258 mg; 249 µmol; 1.0 equiv.) and TD982·2.3TFA·1.9H ₂ O (222 mg; 240 µmol; 1.0 equiv.) were dissolved (with the help of vortexing/gentle heating) in DMSO (2 mL) followed by addition of NMM (220 µL; 2.00 mmol; 8.3 equiv.) and of solid PyAOP (136 mg; 261 µmol; 1.1 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 15 mins at RT followed by addition of DBU (221 µL; 1.48 mmol; 6.2 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 15 mins at RT after which another portion of DBU (36 µL; 241 µmol; 1.0 equiv.) was added. Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 5 mins at RT after which neat TFA (58 µL; 758 µmol; 3.2 equiv.) was added. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with pure product were joined and directly lyophilized. The resulting tetraarginine intermediate NH ₂ -R(N _ω - NO ₂ ) ^D R(Pbf)R(N _ω -NO ₂ ) ^D R(Pbf)-H (≤238 µmol; 1.0 equiv.) was transferred to a glass vial (20 mL) followed by addition of TD981·1.4TFA·1.4H ₂ O (259 mg; 250 µmol; ≥1.1 equiv.), DMSO (2 mL; dissolved with the help of vortexing/gentle heating), NMM (276 µL; 2.51 mmol; ≥10.5 equiv.) and of solid PyAOP (144 mg; 277 µmol; ≥1.2 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 20 mins at RT followed by addition of DBU (263 µL; 1.76 mmol; ≥7.0 equiv.). Mixture was briefly vortexed and the resulting bright yellow solution was further stirred 5 mins at RT after which neat TFA (77 µL; 1.00 mmol; ≥4.0 equiv.) was added. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with pure product were joined and directly lyophilized to give product as white fluffy solid. Yield: 368 mg (66%; 4 steps; based on TD982·2.3TFA·1.9H ₂ O). ESI-MS (LC-MS): 923.6 [M+2H] ²⁺ (theor. [C75H120N28O ₂ 1S3] ²⁺ = 923.4). EA (C75H120N28O ₂ 1S3·3.2TFA·5.3H ₂ O, M _R = 2306.4): C 42.4 (42.8); H 5.8 (5.4); N 17.0 (16.6); F 7.9 (7.6).

Synthesis of TD802: In a glass vial (4 mL), [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O (3.3 mg; 2.8 µmol; 1.0 equiv.) and H ₂ N- GVHFYA-H·1.0TFA·xH ₂ O (3.4 mg; ~4.2 µmol; ~1.5 equiv.) were dissolved in DMSO (1 mL) followed by addition of DIPEA (5.0 µL; 29 µmol; ~10 equiv.) and PyOAP (freshly prepared 100 mM in DMSO; 52 µL; 5.2 µmol; 1.9 equiv.) and the resulting yellow solution was stirred 20 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 4.4 mg (≤96% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1629.5; 1 step; based on [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 0.93 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 0.95 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 1.42 ( ^A CH ₃ , d, 3H, ³ J _HH = 7); 2.03 ( ^V CH‒(CH ₃ ) ₂ , dhept, 1H, ³ J _HH = 7, ³ J _HH = 7); 2.62‒3.81 (mc, CH ₂ –CO, ^H CH ₂ , ^F CH ₂ , ^Y CH ₂ , m, 16+4+2+2+2H); 3.84 ( ^G CH ₂ , d, 1H, ² J _HH = 17); 3.95 ( ^G CH ₂ , d, 1H, ² J _HH = 17); 4.01 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.02 ( ^V CH, d, 1H, ³ J _HH = 7); 4.15 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.35 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.45 ( ^A CH, q, 1H, ³ J _HH = 7); 4.52‒4.66 ( ^H CH, ^F CH, ^Y CH, m, 1+1+1H); 4.85 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.67 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 6.59 ( ^Y arom., dm, 2H, ³ J _HH = 8); 6.96 ( ^Y arom., dm, 2H, ³ J _HH = 8); 7.08‒7.18 (CH ₂ ‒ N ₃ , ^F arom., m, 1+2H); 7.19 ( ^H arom., s, 1H); 7.23‒7.30 ( ^F arom., m, 3H); 7.81 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.82‒7.87 (arom., m, 3H); 7.89 (CH–N ₃ , s, 1H); 8.00 (arom., dm, 2H, ³ J _HH = 8); 8.03 (arom., d, 1H, ⁴ J _HH = 2); 8.24 (arom., t, 1H, ³ J _HH = 8); 8.33 (arom., d, 1H, ⁴ J _HH = 2); 8.48 ( ^H arom., bs, 1H). ESI-HRMS: 1515.5593 [M] ⁺ (theor. [C68H80N18O12Lu ₁ ] ⁺ = 1515.5605).

Synthesis of TD792: In a glass vial (4 mL), [TD785] ⁺ [TFA] ⁻ ·0.6TFA·4.8H ₂ O (3.0 mg; 2.9 µmol; 1.0 equiv.) and H ₂ N- GVHFYA-H·1.0TFA·xH ₂ O peptide (3.4 mg; ~4.2 µmol; ~1.4 equiv.) were dissolved in DMSO (1 mL) followed by addition of DIPEA (5.0 µL; 29 µmol; ~10 equiv.) and PyOAP (freshly prepared 100 m ^M in DMSO; 52 µL; 5.2 µmol; 1.8 equiv.) and the resulting yellow solution was stirred 20 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 4.0 mg (≤89% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1543.3; 1 step; based on [TD785] ⁺ [TFA] ⁻ · ·0.6TFA·4.8H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 0.93 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 0.95 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 1.42 ( ^A CH ₃ , d, 3H, ³ J _HH = 7); 2.03 ( ^V CH‒(CH ₃ ) ₂ , dhept, 1H, ³ J _HH = 7, ³ J _HH = 7); 2.62‒3.81 (mc, CH ₂ –CO, ^H CH ₂ , ^F CH ₂ , ^Y CH ₂ , m, 16+4+2+2+2H); 3.84 ( ^G CH ₂ , d, 1H, ² J _HH = 17); 3.95 ( ^G CH ₂ , d, 1H, ² J _HH = 17); 4.01 (CH ₂ ‒ arom., d, 1H, ² J _HH = 15); 4.02 ( ^V CH, d, 1H, ³ J _HH = 7); 4.14 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.39 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.45 ( ^A CH, q, 1H, ³ J _HH = 7); 4.52‒4.67 ( ^H CH, ^F CH, ^Y CH, m, 1+1+1H); 4.85 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.72 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 6.59 ( ^Y arom., dm, 2H, ³ J _HH = 8); 6.96 ( ^Y arom., dm, 2H, ³ J _HH = 8); 7.09 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 16); 7.10‒7.16 ( ^F arom., m, 2H); 7.21 ( ^H arom., s, 1H); 7.24‒7.30 ( ^F arom., m, 3H); 7.78‒7.86 (arom., m, 4H); 7.89 (CH–N ₃ , s, 1H); 8.00 (arom., dm, 2H, ³ J _HH = 8); 8.03 (arom., d, 1H, ⁴ J _HH = 2); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.33 (arom., d, 1H, ⁴ J _HH = 2); 8.53 ( ^H arom., t, 1H, ⁴ J _HH = 2). ESI-HRMS: 1429.5264 [M] ⁺ (theor. [C68H80N18O12Y1] ⁺ = 1429.5256).

Synthesis of TD901: In a glass vial (4 mL), [TD899] ⁺ [TFA] ⁻ ·0.2TFA·7.0H ₂ O (1.6 mg; 1.4 µmol; 1.0 equiv.) and H ₂ N- GVHFYA-H·1.0TFA·xH ₂ O (1.6 mg; ~2.0 µmol; ~1.4 equiv.) were dissolved in DMSO (500 µL) followed by addition of DIPEA (2.3 µL; 13 µmol; 9 equiv.) and PyOAP (freshly prepared 100 mM in DMSO; 25 µL; 2.5 µmol; 1.7 equiv.) and the resulting yellow solution was stirred 40 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O- ‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 2.0 mg (≤85% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1637.5; 1 step; based on [TD899] ⁺ [TFA] ⁻ ·0.2TFA·7.0H ₂ O). ESI-HRMS: 762.2885 [M+H] ²⁺ (theor. [C ₆₉ H ₈₃ N ₁₈ O ₁₂ Tm ₁ ] ²⁺ = 762.2887). Synthesis of TD902: In a glass vial (4 mL), [TD891] ⁺ [TFA] ⁻ ·0.7TFA·4.6H ₂ O (1.6 mg; 1.4 µmol; 1.0 equiv.) and H ₂ N- GVHFYA-H·1.0TFA·xH ₂ O (1.6 mg; ~2.0 µmol; ~1.4 equiv.) were dissolved in DMSO (500 µL) followed by addition of DIPEA (2.3 µL; 13 µmol; 9.4 equiv.) and PyOAP (freshly prepared 100 mM in DMSO; 25 µL; 2.5 µmol; 1.8 equiv.) and the resulting yellow solution was stirred 40 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O- ‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product as white fluffy solid. Yield: 1.8 mg (≤78% assuming [M] ⁺ [TFA] ⁻ ·xH ₂ O; M _R = 1643.5; 1 step; based on [TD891] ⁺ [TFA] ⁻ ·0.7TFA·4.6H ₂ O). NMR (D ₂ O, pD ~4, assignment was complicated by two distinguishable diastereomeric set of most of the signals): ¹ H δ _H 0.91 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 0.93 ( ^V CH ₃ , d, 3H, ³ J _HH = 7); 1.36 ( ^A CH ₃ , d, 3H, ³ J _HH = 7); 1.90– 4.21 ( ^V CH‒(CH ₃ ) ₂ , mc, CH ₂ –CO, ^H CH ₂ , ^F CH ₂ , ^Y CH ₂ , ^G CH ₂ , CH ₂ ‒arom., ^V CH, ^A CH, m, 1+16+4+2+2+2+2+5+1+1H); 4.21–4.56 ( ^H CH, ^F CH, ^Y CH, m, 1+1+1H); 4.81–4.90 (CH ₂ ‒arom., m, 1H); 5.52– 5.62 (CH ₂ ‒N ₃ , m, 1H); 6.77–7.18 ( ^Y arom., CH ₂ ‒N ₃ , ^F arom., ^H arom., ^F arom., m, 4+1+2+1+3H); 7.34–8.10 (arom., CH–N ₃ , 8+1H); 8.21–8.30 (arom., m, 1H); 8.52–8.58 ( ^H arom., m, 1H). ESI-HRMS: 765.2919 [M+H] ²⁺ (theor. [C69H83N18O12Lu ₁ ] ²⁺ = 765.2917). Synthesis of TD975: In a glass vial (4 mL), [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O (7.1 mg; 6.1 µmol; 1.0 equiv.) and H ₂ N- -[ ^L R(Pbf) ^D R(Pbf)]3-H·1.0TFA·xH ₂ O (21 mg; ~8.1 µmol; ~1.3 equiv.) were dissolved in DMSO (1 mL) followed by addition of NMM (20 µL; 182 µmol; 30 equiv.) and PyOAP (15.5 mg; 29.7 µmol; 5.0 equiv.) and the resulting yellow solution was stirred 20 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with Pbf protected product were joined, evaporated to dryness and twice co-evaporated with MeOH. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and the residue was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid (the amount of TFA was determined by qNMR using external capillary solution of 1,3,5-tris(trifluoromethyl)benzene in CCl ₄ ). Yield: 13.0 mg (~85% assuming [M] ⁺ [TFA] ⁻ ·5.4TFA·xH ₂ O; M _R = 2510; 2 steps; based on [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O). NMR (D ₂ O, pD ~3): ¹ H δ _H 1.41‒2.07 ( ^R CH ₂ , m, 24H); 2.63‒3.88 (mc, CH ₂ –CO, ^R CH ₂ , m, 16+4+12H); 4.05 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.18 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.21–4.57 ( ^R CH, CH ₂ ‒arom., m, 5+1H); 4.53 ( ^R CH, t, 1H, 3J _HH = 7); 4.87 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.69 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.19 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.82 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.88 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.91 (CH–N ₃ , s, 1H); 8.03 (arom., dm, 2H, ³ J _HH = 8); 8.06–8.12 (arom., m, 3H); 8.27 (arom., t, 1H, ³ J _HH = 8); 8.39 (arom., d, 1H, 4J _HH = 2). MALDI-HRMS: 1777.8487 [M] ⁺ (theor. [C70H110N ₃ 4O11Lu ₁ ] ⁺ = 1777.8496). Synthesis of TD989: In a glass vial (4 mL), [TD897] ⁺ [TFA] ⁻ ·1.1TFA·2.6H ₂ O (15.0 mg; 13.4 µmol; 1.0 equiv.) and TD986·3.2TFA·5.3H ₂ O (30.9 mg; 13.4 µmol; 1.0 equiv.) were dissolved in DMSO (1.5 mL) followed by addition of solution of NMM (400 mM, 335 µL; 134 µmol; ~10 equiv.) in DMSO and freshly prepared solution of PyOAP (110 m ^M ; 210 µL; 23.1 µmol; 1.7 equiv.) in DMSO and the resulting yellow solution was stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with fully protected product were joined, evaporated to dryness and twice co- evaporated with MeOH. Residue was dissolved in TFA (3 mL) and stirred overnight at RT to remove Pbf groups. Resulting blue solution was evaporated to dryness and the residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with partly protected product were joined, and evaporated to dryness. Residue was re dissolved in H ₂ O (10 mL) and transferred via syringe through septum to a glass flask (25 mL) already filled with Pd/C (30 mg) and argon secured. Hydrogen gas was then left bubbling through the suspension for 2 days at RT. Mixture was then filtered through syringe microfilter (RC), and the filtrate was evaporated to dryness. Residue was purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid (the amount of TFA was set arbitrary from analogous TD975). Yield: 14.6 mg (~45% assuming [M] ⁺ [TFA] ⁻ ·5.4TFA·xH ₂ O; M _R = 2505; 3 steps; based on [TD897] ⁺ [TFA] ⁻ ·1.1TFA·2.6H ₂ O). MALDI-HRMS: 1771.8412 [M] ⁺ (theor. [C70H83N ₃ 4O11Tm ₁ ] ⁺ = 1771.8435).

Synthesis of TD1011: In a glass vial (4 mL), [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O (15.0 mg; 12.8 µmol; 1.0 equiv.) and TD986·3.2TFA·5.3H ₂ O (31 mg; 13.4 µmol; 1.0 equiv.) were dissolved in DMSO (1.5 mL) followed by addition of solution of NMM (400 mM, 340 µL; 136 µmol; 11 equiv.) in DMSO and freshly prepared solution of PyOAP (110 m ^M ; 210 µL; 23.1 µmol; 1.8 equiv.) in DMSO and the resulting yellow solution was stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with Pbf protected product were joined, evaporated to dryness and twice co- evaporated with MeOH. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and the residue was suspended in 20 % MeCN (3 mL). Mixture was filtered through syringe microfilter (RC) and the filtrate was directly purified by preparative HPLC (C18; H ₂ O‒ MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid (the amount of TFA was determined by qNMR using external capillary solution of 1,3,5-tris(trifluoromethyl)benzene in CCl ₄ ). Yield: 18.4 mg (~55% assuming [M] ⁺ [TFA] ⁻ ·4.5TFA·xH ₂ O; M _R = 2540; 2 steps; based on [TD748] ⁺ [TFA] ⁻ ·1.4TFA·3.2H ₂ O). NMR (D ₂ O, pD ~5): ¹ H δ _H 1.39‒2.07 ( ^R CH ₂ , m, 24H); 2.63‒3.85 (mc, CH ₂ –CO, ^R CH ₂ , m, 16+4+12H); 4.04 (CH ₂ ‒arom., d, 1H, ² J _HH = 15); 4.16 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 4.21–4.66 ( ^R CH, CH ₂ ‒arom., m, 6+1H); 4.86 (CH ₂ ‒arom., d, 1H, ² J _HH = 16); 5.69 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.18 (CH ₂ ‒N ₃ , d, 1H, ² J _HH = 15); 7.81 (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.86j (arom., dd, 1H, ³ J _HH = 8; ⁴ J _HH = 1); 7.90 (CH–N ₃ , s, 1H); 7.95–8.09 (arom., m, 5H); 8.25 (arom., t, 1H, ³ J _HH = 8); 8.37 (arom., d, 1H, ⁴ J _HH = 2). MALDI-HRMS: 1912.8054 [M] ⁺ (theor. [C ₇₀ H ₁₀₇ N ₃₇ O ₁₇ Lu ₁ ] ⁺ = 1912.8048). Synthesis of TD1010: In a glass vial (4 mL), ), [TD897] ⁺ [TFA] ⁻ ·1.1TFA·2.6H ₂ O (10.0 mg; 8.9 µmol; 1.0 equiv.) and TD986·3.2TFA·5.3H ₂ O (21 mg; 9.1 µmol; 1.0 equiv.) were dissolved in DMSO (1.0 mL) followed by addition of solution of NMM (400 m ^M , 230 µL; 92 µmol; 10 equiv.) in DMSO and freshly prepared solution of PyOAP (110 mM; 140 µL; 15.4 µmol; 1.7 equiv.) in DMSO and the resulting yellow solution was stirred 30 min at RT. Mixture was then directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with Pbf protected product were joined, evaporated to dryness and twice co-evaporated with MeOH. Residue was dissolved in TFA (3 mL) and the resulting clear mixture was stirred 16 h at RT. Mixture was evaporated to dryness and the residue was suspended in 20 % MeCN (3 mL). Mixture was filtered through syringe microfilter (RC) and the filtrate was directly purified by preparative HPLC (C18; H ₂ O‒MeCN gradient with TFA additive). Fractions with product were joined and directly lyophilized to give product in the form of trifluoroacetate salt as white fluffy solid (the amount of TFA was set arbitrary from analogous TD1011). Yield: 11.6 mg (~50% assuming [M] ⁺ [TFA] ⁻ ·4.5TFA·xH ₂ O; M _R = 2530; 2 steps; based on [TD897] ⁺ [TFA] ⁻ ·1.1TFA·2.6H ₂ O). MALDI- HRMS: 1906.7973 [M] ⁺ (theor. [C ₇₀ H ₁₀₇ N ₃₇ O ₁₇ Tm ₁ ] ⁺ = 1906.7982).

Example 10: Charts

Chart 1. Formation of 7,5-cz-[Ln(Lig)] from Lig and Ln ¹¹¹ ions (metal dependent click-zip)', conversion determined after 1 hour at 80 °C by analytical

HPLC (H ₂ O-MeCN system with 0. 1% FA additive; detection at 2; rounded to integers; aliquots from reaction mixtures were diluted with H ₂ O, vortexed, centrifuged and then injected to HPLC). Initial component concentrations: 0.5 mM aq. Lig (1.0 equiv.); 1.0 mM aq. Ln ¹¹¹ (2.0 equiv.); 50 mM aq.

MOPS/NaOH buffer pH 7.0 (100 equiv.). Performed in glass vials with magnetic stirrers. Metal ions are sorted by decreasing ionic radius.

L _r ^o _/ d ng ⁿ _i o _f ⁿ _a ⁱ _s dn t ^s _{e s} e _l ^l op w _{r a} ^s o ^{u r} _{e e} ^r _r l _{t s} ^{x (} _i vo f ^o _c d _e ^m n v _r ^{o e} _{i s} ^t _. ^o _r ⁱ n _e h c 1 o 8 ⁱ _t ^t d b ^{a o} _e 5 ^{a r} D _i ^r n ^{a s} _a ^o _t T _a v 10 w _{) e} d N ug ^e _l 8 b ⁿ _i D a ^{C g} _e o ^l g i _a ⁱ _l T- l M n g _r ^{a g} _e ⁵ _, 1 n ⁱ _t ^{o c} _i ⁿ b -n d r n a H o o t _s ^O h n ^a 1 e _e p o _{r s} 0 d ^a 8 h _t ^M _{( f t} y ^e _r o ^{n u} D T n _e ^{h s} _{t s} ^x _i - _z o _t ^{v i} _l o ^e _l ^{m c} - p ^s _{- a} ⁴ _, m o _f ^e _l o 1 u _{f s} ^{c o} h c _i ^e _s w ^o no ^{c n} _a ^a _{c e} ^e _r h ^u _t h ^g g _{r e} ^t o h u ^t n ^x _i o _f h _t ^o n ^{i i ]} ₎ ^{m a} a ^{d g} _{i .} l n _e g ⁰ _{. ,} ^o _i d ^t _i ^v _r ^L ₍ ⁿ _i ^{7 e} _t d ^e _s n ^d _l e ^c d b e ^{t o L} _[ - _i H y ^pr e ^A. o _z c _, n _e ^{f d} _e ^t _{f a} ^s _{l -} 5 _, o ⁱ u s _a ^t _i ^as _{t a} 1 ^c _a ^B w p ) ^{i ]} _c w _{f )} ^e _{r r} ^{o e} _r H u ^e _{c e .} ^{O d} _a 67 ^{p o} _i ⁿ _a ^h _{t e} ^N _/ 5 ^e _l ^v _a d _f o vo S D ^b _i T _{( i} ^h n P s _e u _e m O n ^{v b} b ^s _r ^e _r M L _[ ^{n -} _i ^s _i ^{a t} uo _{s .} q z ^a _t h c- n T _{c .} ^e _l ^c m f g ^{r a} n _a 5 _e n , ^o _c ^t _{c e} ⁱ 1 _t ^e _f ^r _. ^s _e ^{i i} _r u ^t _a n H r o o ₎ ^{n f} _e ^y _{l r t} ^e _t ^{d o} _i ^O _r 6 ^d _i ^{n a e} _s h p ^P - 7 d _{a r e} ^c 5 _s ^c _{a i} ^{u f} _{i c} ^{h c} _tt ^t _e ^o _r ⁱ d ^{p h .} _s %0 D ^e _r n _a uo _{s t} o ^{r 5 T} ₍ ^u _t g _t o h ^m b _{e f} n ^x _i ⁱ _s n g _{r r} mo ^{o L} _e r _e ^{m v} _t u a h ^o _r ^{a s} _t o _e ^s n _i ^{e o} _r u ^h _{t t} n i _e ^o _i h _t ^g _i h m ^{t n d} _a d ^o _e r ^r _e ^x _i ( ^t _c o x ^{a n} _a ^t _e v _r ⁿ _{e e} h ^{t t} _s a _i ^{m a e} _{e l} p ^{R d} _{i a} d ^{d e} _s p _i b _e ^t _a ^e h ^d o n ⁱ m ^. ₎ u ^s _t o ^d _e n _i ^{o s} _a n ^{t o} _i ^w _t ^d f _e o ^c L uq ^a _i p ^{w s m} _r o _r ⁱ N ^o _{f l t} b ^w t ^a O ^y _t ^o _{r e} ^{o v} _i m ^o _f ^{r s} _e C ⁱ _s P ^t _a u S _e P t ? _s L n a _f P ^e _t ^v _i ^r H ^{↓ n} _i ↑ _e d * _/ og ^r _e B ^a d - _{t c} n _, ⁱ _t ^d _e q ^a y ^x _{e I} u 8 ^{l t} _r M ^I _{I s} 4 _a ^e 1 n o ^m _i 1 ^a v _, 0 ^c _e D y O 5 ^p _s T _f ^b 2 _; C ⁾ _{I e} ^{° H} _. ^I _I h ^v _i ^{. s o} _{s e} ^{e h} _s 0 _t 8 ^t _i uq ^u _{i ,} ^a _{c t} ^{e a w} d ^{e d} _{c e} h k ^e _t ⁰ _{. a} 2 ^{r c} _{i I} ^I _I ⁿ _e ^{t e} _e u ^l _{i I(} u ⁿ _i ^I _I noq ^e _r ^w d _s ^e _t ¹ _e ^r n ⁱ e L gn ^{s o} _e ^r _{e .} ⁿ _i ^s _{c r} ^t _f w _s q ^a _a e ^I _I ^I _a P _s - _i ^a , ^d _e ^e _{r r} u M ^c _e A _. 29 ⁿ _{i t} x _i ^{m d} y ⁾ _e 01 m ^{r m} _. ⁰ 1 ^b _I ^I _I g ^r _a D _e ^t _e n o _{i ;} h T ^{) d} _e ^{t c} _f ^d n ^t _{c .} v _{i r} o _s 1 ^{o − e} _s o ^{a i} _{s e} ^r uq ^e _e ^r _{a I} ^I _I gn ^{a i} _c ^r _e m _{s r e} vn ^o _r ^{0 f} _. 1 no ^a _e h ^t o ^{b n h} _i ^{c s} _t ^{( i g} _i ^l _{a c r} ^: ₎ ou L ^t _{e I} ^I _I ^a _e ^e _t p ⁱ _z q ⁱ _{l .} q ^{M ( s} _e - _k ^{a . c ;} _s ^a _s ^{r m} _{e i r} ^o _f M ^{l (} _c ^r _e M _e ^r _{r I} n _t g ^e _t ^{m i} _t ^{s I} _{I l} o ^{i n} _{i a} ⁿ _e h d n n ^{i 5} _. o ^{0 c} _i ^t _e m _{c e} ^{t :} _s n ⁱ _e ^d d ^p _e ^d _e n _e ^{o g} _{a I} ^I _I ^t _a ^. ₎ ⁱ _s d _l d _i n ^t _a ^m n ^{] o} _{) e} h a _t 7 ^t u ^r _t h ^t _i ^o _r 4 ^t _e o 6 n ^{i m} ₍ ^r n ^e _c ^{w p} _e D pu ^. _{) s} ^; _λ n ^s _{l I} ^I n _t a ^o _{I c} ^a _i ^{d T} ₍ n ^o _r 50 _I ^o _i n _t ^v n ^{i g} 1 o 1 ^I _I ⁱ _t ⁿ _e ^s _s ^d _e ^L _[ ^t _a - d z ^e _s D n ^c T ^L _e n ^a _l t _e op ^g n _I ^I _I ⁿ _i ^c - ^y _{l r} ^o _f dn ^d m ^{i d 5} _, o ¹ _r d ^{o a ;} _e ^o _c ^d _e o g y ^e _s ^{c n} _i ^h h ^a _c ^g _i ^{v L} _i ^t _{i l} ^m d ^a _i ^e _r ^d _l ^t _r o ^{a e} _i ^t _{i e} ^] ₎ ^{y w} h ^t m d _{i f} ] ^o _r ^a n ^{I r} _e ^I _I ^I P ^g ₎ ⁿ _i ^f A ^. _{) . i} u ^{t L} _i ^g _{i c} ^] ₎ ^F C ⁾ _{. (} ^{s L v} n ⁿ _{i (} o ^g _i % LP _i u ^I n ^B _I ^L d ^L ₍ ¹ _{. [ .} ^H q ^{I e} - _z ^e _. ^{L i} _[ n ( - _z ^a n ⁰ h o 0 0 ^L _[ ^{- t} _i ^t 0 ^c _{- s} ^c - 61 _z c ^{w d} _e 1 ^{( 5} _, 1 ^m _r ⁵ _, 1 - ^t _c ⁰ _. ^I _I ^I _f ^{a 1} D ⁵ _, 1 ^m _e o _s ^e _t ^: _s T _. a _t ^c _i ^l _f ^t _s ^e _j ⁷ y n ⁱ H ^r _{a f} ^d _e ^{o s n p} m _a ^e _c ^t _i ^o _t ^{a e m} _r n N _e ^r _e ⁿ _a ^o _t n ⁱ _s a _c ^o _f ^o _i r _e ^t _a ^C _e h ^{t f} _f d u bd _s ^s _{e e} ⁿ _e ⁱ _s u ^l _a h ^t p _t ^m _r M‒ n H o o O ^a P ^y _l F 2 ^{O o} _r V ⁿ _i N _. ^d _{e a} d _r H y ^e g t ^{2 (} u ^N _/ S h _^ ^s _e – ^t _r a C ^f _i ^r h LP _t P n ^e O C H _c M 5 01 uo ^r _e ^{2 u} _i L ^d _e q ^{a h} w _I 8 _s ^I ₍ ^d _a P ^x _e M 1 ^e _{I r} n ^r H _l ^t _r o ^m d n ^u _t L _. ^c _i n ^a _c v 0 a ₎ ^x _i q ^a o ^{i i} _{t ,} 5 g y ^l _a O2 _; A ^{m ) (} n M ^{n n} _i ^o _i n ^H _{. i} ^{m s} _a ^{a v} _i y h ^. r C ^t u _s e _t ^{° t} _c ⁰ 0 ^a _. 1 ^e _{r i} q ^u _i c ^{b w e d} _a s _{e ; e} C e ^{8 r )} _. ^{d °} r ^t _a m ^v _i y 0 d 8 ^e _t ⁰ _. ^r u ² ₍ ^c _i n a P _r ^o u ^{b t l} _{i I} ^I _I o s - _i u _{r ,} o ^f q ^{d s e} _{e a} t _{r r} d ⁱ u _e M g A _. ⁾ _e ^. 2 ) 9 ^{h 1} _t o ⁰ _. 1 ^o _s o g ^] ₎ 01 ^r _e uq ^{h r} _{e .} q ⁿ _i ^{s i r} _l ^{( g} _{i e} ^{r 1} w ^a _a e _{r a} 74 D ^t _f a ^a L _as ^r _e ^t _{s f} ^e _r M ^c _e h ^c 6 T D _f ^d _e ^; _s ^r _. n e q o ^{i a u} _t ^{m d 0} y 1 − ^T ₍ ^{o e} _s ⁿ _i g ^{a d} g n ^e _t M ^l _{a e} ^x _{i .} 1 ^{b d} n ⁱ _r ^L _[ ^a _c m ^r _e n ^{t m} _e ⁿ _i ^m _; m n ⁾ _{. e} ^t _r a ^- e _{z e} c ^b - h ^{t t} _e ⁱ o ⁵ _. ^{M. r} _e ^o _i ^v _i ^o _s . ₎ ^d n ^{t d 0:} _s ^r _e ^t _e ^t _c u a q _e h ⁵ _, ⁿ _{i c} ¹ _r 5 o 0 ⁱ _e d _s n ^r _r ^d n _e ^{r e r} _{a s} a _e g ^e _t 1 _s ^r _e nu ^o _i ⁱ _t ^s o ^{i 0} _. 1 n ( ⁿ _i ^{s d} _e 1 v o ^t _{a l .} ^{r c} _{i s} ^r _e m o _r ⁽ o ⁱ p _e D T no ^r; _{λ t} n ^t _e vn ^{f g} _i ^l _{a .} ^m _r ^e _i ^a _c M _f ^c: _{) t} ^e _c n g o ^s _t L ^t _e 0 _. ^{o 7} _fl ^y u _l ⁽ n ^{o e} p ^a n o _a ^c: ou _. q ^M H o ^{t p n} _i ^a _i ⁱ i ^{s v} _{a s} ⁱ _z no _ct ^m ₎ p q ⁱ _l ^{a .} _s r n ^h _c ^a _c - _k ⁱ _t ⁿ h ^t _i ⁱ _z ^a M ^r _{e e} m f _f ^{i n} _i. ^{e e} _{t e e} ^c _i ^c _{e e} u ^d _{e .} ⁱ h d n ^{w -} _k ^; ( g ^{i i} h ^{t l} _c ^t _e o ^s _l ^c _{i s} ^r _r r _e ^{m i} _t ^{s B t} _a n _{s t s} ⁿ n _{e i t} ^d p ^a _i ^l _c g ⁵ _. ^c _i h _c ⁿ _e d ^; _e m H ^{o o v} _t n ^e _t ^{0 t} _e O _t ^m _r ^{u t} o ^{n v} _{i c} ^s _{s e} d n ^{i :} _s n n a ^o _r ^{a o} _t n ^{i B} d _e p ^t _i d _l a _i ^a _l ⁿ o ^o _i ^g _a N _/ ^p _e ^e _{t e} S ^{d a} _t u p e d u n _{e t} ^o d d ^t _i ^g _{e r} ^a n ^{p t t} _a ^m 0 _l ^a n a A ^{I. i} _e d d _l ^d _e d ^r _t n h ^t P n _{c i} O ^{i n g} 6 ^t _{e ) e} n ^e M ^d _e ^a _e v d 11 ^{F m} C ^m a r ^t _e uo _c n ^{w s} _{l .} ^{t o} _{t l} o ^e _s D _{( s} % 1 LP ^o _f ^{m r o} _c ^a _i q _{a s} ⁱ _s ^{s y} _l T _f n _. 0 ^{H r} _{e (s} ^; _{λ t} ^{v a n} _i n ^{d i} _r ^y _l n o ^o _r ^o _i ^o _r t _c dy ^{o e} _I ^{o I} _{i I} h ^t _i o ^t P _. n _t ^{n )} _e ^s _{s . I} o ^{i a} n ^a _l O _r ^c y ^h _s n h ^{w d I} _I n o H o d ^a _e ^{t a} _c ^L _e ^t _c ^v _i u o ⁱ _t p ^g n e ^{h r} _{i e} d ^m _e q ^M m ^{i P} _{r -} o ^e _l ^w h n ^{t i a]} _s ^e _j n ) g ^e d r o n ^c _e ^o _c ^d _e h ^] ₎ ^t n ^{a g} y ⁱ 0 ^{a t} _{e l} ^{m .} _s % r 0 ^g _{i e} d w ^g _i ⁱ e ^{5 L} ₍ n ^r _i ^{s n} _e 01 ^g _i ^d n u _{e s} ^h _t ^L _{( e} n ^t _s ^L N h ^{t ( L ;} _e ^a _i ^t _{r i} n ^o _f ^{r e} m ^C _e d ² _. m ^v _i ^{t I} _e P m _f o ^{L s} _[ ^e _{i f} ^L _[ u ^o _r ^f M n ^{a 5 o} _{r i} d ^. _{) . i} ^{o e o} _r - _z ^c e ^{u c} _e ^o - ^p n - o _z c B - - _t ^] ₎ ‒ g _i O2 ^d H e ^{p f} d C ⁾ _. r ^r _{t e} ^] ₎ ^a LP ^v _{i e} ^t _s ^x _i ⁵ _{, s} ⁱ _t 1 _e ^{5 s a} _{r , ,} 8 H gu ^f _f ^g _i A uq o ¹ 4 ^L ₍ n ^{( f} _i u ^L ₍ ^{F H e a} _i ^{m d a} _{f e} o _s ^h _t, ^p _a ^: _s 1 c _i 1 D _. d _e ^L _[ C ^r _t - L n ^b % o ^t 00 P ^e H ^M _[ ¹ _. 1 o n ^{i w} _t ^d m ^{r e} a _c ^v _e ^l _a T _z n _l H _c, ^{O -} _z ^{0 d} _e ^{t (} f _e ^{a t} _{i f} ^m _r ^c _{- l} ^d _{e a} ^c - h _c ⁰ _. o ^m _{r t e t} n n u o q ⁿ _e ^{i o o} f _a d ^e _s ^d _i ^s _e ^e _{s f} ^{5 r} _{, e} 1 _f ^a _c ^{N i} _{/ t} ^x _e S ⁵ _, 1 ^t _i ^e _j n ^{7 i} H u ^a _c p ^o y ^t _r E _f ^{w o p} mu ^{r n} n ^c _c ^l _{a e t} o n ^l _a ov M n ^m _e ⁿ _e ^r _e S _e P _e P ^o _c A V ^h _t N ^o _i n t _{, . a} ^a O q ^{a o} _i ^t _a ^t _s h y ^{t f} _f u * _/ ^. _r ^r _{e ^} y – ^m _r b 2 M ^s dn ^b o ₎ ^H h ^{m m} _r o N ^a H F _. B ^{( t} _i 0 F ^{C d O w} 5 _{. e e} g _a 3 ^t C r ^° d _; ⁾ _. ⁴ M u ^N _/ a 0 ^e h ⁸ _t u ^v _i ^t _r ‒ ^f _i SP u a O2 ^r _t n C ^{t l} _i h O a d ^q _e C ^H ₍ ^e _c M 5 01 51

L ^d P _e ^O H ^x _{e l} ^t _{a r} a _c o ^N _/ S i _t v y _, P l O O a 2 n ^{a H M} _. h q y ^{t a b} _i ° ^w M C ^m 0 d ^e 0 8 _t 5 t u _; a ^l _i ⁾ _. k d e _{e e} ^v _i r uq ^. _s w _e ^{e u} _i 1 w ⁰ _. ^{d r} _{a e s} 2 t _f ^e _r ^{( r a u} _t ^I _I ^c _i n d _e ^x _i ^M _. q o ^{i n} _i ^{m a} g m n M ⁿ _i r _e ^{o s t} _{i e} ^t _{a c} ^{m 0 d a} _. ^e _r 1 ^c n _e o ^r _{; e} d ⁱ _s m ⁾ _. y r _e ^o _r ^v _i u ^b v ^f q . n ^s _t ^{e d} _{e .} ^{0 t} _r 0 o o _. ^o _s 7 ^c: ₎ u 1 q ⁽ _e H p ^{i .} _z ⁱ _l ^{r a g} _{i a s e} ^{p t} _a ^r _e - _k ^{; t} _i ^f _f ^c _{i s} ^{L l r} _. n e q o g ^{a i .} _e ^t p u _c i _c ^B _t ^e _t M ^l _{a a} t ^t _i p e _r H ⁿ _e n p d ^{i m} _e ⁱ _{c f} ^O _a ⁿ _e o ⁵ _. t ^{0 M : .} _s ^e _r r p on ^N _/ ^p _e ^d _s n _e ^r _f o ^o _i S d _e t P _l d ^o _{i r} ⁱ n a O a n ^{t t} u _{a t} r _t ^{s o c} _{i i} ^t _a m _e o r M ^r n o ^{e t} _e ^{m f} _. q ^m ₍ ^{; o} _t ^a _{s λ c} n _r o n _t n ^g e n ^{a o} _{c a} ^f u ^{i I} o I ⁱ n _t ^{m o} _t d H o ⁿ _e h ^t _e u d _e ^O _r ^{M i} _t n _i d o n _i ^P - ⁱ n ^c _e a ^t _e p ^{w d} m ^s _l ^{d a} _e n _i m ^r _e % ^g _i ^{d o} _{c i} v m t _e ^. _s ^r 0 5 ^{L ;} _e v _{i l} a _i ^s _s ^{r a} _e ^{t d} _{e f} m ^t _i ^t _{i l} y _l ^g _e mo ^{o o} _r dd n ^I n ^{d b} _a ^s _i ^{e f} n ^o _r u ^] ₎ ^{a .} ₎ ^{i y} _l C ^{d b} _a o _e s _a ^r _{t e} ^{t x} _i ^g _i A L ₍ ^F L _e n P ^m _r o e _{r s e} ^a _i ^{m a} _. d ^M _[ % ^H o ^o _f ^{s r} _a e _r b ^d t o n ⁱ _e - ^m _z ¹ _. ^t _e c ^{0 d} _e P _{. e} b o n ^w _t ^d _{e r} o - _f ⁵ _, h ^t _i ^t _c ⁾ _{. t} v ^d _{f i} o lu ^{o m} _r ^r _e 1 p _f ^{w e} _j n ^{n i} uq ^d _l o m ^o _f u ^r _{e t} o ^o n ^{m o} _{i e} ^{t n} _e ^e u 0 o C ^. S P N c ^t _s y h ^t 0 ^{C e} _r * _{/ a} – ^s d 1 n ^{( .} _c p ^m _r o N ^{a 0} _. ^e _r d F n _. ^C _e ^d _e ⁷ p _{: e} ⁷ M gu H p d n ^g _e ^t _r ‒ ^f a O _i ^r _t ^r _{e e} g L h 2 n ^f _{f e} L C ^H ₍ ^e _c u b 5 01 ^e _e o ^g n w u L q 1 ^{i ,} _l - o z ⁱ _r u ^r _e q ^{a t} _{e )} ^{a c} - ^l _a ^t o g h ^e _t M n g _a A ^{; (} _s ⁵ _{, e} ¹ n ^{i m r} _e 1 _. ^{M ,} ₎ o ⁵ _. ^m C g q ^. _s A ^{t 0} h : ^t _i ° ^e _t ^{a r} _e ^r _r ^{( d} _{e s} T d n ^w 0 n M 8 ^{i t} _a o ^{m i} _t R nu ^o _i ^t _a ^s _l a _{i r} ^{t 5} _. ^{s c} _{t i} ^a o ^r u ^d o _e ^{; r} _t n ^v d ^{0: t} _e ⁿ _{i λt} ^e _c ^s _s a _l h n _s 1 u n n g _a ^{m a} n 1 n ^o _c ^g n r o ^o _{i e} ^{r t t} _a ^{m r} _e o ⁱ _{t t} ⁱ f ^; _λ ^r _t h n ^t _i ^t _f ^c _e ⁿ _e ^d n _e a _t d _e ^{a e} _c ^{w a t} _e o ^{m s d} _e ^d p _r o ⁿ n n _{l i} o ^{o a} _i ⁿ _i ^; _e m _f ^r _e m ⁱ _t r _e ^c _{c e t} ^v m ^{r v} _i ^t _i ^o _cl P _. t _e ^t _e ⁿ _e ^s _{s e} ^t _e dd ^a _i ⁾ _. d ^d n ^a _l ^{t ;} op ^{g d} _i ^v _i n ^a n u n _e i m n s ⁱ o A ^I q o ^v _i ^{i r} _e ^t _{i s} ^{F .} ₎ ^e d ^o _cl ^d _e ^r _e % C 0 L 0 v d n ^{a a} _i ^{t m} _r vn ¹ _. 0 P 1 ⁽ o _i ^{o c} A n ^I _f ^r o e ^c h ^t _i ^H o ⁰ _. : ₎ ^{F .} n % ₎ P _. ^: ₎ n ^{w t 7 d} _e H . o C 0 _. ⁱ _t ¹ _. L ⁾ _. o ⁱ _t ^m _e ^t _c ^{pr 7 a} _x ⁰ P ^v _i u ^a _x ^t _s ^e _{j e} ^f H ^e _{f l} h ^t _i ^H o q ^{e e} _l y n p ^{s i} u b ^p p r _e m ^{w t} f ^{o m d} _e 0 t 0 m N ⁿ 1 ^o _c ^C _{e e} h ^t H f _{c e c} ⁽ _t d ^O _a u _t B ^{c t} e _s y ^e _j ⁰ _. ^c H ^r _e M‒ n ^N _{/ i} ^s n ^{i 7} d N ⁿ _e H ^r _i ^a d O2 ^d _e SP O _t ^C h ^pr _t n H ⁽ gu O a ^{n N} _{e e} ^t _{e e /} d M d ^f _f d C ^f _i ^r M _. SP ⁿ _e ‒ n ^a u b ⁿ _e LP _t n q ^a O ^p _e O2 ^d d H _e ^p H ^e _c g H _e d _{l ,} M M _{. l} a ⁽ u C ^f _i ^{O r} _{a l} a ^{a t} _c ⁱ _t ^d _e ^{m x a} L _e 0 q ^t _{e t} ^N _{/ e} y 5 n m P n i ^{( e} S ^l P m _a ^t n _r o _; ⁾ _. H ^g _i H _{l c,} O ^{( g} _i ^a v _, ^v _i ^. _s O _r L ^{- a} _c ^d _e M P _{- z} ⁱ _{t .} L yb O u 2 q ^u _i y ^x _e q - _z i ^c - ^l _a ^t _r o ^{a c} _{) -} D ^{( H e d} _a h ⁰ _. 2 ^{r .} _s % ⁵ _, n ^a v _, M ⁵ _, 1 C ^t _{i I(} ^c _i n r 0 ¹ e ⁵ m y O ^{m o} 0 m ^° 0 ^{w I} _I d o r b ₎ 2 5 ^o _r 8 _t ^e _t M _r ⁱ g m _f o ^s _i ^{o f e ]} ₎ B ^{H (} h _; t _i ⁾ _. ^{f a} u v _i ^] ₎ k ^l _i d ^I _I ^{o n} _i ^s _a o _{r e} ^{u r} _t ^g _i C ^w u ^{. g} _i ^e _{e e} ^t _s ^x _e M ^e _{r i} ^L ₍ ^° d q _s n 0 8 ^e _t ^{e u L} ₍ ^{w r} _{e .} ^c _e 0 _i d n ¹ w q ^{a d a} _i ^m _. ^L _[ ^t u ^l _{i . a} ^{r L} _[ d _s M y d ^a o n ^{d i} _e - _{z a} d c _{s e I} ^{2 I} _{( I} ^c _i - _z ⁿ n ^{c w} _{- a)} ^e _r ^{b u} _t ^{m d} _{e t} ^d f _e ^m _r o - ^h _{t f} ⁵ _, n ^r o _e n o w L _. ^{i 5} _, C 1 ^{( x} _{i .} ⁰ 1 ^t _r o ^{o m} _r ^r m ^o _e 1 _{f s} q g _f C ^m _{; f} p ^{o m e} _r ^{a n} _i ⁾ u ^{r s o °} n _{. s} v _{i e} ^r _a S _{e t} o n ^{6 u} P N ^o _i ^t _a ^~ _t M _a n 0 ^o _i d ^x _i ^{m e} _r ^o _i ^{8t t} _c uq _s n * _/ – ^m _r ⁿ _a ⁰ _. ^c _e ^t _{a ar} ^a _e o ₎ ^m n 1 ^{d m} _r u ^{r e 0} _. o ⁱ 1 ^l _a F _. B ^{( o} _{i ;} t ⁸ _c ⁾ _. y b o o m F ^{h o ( t} _e t C ^{a v} _i u ^d _{e .} ¹ _r ^{f g} _i M _{. r} ^° _e ^r q ^{t e} _r ^{9 , o} ₎ ^s _t L s ^t _r B o - _z ^s _r a 0 h ⁸ m a ⁽ u ^c - ^e _r C ^t _a o ^r _f ⁰ _. 1 _{e (} ^r _a h T ^q _i C R ^l _a ⁵ _, ^r 1 _i ^t _s 5 01 51 b ₎ O2 5 _; A ⁾ d ^{e n} _r u _t ^{m b d ( H} h _. v _{i a)} ^x _i ⁰ _{. e} 1 ^t _r C ^t _i u ° 0 ^w q ^. _s A ^{( m} _; 8 d ^{e u )} _. ^o _{s t} ^e _t ⁰ _i d C n o _i ^v _{i e} ^r _a a u _. l k _i ² _a ^{r °} 0 ^t _c uq _s e d _I ^I _{( I} ^c _i ^{8 a} _e ^{r e} no e _e n no ^t _ar m ⁰ _. 1 ^il _a w ^r _e L _. ⁱ q g uo ^o _r ^{( g} _i ^t _e 1 w r _s ^{a n} _{i e} ^{s t} _a ^{h f s} _t L f ^e _r M ^{e a u} _{t r} ^1r ou - _z ^M. _s ^r _e d ^x _i ^{m c} _{e e} ^t _f q ⁱ _l ^c - ^r _{r e} ^{0 n} _i ^m _. 1 ^{d a a 4} _, 1 n _{; .} ⁱ _t ^s _I m ⁾ _. y b ^d _e ^; _s ^r q ^c _i ^{I r o} _{i e} ^{t t} _c ^v _i ^d _e ⁿ _{i e} g ^{a t} _{e e} ^a uq ^t _r m ^{r d} _e ^{r e o} _{s e} ^e _t M n n ^g n _e ^t _e ^{i m 5} _{a .} ^m _I o m ⁰ _. ^{I i} _s ^{o r} _r 1 ^r _a ^d o n ^{t 0} h e ^{f ( t g} _s o ^{i d} _e ^: _{s i} n v ^s _{t i} n n o L o _s ^r dn ^o _i ^{w s} _l u - _z ^il _{e a} v uo ^t _a ^a _i ^I _I o ^c q ^{i c} - ^t _e no ^{r r} _t ^{v :} _{) l} n ^{a 4} _, o ^{; M c ; :} _λ n t ^e _c ^s _s i _s 1 ^I _t ^r _{. )} n ^a _l q ^. _s n ^{a g} _I ^a _{e x} g ^e _t ^{a r} _e o ⁱ _t no ^o _c M ^r _r ⁱ _t ^a _x ⁱ _{t t} n n ^{i e} _l p n ^{i m s e} _l ^c _e ^t _e ^d _{e e} n m o ^I _I ^{t 5} _. ^c _i ^t p o ^{I o} _ct ^{d c} _e ^0: _e m n ^o _c ^d p ^m _r ; _e m ^o _f ^r e dn _s n ^g _{a t} ^v _i ^o _{c e} P _I ^r _i u ^o _i ^{m c} _e ^t _i d _l a _{i .} ⁾ _. ^I _I d o t ^{r t} _a n ^r h ^{t r} _i d d ^t _i ^v _{i e} ^; _{λ t} n _i d _t ^w _t ^a n ^I uq n ^I _e ^{a e} _c ⁿ n n ^s _{l e} A a _i d ^{F .} ₎ ^e _I ^p _e ⁱ _t ⁿ C 0 _I o ^o _c ^v _e % LP 01 d _{t l} ^c _e ^s a ^t _s ^p _e ¹ _. ⁽ e ⁿ _e n ^a _l d _l ⁰ h ^H o ⁰ _. ^I _I ^t _e ^d o m ^; p ^g n a ^{t t} _i ^{t 7 (} _e v m ⁱ _e m ^{w d} _e ^t H c ^{p g} _{i i} ^t _i ^o _c ^d _e ^{( m} _e ^{t e} _j ^r _{e I} ^I L- d z d _l a ^m _r ^g _{i s} y n ^{i f} _f u c- ^a _i ^t _i ^o _f L- _z ^{s n} _e ^{b 4} _, A n F ^{I r} _e P ^c - N C h ^t H ^I _I ^{I 1 .} _{) .} ⁾ m % 1 _. ⁴ _, † ^o _{r .} CL ¹ _e dn ^O _a P ^v _i m M‒ ^{a N} _/ S f ⁰ u h ^H q ^o _r O2 ^d _e P ] ₎ ^t _i o ^{e f t} 0 ^] ₎ H g ( u ^f O _I ^{I g} _i ^{w L} ₍ ^{m d} _e 0 t 1 ^{( g} _i C _i L ^r _t M n _. q n _{e c} ^{0 L} ₍ P ^{e a L} _[ ^t _s y ^e _{j .} n _c n ^{7 L} H _, M ^I _{I .} d _e - _z ^{s i c} H _[ - _{z l} a ^d _e ^{m m} - N ⁿ _e ^p r ⁴ _, ^C _e h ^{t r} _e ^c _{- c} ⁱ _t ^x _e 05 f ⁴ _, y ^{l t} _{r ; I} ^{I o} _f 1 r _{e f} p ^o M d _f ‒ n u 1 _a o t n O2 ^{a b} _f n v ⁾ _. d ^{o a} _, ^v _i u ^. _{s e} H n y O b 2 q ^{e u} _i o ^o _i N ^t _a H ⁽ g ^O _a ^o _i ^t ₎ ^{H 0} _. ^d _a C u ^f _i ^N _a B h ^t _i ² ₍ ^r – ^m _r o L ^r _{t /} S ^m _r ⁽ F P n P o C ^w _I ^I _I ^c _i no . H ^e 0 _{l c} F ^° d 1 ^a _, O M ⁱ M _. 1 08 ^e _t u _r g n _i t _{c r} ⁱ _t ^d _{e .} ¹ _t ^l _i ^I a y ^x _e q ^{a t} _r ^a _I ^{o s} k d e M _a e h ^l _a ^t _r a _r o M h ^e _e ^r _{e .} ^c _e C ⁿ _a v m C w w ^q _a d 5 01 o ⁱ _s ^{t g r} _e ^d _e L _. v dn q n u ^{a o} _c o M : ^{r 2} _. ^; _λ ^m 0 _t ⁵ _. ^{. 1 a} n ⁰ _s : H o _s ^r _e ^r _r p ⁱ _t n t _a ^c _e ^o _i ⁱ _t t ^{s c} ) ^t _{e a} ^r _{t i} ^t p ⁱ _z ^d n _e e n - _k ^; _e c _i ^v _{c i} n ^g _a l _c ^t _i ^o d _ct ^m h t d ^{t a n} _{e i} n _e d A n ^w o ^s _e n _e ^F p b p m ^u e % ^o _{t c t} d ¹ _{. l} ⁰ _l ^s _e a ^{t t} h ^a _{i e} ^t _i ^t _i ^f n _r o m ^{w I i} _l ^{m .} ₎ d n _e a _e C p k _l ^t _s L p a y P ^{E ( s H c g} _{i i} N o ^{t L C} _e ^t _s d m M _e ^a _l o ^{t p r} _f ‒ _c n s O2 ^e _j ⁱ n ^d _e r _e H ^{i ( n m} _r m o C _e h ^o _{f s} L ^{t r i} P d _e g _i H n P a _. ⁾ L _l - _z ^a _c ^d _. v ⁱ _e x _i u c _{- t} y _e ^t q 4 _, ^{l 1} _{a r} n o ^e 0 d ^a v _, 01 n yb O2 ^I _; a ₎ ^H s g _i B ^C L ^{- (} h z C ^t _i ^{I ‒} i c- ^{° w L 5} _, 0 d 1 8 ^e _{t I} = f _t u ^l _i M o ^a n ^y _a d ^(r _e o _i ^d _e ^{r f} _f t _a ¹ _e w u b ^m d r ⁿ _s e 3 O o _{f a) r t} ^u A _t C x _I )2 n _e ⁽ _i d C ^m M ^{( n} _e ^° n _/ e _t p 0 ^o _{i e} ^{8 t a} _r d ^t _c l _a ^a o a ^t _{r e} ^r B _{. e} uo m q m _i ^{h o a l} _a ¹ _r ^f M r _e ^s _t o ^{m k} _l ^t _f u 0 q 5 A _. ^{a i} _{l ;} 4 ^{d 1} _e ⁾ _. n ^{a; v} _i t _{i s r} m ^r uq a ^r _{e e} g ^e h ^t C _e ^e _t ⁰ _. d ⁿ _i ¹ ₍ 5 2q m ^c _e p ^s _i n _i m _e h _t ^(r _e ^t _e mo x _a ^l _e ^r n o ^e _{c .} ⁿ _e ) _s uq ^. ₎ m _r ^e _s o _e ⁰ _. 7 ^{f s l} _l H l u p a ₍ ^p _{, e} y ^{r r} _e e _{r e} ^f _f f vo u e _t ^c y _e ^{b l} _a ^r H n ^{O n} _{a a} o e ⁱ _s ^{r N} _/ S b _e v P o ^t n ⁱ O n d w ^r M _. o _a d q h ^s n ^{a s a} _t n a ^{s i w} y M h ^{b c} _i ^d _e ^{m 0} _. h ⁿ _i 1 w _: , m ^s e ^{r t} _{e e a} ^{t t} _a t _{i e} p ^{d l} _e h ⁱ _c 72 _cf e _r 5 ^{o p} D n e _l ^{T o} _i b _i dn ^t _a s _i ^{a r} _t v 1 n ^{e a} 54 _c n d _e D ^{o n} _{c i} ^{Ts ( a} _t n _e o ^t C a ^{° c l} _e ⁰ _. 0 e _r h ^c 4 u _{t I} ^{I x} _{I t i} d ^{a) m} G _r n _f ^e o _k o _{i s} ^u _r t _c ^e _i B a _{; e} ^t _i R ^v _i T t _i ⁵ _. x Ѱ _a ^{0 l} _e ^; _r R ^e _{z :} d _. y 5 ^l _a n _e ¹ n g _e ^t _r ^a a R L h M C N ^, _r u ^o _i ^t _e o ^t _c a n h _e ^{r g 1} _a r _e m ^{m t} h f ^o _r ^{f t} _i a ^d _e ^s _t ^w o ^s 1 n _i u _l q ^a _i m ^{r i} _l ^{v ƒ} e ^{t a s} e ^; _{s s} ^a _l d ^r e _e ^g n t g a ^e _t ^{i l} _e n ^{i d} _e h ^c o ^{t m} _r t _c ^d _e ^o _f a _t d ^{r n} _i n _{e f} u ^P. ₎ o ^o _r n _; CL o ⁱ _t m c ⁿ P a 0 ^{H r} o f 8 : 2 ^{t )} _{t s} ^{a d} _e ^{t s} _e n _c e ⁿ _{j t} o ⁱ _t n r _e ^c n _e ^{i n i t} _{e e} h c _i ^{d t} _e ^; _e ^t d n _i ^v _i n ^{a k t} _i d ^d n d _e o ⁱ _t ^a gu a ^f _{i x} A e _l ^{F r} _t n p % ^e _c m ¹ _. o ⁰ _, d ^c h _{e e} ^{x d t} _{i e} d ^{w t} _r i _c ov a ^{m (} _e ^t _{s ,} n C y ^{o ° s} _i ^t _a 0 N x 8 ^t _a ^C _e ^e _l p l M‒ m C o H O2 ^c - e ^M H ⁽ _rt 0 _. C ⁿ 6 _{e .} L v q P ^e _r a H n _l ^{p i a s} _c o e ^{i t} d t _{t a} y l _e ^l _a ^e _t u n ^{l h} _c ^a _i d f y y ^{l o b} n ^h _{e t} ^{t o} _i n _a ⁱ _r t p a o i _c ^{m o} _r o _s ¹ p p ^s d i n _{a e} D _. ^a k ^r _e 7 ^e _e w 1 ^t _r ^w _s 1 ^e _{r .} u _t ^s _r a _, h ^y _a ^x _i ^e _r ^r _i C d m ^t _s 5 0 1 _, 0 7 _, 1 ^{( 4} _, l ^{3 1} - C e n n L a _. q3 ^c _e d ^a g od ⁿ _i o d l _c no4 ^; _e ^y _c p ^{s m} _i ^{y t} _a ^a _{z e} ^r _r c o . _t ⁼ _e a ^{c d a} _r ^t h n ^x; m _e ^t - ^t _i . _{t e} n _e m _e ^{t e} _a ^o _r 0 ^{w d} m _r ^{l u} _e ^{f 1} _{, e s} h ^d _e ⁷ _, ^{x 4} _{, i} e _r u _s ^a _e ^{ct v} _i ^{r 1} - ^ms m _c a _e d ⁾ _{l a} a _{e r t} n ^, _{) .} ^y _z ^w m o ⁱ _if ^d _l g ^{n )} _{. r r} p ^o o ⁿ _{i r} ^t _e ^v _i o ⁱ ₎ n ^b _t ⁱ p _f b o uq ) L L ^{µ o} _i 0 ^t d _{t r c} ^e _t h ⁿ _i ^t _i ^{e 0} _. 0 ^a _r g o ⁿ -4 ^{1 µ} 0 2 ^{f i} _l p a ⁽ - ^; _l o 0 _; = h 2 _; ⁰ _{. y;} ^g _i ^t h _a d ² ₍ - _' m µ ⁶ _. ^{7 3} H ⁾ _{t ;} ^e _l ^' _' 1 p ^/ _x ^s _r u g ² _{, ;} H ^{( -} p ^r ₍ ( _e p o n h ⁱ _s ^' _' L r 2 ^, _' ^µ 0 r _e ^f _f x f u ^{e n} o ² f ^{b =} _i ( _, 0 ½ ^{f d} 2 1 _; u ^{y t} _e b H n y ^, ₎ O2 o ^e _f ^{i a} _l L H ^O _{a i} O _a ^N _/ ^t _{a l} S u - _f p m ^{H q l} n e _a ^s _i h d _t ⁵ _. ^{i 0} ₍ M N _/ P O ⁽ _s a on _e ^m A F ^{M y} _a ^d _{e s} ⁱ b ⁰ _. 0 M M ^c _e ^s _s g ^u _t ¹ ₍ m ^d 0 ^{m l} _a ^e 0 00 ⁱ _r ⁿ _{i t} p ^t _t ^{f i} _{r e} o d ^{i n x} _{e f e} d _r 5 ⁵ _e n _s ^h _t ⁿ _e ^o p _l h ^t _i h ^{t w} _i o ⁱ p y _f p ^h _c x ^t _i o d ^w _r E ^o _{r e i} ^d _e ^{e l} _i y ^{b o} _r ⁿ _I dy z ^{l z} _a ^r _e h ^∞ _{a i} ^{l r} _{t a} ^{b t d} _{s e e e} ^. _s ^r _{: e} n ^a _r ^{t u r} _{t e} ^{u t} _t ⁱ n _{e f} ^t _a h ^{o l} _e ^T m _i ^t _{a e} ^t h ^. ₎ o ^r _a d e n r _{e e e} r _e ^r _e C ^{t s} _i p ⁱ _c w _. × ^{o )} _{t ) e} ^e _I w w _a ^{n 2 r} _{e r} a p _c ⁱ L _{a (} ^t _{s s t} ^I _{I ) )} ^t _a ^t n ^{l e} _c µ L µ ^d _s n ^{a =} _i d no ⁱ _t aa 2 n o ( 2 ½ o ^r t ^{( o} _i ^{c t} ₍ ^u _{l t} s o ^s _t ^t _a ⁱ _c ^y _{a t} ^{w n} _tf ^o _s ^e _t ⁾ _l u o q u i _l q ⁱ _l ^o _s ^c _{e a} ^{t o s} _i ^d _s ^k ya A A D = n t ^o m _{c c} u S ^o _t ^r _t S ^e _t A B ƒ * ^ ^B _: d n _e g _e L 5 _e ^r _e ^a w d ^, _r u ^o _i ^{t t} _{e s} ^e _s o _c a n ^e _r ^{u h} _e ^{r g} _a ^u _t y _i ^{l 1 c} m ^{m x} _{t e} ^r _e ^t _f ^o _r h ^t _i ^{m r} g _i ^{a fs} _t ^{w n} _i ^{d t} _l ⁿ _e ^d _e o ^{s n} u _l a _i ^u _i q _s ^h _t m ⁱ _l ^{v e} _{r e} ^s _{s e} ^r _e ^r _e ^{t a} e ^; _s ^a _l h ^w d ^r _e ^g T _. ^{s )} _{t e} g _. ^{n e} n ⁱ a ^t _a ^l _{t e} n ^{i d} _e ^v _i ^t u _a hq n o ^{m e r} _e ^{c t} _r o _f ⁰ _. p ^t _c ^d _e ^r u ^a _t d _e ⁷ S ^; _{l .} ⁿ _i n ^P f u o o n ^o _r ^. _{) ;} C o _i Lm n m P ^{µ t} _a o ⁰ _. g ⁱ u ^. _{) t} c ⁿ 0 ^H o7 _; ^f _i ^r _t g n _{i . .} p _a ^r L ^{n t} _f 82 ^t t pu u o _{: t} ^d _e ^µ _e ⁵ _. ^{c i} _f ^o _{r r} ⁾ _s ^a n ^t _c y _e ^{g g} S ^s _e o 7 ^b h ^t S ^P _I ⁿ _t ^{i r} _t ^e _j c n ⁱ 1; ^d n ^{i P} _I T _e n _e ^t _e ⁿ _e M _e w ^d _e ^T d _f o ^{i c d} h ^{t m} o 0 ^l _l d ^e _{s s} ⁱ _i ^{t ;} _e dn0 ^o 4 _f u ⁽ ₎ ^l _c n ^y _{l s e} S ⁱ ₍ ^o _r ^y _l ^{n v} _i ^{t a o} _i k _i d ^d _e HO ^M - ^. _{) s} d h y _r d n d t ^h y o ^a gu h ⁱ _t ^f _i a C ^s _t n h _l ^a _x A F ^r _t N _. ^{L s} _i x o ^t _i ^e _l ^e _l n % ^e q y ^{e m} w ^{a b} d 6 _e ^l _a ^r p ¹ _{. c,} d ^{d n} _f ^t _{a a} mo ^{0 d} _e ⁿ _{e a a} ^{o l} ₎ ^m _e ^p r g i _f ⁱ _l d h ^{a c} t ^o _i ^o _e h ^t _i ^x _e r ^c _/ p _{t e} ^{d t} d ^w _r o L ^µ n ⁿ _e ⁱ _c v o _e p u u ^m _{e ,} 95 ^{c r ( s} _{a e} ^o _r ^d a a ^{p ( t} _s ⁰ _. w _. o h n ^{t g d r} _e C y e S ^{s 7 P n} _i ^° 0 N HO2 H n ^y _a ⁽ x v _I m ^{8 C} _e ^pr _, o ^s _. ^{e ) i} _{s s} a _l ^{o T} p d ^t _c ^r _e ^t _e ^t _{a e l} M ^f _f u ^v _i ^r _e n m ^e _t ^a _t ‒ n ^d Cu vn ^o _i o ^c _e ⁱ y ^l O2 ^B q o ^t _a ^{c l} _l h ^t _s u ^H H H ^{e c i 1} _. ^l _{l c} ^d _e ^o _{c i} ^o _r ^{M ( O} _a ^{1 u} _f ^o _s p _e w s ^p _i ^r _{e e} ^t og ⁰ _. C 1 _. L ^N _/ ^; _l ⁽ _i o T d m R _e ^z _{- a} k ^{w s} _t ^l _e ⁱ _r q P SP h _e H b ^a _l O ^µ _t ^{h 1} _. ^a _t ^c _{i r} ^{l o} _c ⁿ _{i f a} o ^c p ^: _{s t} n t o ^{i a} e n ^s _{c e} ^{i t} _t M y _. l q 1 _; ^h 6 _{s s} n ^a _a ^{t k} _c ⁿ _a c _a ^l _{e a} n ^a h L ¹ _a ^{µ d} o ⁱ _t ^y _l ^{d a} _r b ^e _f ^h _c ^a y ^t _i ⁵ _{. e} 3 ^r _r ^u 2 ⁱ _l n t o ^{o l} _a n ⁱ _l d n ^{i -} _{f f} ^{b w l o h} _t ^d _e ; ^{s s} M ⁿ _e ^k _c ^e _t ^o _i ^s o ^a _l ^t _{i e a} n n ^z u h ^o _i o _i ^l o dd ^l _{a e} ^t _{a a} ^r _t m ^h _t ^t _s ^s _I h A V T ⁱ _c ^{m o} _s ^{1 u} d _e n - - ∞ _^ — ^s _i n _e D _. ^a k ^r _e 8 ^{e 1} _e w _s t _{. r} ^w a 1 ^e _{r ,} ^u _t ^s _r h ^{y x e} _r C _{a i} ^r d m _i ^t _s 5 01 0 1 _, 0 7 _, 1 ^{r (} _e 3 w 4 _, l _s 1- C ^e _r e n ^u _t n L a _. ^x _i c _e q d ^{a m} o g g n _i ⁿ _i 1 do dn ^t _l l _c ; _e ^y o ^u _{s c} p ^{s e} _{r e} 3 ^m _i ^{y t} _a ^a _{z e} ^r _r h c T e a a o . _r ^c _{. t} ⁼ h ⁾ _. x ^{d t} m _e ^{t t} _i ^v _{i t} ⁿ _e ^; - ^w u . _e ^{o n} _e m ^t _r 0 q e _a ^{l f 1} _, ^d _e ^e m _{r e} e h ^d _e ⁷ _, ^x _i ⁰ _{. r} ^u _s ^{c v} _i ⁴ _, ^{m 7; u} _{l s} ^a _e ^t _c ^r _e ¹ - a _e m _r ^a _t ^{d ) s} _a o , _{. l} y ^w m m o ⁿ _{i ) r} ⁱ _{r f} ^d _l g _z ⁾ _. ^µ o ⁿ _i ⁿ _e ^v _i ⁰ _. o ⁱ p r ₎ ^o n ^{b t} _t b uq 7 p ₎ L ^o d ⁱ _ft ^o _r ^e _; L L ^µ _i 0 ^t _c ^e _t µ 0 ^a h ^{n t} _i ⁰ _. ^µ g _i o ⁿ - ^{1 5} _. 2 _r ^{f i} _l p 4 ^{( ;} _l 7 00 _; = h 2 ^g _a ^t _{a -} 2 o 1; ; ⁰ _. 6 _. ⁷ _{y; i} ) _t h _{( ;} ^{d - e} _' m M l ^' _' ^µ 1 ^{m 3} Hp ^/ H ⁽ _x ^{s -} _{r (} u g ² _{, ;} 0 o n ^{i '} _' L 0 p ^{r (} _e p f _f x ^h _s e ⁿ _{i r} 2 o ^, _' ^µ 4 2 _, 00 ^{( r} _e ^f u f ^{b =} (½ ^f 1 H d 2 _; O u ^{y t} _e y ^, ₎ O2 a b H n H ^O _a ^o _i ^e _f t _a ⁱ _l ^{a -} _l L f p m ^H N n _. q O _a ^N _/ N S u / ^{q l} _a ^s _i d ⁵ _. ⁱ M ^a d P _e h _t ⁰ ₍ ⁿ A O ⁽ _s a on _e ^{m 0} _{a )} F ^{M y} _a ^d _{e s} ⁱ b _. 0 L M M ^c _e ^s _s g ^u _t ¹ ₍ ^{µ m} 5 ^{m d} 0 ^l _a ^{e i} _r ⁿ _i p ^t _t ^{f i} _{r e} 95 f o d ^{i (} 2 1 0 _t n ^x _{e e} d n _r o O2 h ⁵ _e t _i h ^t _i n _s o ^{i h} _{t e} p _l y _f p ^h _c H _, w ^w px ^t _i o _r E ^o _r ⁾ _. d _e ^{d e l} _i ^{o z} _{r i e} ⁿ dy ^v _i u l _a ^z _i y ^b _a l ^{b t} _s ^r _{e I} h q r _e ^. _{s :} ^a _r ^e t _a u ^r _t ^d _{e e} ^{u t} _{t e} ^t _a h ^r _e n o _i ^{t t} _e ^{1 t} _. 1 n _e ⁱ e n _{f e} ^l _e ^T m _a h ^. ₎ o ^r _a d ^{i ;} _l o _I ^{r I} _{I e e} ^r w _e ^r _e C ^t × ^s _i w _. ⁾ _{t )} ^o _e p ^e _{c r} a _c m µ ) w _{) a} ^{t n} _a ² ₍ ^r _e p n ^t _{s s} ⁱ _t ¹ _. L µ L _a ^t 2 ^{µ d} _s ^{l a} _i n ^e _c 1 _; n n ^{= d} o ⁱ _t aa L ( 2 s _t ^{( o} _i o t ^{c t} ₍ ½ o t ^w _t ^u _l ^r _t e _t ^{µ 5} _. o ^s _{t a} o ⁱ _c ^y _a ⁿ _{a f} ^o _s ⁾ _l 3 u u ^c _e ^o y 2 q ⁱ _l q ⁱ _l ^o _s ^s _i ^{d t} _s = n m ^k _c a ; u ^o _t ^r _t M A A D _t ^o _c S S ^e _t m A B ƒ * ^ ^B _: d n _e g _e L 5 _s ^a d ^, _r ^o _i ^e _s u ^u o ^t _c a _e y ^{h r l} _t ^{1 c} m _e ^r _e ^r _i ^t _f ^{o a} _r ^{f d d s} _t ⁿ _{e e} o ^h _t ⁿ _i uq ⁱ _{l e} m ^r _e ^r _e ^{t a w} _e ^; _s d ^r _e ^s _{t e} g ⁿ _a ^t _a ^{e l} _t n ^t _{a e} h ⁱ n ^r _e ^c op ^t _c ^{t d} _e ^. u ^a _t d _s ^{r ƒ} S _. ⁿ _i nu _e ^r _r n _f ^o _i ^{o o} _r ⁱ _t ^t _a n _; o m ^{s c} _i g ⁱ u _t ^f _i ^{c n t} a 0 _e 8 n ^r _t ^r _f 2 ^g _a ⁿ _{e :} ⁾ _t ^c _s ^{a m} y ^s _e no h ^t _i ^{b n} _t ⁱ _t ^{w d} _e ^r _e ^c n _e ^t _e ^s _l w ^{i d a} _i o ^l _l ^c _i ^{t o} _{f e} ^; _e ^{v v} _i ^s _s a ₎ ⁿ _i ^t _{i l} gS ^k d n d n ^{i M} - o ⁱ _t ^{a d} C ^a _{e x} A ^{L F m} _r y ^e _l ^b p % ^d m ¹ _. ^o _f ^r _e o ⁰ _e c ^{P m} _{r e} h ^t _i ^. ₎ ⁱ _f ^d d ^w Co ⁱ Ln _c ^m P ^c a ⁽ _e ^t _s ^{H s} _a C y o ° ^{s t w} _. n 0 N ^d _e ^t o ^y _c ⁱ _a ^{8 C} _{e s} ^{s r} _s ^t _a ^e _{j e} ^a _l M‒ n ⁱ v nno ^o _i C O2 ⁿ _e ^{c t} _a ^H H h ^{t l} _l ⁱ _c ^{M (} d ^u _f ^o _s ¹ _. C n s _i 0 _. LP ^{a (} T d q H ^d _e R _e ^a _t ^h n _l a ^x _e ^{t a} _tr ^{i h o} _f ^s _{c r e} ^{i t} _t o a y ^l v a _, 6 ¹ _s n ^l _e n O2 ^d o _e ^{i r} _t ^h _r ^u _c ^a y ^{H i} _{l f} ^b h _t o ^{o h s s} n _t ^t _i n ^{w n} d _e ^k _c ^o _i ^h _t o ^{t t} _a o s ⁱ _c ^{m e} _t u o _s ^{1 l} _i s d d i n _e D _. ^a k ^r 9 ^e _e w 1 _{e s} t _r ^{w e} _r a 1 _, ^u _t h ^{y x} _i C _a d m 5

0 1 _, 0 ^r _e ^a _f ^e _r ^o _i 7 _, 1 ⁽ w d o 4 _e ^{f t} _{c ,} l ³ _s ^e _s ^{s 1} - C ^e _r ^u _r d ^a u ⁿ _{a e} ^r e n ^u _t y n L a _. ^x _i ^l _t ^{o c} _{c ) e} ^P ₍ m o ^c _e q d ^{a m} _e ^r g g _i h _e d ^t o ^{r t} _{r a} ^{f s} _t ^. _s d ⁿ _i ⁿ _i o d ^t _l ⁿ _{e e} ^l v _e h o c u ^r _e ^{r l} _c no ^u _s ^h _t ^o e C _t q n ⁱ _{l r} ⁱ _t ^{s ;} _e ^y _c p i ^{a s e} _{r e} ^r _{r e} ^r _e ^° 0 _e ^{r a} h ^{w 8} _a ^; _s ^c _i p ^r _e ^t _e m ^{y t} _{a z} c _e a a o T ^t _a ^, ₎ g n r ^c _. ^{s )} _{t .} ⁿ _l ^I ₍ ^e _t n ^g _a . _t ^{= d t} _e h ^t _i ^v _{i a} ^t _a C H _s e _t ⁱ o ^{m n} _e ^x; _e m o ^t -0 ^w uq n ^{r M a} _i ^t h ^t _i m ^{t e} _{r a r} l ^{f 1} _, ^d _e ^e _e pu ⁰ _. ^d _e ^d _e d ^{w s u} _{e s} h ^d _e ⁷ _, ^x _i ⁰ _{. e} ^{t v} _i ⁴ _, ^{m 7} S 3 . _. q ^m _r n _l e u ^{a a c} _i r ^{1 ;} _l n ^a _t ^o _r ^v m _c a _e d - ⁾ _l ^s _a o ^o _i ⁿ _i n ⁱ _; ^s _{s r t} n _i ^, _{) .} ^y _z ^w) m . ^{µ t} _a g g _s ⁿ m ^a _l o ⁱ _r p _{f )} ^{o d} _l g o ⁿ _i n ^{b t} _t ⁿ _e b ^v _i u ⁰ _. u d 7 ^f _i ⁱ _i n ⁿ 5 ^g n r _{c i t} ^{a a} _t 82 ⁱ L ^o _i d ⁱ _ft ^o _r q ^e _; L ⁿ o n _t ^d _e µ0 ^t _c ^e _t ⁿ _i ^t _i ⁰ _. ^µ _e c ⁿ _i ^o _c ^{- a} n ^m _r 0 ^a _r hg op ⁿ -4 ^{1 5} _. y m ^a _e ^t o ^o _f 2 _; ^{f i} _l h _a ⁽ - ^; _l o 71 ^{b l} _{a a} ^{l 0} = _e ⁱ _t ^r _{e . y} ^g _i ^t _a ² ₍ m ; ^d _e u h ^c _e ^t _e ^{P 7} _; ⁾ h _; ^{d -} _' ^' _' ^µ M wo ^d _i ^c, ₎ ^{d .} ₎ C H _t p ^{/ s} _r ^e _l 1 g ^{2 (} _x - ₍ u _{, ;} ^{m l} _l ^v _i d ^{S ;} _e L o n ^{i '} _' L 00 ^o _f n ⁱ _{( e} ^v _i P n _e ^r _e p f m _f x ^h _s e ⁿ _{i r} 2 o ^, _' ^µ 0 4 ⁽ ₎ S d ^t _a ^t _i ^{H f 2} _, 01 H ⁿ _a g d u ^e u _j d o ^t r ^{b =} (½ ^d 2 _; O ^M - C _e ^{t u} _s H ^y _a n ^a A ^d _e n ^{t e} _e y ^, ₎ O2 a a N ^{L l} _e ^o _c ^{F t} _{c e} ^O _a ^o _{i f} ⁱ _l ^a _l L m ^H _. y ^h _{c e} % ^e _j n m ^t _a - _f p l ^s _i n ⁱ q ^{a b} _t d ⁱ _t ¹ _. ⁱ r ^N _/ o S u r P ^q _{e a} p O ⁽ h d ⁵ _. M d ^d _e ⁿ _e ^p _e y _{s t} ^{0 n} _e o ⁰ ₍ ^{m n} _a ^m _r ^r _a p- h ^t h ^t a ^a n _{s e} ⁰ _{. )} ⁱ _f ^p _e ^t _{i a} ^w dn L ^{M c} _e ^d _e ⁱ b 0 L n ^o _t g ^u _t ^{1 µ} o n ^l _e ^{a µ} M 0 ^{d s} _s 0 ^{m l} _a ^e _r ⁿ _i p ^t _t ^f _{( r e} 9 ^{c i} o d 5 ^{( s} _a ^s h ^m e ^{t c} _e g ^t _s ^d _e y ^x _e 2 0 ( 0 ⁱ _t O2 ^{5 n} h _e ^x _e ⁱ _f d ⁱ _r n _{s e} O ^w _{. a} g n ⁱ o ^{i h} _t ⁿ _e ^o p _l 2 h n ^y _{a c} H _, o ⁱ _s ^s _s ^u _{j t} ^{s t} _r n ^r _a N o t v s ^C _, H ^t _i p y ^t _{f i} o p E ^{o )} _. ^r _e ^{a o} _{c f e} ⁰ _. h ^w x ^{e l} _{i r r} d ^v _i v n o _{i e} ^t o _s M‒ ^{7 d w} _e y ^b _a ^o _r ^{r n} _I y uq no ^t _{a a} n O2 Hp d ^z _i e ^l _a ^{b t d} _{s e e e e} ^. _s ^r _: h u ^r _{t e} n ^a _r ^{e c i t 1} _. ^l _{l c} ^l _e h o c ⁱ _{t ,} c H ^{( r} _e u _e ^t _t ⁱ _f ^t _a h ^{o l} _{i e e} ^T. m ^t _a ^{t 1 u ;} _{l f} ^{o (} _s ^s _i - _{e a} d ^r _f C ^f _f L u d e n r _{e e e} r _e ^r h _{) e} C ^t o × ^s _i ^r w _. ^o _a d p ⁱ _c o T d ⁱ _{t :} a m R _e ⁾ P ^{b )} _{t ) e} ^{r e} _{r c} ^µ _t ^h _t ^p _{e s r} ^p _a ^c _i H S t _l P w w _a ^{n 2} _{( e} ^t _s p ⁱ _t ¹ _. ^{a o} _f ^x _e n ^a _c O L ₎ µ L ^t _{a a} d ^t _s n n ^{l a} 2 ^{µ =} _{i s} d n ^e o _c a 1 ^h _{s e} ⁱ _k ⁱ _t ^M a _; 6 1 n ^hl _s y ^l _a h ^t _i ( 2 n o ( ^o _i ½ o ⁱ _t ^{r t c t} ₍ ^w _t ^u _{l t} L e _t ^{µ d} o e ⁱ _{t e} u _l d ⁱ _s n o ^y _l ^{a w s} o ^s _{t a} u o ⁱ _c ^y _{a t} c q uq _e ⁿ _{a f} ^o _s o ⁾ _l ⁵ _. ^r _r o m ^o y 3 _r y ^d _e 2 ⁱ _t ^{s s} _f ^d _y ^{b z} _i i _l ^o _s ^s _i ^{d t} _s ^k _c a ; = n o mu ^o _t ^r _t M ⁿ _e ^k _c o o _e h ^d _e ^l _a g _e ⁿ _i ^r _t A A D _{t c} S S ^e _t m ^h _t ^t _{s a} v d ⁱ _t m ^u _e ^ _a e _l ^{p r} _e n B ƒ * _e ^t _e C _{e .} ^{p r} d d _e w d 1 ^{i n} _e ² _{c )} a L ⁽ _s e ^g _e ^t _r ⁽ a k d _r u _t L h ^e _e ⁿ _a g ^x _i C w ⁱ _l m 5 01 51 _I ^I _{I f} o ^e _r ^o _{i e} ^{f t s} _{c r} d ^a u ⁿ _{a e} o _{c )} ^r e ^P ₍ m h _e ^o _r t ^{r t} e _a ^{f l s} _t ^. _s v _e o ^h o c u ^r _e ^r _r C _t q ° ^{n i} _l ⁱ _t ^s 0 _e ^{r a 8} _a ^; _s ^c _i t ^r a ^p, _e ^t g _e n l ₎ ^e _t ^g C ^I ₍ n _a H _s e _t ⁱ o ^{m M a} _i ^t h ^t . ^d _i 0 ^d 2 _{e e} d ^w .q ^m _r n ^s _l a _i a ^e _t u n _i n ^{o i} _r; ^{v s} _{s s} g m ^a _l d ⁱ _c ⁿ _i n ^a _i ⁿ 5 ^g n o ^a _t 8 ^{i n} _i n 2 ^{d o} _e m _{c t} a ^- _e ^{a l} _a ^t n ^m _{r a} o ⁱ _t ^o _f u ^l _e ^{c d} _e ^r _{e i} h ^{c t P ,} _{e )} ^{d .} ₎ y _. ^v _i ^; C d ^{S e y} _t n ⁱ _{( e} L e ^v _i P o ^e _i o d ^t _a ^t _i ^H m e m ⁿ _a g d o u _j d ^{t d} _e d _e m _i ^t _a n ^{a d l} _e a m _e ^o _c A F ^t _c c ^{a h c} _{i c e} ^e _{j t} d ⁱ _t % n 1 _. ⁱ a ^t _a ⁿ _e ^p _e ^{0 n} _e m h o _r p ^r _a p- h ^t h ^{t a i} _l ^p _e ^t _i dn h ^a g h ^o _{t a} ^l _e ^{w a} u g n ⁱ h ^m _e ^{d o} _{e r} u o ^s _e ^{c t} _s ^{x h} _{r .} ^t _a gn y _e ^t _{r e} ^h _{t e} H g ⁱ _t ^s o a ^t e _a ^{l O} - ^u _j n ^r _a N t v s ^C _{e ,} 0 ^h _{e . c e} ^h _c ^A - ^{o g} _{c f i e} M t o _s ‒ ⁷ H h _e h ^t L- _{a z} ^l _e no O i _t 2 p H _, o o ^c - ^h _c ^{c ( r} _e d ^t d ⁵ _, - _{e a} C ^f _f e ^e _t ¹ d ^r _f: L u c _e ^c d ⁱ _t ⁾ n _{e s} P ^b S n n n ^p _e o n ^{a p} _a ^c _i H t P c o ^g _i ^x _{e l} a O s ^{c s} L- _e n ⁱ _{c k} ⁱ _t y ^M e _{i z} ^h d _e d ^c - ^l _{e s} ^l _a h ^t _i d ⁱ _s n p ⁱ _t ⁵ _, o ^y _l ^{a w} e ^p _e 1 m ^o _r y ^d _e p _a ^p _f o _f ^{d x} _a o _y ^{b z} _{i e} ^x _e mu _e h ^d _e ^l _a g _e ⁿ _i ^r _t H H S _a v d ⁱ _t m ^u _e " _a e _l ^r _e n # ^p _e ^t _e C _{e .} ^{p r} d d _e d 2 ^{i n} _e ² _{c )} w g _e ^t a L _{s r} ^{( ( e} a k d _r u L h ^e _e ⁿ _{a t} g ^x _i C w ⁱ _l m 5 188

3 © e w a w w 'Ji a

Legend: ¹ Hexapeptide is connected to the chelate through aromatic amide moiety.

" Hexapeptide is connected to the chelate through aliphatic amide moiety.

# Sum of 7,5-cz-Lig and 7,5-cz-Lig-A-OH.

5 Chart 23. Cleavage of model hexapeptide-chelate conjugates into parent chelate and individual amino acids in aq. 1.0 M HC1 at 80 °C over the course of 1 week (acid peptide hydrolysis kinetics')-, fractions of starting chelate-peptide conjugate (S), chelate-containing intermediates (7), parent chelate (P) and free ligand (L) determined by analytical HPLC (H ₂ O-MeCN system with 0. 1% FA additive; detection at 285 run; rounded to integers; aliquots from reaction mixtures were neutralized with MOPS buffer, pH 7.0, vortexed and then injected to HPLC). Performed in glass vials with magnetic stirrers. hd n H c5 N e

NJ a 'Ji a a oo

_I ^I _I ^t _s a _l o 0 h ^t _i 4 ^{t (} _a ^c _i o g w ^f o ^t d b ^s h w _e ^u _j ^e _z p _, b n ^s _t r u ^t o ^c - ^e _l y l ^l _a m _e ^{f f} _r P _e n y ^l _{f -} u o T d P p _e ^a h ⁿ _{e ;} ^b S ⁿ _e ^{C t} p ⁿ _e d ^h _t M E p ^{v n} _{a e} E P E _{i t} ^r _e C- E ₎ g _f u w F ^{H e} _t ^{o o} _s R h C ^t _i ^a _c w ⁱ _l n d o _i ^e _t n t o ⁱ _t C p ^{t ( ( i} _{a e} ^u _l s _l n _r ^{t r} _t l n ^p _{i e} ^o _i ^p o ^{s t} n ^{i e} _c y ^l _l g c _a n ^c _i h ^c _a no u ⁿ _i ^t _l w ^f _i o _r d ^e o ^, _s ^{c f l} _e ^r u ^{s G} n _a n _{a e i} ^{c :} _l ^{m s} R _. o h ^o _i ^t _a ^f _{a c} ^c M ^w C ^{° o} _{t t} u ⁿ _i b ^m m 0 o _r ^D m ^{5 8 P o} _. ^{u 0} _i d ^. _e ^t _{a )} m s _e ^u _{c i e} ^h _c ^M _s y _a t _a ^d _e ^t _a g ^a _e ^{r .} ₎ T ^d g m u _{j I} ^u _j n o ^t R _, ^{7 d} . n o _e y o M ^c - ^d _e ^{g r} _{r t .} ^c - P P d d ^× 0 ⁱ _t ^{s e} _i ^y _t e _i P ^R P n _{a e} 09 d o o P m C ^{i C} 4 e m e ^{( ( r} _e ^{( n} _{a )} 1 ^d _e 2 w ^d _e g L d _i ^d _i 1 d 0 ⁿ _e ¹ ₎ L u ^µ m ^a m 1 ^{p c} _s ^o _t n ^{µ f} _i ^r _t 00 i ^{a t} _a ^c _i D u ^{i t} d 05 n 5 _{, a} ^T d ^s _e ^e _{r ,} ^e _c ^M m h o _r p n ^{r a i} _l ^a d ^r _e M _e ^r _e ⁰ _. 0 n ^{f a} _s n ^m w ³ ₍ h ^a h 10 S ^a _r ⁰ _. 5 _{s l} g g ^{t ( e} _l C u o _r u 1 B o ^s p ^{H h} _r D t ^h _{t .} T ^P _a ^s _{e ,} h ^t _i ^{w t} _a m h g ^a _s ^t _{i e} ^t _{a e} l ^t H 9 n e _a ^{l O} - 89 ^w o ⁱ _s ^u _{j ,} n n ^{w o} _i d ^e _t h _{e c} ^h _c ^A - D ^d _e ⁿ _e o g T _, h ^p _s ^{c t} _a P b ^a _{e e} h _{e i} t h ^t L- 5 ^s _a u P ^u _c ^r _{t z} 7 ^w S _. C n ⁱ _e ^r o o ^c - 9 D ^, ₎ ¹ _{− f} ^r _{e e} td ^{t e} _t d ⁵ _, T T L ^o n ^t _f ^{w s c e} _t ¹ _f R e ^c n _e d ^o _, ^m o A _t g 70 ⁱ _{t .} ^e _l ^l _e n n n ^{a s} _e o no ^g _i ⁱ _t ^{1 u} _l o C ^{° p r} _e ^× 0 ^{× s} 7 g c ^s _i ^{c s} _i L- _z p o 5 ⁵ _. ^k _c 3 _t ⁿ _{i r} 2 ^{2 o} _t ^{a t} _{l e e} ^{c (} n ^h u d ⁱ - _t d ⁱ _t ⁵ _, ^p g ^d _e ^o _i ^{t S.} ₎ ^{2 s} _e p _e ^{p p} _e 1 _f n ⁱ _t g a ^p _a ^{o a} u _{a r} ^{f t} _i ^r _t h ^{d r} _t n ^{c e} _{a e} R t _{. a} S c ^e b B x _e ^x _e mu _e n n n o ^{t u} _c ^P H H S _e p ^e _c o l _e ^c n n L " ^{r a} o ^{i i n m} # ^l _{e e s e} ¹ C _. w ^o _{t ) )} ^{n s} _e ^{h p} _t h s _e ^t _i ^. _e d 4 ^a _c ^r _e ^w k n _e ² _i ⁱ _t g _e ^t _r a ^m _e ^o _i ^u _s b _f ^{w d a} _t p L h ku ⁱ _t ^{o s} _{l e} h ^u L ^l _e ^s _a ^l _l C ^e _l ⁿ _a µ C w ^e _c 5 01 g d n n _a ⁱ _s u + _{) )} ] ^s 8 _e 4 d 7 o D ^{m T} _[ S ( M z _/ - _I m S 3 ^E 4 d 8 n ‒ ^a 14 V + 8 ^{U h C} _{t I} o E b f _f o o n ⁽ o n i _t o ⁱ C ^a _{t r} ^{a .} _s g _r e _t ^b _i n o n ^{l i} _{a i} c ^t _a S n ^r _t p n M ^{o -} _I ^d S _e ^e _c s no E _{a ;} ^{b c s} _a n m w n o 5 ^w n n 82 o ^k t ⁱ _t h a ^{a t} _i n _c ⁱ o _f ^{w i} _t ⁱ _t 7 a _r ⁿ _a 98 g u D e _t q ^T n _e i h d D n T V ^T U _: ^+. ₎ ^a 8 ] 47 S 79 D M- 8 D T _{f .} C ^T o P D _{[ s} C T ^L y ^{( b z} _/ n ^I o y d ^{m i} _t ^b e ⁱ _f 7 ^u _l i _t 3 o ^d _e s ⁱ _f n 8 ⁱ a ‒ ^k _{t c} ⁿ u 5 q 3 o 8 ^t _{a s} u q b _c L 5 Abbreviations and definitions cyclene 1,4,7,10-tetraazacyclododecane Cbz benzylchloroformate Bu terc-butyl Boc benzyloxycarbonyl DCM dichloromethane TFA trifluoroacetic acid TIPS triisopropylsilyl TMS trimethylsilyl Ph phenyl Fmoc fluorenylmethyloxykarbonyl iPr isopropyl MOPS 3-(N-morpholino)propanesulfonic acid DIPEA N,N-Diisopropylethylamine LC-MS liquid chromatography – mass spectrometry MRI magnetic resonance imaging aryl substituent derived from at least one aromatic hydrocarbon ring by removal of one hydrogen atom from the aromatic ring, e.g. phenyl or naphtyl alkyl substituent derived from an alkane (linear or branched) which is derived from an alkane by removal of one hydrogen atom, e.g. methyl or ethyl arylalkyl substituent derived from an aryl-substituted alkane (linear or branched) which is derived from an alkane by removal of one hydrogen atom from the alkane chain., e.g. benzyl arylalkynyl substituent derived from an aryl-substituted alkyne by removing one hydrogen (thus containing a triple bond), which may be linear or branched click-zip closed cage ligand or complex, wherein the click reaction between the azide and the triple bond took place and the triazole bridge was formed, thereby “zipping” the metal coordination place. 1,5-cz-[M(Lig)] from Lig and M ions is a general notation of the coordination compounds according to the present invention. “1,5-cz-“ stands for a 1,5-triazole bridged cage, [M(Lig)] stands for a coordination compound of a metal cation and a ligand (the compound according to general formula (I)).